(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 November 2010 (04.11.2010)

PCT

(10) International Publication Number
WO 2010/127029 A1

(51) **International Patent Classification**:
A61K 31/7088 (2006.01) *A61K 39/395* (2006.01)

(21) **International Application Number**:
PCT/US2010/032816

(22) **International Filing Date**:
28 April 2010 (28.04.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

61/174,746	1 May 2009 (01.05.2009)	US
61/178,010	13 May 2009 (13.05.2009)	US
61/245,784	25 September 2009 (25.09.2009)	US

(71) **Applicant** *(for all designated States except US)*: **OPHTHOTECH CORPORATION** [US/US]; One Penn Plaza, 35th Floor, New York, NY 10119 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **PATEL, Samir** [US/US]; Ophthotech Corporation, One Penn Plaza, 35th Floor, New York, NY 10119 (US). **MASONSON, Harvey** [US/US]; Ophthotech Corporation, One Penn Plaza, 35th Floor, New York, NY 10119 (US).

(74) **Agents**: **LANGER, Matthew, E.** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2010/127029 A1

(54) **Title**: METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES

(57) **Abstract**: [00396] This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of a PDGF antagonist and a VEGF antagonist to a mammal in need thereof.

METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES

1. RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 61/174,746, filed May 1, 2009, U.S. Provisional Application No. 61/178,010, filed May 13, 2009, and U.S. Provisional Application No. 61/245,784, filed September 25, 2009, each of which is incorporated by reference herein in its entirety.

2. FIELD OF THE INVENTION

[0002] This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of (a) ARC-127, Antagonist A, Antagonist B, Antagonist C, Antagonist D, 1B3 antibody, CDP860, IMC-3G3, imatinib, 162.62 antibody, 163.31 antibody, 169.14 antibody, 169.31 antibody, αR1 antibody, 2A1E2 antibody, M4TS.11 antibody, M4TS.22 antibody, A10, brefeldin A, sunitinib, Hyb 120.1.2.1.2 antibody, Hyb 121.6.1.1.1 antibody, Hyb 127.5.7.3.1 antibody, Hyb 127.8.2.2.2 antibody, Hyb 1.6.1 antibody, Hyb 1.11.1 antibody, Hyb 1.17.1 antibody, Hyb 1.18.1 antibody, Hyb 1.19.1 antibody, Hyb 1.23.1 antibody, Hyb 1.24 antibody, Hyb 1.25 antibody, Hyb 1.29 antibody, Hyb 1.33 antibody, Hyb 1.38 antibody, Hyb 1.39 antibody, Hyb 1.40 antibody, Hyb 1.45 antibody, Hyb 1.46 antibody, Hyb 1.48 antibody, Hyb 1.49 antibody, Hyb 1.51 antibody, Hyb 6.4.1 antibody, F3 antibody, Humanized F3 antibody, C1 antibody, Humanized C1 antibody, 6.4 antibody, anti-mPDGF-C goat IgG antibody, C3.1 antibody, 5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine, interferon, protamine, PDGFR-B1 monoclonal antibody, PDGFR-B2 monoclonal antibody, 6D11 monoclonal antibody, Sis 1 monoclonal antibody, PR7212 monoclonal antibody, PR292 monoclonal antibody, HYB 9610 monoclonal antibody, HYB 9611 monoclonal antibody, HYB 9612 monoclonal antibody, HYB 9613 monoclonal antibody, 4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide, 4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea, CGP 53716, human antibody g162, pyrazolo[3,4-g]quinoxaline, 6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole, 1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine, 4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline, 4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one, (4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone, 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide, trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol, (Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid, 5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid, 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine, N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea, 1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline, 1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline, 1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline, AG1295, AG1296, 3-arylquinoline, 4-pyridyl-2-arylpyrimidine, sorafenib, MLN518, PKC412, AMN107, suramin, or neomycin, or a pharmaceutically acceptable salt thereof and (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof, to a mammal in need thereof.

3. BACKGROUND OF THE INVENTION

[0003] Various disorders of the eye are characterized, caused by, or result in choroidal, retinal or iris neovascularization or retinal edema. One of these disorders is macular degeneration. Age-related macular degeneration (AMD) is a disease that affects approximately one in ten Americans over the age of 65. One type of AMD, "wet-AMD" accounts for only 10% of age-related macular degeneration cases but results in 90% of cases of legal blindness from macular degeneration in the elderly. Another disorder of the eye is diabetic retinopathy. Diabetic retinopathy can affect up to 80% of all patients having diabetes for 10 years or more and is the third leading cause of adult blindness, accounting for almost 7% of blindness in the USA. Other disorders include hypertensive retinopathy, central serous chorioretinopathy, cystoid macular edema, Coats disease and ocular or adnexal neoplasms such as choroidal hemangioma, retinal pigment epithelial carcinoma and intraocular lymphoma.

[0004] Therefore, although advances in the understanding of the molecular events accompanying neovascularization have been made, there exists a need to utilize this understanding to develop improved methods for treating or preventing neovascular diseases disorders, including ocular neovascular diseases and disorders such as the neovascularization that occurs with AMD and diabetic retinopathy.

4. SUMMARY OF THE INVENTION

[0005] In one aspect the invention provides methods for treating or preventing an ophthalmological disease, comprising administering to a mammal in need thereof an effective amount of (a) ARC-127 or imatinib, or a pharmaceutically acceptable salt thereof; and (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, ORA102, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof.

[0006] In another aspect the invention provides methods for treating or preventing an ophthalmological disease, comprising administering to a mammal in need thereof an effective amount of (a) 1B3 antibody, CDP860, IMC-3G3, 162.62 antibody, 163.31 antibody, 169.14 antibody, 169.31 antibody, αR1 antibody, 2A1E2 antibody, M4TS.11 antibody, M4TS.22 antibody, A10, brefeldin A, sunitinib, Hyb 120.1.2.1.2 antibody, Hyb 121.6.1.1.1 antibody, Hyb 127.5.7.3.1 antibody, Hyb 127.8.2.2.2 antibody, Hyb 1.6.1 antibody, Hyb 1.11.1 antibody, Hyb 1.17.1 antibody, Hyb 1.18.1 antibody, Hyb 1.19.1 antibody, Hyb 1.23.1 antibody, Hyb 1.24 antibody, Hyb 1.25 antibody, Hyb 1.29 antibody, Hyb 1.33 antibody, Hyb 1.38 antibody, Hyb 1.39 antibody, Hyb 1.40 antibody, Hyb 1.45 antibody, Hyb 1.46 antibody, Hyb 1.48 antibody, Hyb 1.49 antibody, Hyb 1.51 antibody, Hyb 6.4.1 antibody, F3 antibody, Humanized F3 antibody, C1 antibody, Humanized C1 antibody, 6.4 antibody, anti-mPDGF-C goat IgG antibody, C3.1 antibody, 5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine, interferon, protamine, PDGFR-B1 monoclonal antibody, PDGFR-B2 monoclonal antibody, 6D11 monoclonal antibody, Sis 1 monoclonal antibody, PR7212 monoclonal antibody, PR292 monoclonal antibody, HYB 9610 monoclonal antibody, HYB 9611 monoclonal antibody, HYB 9612 monoclonal antibody, HYB 9613 monoclonal antibody, 4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide, 4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea, CGP 53716, human antibody g162, pyrazolo[3,4-g]quinoxaline, 6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole, 1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine, 4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline, 4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one, (4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone, 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide, trans-4-[(6,7-

dimethoxyquinoxaline-2-yl)amino]cyclohexanol, (Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid, 5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid, 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine, N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea, 1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline, 1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline, 1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline, AG1295, AG1296, 3-arylquinoline, 4-pyridyl-2-arylpyrimidine, sorafenib, MLN518, PKC412, AMN107, suramin, or neomycin, or a pharmaceutically acceptable salt thereof; and (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof.

[0007] In another aspect the invention provides methods for treating or preventing an ophthalmological disease, comprising administering to a mammal in need thereof an effective amount of (a) ARC-127 or imatinib, or a pharmaceutically acceptable salt thereof; and (b) 2C3 antibody or pegaptanib, or a pharmaceutically acceptable salt thereof, wherein the ophthalmological disease is choroidal vasculopathy, condition associated with choroidal neovascularization, hypertensive retinopathy, sickle cell retinopathy, condition associated with peripheral retinal neovascularization, retinopathy of prematurity, venous occlusive disease, arterial occlusive disease, central serous chorioretinopathy, cystoid macular edema, retinal telangiectasia, arterial macroaneurysm, retinal angiomatosis, radiation-induced retinopathy, or a neoplasm.

[0008] In another aspect the invention provides methods for treating or preventing an ophthalmological disease, comprising administering to a mammal in need thereof an effective amount of (a) Antagonist A, a compound of Formula A or a pharmaceutically acceptable salt thereof; and (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof.

[0009] In another aspect the invention provides methods for treating or preventing an ophthalmological disease, comprising administering to a mammal in need thereof an effective amount of (a) Antagonist B, a compound of Formula B or a pharmaceutically acceptable salt thereof; and (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof.

[0010] In another aspect the invention provides methods for treating or preventing an ophthalmological disease, comprising administering to a mammal in need thereof an effective amount of (a) Antagonist C, a compound of Formula C or a pharmaceutically acceptable salt thereof; and (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin,

decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof.

[0011] In another aspect the invention provides methods for treating or preventing an ophthalmological disease, comprising administering to a mammal in need thereof an effective amount of (a) Antagonist D, a compound of Formula E or a pharmaceutically acceptable salt thereof; and (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof.

[0012] In another aspect the invention provides methods for treating or preventing an ophthalmological disease, comprising administering to a mammal in need thereof an effective amount of (a) 1B3 antibody, CDP860, IMC-3G3, 162.62 antibody, 163.31 antibody, 169.14 antibody, 169.31 antibody, αR1 antibody, 2A1E2 antibody, M4TS.11 antibody, M4TS.22 antibody, Hyb 120.1.2.1.2 antibody, Hyb 121.6.1.1.1 antibody, Hyb 127.5.7.3.1 antibody, Hyb 127.8.2.2.2 antibody, Hyb 1.6.1 antibody, Hyb 1.11.1 antibody, Hyb 1.17.1 antibody, Hyb 1.18.1 antibody, Hyb 1.19.1 antibody, Hyb 1.23.1 antibody, Hyb 1.24 antibody, Hyb 1.25 antibody, Hyb 1.29 antibody, Hyb 1.33 antibody, Hyb 1.38 antibody, Hyb 1.39 antibody, Hyb 1.40 antibody, Hyb 1.45 antibody, Hyb 1.46 antibody, Hyb 1.48 antibody, Hyb 1.49 antibody, Hyb 1.51 antibody, Hyb 6.4.1 antibody, F3 antibody, Humanized F3 antibody, C1 antibody, Humanized C1 antibody, 6.4 antibody, anti-mPDGF-C goat IgG antibody, C3.1 antibody, PDGFR-B1 monoclonal antibody, PDGFR-B2 monoclonal antibody, 6D11 monoclonal antibody, Sis 1 monoclonal antibody, PR7212 monoclonal antibody, PR292 monoclonal antibody, HYB 9610 monoclonal antibody, HYB 9611 monoclonal antibody, HYB 9612 monoclonal antibody, or HYB 9613 monoclonal antibody, or a pharmaceutically acceptable salt thereof; and (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof.

[0013] The invention provides compositions comprising an effective amount of (a) ARC-127, Antagonist A, Antagonist B, Antagonist C, Antagonist D, 1B3 antibody, CDP860, IMC-3G3, imatinib, 162.62 antibody, 163.31 antibody, 169.14 antibody, 169.31 antibody, αR1 antibody, 2A1E2 antibody, M4TS.11 antibody, M4TS.22 antibody, A10, brefeldin A, sunitinib, Hyb 120.1.2.1.2 antibody, Hyb 121.6.1.1.1 antibody, Hyb 127.5.7.3.1 antibody, Hyb 127.8.2.2.2 antibody, Hyb 1.6.1 antibody, Hyb 1.11.1 antibody, Hyb 1.17.1 antibody, Hyb 1.18.1 antibody, Hyb 1.19.1 antibody, Hyb 1.23.1 antibody, Hyb 1.24 antibody, Hyb 1.25 antibody, Hyb 1.29 antibody, Hyb 1.33 antibody, Hyb 1.38 antibody, Hyb 1.39 antibody, Hyb 1.40 antibody, Hyb 1.45 antibody, Hyb 1.46 antibody, Hyb 1.48 antibody, Hyb 1.49 antibody, Hyb 1.51 antibody, Hyb 6.4.1 antibody, F3 antibody, Humanized F3 antibody, C1 antibody, Humanized C1 antibody, 6.4 antibody, anti-mPDGF-C goat IgG antibody, C3.1 antibody, 5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine, interferon, protamine, PDGFR-B1 monoclonal antibody, PDGFR-B2 monoclonal antibody, 6D11 monoclonal antibody, Sis 1 monoclonal antibody, PR7212 monoclonal

antibody, PR292 monoclonal antibody, HYB 9610 monoclonal antibody, HYB 9611 monoclonal antibody, HYB 9612 monoclonal antibody, HYB 9613 monoclonal antibody, 4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide, 4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea, CGP 53716, human antibody g162, pyrazolo[3,4-g]quinoxaline, 6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole, 1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine, 4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline, 4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one, (4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone, 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide, trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol, (Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid, 5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid, 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine, N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea, 1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline, 1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline, 1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline, AG1295, AG1296, 3-arylquinoline, 4-pyridyl-2-arylpyrimidine, sorafenib, MLN518, PKC412, AMN107, suramin, or neomycin, or a pharmaceutically acceptable salt thereof; (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier or vehicle.

[0014] The invention provides compositions comprising an effective amount of (a) Antagonist A or a pharmaceutically acceptable salt thereof; (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier or vehicle.

[0015] The invention provides compositions comprising an effective amount of (a) Antagonist B or a pharmaceutically acceptable salt thereof; (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier or vehicle.

[0016] The invention provides compositions comprising an effective amount of (a) Antagonist C or a pharmaceutically acceptable salt thereof; (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein,

sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier or vehicle.

[0017] The invention provides compositions comprising an effective amount of (a) Antagonist D or a pharmaceutically acceptable salt thereof; (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier or vehicle.

[0018] In another aspect the invention provides Antagonist A or a pharmaceutically acceptable salt thereof.

[0019] In another aspect the invention provides compositions comprising Antagonist A or a pharmaceutically acceptable salt thereof.

[0020] In another aspect the invention provides compositions comprising: (a) an effective amount of Antagonist A or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier or vehicle.

[0021] In another aspect the invention provides compounds of Formula B and a pharmaceutically acceptable salt thereof.

[0022] In another aspect the invention provides compositions comprising a compound of Formula B or a pharmaceutically acceptable salt thereof.

[0023] In another aspect the invention provides compositions comprising: (a) an effective amount of a compound of Formula B or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier or vehicle.

[0024] In another aspect the invention provides a compound of Formula C or a pharmaceutically acceptable salt thereof.

[0025] In another aspect the invention provides compositions comprising a compound of Formula C or a pharmaceutically acceptable salt thereof.

[0026] In another aspect the invention provides compositions comprising: (a) an effective amount of a compound of Formula C or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier or vehicle.

[0027] In another aspect the invention provides methods and compositions as described above, wherein Antagonist A, Antagonist B, Antagonist C or Antagonist D is linked with one or more nonphysiologically active groups, lipophilic groups or high-molecular weight compounds.

5. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Reference is made to the following detailed description, which sets forth illustrative embodiments and the accompanying drawings of which:

[0029] Figure 1 (A) is a schematic representation of the nucleic acid sequence of a human PDGF-B (GenBank Accession No. X02811) (SEQ ID NO: 1).

[0030] Figure 1 (B) is a schematic representation of the amino acid sequence of a human PDGF-B (GenBank Accession No. CAA26579) (SEQ ID NO: 2).

[0031] Figure 1 (C) is a schematic representation of the nucleic acid sequence of a human PDGF-A (GenBank Accession No. X06374) (SEQ ID NO: 11).

[0032] Figure 1 (D) is a schematic representation of the polypeptide sequence of a human PDGF-A (GenBank Accession No. CAA29677) (SEQ ID NO: 12).

[0033] Figure 1 (E) is a schematic representation of the nucleic acid sequence of a human PDGF-C (GenBank Accession No. NM_016205) (SEQ ID NO: 17).

[0034] Figure 1 (F) is a schematic representation of the polypeptide sequence of a human PDGF-C (GenBank Accession No. NP_057289) (SEQ ID NO: 18).

[0035] Figure 1 (G) is a schematic representation of the nucleic acid sequence of a human PDGF-D, variant 1 (GenBank Accession No. NM_025208) (SEQ ID NO: 19).

[0036] Figure 1 (H) is a schematic representation of the polypeptide sequence of a human PDGF-D, variant 1 (GenBank Accession No. NP_079484) (SEQ ID NO: 20).

[0037] Figure 1 (I) is a schematic representation of the nucleic acid sequence of a human PDGF-D, variant 2 (GenBank Accession No. NM_033135) (SEQ ID NO: 21).

[0038] Figure 1 (J) is a schematic representation of the polypeptide sequence of a human PDGF-D, variant 2 (GenBank Accession No. NP_149126) (SEQ ID NO: 22).

[0039] Figure 2 (A) is a schematic representation of the nucleic acid sequence of a human VEGF (GenBank Accession No: NM_003376) (SEQ ID NO: 3).

[0040] Figure 2 (B) is a schematic representation of the amino acid sequence of a human VEGF polypeptide (GenBank Accession No. NP_003367) (SEQ ID NO: 4).

[0041] Figure 3 (A) is a schematic representation of the nucleic acid sequence of a human PDGFR-B (GenBank Accession No. NM_002609) (SEQ ID NO: 5).

[0042] Figure 3 (B) is a schematic representation of the polypeptide sequence of a human PDGFR-B (GenBank Accession No. NP_002600) (SEQ ID NO: 6).

[0043] Figure 3 (C) is a schematic representation of the nucleic acid sequence of a human PDGFR-A (GenBank Accession No. NM_006206) (SEQ ID NO: 13).

[0044] Figure 3 (D) is a schematic representation of the polypeptide sequence of a human PDGFR-A (GenBank Accession No. NP_006197) (SEQ ID NO: 14).

[0045] Figure 4 (A) is a schematic representation of the nucleic acid sequence of a human VEGFR-1 (Flt-1) (GenBank Accession No. AF063657) (SEQ ID NO: 7).

[0046] Figure 4 (B) is schematic a representation of the polypeptide sequence of a human VEGFR-1 (Flt-1) (GenBank Accession No.) (SEQ ID NO: 8).

[0047] Figure 4 (C) is a schematic representation of the nucleic acid sequence of a human VEGFR-2 (KDR/Flk-1) (GenBank Accession No. AF035121) (SEQ ID NO: 9).

[0048] Figure 4 (D) is a schematic representation of the polypeptide sequence of a human VEGFR-2 (KDR/Flk-1) (GenBank Accession No. AAB88005) (SEQ ID NO: 10).

[0049] Figure 5 is a graph of change in mean foveal thickness from a baseline over a 12 week period when treated with Antagonist A and ranibizumab (as the commercially available composition Lucentis®). The square symbol represents foveal thickness in the central subfield and diamond symbol represents foveal thickness in the central point.

[0050] Figure 6 shows Formula A, wherein w is an integer from 2 to 12.

[0051] Figure 7 shows the chemical structure of Antagonist A.

[0052] Figure 8 shows Formula B, wherein w is an integer from 2 to 12.

[0053] Figure 9 shows the chemical structure of Antagonist B.

[0054] Figure 10 shows Formula C, wherein w is an integer from 2 to 12.

[0055] Figure 11 shows the chemical structure of Antagonist C.

[0056] Figure 12 shows the chemical structure of Antagonist D.

[0057] Figure 13 shows Formula E, wherein L is a linker, Y is 0 or 1, R is a nonphysiologically active group, lipophilic group or High Molecular Weight Compound, and X is an integer ranging from 1 to 4

6. DETAILED DESCRIPTION OF THE INVENTION

[0058] 5.1 Definitions and Abbreviations

[0059] As used herein, the following terms and phrases shall have the meanings set forth below. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of skill in the art to which this invention belongs.

[0060] The term "about" a referenced numeric indication means the referenced numeric indication plus or minus up to 10% of that referenced numeric indication. For example, "about 100" means from 90 to 110.

[0061] The term "antagonist" refers to an agent that inhibits, either partially or fully, the activity or production of a target molecule. In particular, the term "antagonist," as applied selectively herein, means an agent capable of decreasing levels of gene expression, mRNA levels, protein levels or protein activity of the target molecule. Illustrative forms of antagonists include, for example, proteins, polypeptides, peptides (such as cyclic peptides), antibodies or antibody fragments, peptide mimetics, nucleic acid molecules, antisense molecules, ribozymes, aptamers, RNAi molecules, and small organic molecules. Illustrative non-limiting mechanisms of antagonist inhibition include repression of ligand synthesis and/or stability (*e.g.*, using, antisense, ribozymes or RNAi compositions targeting the ligand gene/nucleic acid), blocking of binding of the ligand to its cognate receptor (*e.g.*, using anti-ligand aptamers, antibodies or a soluble, decoy cognate receptor), repression of receptor synthesis and/or stability (*e.g.*, using, antisense, ribozymes or RNAi compositions targeting the ligand receptor gene/nucleic acid), blocking of the binding of the receptor to its cognate receptor (*e.g.*, using receptor antibodies) and blocking of the activation of the receptor by its cognate ligand (*e.g.*, using receptor tyrosine kinase inhibitors). In addition, the antagonist may directly or indirectly inhibit the target molecule.

[0062] The term "antibody fragment" includes a portion of an antibody that is an antigen binding fragment or single chains thereof. An antibody fragment can be a synthetically or genetically engineered polypeptide. Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the V_L, V_H, C_L and C_{H1} domains; (ii) a $F(ab')_2$ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the V_H and C_{H1} domains; (iv) a Fv fragment consisting of the V_L and V_H domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a V_H domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, V_L and V_H, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V_L and V_H regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding fragment" of an antibody. These antibody fragments are obtained using conventional techniques known to those in the art, and the fragments can be screened for utility in the same manner as whole antibodies.

[0063] The term "aptamer" refers to a peptide or nucleic acid that has an inhibitory effect on a target. Inhibition of the target by the aptamer can occur by binding of the target, by catalytically altering the target, by reacting with the target in a way which modifies the target or the functional activity of the target, by ionically or covalently attaching to the target as in a suicide inhibitor or by facilitating the reaction between the target and another molecule. Aptamers can be peptides, ribonucleotides, deoxyribonucleotides, other nucleic acids or a mixture of the different

types of nucleic acids. Aptamers can comprise one or more modified amino acid, bases, sugars, polyethylene glycol spacers or phosphate backbone units as described in further detail herein.

[0064] A nucleotide sequence is "complementary" to another nucleotide sequence if each of the bases of the two sequences matches, *i.e.*, are capable of forming Watson Crick base pairs. The complement of a nucleic acid strand can be the complement of a coding strand or the complement of a non-coding strand.

[0065] The phrase "conserved residue" refers to an amino acid of a group of amino acids having particular common properties. A functional way to define common properties among individual amino acids is to analyze the normalized frequencies of amino acid changes among corresponding proteins of homologous organisms. According to such analyses, groups of amino acids may be characterized where amino acids within a group exchange preferentially with each other, and therefore resemble each other most in their impact on the overall protein structure (Schulz, G. E. and R. H. Schirmer, Principles of Protein Structure, Springer-Verlag). Examples of amino acid groups defined in this manner include:

[0066] (i) a charged group, consisting of Glu and Asp, Lys, Arg and His,

[0067] (ii) a positively-charged group, consisting of Lys, Arg and His,

[0068] (iii) a negatively-charged group, consisting of Glu and Asp,

[0069] (iv) an aromatic group, consisting of Phe, Tyr and Trp,

[0070] (v) a nitrogen ring group, consisting of His and Trp,

[0071] (vi) a large aliphatic nonpolar group, consisting of Val, Leu and Ile,

[0072] (vii) a slightly-polar group, consisting of Met and Cys,

[0073] (viii) a small-residue group, consisting of Ser, Thr, Asp, Asn, Gly, Ala, Glu, Gln and Pro,

[0074] (ix) an aliphatic group consisting of Val, Leu, Ile, Met and Cys, and

[0075] (x) a small hydroxyl group consisting of Ser and Thr.

[0076] Members of each of the above groups are conserved residues.

[0077] The term "label" includes, but is not limited to, a radioactive isotope, a fluorophore, a chemiluminescent moiety, an enzyme, an enzyme substrate, an enzyme cofactor, an enzyme inhibitor, a dye, a metal ion, a ligand (*e.g.*, biotin or a hapten) and the like. Examples of fluorophore labels include fluorescein, rhodamine, dansyl, umbelliferone, Texas red, luminol, NADPH, alpha-beta-galactosidase and horseradish peroxidase.

[0078] The term "nucleic acid" refers to a polynucleotide such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). The term also includes analogs of RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides, ESTs, chromosomes, cDNAs, mRNAs, and rRNAs.

[0079] The terms "RNA interference," "RNAi," "miRNA," and "siRNA" refer to any method by which expression of a gene or gene product is decreased by introducing into a target cell one or more double-stranded RNAs, which are homologous to a gene of interest (particularly to the messenger RNA of the gene of interest, *e.g.*, PDGF or VEGF).

[0080] The term "neovascularization" refers to new blood vessel formation in abnormal tissue or in abnormal positions.

[0081] The term "angiogenesis" refers to formation of new blood vessels in normal or in abnormal tissue or positions.

[0082] The term "ophthalmological disease" includes diseases of the eye and the ocular adnexa.

[0083] The term "ocular neovascular disorder" refers to an ocular disorder characterized by neovascularization. In one embodiment, the ocular neovascular disorder is a disorder other than cancer. Examples of ocular neovascular disorders include diabetic retinopathy and age-related macular degeneration.

[0084] The term "mammal" includes a human, monkey, cow, hog, sheep, horse, dog, and cat.

[0085] The term "PDGF" refers to a platelet-derived growth factor that regulates cell growth or division. As used herein, the term "PDGF" includes the various subtypes of PDGF including PDGF-B (see Figure 1(A) and (B)), PDGF-A (see Figure 1(C) and (D)), PDGF-C (see Figure 1(E) and (F)), PDGF-D, variants 1 and 2 (see Figure 1(G), (H), (I) and (J)), and dimerized forms thereof, including PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD. Platelet derived growth factors includes homo- or heterodimers of A-chain (PDGF-A) and B-chain (PDGF-B) that exert their action via binding to and dimerization of two related receptor tyrosine kinase platelet-derived growth factor cell surface receptors (*i.e.*, PDGFRs), PDGFR-α (see Figure 3 (C) and (D)) and PDGFR-β (see Figure 3 (A) and (B)). In addition, PDGF-C and PDGF-D, two additional protease-activated ligands for the PDGFR complexes, have been identified (Li *et al.*, (2000) Nat. Cell. Biol. 2: 302-9; Bergsten *et al.*, (2001) Nat. Cell. Biol. 3: 512-6; and Uutele *et al.*, (2001) Circulation 103: 2242-47). Due to the different ligand binding specificities of the PDGFRs, it is known that PDGFR-α/α binds PDGF-AA, PDGF-BB, PDGF-AB, and PDGF-CC; PDGFR-β/β binds PDGF-BB and PDGF-DD; whereas PDGFR-α/β binds PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD (Betsholtz *et al.*, (2001) BioEssays 23: 494-507). As used herein, the term "PDGF" also refers to those members of the class of growth factors that induce DNA synthesis and mitogenesis through the binding and activation of a PDGFR on a responsive cell type. PDGFs can effect, for example: directed cell migration (chemotaxis) and cell activation; phospholipase activation; increased phosphatidylinositol turnover and prostaglandin metabolism; stimulation of both collagen and collagenase synthesis by responsive cells; alteration of cellular metabolic activities, including matrix synthesis, cytokine production, and lipoprotein uptake; induction, indirectly, of a proliferative response in cells lacking PDGF receptors; and potent vasoconstrictor activity. The term "PDGF" can be used to refer to a "PDGF" polypeptide, a "PDGF" encoding gene or nucleic acid, or a dimerized form thereof.

[0086] The term "PDGF-A" refers to an A chain polypeptide of PDGF or its corresponding encoding gene or nucleic acid.

[0087] The term "PDGF-B" refers to a B chain polypeptide of PDGF or its corresponding encoding gene or nucleic acid.

[0088] The term "PDGF-C" refers to a C chain polypeptide of PDGF or its corresponding encoding gene or nucleic acid.

[0089] The term "PDGF-D" refers to a D chain polypeptide of PDGF or its corresponding encoding gene or nucleic acid, including variants 1 and 2 of the D chain polypeptide of PDGF.

[0090] The term "PDGF-AA" refers to a dimer having two PDGF-A chain polypeptides.

[0091] The term "PDGF-AB" refers to a dimer having one PDGF-A chain polypeptide and one PDGF-B chain polypeptide.

[0092] The term "PDGF-BB" refers to a dimer having two PDGF-B chain polypeptides.

[0093] The term "PDGF-CC" refers to a dimer having two PDGF-C chain polypeptides.

[0094] The term "PDGF-DD" refers to a dimer having two PDGF-D chain polypeptides.

[0095] The term "VEGF" refers to a vascular endothelial growth factor that induces angiogenesis or an angiogenic process. As used herein, the term "VEGF" includes the various subtypes of VEGF (also known as vascular permeability factor (VPF) and VEGF-A) (see Figure 2(A) and (B)) that arise by, *e.g.*, alternative splicing of the VEGF-A/VPF gene including $VEGF_{121}$, $VEGF_{165}$ and $VEGF_{189}$. Further, as used herein, the term "VEGF" includes VEGF-related angiogenic factors such as PIGF (placenta growth factor), VEGF-B, VEGF-C, VEGF-D and VEGF-E, which act through a cognate VEFG receptor (*i.e.*, VEGFR) to induce angiogenesis or an angiogenic process. The term "VEGF" includes any member of the class of growth factors that binds to a VEGF receptor such as VEGFR-1

(Flt-1) (see Figure 4(A) and (B)), VEGFR-2 (KDR/Flk-1) (see Figure 4(C) and (D)), or VEGFR-3 (FLT-4). The term "VEGF" can be used to refer to a "VEGF" polypeptide or a "VEGF" encoding gene or nucleic acid.

[0096] The term "PDGF antagonist" refers to an agent that reduces, or inhibits, either partially or fully, the activity or production of a PDGF. A PDGF antagonist can directly or indirectly reduce or inhibit the activity or production of a specific PDGF such as PDGF-B. Furthermore, "PDGF antagonists" consistent with the above definition of "antagonist," include agents that act on a PDGF ligand or its cognate receptor so as to reduce or inhibit a PDGF-associated receptor signal. Examples of "PDGF antagonists" include antisense molecules, ribozymes or RNAi that target a PDGF nucleic acid; anti-PDGF aptamers, anti-PDGF antibodies to PDGF itself or its receptor, or soluble PDGF receptor decoys that prevent binding of a PDGF to its cognate receptor; antisense molecules, ribozymes or RNAi that target a cognate PDGF receptor (PDGFR) nucleic acid; anti-PDGFR aptamers or anti-PDGFR antibodies that bind to a cognate PDGFR receptor; and PDGFR tyrosine kinase inhibitors.

[0097] The term "VEGF antagonist" refers to an agent that reduces, or inhibits, either partially or fully, the activity or production of a VEGF. A VEGF antagonist can directly or indirectly reduce or inhibit the activity or production of a specific VEGF such as $VEGF_{165}$. Furthermore, "VEGF antagonists" consistent with the above definition of "antagonist," include agents that act on either a VEGF ligand or its cognate receptor so as to reduce or inhibit a VEGF-associated receptor signal. Examples of "VEGF antagonists" include antisense molecules, ribozymes or RNAi that target a VEGF nucleic acid; anti-VEGF aptamers, anti-VEGF antibodies to VEGF itself or its receptor, or soluble VEGF receptor decoys that prevent binding of a VEGF to its cognate receptor; antisense molecules, ribozymes, or RNAi that target a cognate VEGF receptor (VEGFR) nucleic acid; anti-VEGFR aptamers or anti-VEGFR antibodies that bind to a cognate VEGFR receptor; and VEGFR tyrosine kinase inhibitors.

[0098] The term "effective amount," when used in connection with an ophthalmological disease, refers to an amount of a PDGF antagonist of Table 1 or Table (below) and a VEGF antagonist of Table 1 or Table 2 that is useful to treat or prevent an ophthalmological disease. The "effective amount" can vary depending upon the mode of administration, specific locus of the ophthalmological disease, the age, body weight, and general health of the mammal. The administration of the PDGF antagonist of Table 1 or Table 2 can occur prior to, subsequent to or concurrently with administration of the VEGF antagonist of Table 1 or Table 2. In one embodiment, the PDGF antagonist of Table 1 or Table 2 and VEGF antagonist of Table 1 or Table 2 are administered as components of the same composition. The effective amount is the total amount of the PDGF antagonist and the VEGF antagonist that is useful for treating or preventing an ophthalmological disease, even if the amount of the PDGF antagonist without the VEGF antagonist, or the VEGF antagonist without the PDGF antagonist, is ineffective to treat or prevent the ophthalmological disease.

[0099] A "variant" of polypeptide X refers to a polypeptide having the amino acid sequence of polypeptide X in which is altered in one or more amino acid residues. The variant can have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (*e.g.*, replacement of leucine with isoleucine). More rarely, a variant can have "nonconservative" changes (*e.g.*, replacement of glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without eliminating biological or immunological activity can be determined using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

[00100] The term "variant," when used in the context of a polynucleotide sequence, can encompass a polynucleotide sequence related to that of gene or the coding sequence thereof. This definition also includes, for example, "allelic," "splice," "species," or "polymorphic" variants. A splice variant can have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during

mRNA processing. The corresponding polypeptide can possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species.

[00101] 5.2 Methods for Treating or Preventing an Ophthalmological disease

[00102] Accordingly, the invention provides methods and compositions useful for treating or preventing an ophthalmological disease. In several embodiments of the present invention, the methods for treating or preventing an ophthalmological disease comprise administration of an effective amount of (a) ARC-127, Antagonist A, Antagonist B, Antagonist C, Antagonist D, 1B3 antibody, CDP860, IMC-3G3, imatinib, 162.62 antibody, 163.31 antibody, 169.14 antibody, 169.31 antibody, αR1 antibody, 2A1E2 antibody, M4TS.11 antibody, M4TS.22 antibody, A10, brefeldin A, sunitinib, Hyb 120.1.2.1.2 antibody, Hyb 121.6.1.1.1 antibody, Hyb 127.5.7.3.1 antibody, Hyb 127.8.2.2.2 antibody, Hyb 1.6.1 antibody, Hyb 1.11.1 antibody, Hyb 1.17.1 antibody, Hyb 1.18.1 antibody, Hyb 1.19.1 antibody, Hyb 1.23.1 antibody, Hyb 1.24 antibody, Hyb 1.25 antibody, Hyb 1.29 antibody, Hyb 1.33 antibody, Hyb 1.38 antibody, Hyb 1.39 antibody, Hyb 1.40 antibody, Hyb 1.45 antibody, Hyb 1.46 antibody, Hyb 1.48 antibody, Hyb 1.49 antibody, Hyb 1.51 antibody, Hyb 6.4.1 antibody, F3 antibody, Humanized F3 antibody, C1 antibody, Humanized C1 antibody, 6.4 antibody, anti-mPDGF-C goat IgG antibody, C3.1 antibody, 5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine, interferon, protamine, PDGFR-B1 monoclonal antibody, PDGFR-B2 monoclonal antibody, 6D11 monoclonal antibody, Sis 1 monoclonal antibody, PR7212 monoclonal antibody, PR292 monoclonal antibody, HYB 9610 monoclonal antibody, HYB 9611 monoclonal antibody, HYB 9612 monoclonal antibody, HYB 9613 monoclonal antibody, 4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide, 4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea, CGP 53716, human antibody g162, pyrazolo[3,4-g]quinoxaline, 6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole, 1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine, 4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline, 4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one, (4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone, 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide, trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol, (Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid, 5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid, 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine, N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea, 1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline, 1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline, 1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline, AG1295, AG1296, 3-arylquinoline, 4-pyridyl-2-arylpyrimidine, sorafenib, MLN518, PKC412, AMN107, suramin, or neomycin, or a pharmaceutically acceptable salt thereof; and (b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof (see Table 1). ARC-127, Antagonist A, Antagonist B, Antagonist C, Antagonist D, 1B3 antibody, CDP860, IMC-3G3, imatinib, 162.62 antibody, 163.31 antibody, 169.14 antibody, 169.31 antibody, αR1 antibody, 2A1E2 antibody, M4TS.11 antibody, M4TS.22 antibody, A10, brefeldin A, sunitinib, Hyb 120.1.2.1.2 antibody, Hyb 121.6.1.1.1 antibody, Hyb 127.5.7.3.1 antibody, Hyb 127.8.2.2.2 antibody, Hyb 1.6.1 antibody, Hyb 1.11.1 antibody, Hyb 1.17.1 antibody, Hyb 1.18.1 antibody, Hyb 1.19.1 antibody, Hyb 1.23.1 antibody, Hyb 1.24 antibody, Hyb 1.25 antibody, Hyb 1.29

antibody, Hyb 1.33 antibody, Hyb 1.38 antibody, Hyb 1.39 antibody, Hyb 1.40 antibody, Hyb 1.45 antibody, Hyb 1.46 antibody, Hyb 1.48 antibody, Hyb 1.49 antibody, Hyb 1.51 antibody, Hyb 6.4.1 antibody, F3 antibody, Humanized F3 antibody, C1 antibody, Humanized C1 antibody, 6.4 antibody, anti-mPDGF-D goat IgG antibody, C3.1 antibody, 5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine, interferon, protamine, PDGFR-B1 monoclonal antibody, PDGFR-B2 monoclonal antibody, 6D11 monoclonal antibody, Sis 1 monoclonal antibody, PR7212 monoclonal antibody, PR292 monoclonal antibody, HYB 9610 monoclonal antibody, HYB 9611 monoclonal antibody, HYB 9612 monoclonal antibody, HYB 9613 monoclonal antibody, 4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide, 4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea, CGP 53716, human antibody g162, pyrazolo[3,4-g]quinoxaline, 6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole, 1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine, 4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline, 4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one, (4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone, 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide, trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol, (Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid, 5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid, 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine, N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea, 1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline, 1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline, 1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline, AG1295, AG1296, 3-arylquinoline, 4-pyridyl-2-arylpyrimidine, sorafenib, MLN518, PKC412, AMN107, suramin, and neomycin, and their pharmaceutically acceptable salts are agents that inhibit platelet-derived growth factor (PDGF). Ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, and G6-31 antibody, and their pharmaceutically acceptable salts are agents that inhibit vascular endothelial growth factor (VEGF). Specific PDGF antagonist-VEGF antagonist pairs useful in the present methods or compositions are set forth in Table 2 (pairs A-EID). The PDGF antagonist or VEGF antagonist of Tables 1 and 2 can be in the form of a pharmaceutically acceptable salt. In the present methods, the PDGF antagonist of any of pairs A-EID can be administered prior to, subsequently to or concurrently with administration of the VEGF antagonist of any of pairs A-EID. In a particular embodiment, the PDGF antagonist is Antagonist A or a pharmaceutically acceptable salt thereof. In another particular embodiment, the PDGF antagonist is Antagonist B or a pharmaceutically acceptable salt thereof. In another particular embodiment, the PDGF antagonist is Antagonist C or a pharmaceutically acceptable salt thereof. In another particular embodiment, the PDGF antagonist is Antagonist D or a pharmaceutically acceptable salt thereof. In another embodiment, the VEGF antagonist is ranibizumab, bevacizumab or aflibercept, or a pharmaceutically acceptable salt thereof. In further embodiments, the methods can further comprise administering another agent that is useful for treating or preventing an ophthalmological disease, such as volociximab.

[00103] Table 1. List of (a) PDGF antagonists and (b) VEGF antagonists

(a) PDGF Antagonists	(b) VEGF Antagonists
ARC-127	ranibizumab
A compound of Formula A	bevacizumab

Antagonist A	aflibercept
A compound of Formula B	KH902 VEGF receptor-Fc fusion protein
Antagonist B	2C3 antibody
A compound of Formula C	ORA102
Antagonist C	pegaptanib
Antagonist D	bevasiranib
A compound of Formula E	SIRNA-027
1B3 antibody	decursin
CDP860	decursinol
IMC-3G3	picropodophyllin
Imatinib	guggulsterone
162.62 antibody	PLG101
163.31 antibody	eicosanoid LXA4
169.14 antibody	PTK787
169.31 antibody	pazopanib
αR1 antibody	axitinib
2A1E2 antibody	CDDO-Me
M4TS.11 antibody	CDDO-Imm
M4TS.22 antibody	shikonin
A10	beta-hydroxyisovalerylshikonin
brefeldin A	ganglioside GM3
Sunitinib	DC101 antibody
Hyb 120.1.2.1.2 antibody	Mab25 antibody
Hyb 121.6.1.1.1 antibody	Mab73 antibody
Hyb 127.5.7.3.1 antibody	4A5 antibody
Hyb 127.8.2.2.2 antibody	4E10 antibody
Hyb 1.6.1 antibody	5F12 antibody
Hyb 1.11.1 antibody	VA01 antibody
Hyb 1.17.1 antibody	BL2 antibody
Hyb 1.18.1 antibody	VEGF-related protein
Hyb 1.19.1 antibody	sFLT01
Hyb 1.23.1 antibody	sFLT02
Hyb 1.24 antibody	Peptide B3
Hyb 1.25 antibody	TG100801
Hyb 1.29 antibody	sorafenib
Hyb 1.33 antibody	G6-31 antibody
Hyb 1.38 antibody	A fusion antibody substance that specifically binds to one or more of a human vascular endothelial growth factor-A (VEGF-A), human vascular endothelial growth factor-B (VEGF-B), human vascular endothelial growth factor-C

	(VEGF-C), human vascular endothelial growth factor-D (VEGF-D), or human vascular endothelial growth factor-E (VEGF-E)
Hyb 1.39 antibody	An antibody that binds to an epitope of VEGF
Hyb 1.40 antibody	
Hyb 1.45 antibody	
Hyb 1.46 antibody	
Hyb 1.48 antibody	
Hyb 1.49 antibody	
Hyb 1.51 antibody	
Hyb 6.4.1 antibody	
F3 antibody	
Humanized F3 antibody	
C1 antibody	
Humanized C1 antibody	
6.4 antibody	
anti-mPDGF-C goat IgG antibody	
C3.1 antibody	
5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	
Interferon	
Protamine	
PDGFR-B1 monoclonal antibody	
PDGFR-B2 monoclonal antibody	
6D11 monoclonal antibody	
Sis 1 monoclonal antibody	
PR7212 monoclonal antibody	
PR292 monoclonal antibody	
HYB 9610 monoclonal antibody	
HYB 9611 monoclonal antibody	
HYB 9612 monoclonal antibody	
HYB 9613 monoclonal antibody	
4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	
4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	
CGP 53716 small molecule	
human antibody g162	
pyrazolo[3,4-g]quinoxaline	
6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	

1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	
4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	
4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	
(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	
5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	
trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	
(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	
5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	
1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	
N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	
1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	
1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	
1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	
AG1295	
AG1296	
3-arylquinoline	
4-pyridyl-2-arylpyrimidine	
Sorafenib	
MLN518	
PKC412	
AMN107	
Suramin	
Neomycin	
A fusion antibody substance that specifically binds to one or more of a human platelet-derived growth factor-A (PDGF-A), human	

platelet-derived growth factor-B (PDGF-B), human platelet-derived growth factor-C (PDGF-C), or human platelet-derived growth factor-D (PDGF-D)	
An antibody that binds to an epitope of PDGF	

[00104] Table 2. List of specific PDGF antagonist-VEGF antagonist pairs

Pair	(a) PDGF Antagonist	(b) VEGF Antagonist
A	ARC-127	ranibizumab
B	ARC-127	bevacizumab
C	ARC-127	aflibercept
D	ARC-127	KH902 VEGF receptor-Fc fusion protein
E	ARC-127	2C3 antibody
F	ARC-127	ORA102
G	ARC-127	pegaptanib
H	ARC-127	bevasiranib
I	ARC-127	SIRNA-027
J	ARC-127	decursin
K	ARC-127	decursinol
L	ARC-127	picropodophyllin
M	ARC-127	guggulsterone
N	ARC-127	PLG101
O	ARC-127	eicosanoid LXA4
P	ARC-127	PTK787
Q	ARC-127	pazopanib
R	ARC-127	axitinib
S	ARC-127	CDDO-Me
T	ARC-127	CDDO-Imm
U	ARC-127	shikonin
V	ARC-127	beta-hydroxyisovalerylshikonin
W	ARC-127	ganglioside GM3
X	ARC-127	DC101 antibody
Y	ARC-127	Mab25 antibody
Z	ARC-127	Mab73 antibody
AA	ARC-127	4A5 antibody
AB	ARC-127	4E10 antibody
AC	ARC-127	5F12 antibody
AD	ARC-127	VA01 antibody
AE	ARC-127	BL2 antibody
AF	ARC-127	VEGF-related protein
AG	ARC-127	sFLT01

AH	ARC-127	sFLT02
AI	ARC-127	Peptide B3
AJ	ARC-127	TG100801
AK	ARC-127	sorafenib
AL	ARC-127	G6-31 antibody
AM	A compound of Formula A	ranibizumab
AN	A compound of Formula A	bevacizumab
AO	A compound of Formula A	aflibercept
AP	A compound of Formula A	KH902 VEGF receptor-Fc fusion protein
AQ	A compound of Formula A	2C3 antibody
AR	A compound of Formula A	ORA102
AS	A compound of Formula A	pegaptanib
AT	A compound of Formula A	bevasiranib
AU	A compound of Formula A	SIRNA-027
AV	A compound of Formula A	decursin
AW	A compound of Formula A	decursinol
AX	A compound of Formula A	picropodophyllin
AY	A compound of Formula A	guggulsterone
AZ	A compound of Formula A	PLG101
BA	A compound of Formula A	eicosanoid LXA4
BB	A compound of Formula A	PTK787
BC	A compound of Formula A	pazopanib
BD	A compound of Formula A	axitinib
BE	A compound of Formula A	CDDO-Me
BF	A compound of Formula A	CDDO-Imm
BG	A compound of Formula A	shikonin
BH	A compound of Formula A	beta-hydroxyisovalerylshikonin
BI	A compound of Formula A	ganglioside GM3
BJ	A compound of Formula A	DC101 antibody
BK	A compound of Formula A	Mab25 antibody
BL	A compound of Formula A	Mab73 antibody
BM	A compound of Formula A	4A5 antibody
BN	A compound of Formula A	4E10 antibody
BO	A compound of Formula A	5F12 antibody
BP	A compound of Formula A	VA01 antibody
BQ	A compound of Formula A	BL2 antibody
BR	A compound of Formula A	VEGF-related protein
BS	A compound of Formula A	sFLT01
BT	A compound of Formula A	sFLT02
BU	A compound of Formula A	Peptide B3
BV	A compound of Formula A	TG100801

BW	A compound of Formula A	sorafenib
BX	A compound of Formula A	G6-31 antibody
BY	Antagonist A	ranibizumab
BZ	Antagonist A	bevacizumab
CA	Antagonist A	aflibercept
CB	Antagonist A	KH902 VEGF receptor-Fc fusion protein
CC	Antagonist A	2C3 antibody
CD	Antagonist A	ORA102
CE	Antagonist A	pegaptanib
CF	Antagonist A	bevasiranib
CG	Antagonist A	SIRNA-027
CH	Antagonist A	decursin
CI	Antagonist A	decursinol
CJ	Antagonist A	picropodophyllin
CK	Antagonist A	guggulsterone
CL	Antagonist A	PLG101
CM	Antagonist A	eicosanoid LXA4
CN	Antagonist A	PTK787
CO	Antagonist A	pazopanib
CP	Antagonist A	axitinib
CQ	Antagonist A	CDDO-Me
CR	Antagonist A	CDDO-Imm
CS	Antagonist A	shikonin
CT	Antagonist A	beta-hydroxyisovalerylshikonin
CU	Antagonist A	ganglioside GM3
CV	Antagonist A	DC101 antibody
CW	Antagonist A	Mab25 antibody
CX	Antagonist A	Mab73 antibody
CY	Antagonist A	4A5 antibody
CZ	Antagonist A	4E10 antibody
DA	Antagonist A	5F12 antibody
DB	Antagonist A	VA01 antibody
DC	Antagonist A	BL2 antibody
DD	Antagonist A	VEGF-related protein
DE	Antagonist A	sFLT01
DF	Antagonist A	sFLT02
DG	Antagonist A	Peptide B3
DH	Antagonist A	TG100801
DI	Antagonist A	sorafenib
DJ	Antagonist A	G6-31 antibody
DK	A compound of Formula B	ranibizumab

DL	A compound of Formula B	bevacizumab
DM	A compound of Formula B	aflibercept
DN	A compound of Formula B	KH902 VEGF receptor-Fc fusion protein
DO	A compound of Formula B	2C3 antibody
DP	A compound of Formula B	ORA102
DQ	A compound of Formula B	pegaptanib
DR	A compound of Formula B	bevasiranib
DS	A compound of Formula B	SIRNA-027
DT	A compound of Formula B	decursin
DU	A compound of Formula B	decursinol
DV	A compound of Formula B	picropodophyllin
DW	A compound of Formula B	guggulsterone
DX	A compound of Formula B	PLG101
DY	A compound of Formula B	eicosanoid LXA4
DZ	A compound of Formula B	PTK787
EA	A compound of Formula B	pazopanib
EB	A compound of Formula B	axitinib
EC	A compound of Formula B	CDDO-Me
ED	A compound of Formula B	CDDO-Imm
EE	A compound of Formula B	shikonin
EF	A compound of Formula B	beta-hydroxyisovalerylshikonin
EG	A compound of Formula B	ganglioside GM3
EH	A compound of Formula B	DC101 antibody
EI	A compound of Formula B	Mab25 antibody
EJ	A compound of Formula B	Mab73 antibody
EK	A compound of Formula B	4A5 antibody
EL	A compound of Formula B	4E10 antibody
EM	A compound of Formula B	5F12 antibody
EN	A compound of Formula B	VA01 antibody
EO	A compound of Formula B	BL2 antibody
EP	A compound of Formula B	VEGF-related protein
EQ	A compound of Formula B	sFLT01
ER	A compound of Formula B	sFLT02
ES	A compound of Formula B	Peptide B3
ET	A compound of Formula B	TG100801
EU	A compound of Formula B	sorafenib
EV	A compound of Formula B	G6-31 antibody
EW	Antagonist B	ranibizumab
EX	Antagonist B	bevacizumab
EY	Antagonist B	aflibercept
EZ	Antagonist B	KH902 VEGF receptor-Fc fusion protein

FA	Antagonist B	2C3 antibody
FB	Antagonist B	ORA102
FC	Antagonist B	pegaptanib
FD	Antagonist B	bevasiranib
FE	Antagonist B	SIRNA-027
FF	Antagonist B	decursin
FG	Antagonist B	decursinol
FH	Antagonist B	picropodophyllin
FI	Antagonist B	guggulsterone
FJ	Antagonist B	PLG101
FK	Antagonist B	eicosanoid LXA4
FL	Antagonist B	PTK787
FM	Antagonist B	pazopanib
FN	Antagonist B	axitinib
FO	Antagonist B	CDDO-Me
FP	Antagonist B	CDDO-Imm
FQ	Antagonist B	shikonin
FR	Antagonist B	beta-hydroxyisovalerylshikonin
FS	Antagonist B	ganglioside GM3
FT	Antagonist B	DC101 antibody
FU	Antagonist B	Mab25 antibody
FV	Antagonist B	Mab73 antibody
FW	Antagonist B	4A5 antibody
FX	Antagonist B	4E10 antibody
FY	Antagonist B	5F12 antibody
FZ	Antagonist B	VA01 antibody
GA	Antagonist B	BL2 antibody
GB	Antagonist B	VEGF-related protein
GC	Antagonist B	sFLT01
GD	Antagonist B	sFLT02
GE	Antagonist B	Peptide B3
GF	Antagonist B	TG100801
GG	Antagonist B	sorafenib
GH	Antagonist B	G6-31 antibody
GI	A compound of Formula C	ranibizumab
GJ	A compound of Formula C	bevacizumab
GK	A compound of Formula C	aflibercept
GL	A compound of Formula C	KH902 VEGF receptor-Fc fusion protein
GM	A compound of Formula C	2C3 antibody
GN	A compound of Formula C	ORA102
GO	A compound of Formula C	pegaptanib

GP	A compound of Formula C	bevasiranib
GQ	A compound of Formula C	SIRNA-027
GR	A compound of Formula C	decursin
GS	A compound of Formula C	decursinol
GT	A compound of Formula C	picropodophyllin
GU	A compound of Formula C	guggulsterone
GV	A compound of Formula C	PLG101
GW	A compound of Formula C	eicosanoid LXA4
GX	A compound of Formula C	PTK787
GY	A compound of Formula C	pazopanib
GZ	A compound of Formula C	axitinib
HA	A compound of Formula C	CDDO-Me
HB	A compound of Formula C	CDDO-Imm
HC	A compound of Formula C	shikonin
HD	A compound of Formula C	beta-hydroxyisovalerylshikonin
HE	A compound of Formula C	ganglioside GM3
HF	A compound of Formula C	DC101 antibody
HG	A compound of Formula C	Mab25 antibody
HH	A compound of Formula C	Mab73 antibody
HI	A compound of Formula C	4A5 antibody
HJ	A compound of Formula C	4E10 antibody
HK	A compound of Formula C	5F12 antibody
HL	A compound of Formula C	VA01 antibody
HM	A compound of Formula C	BL2 antibody
HN	A compound of Formula C	VEGF-related protein
HO	A compound of Formula C	sFLT01
HP	A compound of Formula C	sFLT02
HQ	A compound of Formula C	Peptide B3
HR	A compound of Formula C	TG100801
HS	A compound of Formula C	sorafenib
HT	A compound of Formula C	G6-31 antibody
HU	Antagonist C	ranibizumab
HV	Antagonist C	bevacizumab
HW	Antagonist C	aflibercept
HX	Antagonist C	KH902 VEGF receptor-Fc fusion protein
HY	Antagonist C	2C3 antibody
HZ	Antagonist C	ORA102
IA	Antagonist C	pegaptanib
IB	Antagonist C	bevasiranib
IC	Antagonist C	SIRNA-027
ID	Antagonist C	decursin

IE	Antagonist C	decursinol
IF	Antagonist C	picropodophyllin
IG	Antagonist C	guggulsterone
IH	Antagonist C	PLG101
IK	Antagonist C	eicosanoid LXA4
IL	Antagonist C	PTK787
IM	Antagonist C	pazopanib
IN	Antagonist C	axitinib
IO	Antagonist C	CDDO-Me
IP	Antagonist C	CDDO-Imm
IQ	Antagonist C	shikonin
IR	Antagonist C	beta-hydroxyisovalerylshikonin
IIS	Antagonist C	ganglioside GM3
IT	Antagonist C	DC101 antibody
IU	Antagonist C	Mab25 antibody
IV	Antagonist C	Mab73 antibody
IW	Antagonist C	4A5 antibody
IX	Antagonist C	4E10 antibody
IY	Antagonist C	5F12 antibody
IZ	Antagonist C	VA01 antibody
JA	Antagonist C	BL2 antibody
JB	Antagonist C	VEGF-related protein
JC	Antagonist C	sFLT01
JD	Antagonist C	sFLT02
JE	Antagonist C	Peptide B3
JF	Antagonist C	TG100801
JG	Antagonist C	sorafenib
JH	Antagonist C	G6-31 antibody
JI	Antagonist D	ranibizumab
JK	Antagonist D	bevacizumab
JL	Antagonist D	aflibercept
JM	Antagonist D	KH902 VEGF receptor-Fc fusion protein
JN	Antagonist D	2C3 antibody
JO	Antagonist D	ORA102
JP	Antagonist D	pegaptanib
JQ	Antagonist D	bevasiranib
JR	Antagonist D	SIRNA-027
JS	Antagonist D	decursin
JT	Antagonist D	decursinol
JU	Antagonist D	picropodophyllin
JV	Antagonist D	guggulsterone

JW	Antagonist D	PLG101
JX	Antagonist D	eicosanoid LXA4
JY	Antagonist D	PTK787
JZ	Antagonist D	pazopanib
KA	Antagonist D	axitinib
KB	Antagonist D	CDDO-Me
KC	Antagonist D	CDDO-Imm
KD	Antagonist D	shikonin
KE	Antagonist D	beta-hydroxyisovalerylshikonin
KF	Antagonist D	ganglioside GM3
KG	Antagonist D	DC101 antibody
KH	Antagonist D	Mab25 antibody
KI	Antagonist D	Mab73 antibody
KJ	Antagonist D	4A5 antibody
KK	Antagonist D	4E10 antibody
KL	Antagonist D	5F12 antibody
KM	Antagonist D	VA01 antibody
KN	Antagonist D	BL2 antibody
KO	Antagonist D	VEGF-related protein
KP	Antagonist D	sFLT01
KQ	Antagonist D	sFLT02
KR	Antagonist D	Peptide B3
KS	Antagonist D	TG100801
KT	Antagonist D	sorafenib
KU	Antagonist D	G6-31 antibody
KV	A compound of Formula E	ranibizumab
KW	A compound of Formula E	bevacizumab
KX	A compound of Formula E	aflibercept
KY	A compound of Formula E	KH902 VEGF receptor-Fc fusion protein
KZ	A compound of Formula E	2C3 antibody
LA	A compound of Formula E	ORA102
LB	A compound of Formula E	pegaptanib
LC	A compound of Formula E	bevasiranib
LD	A compound of Formula E	SIRNA-027
LE	A compound of Formula E	decursin
LF	A compound of Formula E	decursinol
LG	A compound of Formula E	picropodophyllin
LH	A compound of Formula E	guggulsterone
LI	A compound of Formula E	PLG101
LJ	A compound of Formula E	eicosanoid LXA4
LK	A compound of Formula E	PTK787

LL	A compound of Formula E	pazopanib
LM	A compound of Formula E	axitinib
LN	A compound of Formula E	CDDO-Me
LO	A compound of Formula E	CDDO-Imm
LP	A compound of Formula E	shikonin
LQ	A compound of Formula E	beta-hydroxyisovalerylshikonin
LR	A compound of Formula E	ganglioside GM3
LS	A compound of Formula E	DC101 antibody
LT	A compound of Formula E	Mab25 antibody
LU	A compound of Formula E	Mab73 antibody
LV	A compound of Formula E	4A5 antibody
LW	A compound of Formula E	4E10 antibody
LX	A compound of Formula E	5F12 antibody
LY	A compound of Formula E	VA01 antibody
LZ	A compound of Formula E	BL2 antibody
MA	A compound of Formula E	VEGF-related protein
MB	A compound of Formula E	sFLT01
MC	A compound of Formula E	sFLT02
MD	A compound of Formula E	Peptide B3
ME	A compound of Formula E	TG100801
MF	A compound of Formula E	sorafenib
MG	A compound of Formula E	G6-31 antibody
MH	1B3 antibody	ranibizumab
MI	1B3 antibody	bevacizumab
MJ	1B3 antibody	aflibercept
MK	1B3 antibody	KH902 VEGF receptor-Fc fusion protein
ML	1B3 antibody	2C3 antibody
MM	1B3 antibody	ORA102
MN	1B3 antibody	pegaptanib
MO	1B3 antibody	bevasiranib
MP	1B3 antibody	SIRNA-027
MQ	1B3 antibody	decursin
MR	1B3 antibody	decursinol
MS	1B3 antibody	picropodophyllin
MT	1B3 antibody	guggulsterone
MU	1B3 antibody	PLG101
MV	1B3 antibody	eicosanoid LXA4
MW	1B3 antibody	PTK787
MX	1B3 antibody	pazopanib
MY	1B3 antibody	axitinib
MZ	1B3 antibody	CDDO-Me

NA	1B3 antibody	CDDO-Imm
NB	1B3 antibody	shikonin
NC	1B3 antibody	beta-hydroxyisovalerylshikonin
ND	1B3 antibody	ganglioside GM3
NE	1B3 antibody	DC101 antibody
NF	1B3 antibody	Mab25 antibody
NG	1B3 antibody	Mab73 antibody
NH	1B3 antibody	4A5 antibody
NI	1B3 antibody	4E10 antibody
NJ	1B3 antibody	5F12 antibody
NK	1B3 antibody	VA01 antibody
NL	1B3 antibody	BL2 antibody
NM	1B3 antibody	VEGF-related protein
NN	1B3 antibody	sFLT01
NO	1B3 antibody	sFLT02
NP	1B3 antibody	Peptide B3
NQ	1B3 antibody	TG100801
NR	1B3 antibody	sorafenib
NS	1B3 antibody	G6-31 antibody
NT	CDP860	ranibizumab
NY	CDP860	bevacizumab
NV	CDP860	aflibercept
NW	CDP860	KH902 VEGF receptor-Fc fusion protein
NX	CDP860	2C3 antibody
NY	CDP860	ORA102
NZ	CDP860	pegaptanib
OA	CDP860	bevasiranib
OB	CDP860	SIRNA-027
OC	CDP860	decursin
OD	CDP860	decursinol
OE	CDP860	picropodophyllin
OF	CDP860	guggulsterone
OG	CDP860	PLG101
OH	CDP860	eicosanoid LXA4
OI	CDP860	PTK787
OJ	CDP860	pazopanib
OK	CDP860	axitinib
OL	CDP860	CDDO-Me
OM	CDP860	CDDO-Imm
ON	CDP860	shikonin
OO	CDP860	beta-hydroxyisovalerylshikonin

OP	CDP860	ganglioside GM3
OQ	CDP860	DC101 antibody
OR	CDP860	Mab25 antibody
OS	CDP860	Mab73 antibody
OT	CDP860	4A5 antibody
OY	CDP860	4E10 antibody
OV	CDP860	5F12 antibody
OW	CDP860	VA01 antibody
OX	CDP860	BL2 antibody
OY	CDP860	VEGF-related protein
OZ	CDP860	sFLT01
PA	CDP860	sFLT02
PB	CDP860	Peptide B3
PC	CDP860	TG100801
PD	CDP860	sorafenib
PE	CDP860	G6-31 antibody
PF	IMC-3G3	ranibizumab
PG	IMC-3G3	bevacizumab
PH	IMC-3G3	aflibercept
PI	IMC-3G3	KH902 VEGF receptor-Fc fusion protein
PJ	IMC-3G3	2C3 antibody
PK	IMC-3G3	ORA102
PL	IMC-3G3	pegaptanib
PM	IMC-3G3	bevasiranib
PN	IMC-3G3	SIRNA-027
PO	IMC-3G3	decursin
PP	IMC-3G3	decursinol
PQ	IMC-3G3	picropodophyllin
PR	IMC-3G3	guggulsterone
PS	IMC-3G3	PLG101
PT	IMC-3G3	eicosanoid LXA4
PY	IMC-3G3	PTK787
PV	IMC-3G3	pazopanib
PW	IMC-3G3	axitinib
PX	IMC-3G3	CDDO-Me
PY	IMC-3G3	CDDO-Imm
PZ	IMC-3G3	shikonin
QA	IMC-3G3	beta-hydroxyisovalerylshikonin
QB	IMC-3G3	ganglioside GM3
QC	IMC-3G3	DC101 antibody
QD	IMC-3G3	Mab25 antibody

QE	IMC-3G3	Mab73 antibody
QF	IMC-3G3	4A5 antibody
QG	IMC-3G3	4E10 antibody
QH	IMC-3G3	5F12 antibody
QI	IMC-3G3	VA01 antibody
QJ	IMC-3G3	BL2 antibody
QK	IMC-3G3	VEGF-related protein
QL	IMC-3G3	sFLT01
QM	IMC-3G3	sFLT02
QN	IMC-3G3	Peptide B3
QO	IMC-3G3	TG100801
QP	IMC-3G3	sorafenib
QQ	IMC-3G3	G6-31 antibody
QR	Imatinib	ranibizumab
QS	Imatinib	bevacizumab
QT	Imatinib	aflibercept
QY	Imatinib	KH902 VEGF receptor-Fc fusion protein
QV	Imatinib	2C3 antibody
QW	Imatinib	ORA102
QX	Imatinib	pegaptanib
QY	Imatinib	bevasiranib
QZ	Imatinib	SIRNA-027
RA	Imatinib	decursin
RB	Imatinib	decursinol
RC	Imatinib	picropodophyllin
RD	Imatinib	guggulsterone
RE	Imatinib	PLG101
RF	Imatinib	eicosanoid LXA4
RG	Imatinib	PTK787
RH	Imatinib	pazopanib
RI	Imatinib	axitinib
RJ	Imatinib	CDDO-Me
RK	Imatinib	CDDO-Imm
RL	Imatinib	shikonin
RM	Imatinib	beta-hydroxyisovalerylshikonin
RN	Imatinib	ganglioside GM3
RO	Imatinib	DC101 antibody
RP	Imatinib	Mab25 antibody
RQ	Imatinib	Mab73 antibody
RR	Imatinib	4A5 antibody
RS	Imatinib	4E10 antibody

RT	Imatinib	5F12 antibody
RY	Imatinib	VA01 antibody
RV	Imatinib	BL2 antibody
RW	Imatinib	VEGF-related protein
RX	Imatinib	sFLT01
RY	Imatinib	sFLT02
RZ	Imatinib	Peptide B3
SA	Imatinib	TG100801
SB	Imatinib	sorafenib
SC	Imatinib	G6-31 antibody
SD	162.62 antibody	ranibizumab
SE	162.62 antibody	bevacizumab
SF	162.62 antibody	aflibercept
SG	162.62 antibody	KH902 VEGF receptor-Fc fusion protein
SH	162.62 antibody	2C3 antibody
SI	162.62 antibody	ORA102
SJ	162.62 antibody	pegaptanib
SK	162.62 antibody	bevasiranib
SL	162.62 antibody	SIRNA-027
SM	162.62 antibody	decursin
SN	162.62 antibody	decursinol
SO	162.62 antibody	picropodophyllin
SP	162.62 antibody	guggulsterone
SQ	162.62 antibody	PLG101
SR	162.62 antibody	eicosanoid LXA4
SS	162.62 antibody	PTK787
ST	162.62 antibody	pazopanib
SY	162.62 antibody	axitinib
SV	162.62 antibody	CDDO-Me
SW	162.62 antibody	CDDO-Imm
SX	162.62 antibody	shikonin
SY	162.62 antibody	beta-hydroxyisovalerylshikonin
SZ	162.62 antibody	ganglioside GM3
TA	162.62 antibody	DC101 antibody
TB	162.62 antibody	Mab25 antibody
TC	162.62 antibody	Mab73 antibody
TD	162.62 antibody	4A5 antibody
TE	162.62 antibody	4E10 antibody
TF	162.62 antibody	5F12 antibody
TG	162.62 antibody	VA01 antibody
TH	162.62 antibody	BL2 antibody

TI	162.62 antibody	VEGF-related protein
TJ	162.62 antibody	sFLT01
TK	162.62 antibody	sFLT02
TL	162.62 antibody	Peptide B3
TM	162.62 antibody	TG100801
TN	162.62 antibody	sorafenib
TO	162.62 antibody	G6-31 antibody
TP	163.31 antibody	ranibizumab
TQ	163.31 antibody	bevacizumab
TR	163.31 antibody	aflibercept
TS	163.31 antibody	KH902 VEGF receptor-Fc fusion protein
TT	163.31 antibody	2C3 antibody
TY	163.31 antibody	ORA102
TV	163.31 antibody	pegaptanib
TW	163.31 antibody	bevasiranib
TX	163.31 antibody	SIRNA-027
TY	163.31 antibody	decursin
TZ	163.31 antibody	decursinol
UA	163.31 antibody	picropodophyllin
UB	163.31 antibody	guggulsterone
UC	163.31 antibody	PLG101
UD	163.31 antibody	eicosanoid LXA4
UE	163.31 antibody	PTK787
UF	163.31 antibody	pazopanib
UG	163.31 antibody	axitinib
UH	163.31 antibody	CDDO-Me
UI	163.31 antibody	CDDO-Imm
UJ	163.31 antibody	shikonin
UK	163.31 antibody	beta-hydroxyisovalerylshikonin
UL	163.31 antibody	ganglioside GM3
UM	163.31 antibody	DC101 antibody
UN	163.31 antibody	Mab25 antibody
UO	163.31 antibody	Mab73 antibody
UP	163.31 antibody	4A5 antibody
UQ	163.31 antibody	4E10 antibody
UR	163.31 antibody	5F12 antibody
US	163.31 antibody	VA01 antibody
UT	163.31 antibody	BL2 antibody
UY	163.31 antibody	VEGF-related protein
UV	163.31 antibody	sFLT01
UW	163.31 antibody	sFLT02

UX	163.31 antibody	Peptide B3
UY	163.31 antibody	TG100801
UZ	163.31 antibody	sorafenib
VA	163.31 antibody	G6-31 antibody
VB	169.14 antibody	ranibizumab
VC	169.14 antibody	bevacizumab
VD	169.14 antibody	aflibercept
VE	169.14 antibody	KH902 VEGF receptor-Fc fusion protein
VF	169.14 antibody	2C3 antibody
VG	169.14 antibody	ORA102
VH	169.14 antibody	pegaptanib
VI	169.14 antibody	bevasiranib
VJ	169.14 antibody	SIRNA-027
VK	169.14 antibody	decursin
VL	169.14 antibody	decursinol
VM	169.14 antibody	picropodophyllin
VN	169.14 antibody	guggulsterone
VO	169.14 antibody	PLG101
VP	169.14 antibody	eicosanoid LXA4
VQ	169.14 antibody	PTK787
VR	169.14 antibody	pazopanib
VS	169.14 antibody	axitinib
VT	169.14 antibody	CDDO-Me
VU	169.14 antibody	CDDO-Imm
VV	169.14 antibody	shikonin
VW	169.14 antibody	beta-hydroxyisovalerylshikonin
VX	169.14 antibody	ganglioside GM3
VY	169.14 antibody	DC101 antibody
VZ	169.14 antibody	Mab25 antibody
WA	169.14 antibody	Mab73 antibody
WB	169.14 antibody	4A5 antibody
WC	169.14 antibody	4E10 antibody
WD	169.14 antibody	5F12 antibody
WE	169.14 antibody	VA01 antibody
WF	169.14 antibody	BL2 antibody
WG	169.14 antibody	VEGF-related protein
WH	169.14 antibody	sFLT01
WI	169.14 antibody	sFLT02
WJ	169.14 antibody	Peptide B3
WK	169.14 antibody	TG100801
WL	169.14 antibody	sorafenib

WM	169.14 antibody	G6-31 antibody
WN	169.31 antibody	ranibizumab
WO	169.31 antibody	bevacizumab
WP	169.31 antibody	aflibercept
WQ	169.31 antibody	KH902 VEGF receptor-Fc fusion protein
WR	169.31 antibody	2C3 antibody
WS	169.31 antibody	ORA102
WT	169.31 antibody	pegaptanib
WU	169.31 antibody	bevasiranib
WV	169.31 antibody	SIRNA-027
WW	169.31 antibody	decursin
WX	169.31 antibody	decursinol
WY	169.31 antibody	picropodophyllin
WZ	169.31 antibody	guggulsterone
XA	169.31 antibody	PLG101
XB	169.31 antibody	eicosanoid LXA4
XC	169.31 antibody	PTK787
XD	169.31 antibody	pazopanib
XE	169.31 antibody	axitinib
XF	169.31 antibody	CDDO-Me
XG	169.31 antibody	CDDO-Imm
XH	169.31 antibody	shikonin
XI	169.31 antibody	beta-hydroxyisovalerylshikonin
XJ	169.31 antibody	ganglioside GM3
XK	169.31 antibody	DC101 antibody
XL	169.31 antibody	Mab25 antibody
XM	169.31 antibody	Mab73 antibody
XN	169.31 antibody	4A5 antibody
XO	169.31 antibody	4E10 antibody
XP	169.31 antibody	5F12 antibody
XQ	169.31 antibody	VA01 antibody
XR	169.31 antibody	BL2 antibody
XS	169.31 antibody	VEGF-related protein
XT	169.31 antibody	sFLT01
XU	169.31 antibody	sFLT02
XV	169.31 antibody	Peptide B3
XW	169.31 antibody	TG100801
XX	169.31 antibody	sorafenib
XY	169.31 antibody	G6-31 antibody
XZ	αR1 antibody	ranibizumab
YA	αR1 antibody	bevacizumab

YB	αR1 antibody	aflibercept
YC	αR1 antibody	KH902 VEGF receptor-Fc fusion protein
YD	αR1 antibody	2C3 antibody
YE	αR1 antibody	ORA102
YF	αR1 antibody	pegaptanib
YG	αR1 antibody	bevasiranib
YH	αR1 antibody	SIRNA-027
YI	αR1 antibody	decursin
YJ	αR1 antibody	decursinol
YK	αR1 antibody	picropodophyllin
YL	αR1 antibody	guggulsterone
YM	αR1 antibody	PLG101
YN	αR1 antibody	eicosanoid LXA4
YO	αR1 antibody	PTK787
YP	αR1 antibody	pazopanib
YQ	αR1 antibody	axitinib
YR	αR1 antibody	CDDO-Me
YS	αR1 antibody	CDDO-Imm
YT	αR1 antibody	shikonin
YU	αR1 antibody	beta-hydroxyisovalerylshikonin
YV	αR1 antibody	ganglioside GM3
YW	αR1 antibody	DC101 antibody
YX	αR1 antibody	Mab25 antibody
YY	αR1 antibody	Mab73 antibody
YZ	αR1 antibody	4A5 antibody
ZA	αR1 antibody	4E10 antibody
ZB	αR1 antibody	5F12 antibody
ZC	αR1 antibody	VA01 antibody
ZD	αR1 antibody	BL2 antibody
ZE	αR1 antibody	VEGF-related protein
ZF	αR1 antibody	sFLT01
ZG	αR1 antibody	sFLT02
ZH	αR1 antibody	Peptide B3
ZI	αR1 antibody	TG100801
ZJ	αR1 antibody	sorafenib
ZK	αR1 antibody	G6-31 antibody
ZL	2A1E2 antibody	ranibizumab
ZM	2A1E2 antibody	bevacizumab
ZN	2A1E2 antibody	aflibercept

ZO	2A1E2 antibody	KH902 VEGF receptor-Fc fusion protein
ZP	2A1E2 antibody	2C3 antibody
ZQ	2A1E2 antibody	ORA102
ZR	2A1E2 antibody	pegaptanib
ZS	2A1E2 antibody	bevasiranib
ZT	2A1E2 antibody	SIRNA-027
ZU	2A1E2 antibody	decursin
ZV	2A1E2 antibody	decursinol
ZW	2A1E2 antibody	picropodophyllin
ZX	2A1E2 antibody	guggulsterone
ZY	2A1E2 antibody	PLG101
ZZ	2A1E2 antibody	eicosanoid LXA4
AAA	2A1E2 antibody	PTK787
AAB	2A1E2 antibody	pazopanib
AAC	2A1E2 antibody	axitinib
AAD	2A1E2 antibody	CDDO-Me
AAE	2A1E2 antibody	CDDO-Imm
AAF	2A1E2 antibody	shikonin
AAG	2A1E2 antibody	beta-hydroxyisovalerylshikonin
AAH	2A1E2 antibody	ganglioside GM3
AAI	2A1E2 antibody	DC101 antibody
AAJ	2A1E2 antibody	Mab25 antibody
AAK	2A1E2 antibody	Mab73 antibody
AAL	2A1E2 antibody	4A5 antibody
AAM	2A1E2 antibody	4E10 antibody
AAN	2A1E2 antibody	5F12 antibody
AAO	2A1E2 antibody	VA01 antibody
AAP	2A1E2 antibody	BL2 antibody
AAQ	2A1E2 antibody	VEGF-related protein
AAR	2A1E2 antibody	sFLT01
AAS	2A1E2 antibody	sFLT02
AAT	2A1E2 antibody	Peptide B3
AAU	2A1E2 antibody	TG100801
AAV	2A1E2 antibody	sorafenib
AAW	2A1E2 antibody	G6-31 antibody
AAX	M4TS.11 antibody	ranibizumab
AAY	M4TS.11 antibody	bevacizumab
AAZ	M4TS.11 antibody	aflibercept
ABA	M4TS.11 antibody	KH902 VEGF receptor-Fc fusion protein

ABB	M4TS.11 antibody	2C3 antibody
ABC	M4TS.11 antibody	ORA102
ABD	M4TS.11 antibody	pegaptanib
ABE	M4TS.11 antibody	bevasiranib
ABF	M4TS.11 antibody	SIRNA-027
ABG	M4TS.11 antibody	decursin
ABH	M4TS.11 antibody	decursinol
ABI	M4TS.11 antibody	picropodophyllin
ABJ	M4TS.11 antibody	guggulsterone
ABK	M4TS.11 antibody	PLG101
ABL	M4TS.11 antibody	eicosanoid LXA4
ABM	M4TS.11 antibody	PTK787
ABN	M4TS.11 antibody	pazopanib
ABO	M4TS.11 antibody	axitinib
ABP	M4TS.11 antibody	CDDO-Me
ABQ	M4TS.11 antibody	CDDO-Imm
ABR	M4TS.11 antibody	shikonin
ABS	M4TS.11 antibody	beta-hydroxyisovalerylshikonin
ABT	M4TS.11 antibody	ganglioside GM3
ABU	M4TS.11 antibody	DC101 antibody
ABV	M4TS.11 antibody	Mab25 antibody
ABW	M4TS.11 antibody	Mab73 antibody
ABX	M4TS.11 antibody	4A5 antibody
ABY	M4TS.11 antibody	4E10 antibody
ABZ	M4TS.11 antibody	5F12 antibody
ACA	M4TS.11 antibody	VA01 antibody
ACB	M4TS.11 antibody	BL2 antibody
ACC	M4TS.11 antibody	VEGF-related protein
ACD	M4TS.11 antibody	sFLT01
ACE	M4TS.11 antibody	sFLT02
ACF	M4TS.11 antibody	Peptide B3
ACG	M4TS.11 antibody	TG100801
ACH	M4TS.11 antibody	sorafenib
ACI	M4TS.11 antibody	G6-31 antibody
ACJ	M4TS.22 antibody	ranibizumab
ACK	M4TS.22 antibody	bevacizumab
ACL	M4TS.22 antibody	aflibercept
ACM	M4TS.22 antibody	KH902 VEGF receptor-Fc fusion protein
ACN	M4TS.22 antibody	2C3 antibody
ACO	M4TS.22 antibody	ORA102
ACP	M4TS.22 antibody	pegaptanib

ACQ	M4TS.22 antibody	bevasiranib
ACR	M4TS.22 antibody	SIRNA-027
ACS	M4TS.22 antibody	decursin
ACT	M4TS.22 antibody	decursinol
ACU	M4TS.22 antibody	picropodophyllin
ACV	M4TS.22 antibody	guggulsterone
ACW	M4TS.22 antibody	PLG101
ACX	M4TS.22 antibody	eicosanoid LXA4
ACY	M4TS.22 antibody	PTK787
ACZ	M4TS.22 antibody	pazopanib
ADA	M4TS.22 antibody	axitinib
ADB	M4TS.22 antibody	CDDO-Me
ADC	M4TS.22 antibody	CDDO-Imm
ADD	M4TS.22 antibody	shikonin
ADE	M4TS.22 antibody	beta-hydroxyisovalerylshikonin
ADF	M4TS.22 antibody	ganglioside GM3
ADG	M4TS.22 antibody	DC101 antibody
ADH	M4TS.22 antibody	Mab25 antibody
ADI	M4TS.22 antibody	Mab73 antibody
ADJ	M4TS.22 antibody	4A5 antibody
ADK	M4TS.22 antibody	4E10 antibody
ADL	M4TS.22 antibody	5F12 antibody
ADM	M4TS.22 antibody	VA01 antibody
ADN	M4TS.22 antibody	BL2 antibody
ADO	M4TS.22 antibody	VEGF-related protein
ADP	M4TS.22 antibody	sFLT01
ADQ	M4TS.22 antibody	sFLT02
ADR	M4TS.22 antibody	Peptide B3
ADS	M4TS.22 antibody	TG100801
ADT	M4TS.22 antibody	sorafenib
ADU	M4TS.22 antibody	G6-31 antibody
ADV	A10	ranibizumab
ADW	A10	bevacizumab
ADX	A10	aflibercept
ADY	A10	KH902 VEGF receptor-Fc fusion protein
ADZ	A10	2C3 antibody
AEA	A10	ORA102
AEB	A10	pegaptanib
AEC	A10	bevasiranib
AED	A10	SIRNA-027
AEE	A10	decursin

AEF	A10	decursinol
AEG	A10	picropodophyllin
AEH	A10	guggulsterone
AEI	A10	PLG101
AEJ	A10	eicosanoid LXA4
AEK	A10	PTK787
AEL	A10	pazopanib
AEM	A10	axitinib
AEN	A10	CDDO-Me
AEO	A10	CDDO-Imm
AEP	A10	shikonin
AEQ	A10	beta-hydroxyisovalerylshikonin
AER	A10	ganglioside GM3
AES	A10	DC101 antibody
AET	A10	Mab25 antibody
AEU	A10	Mab73 antibody
AEV	A10	4A5 antibody
AEW	A10	4E10 antibody
AEX	A10	5F12 antibody
AEY	A10	VA01 antibody
AEZ	A10	BL2 antibody
AFA	A10	VEGF-related protein
AFB	A10	sFLT01
AFC	A10	sFLT02
AFD	A10	Peptide B3
AFE	A10	TG100801
AFF	A10	sorafenib
AFG	A10	G6-31 antibody
AFH	brefeldin A	ranibizumab
AFI	brefeldin A	bevacizumab
AFJ	brefeldin A	aflibercept
AFK	brefeldin A	KH902 VEGF receptor-Fc fusion protein
AFL	brefeldin A	2C3 antibody
AFM	brefeldin A	ORA102
AFN	brefeldin A	pegaptanib
AFO	brefeldin A	bevasiranib
AFP	brefeldin A	SIRNA-027
AFQ	brefeldin A	decursin
AFR	brefeldin A	decursinol
AFS	brefeldin A	picropodophyllin
AFT	brefeldin A	guggulsterone

AFU	brefeldin A	PLG101
AFV	brefeldin A	eicosanoid LXA4
AFW	brefeldin A	PTK787
AFX	brefeldin A	pazopanib
AFY	brefeldin A	axitinib
AFZ	brefeldin A	CDDO-Me
AGA	brefeldin A	CDDO-Imm
AGB	brefeldin A	shikonin
AGC	brefeldin A	beta-hydroxyisovalerylshikonin
AGD	brefeldin A	ganglioside GM3
AGE	brefeldin A	DC101 antibody
AGF	brefeldin A	Mab25 antibody
AGG	brefeldin A	Mab73 antibody
AGH	brefeldin A	4A5 antibody
AGI	brefeldin A	4E10 antibody
AGJ	brefeldin A	5F12 antibody
AGK	brefeldin A	VA01 antibody
AGL	brefeldin A	BL2 antibody
AGM	brefeldin A	VEGF-related protein
AGN	brefeldin A	sFLT01
AGO	brefeldin A	sFLT02
AGP	brefeldin A	Peptide B3
AGQ	brefeldin A	TG100801
AGR	brefeldin A	sorafenib
AGS	brefeldin A	G6-31 antibody
AGT	sunitinib	ranibizumab
AGU	sunitinib	bevacizumab
AGV	sunitinib	aflibercept
AGW	sunitinib	KH902 VEGF receptor-Fc fusion protein
AGX	sunitinib	2C3 antibody
AGY	sunitinib	ORA102
AGZ	sunitinib	pegaptanib
AHA	sunitinib	bevasiranib
AHB	sunitinib	SIRNA-027
AHC	sunitinib	decursin
AHD	sunitinib	decursinol
AHE	sunitinib	picropodophyllin
AHF	sunitinib	guggulsterone
AHG	sunitinib	PLG101
AHH	sunitinib	eicosanoid LXA4
AHI	sunitinib	PTK787

AHJ	sunitinib	pazopanib
AHK	sunitinib	axitinib
AHL	sunitinib	CDDO-Me
AHM	sunitinib	CDDO-Imm
AHN	sunitinib	shikonin
AHO	sunitinib	beta-hydroxyisovalerylshikonin
AHP	sunitinib	ganglioside GM3
AHQ	sunitinib	DC101 antibody
AHR	sunitinib	Mab25 antibody
AHS	sunitinib	Mab73 antibody
AHT	sunitinib	4A5 antibody
AHU	sunitinib	4E10 antibody
AHV	sunitinib	5F12 antibody
AHW	sunitinib	VA01 antibody
AHX	sunitinib	BL2 antibody
AHY	sunitinib	VEGF-related protein
AHZ	sunitinib	sFLT01
AIA	sunitinib	sFLT02
AIB	sunitinib	Peptide B3
AIC	sunitinib	TG100801
AID	sunitinib	sorafenib
AIE	Sunitinib	G6-31 antibody
AIF	Hyb 120.1.2.1.2 antibody	ranibizumab
AIG	Hyb 120.1.2.1.2 antibody	bevacizumab
AIH	Hyb 120.1.2.1.2 antibody	aflibercept
AII	Hyb 120.1.2.1.2 antibody	KH902 VEGF receptor-Fc fusion protein
AIJ	Hyb 120.1.2.1.2 antibody	2C3 antibody
AIK	Hyb 120.1.2.1.2 antibody	ORA102
AIL	Hyb 120.1.2.1.2 antibody	pegaptanib
AIM	Hyb 120.1.2.1.2 antibody	bevasiranib
AIN	Hyb 120.1.2.1.2 antibody	SIRNA-027
AIO	Hyb 120.1.2.1.2 antibody	decursin
AIP	Hyb 120.1.2.1.2 antibody	decursinol
AIQ	Hyb 120.1.2.1.2 antibody	picropodophyllin
AIR	Hyb 120.1.2.1.2 antibody	guggulsterone
AIS	Hyb 120.1.2.1.2 antibody	PLG101
AIT	Hyb 120.1.2.1.2 antibody	eicosanoid LXA4
AIU	Hyb 120.1.2.1.2 antibody	PTK787
AIV	Hyb 120.1.2.1.2 antibody	pazopanib
AIW	Hyb 120.1.2.1.2 antibody	axitinib
AIX	Hyb 120.1.2.1.2 antibody	CDDO-Me

AIY	Hyb 120.1.2.1.2 antibody	CDDO-Imm
AIZ	Hyb 120.1.2.1.2 antibody	shikonin
AJA	Hyb 120.1.2.1.2 antibody	beta-hydroxyisovalerylshikonin
AJB	Hyb 120.1.2.1.2 antibody	ganglioside GM3
AJC	Hyb 120.1.2.1.2 antibody	DC101 antibody
AJD	Hyb 120.1.2.1.2 antibody	Mab25 antibody
AJE	Hyb 120.1.2.1.2 antibody	Mab73 antibody
AJF	Hyb 120.1.2.1.2 antibody	4A5 antibody
AJG	Hyb 120.1.2.1.2 antibody	4E10 antibody
AJH	Hyb 120.1.2.1.2 antibody	5F12 antibody
AJI	Hyb 120.1.2.1.2 antibody	VA01 antibody
AJJ	Hyb 120.1.2.1.2 antibody	BL2 antibody
AJK	Hyb 120.1.2.1.2 antibody	VEGF-related protein
AJL	Hyb 120.1.2.1.2 antibody	sFLT01
AJM	Hyb 120.1.2.1.2 antibody	sFLT02
AJN	Hyb 120.1.2.1.2 antibody	Peptide B3
AJO	Hyb 120.1.2.1.2 antibody	TG100801
AJP	Hyb 120.1.2.1.2 antibody	sorafenib
AJQ	Hyb 120.1.2.1.2 antibody	G6-31 antibody
AJR	Hyb 121.6.1.1.1 antibody	ranibizumab
AJS	Hyb 121.6.1.1.1 antibody	bevacizumab
AJT	Hyb 121.6.1.1.1 antibody	aflibercept
AJU	Hyb 121.6.1.1.1 antibody	KH902 VEGF receptor-Fc fusion protein
AJV	Hyb 121.6.1.1.1 antibody	2C3 antibody
AJW	Hyb 121.6.1.1.1 antibody	ORA102
AJX	Hyb 121.6.1.1.1 antibody	pegaptanib
AJY	Hyb 121.6.1.1.1 antibody	bevasiranib
AJZ	Hyb 121.6.1.1.1 antibody	SIRNA-027
AKA	Hyb 121.6.1.1.1 antibody	decursin
AKB	Hyb 121.6.1.1.1 antibody	decursinol
AKC	Hyb 121.6.1.1.1 antibody	picropodophyllin
AKD	Hyb 121.6.1.1.1 antibody	guggulsterone
AKE	Hyb 121.6.1.1.1 antibody	PLG101
AKF	Hyb 121.6.1.1.1 antibody	eicosanoid LXA4
AKG	Hyb 121.6.1.1.1 antibody	PTK787
AKH	Hyb 121.6.1.1.1 antibody	pazopanib
AKI	Hyb 121.6.1.1.1 antibody	axitinib
AKJ	Hyb 121.6.1.1.1 antibody	CDDO-Me
AKK	Hyb 121.6.1.1.1 antibody	CDDO-Imm
AKL	Hyb 121.6.1.1.1 antibody	shikonin
AKM	Hyb 121.6.1.1.1 antibody	beta-hydroxyisovalerylshikonin

AKN	Hyb 121.6.1.1.1 antibody	ganglioside GM3
AKO	Hyb 121.6.1.1.1 antibody	DC101 antibody
AKP	Hyb 121.6.1.1.1 antibody	Mab25 antibody
AKQ	Hyb 121.6.1.1.1 antibody	Mab73 antibody
AKR	Hyb 121.6.1.1.1 antibody	4A5 antibody
AKS	Hyb 121.6.1.1.1 antibody	4E10 antibody
AKT	Hyb 121.6.1.1.1 antibody	5F12 antibody
AKU	Hyb 121.6.1.1.1 antibody	VA01 antibody
AKV	Hyb 121.6.1.1.1 antibody	BL2 antibody
AKW	Hyb 121.6.1.1.1 antibody	VEGF-related protein
AKX	Hyb 121.6.1.1.1 antibody	sFLT01
AKY	Hyb 121.6.1.1.1 antibody	sFLT02
AKZ	Hyb 121.6.1.1.1 antibody	Peptide B3
ALA	Hyb 121.6.1.1.1 antibody	TG100801
ALB	Hyb 121.6.1.1.1 antibody	sorafenib
ALC	Hyb 121.6.1.1.1 antibody	G6-31 antibody
ALD	Hyb 127.5.7.3.1 antibody	ranibizumab
ALE	Hyb 127.5.7.3.1 antibody	bevacizumab
ALF	Hyb 127.5.7.3.1 antibody	aflibercept
ALG	Hyb 127.5.7.3.1 antibody	KH902 VEGF receptor-Fc fusion protein
ALH	Hyb 127.5.7.3.1 antibody	2C3 antibody
ALI	Hyb 127.5.7.3.1 antibody	ORA102
ALJ	Hyb 127.5.7.3.1 antibody	pegaptanib
ALK	Hyb 127.5.7.3.1 antibody	bevasiranib
ALL	Hyb 127.5.7.3.1 antibody	SIRNA-027
ALM	Hyb 127.5.7.3.1 antibody	decursin
ALN	Hyb 127.5.7.3.1 antibody	decursinol
ALO	Hyb 127.5.7.3.1 antibody	picropodophyllin
ALP	Hyb 127.5.7.3.1 antibody	guggulsterone
ALQ	Hyb 127.5.7.3.1 antibody	PLG101
ALR	Hyb 127.5.7.3.1 antibody	eicosanoid LXA4
ALS	Hyb 127.5.7.3.1 antibody	PTK787
ALT	Hyb 127.5.7.3.1 antibody	pazopanib
ALU	Hyb 127.5.7.3.1 antibody	axitinib
ALV	Hyb 127.5.7.3.1 antibody	CDDO-Me
ALW	Hyb 127.5.7.3.1 antibody	CDDO-Imm
ALX	Hyb 127.5.7.3.1 antibody	shikonin
ALY	Hyb 127.5.7.3.1 antibody	beta-hydroxyisovalerylshikonin
ALZ	Hyb 127.5.7.3.1 antibody	ganglioside GM3
AMA	Hyb 127.5.7.3.1 antibody	DC101 antibody
AMB	Hyb 127.5.7.3.1 antibody	Mab25 antibody

AMC	Hyb 127.5.7.3.1 antibody	Mab73 antibody
AMD	Hyb 127.5.7.3.1 antibody	4A5 antibody
AME	Hyb 127.5.7.3.1 antibody	4E10 antibody
AMF	Hyb 127.5.7.3.1 antibody	5F12 antibody
AMG	Hyb 127.5.7.3.1 antibody	VA01 antibody
AMH	Hyb 127.5.7.3.1 antibody	BL2 antibody
AMI	Hyb 127.5.7.3.1 antibody	VEGF-related protein
AMJ	Hyb 127.5.7.3.1 antibody	sFLT01
AMK	Hyb 127.5.7.3.1 antibody	sFLT02
AML	Hyb 127.5.7.3.1 antibody	Peptide B3
AMM	Hyb 127.5.7.3.1 antibody	TG100801
AMN	Hyb 127.5.7.3.1 antibody	sorafenib
AMO	Hyb 127.5.7.3.1 antibody	G6-31 antibody
AMP	Hyb 127.8.2.2.2 antibody	ranibizumab
AMQ	Hyb 127.8.2.2.2 antibody	bevacizumab
AMR	Hyb 127.8.2.2.2 antibody	aflibercept
AMS	Hyb 127.8.2.2.2 antibody	KH902 VEGF receptor-Fc fusion protein
AMT	Hyb 127.8.2.2.2 antibody	2C3 antibody
AMU	Hyb 127.8.2.2.2 antibody	ORA102
AMV	Hyb 127.8.2.2.2 antibody	pegaptanib
AMW	Hyb 127.8.2.2.2 antibody	bevasiranib
AMX	Hyb 127.8.2.2.2 antibody	SIRNA-027
AMY	Hyb 127.8.2.2.2 antibody	decursin
AMZ	Hyb 127.8.2.2.2 antibody	decursinol
ANA	Hyb 127.8.2.2.2 antibody	picropodophyllin
ANB	Hyb 127.8.2.2.2 antibody	guggulsterone
ANC	Hyb 127.8.2.2.2 antibody	PLG101
AND	Hyb 127.8.2.2.2 antibody	eicosanoid LXA4
ANE	Hyb 127.8.2.2.2 antibody	PTK787
ANF	Hyb 127.8.2.2.2 antibody	pazopanib
ANG	Hyb 127.8.2.2.2 antibody	axitinib
ANH	Hyb 127.8.2.2.2 antibody	CDDO-Me
ANI	Hyb 127.8.2.2.2 antibody	CDDO-Imm
ANJ	Hyb 127.8.2.2.2 antibody	shikonin
ANK	Hyb 127.8.2.2.2 antibody	beta-hydroxyisovalerylshikonin
ANL	Hyb 127.8.2.2.2 antibody	ganglioside GM3
ANM	Hyb 127.8.2.2.2 antibody	DC101 antibody
ANN	Hyb 127.8.2.2.2 antibody	Mab25 antibody
ANO	Hyb 127.8.2.2.2 antibody	Mab73 antibody
ANP	Hyb 127.8.2.2.2 antibody	4A5 antibody
ANQ	Hyb 127.8.2.2.2 antibody	4E10 antibody

ANR	Hyb 127.8.2.2.2 antibody	5F12 antibody
ANS	Hyb 127.8.2.2.2 antibody	VA01 antibody
ANT	Hyb 127.8.2.2.2 antibody	BL2 antibody
ANU	Hyb 127.8.2.2.2 antibody	VEGF-related protein
ANV	Hyb 127.8.2.2.2 antibody	sFLT01
ANW	Hyb 127.8.2.2.2 antibody	sFLT02
ANX	Hyb 127.8.2.2.2 antibody	Peptide B3
ANY	Hyb 127.8.2.2.2 antibody	TG100801
ANZ	Hyb 127.8.2.2.2 antibody	sorafenib
AOA	Hyb 127.8.2.2.2 antibody	G6-31 antibody
AOB	Hyb 1.6.1 antibody	ranibizumab
AOC	Hyb 1.6.1 antibody	bevacizumab
AOD	Hyb 1.6.1 antibody	aflibercept
AOE	Hyb 1.6.1 antibody	KH902 VEGF receptor-Fc fusion protein
AOF	Hyb 1.6.1 antibody	2C3 antibody
AOG	Hyb 1.6.1 antibody	ORA102
AOH	Hyb 1.6.1 antibody	pegaptanib
AOI	Hyb 1.6.1 antibody	bevasiranib
AOJ	Hyb 1.6.1 antibody	SIRNA-027
AOK	Hyb 1.6.1 antibody	decursin
AOL	Hyb 1.6.1 antibody	decursinol
AOM	Hyb 1.6.1 antibody	picropodophyllin
AON	Hyb 1.6.1 antibody	guggulsterone
AOO	Hyb 1.6.1 antibody	PLG101
AOP	Hyb 1.6.1 antibody	eicosanoid LXA4
AOQ	Hyb 1.6.1 antibody	PTK787
AOR	Hyb 1.6.1 antibody	pazopanib
AOS	Hyb 1.6.1 antibody	axitinib
AOT	Hyb 1.6.1 antibody	CDDO-Me
AOU	Hyb 1.6.1 antibody	CDDO-Imm
AOV	Hyb 1.6.1 antibody	shikonin
AOW	Hyb 1.6.1 antibody	beta-hydroxyisovalerylshikonin
AOX	Hyb 1.6.1 antibody	ganglioside GM3
AOY	Hyb 1.6.1 antibody	DC101 antibody
AOZ	Hyb 1.6.1 antibody	Mab25 antibody
APA	Hyb 1.6.1 antibody	Mab73 antibody
APB	Hyb 1.6.1 antibody	4A5 antibody
APC	Hyb 1.6.1 antibody	4E10 antibody
APD	Hyb 1.6.1 antibody	5F12 antibody
APE	Hyb 1.6.1 antibody	VA01 antibody
APF	Hyb 1.6.1 antibody	BL2 antibody

APG	Hyb 1.6.1 antibody	VEGF-related protein
APH	Hyb 1.6.1 antibody	sFLT01
API	Hyb 1.6.1 antibody	sFLT02
APJ	Hyb 1.6.1 antibody	Peptide B3
APK	Hyb 1.6.1 antibody	TG100801
APL	Hyb 1.6.1 antibody	sorafenib
APM	Hyb 1.6.1 antibody	G6-31 antibody
APN	Hyb 1.11.1 antibody	ranibizumab
APO	Hyb 1.11.1 antibody	bevacizumab
APP	Hyb 1.11.1 antibody	aflibercept
APQ	Hyb 1.11.1 antibody	KH902 VEGF receptor-Fc fusion protein
APR	Hyb 1.11.1 antibody	2C3 antibody
APS	Hyb 1.11.1 antibody	ORA102
APT	Hyb 1.11.1 antibody	pegaptanib
APU	Hyb 1.11.1 antibody	bevasiranib
APV	Hyb 1.11.1 antibody	SIRNA-027
APW	Hyb 1.11.1 antibody	decursin
APX	Hyb 1.11.1 antibody	decursinol
APY	Hyb 1.11.1 antibody	picropodophyllin
APZ	Hyb 1.11.1 antibody	guggulsterone
AQA	Hyb 1.11.1 antibody	PLG101
AQB	Hyb 1.11.1 antibody	eicosanoid LXA4
AQC	Hyb 1.11.1 antibody	PTK787
AQD	Hyb 1.11.1 antibody	pazopanib
AQE	Hyb 1.11.1 antibody	axitinib
AQF	Hyb 1.11.1 antibody	CDDO-Me
AQG	Hyb 1.11.1 antibody	CDDO-Imm
AQH	Hyb 1.11.1 antibody	shikonin
AQI	Hyb 1.11.1 antibody	beta-hydroxyisovalerylshikonin
AQJ	Hyb 1.11.1 antibody	ganglioside GM3
AQK	Hyb 1.11.1 antibody	DC101 antibody
AQL	Hyb 1.11.1 antibody	Mab25 antibody
AQM	Hyb 1.11.1 antibody	Mab73 antibody
AQN	Hyb 1.11.1 antibody	4A5 antibody
AQO	Hyb 1.11.1 antibody	4E10 antibody
AQP	Hyb 1.11.1 antibody	5F12 antibody
AQQ	Hyb 1.11.1 antibody	VA01 antibody
AQR	Hyb 1.11.1 antibody	BL2 antibody
AQS	Hyb 1.11.1 antibody	VEGF-related protein
AQT	Hyb 1.11.1 antibody	sFLT01
AQU	Hyb 1.11.1 antibody	sFLT02

AQV	Hyb 1.11.1 antibody	Peptide B3
AQW	Hyb 1.11.1 antibody	TG100801
AQX	Hyb 1.11.1 antibody	sorafenib
AQY	Hyb 1.11.1 antibody	G6-31 antibody
AQZ	Hyb 1.17.1 antibody	ranibizumab
ARA	Hyb 1.17.1 antibody	bevacizumab
ARB	Hyb 1.17.1 antibody	aflibercept
ARC	Hyb 1.17.1 antibody	KH902 VEGF receptor-Fc fusion protein
ARD	Hyb 1.17.1 antibody	2C3 antibody
ARE	Hyb 1.17.1 antibody	ORA102
ARF	Hyb 1.17.1 antibody	pegaptanib
ARG	Hyb 1.17.1 antibody	bevasiranib
ARH	Hyb 1.17.1 antibody	SIRNA-027
ARI	Hyb 1.17.1 antibody	decursin
ARJ	Hyb 1.17.1 antibody	decursinol
ARK	Hyb 1.17.1 antibody	picropodophyllin
ARL	Hyb 1.17.1 antibody	guggulsterone
ARM	Hyb 1.17.1 antibody	PLG101
ARN	Hyb 1.17.1 antibody	eicosanoid LXA4
ARO	Hyb 1.17.1 antibody	PTK787
ARP	Hyb 1.17.1 antibody	pazopanib
ARQ	Hyb 1.17.1 antibody	axitinib
ARR	Hyb 1.17.1 antibody	CDDO-Me
ARS	Hyb 1.17.1 antibody	CDDO-Imm
ART	Hyb 1.17.1 antibody	shikonin
ARU	Hyb 1.17.1 antibody	beta-hydroxyisovalerylshikonin
ARV	Hyb 1.17.1 antibody	ganglioside GM3
ARW	Hyb 1.17.1 antibody	DC101 antibody
ARX	Hyb 1.17.1 antibody	Mab25 antibody
ARY	Hyb 1.17.1 antibody	Mab73 antibody
ARZ	Hyb 1.17.1 antibody	4A5 antibody
ASA	Hyb 1.17.1 antibody	4E10 antibody
ASB	Hyb 1.17.1 antibody	5F12 antibody
ASC	Hyb 1.17.1 antibody	VA01 antibody
ASD	Hyb 1.17.1 antibody	BL2 antibody
ASE	Hyb 1.17.1 antibody	VEGF-related protein
ASF	Hyb 1.17.1 antibody	sFLT01
ASG	Hyb 1.17.1 antibody	sFLT02
ASH	Hyb 1.17.1 antibody	Peptide B3
ASI	Hyb 1.17.1 antibody	TG100801
ASJ	Hyb 1.17.1 antibody	sorafenib

ASK	Hyb 1.17.1 antibody	G6-31 antibody
ASL	Hyb 1.18.1 antibody	ranibizumab
ASM	Hyb 1.18.1 antibody	bevacizumab
ASN	Hyb 1.18.1 antibody	aflibercept
ASO	Hyb 1.18.1 antibody	KH902 VEGF receptor-Fc fusion protein
ASP	Hyb 1.18.1 antibody	2C3 antibody
ASQ	Hyb 1.18.1 antibody	ORA102
ASR	Hyb 1.18.1 antibody	pegaptanib
ASS	Hyb 1.18.1 antibody	bevasiranib
AST	Hyb 1.18.1 antibody	SIRNA-027
ASU	Hyb 1.18.1 antibody	decursin
ASV	Hyb 1.18.1 antibody	decursinol
ASW	Hyb 1.18.1 antibody	picropodophyllin
ASX	Hyb 1.18.1 antibody	guggulsterone
ASY	Hyb 1.18.1 antibody	PLG101
ASZ	Hyb 1.18.1 antibody	eicosanoid LXA4
ATA	Hyb 1.18.1 antibody	PTK787
ATB	Hyb 1.18.1 antibody	pazopanib
ATC	Hyb 1.18.1 antibody	axitinib
ATD	Hyb 1.18.1 antibody	CDDO-Me
ATE	Hyb 1.18.1 antibody	CDDO-Imm
ATF	Hyb 1.18.1 antibody	shikonin
ATG	Hyb 1.18.1 antibody	beta-hydroxyisovalerylshikonin
ATH	Hyb 1.18.1 antibody	ganglioside GM3
ATI	Hyb 1.18.1 antibody	DC101 antibody
ATJ	Hyb 1.18.1 antibody	Mab25 antibody
ATK	Hyb 1.18.1 antibody	Mab73 antibody
ATL	Hyb 1.18.1 antibody	4A5 antibody
ATM	Hyb 1.18.1 antibody	4E10 antibody
ATN	Hyb 1.18.1 antibody	5F12 antibody
ATO	Hyb 1.18.1 antibody	VA01 antibody
ATP	Hyb 1.18.1 antibody	BL2 antibody
ATQ	Hyb 1.18.1 antibody	VEGF-related protein
ATR	Hyb 1.18.1 antibody	sFLT01
ATS	Hyb 1.18.1 antibody	sFLT02
ATT	Hyb 1.18.1 antibody	Peptide B3
ATU	Hyb 1.18.1 antibody	TG100801
ATV	Hyb 1.18.1 antibody	sorafenib
ATW	Hyb 1.18.1 antibody	G6-31 antibody
ATX	Hyb 1.19.1 antibody	ranibizumab
ATY	Hyb 1.19.1 antibody	bevacizumab

ATZ	Hyb 1.19.1 antibody	aflibercept
AUA	Hyb 1.19.1 antibody	KH902 VEGF receptor-Fc fusion protein
AUB	Hyb 1.19.1 antibody	2C3 antibody
AUC	Hyb 1.19.1 antibody	ORA102
AUD	Hyb 1.19.1 antibody	pegaptanib
AUE	Hyb 1.19.1 antibody	bevasiranib
AUF	Hyb 1.19.1 antibody	SIRNA-027
AUG	Hyb 1.19.1 antibody	decursin
AUH	Hyb 1.19.1 antibody	decursinol
AUI	Hyb 1.19.1 antibody	picropodophyllin
AUJ	Hyb 1.19.1 antibody	guggulsterone
AUK	Hyb 1.19.1 antibody	PLG101
AUL	Hyb 1.19.1 antibody	eicosanoid LXA4
AUM	Hyb 1.19.1 antibody	PTK787
AUN	Hyb 1.19.1 antibody	pazopanib
AUO	Hyb 1.19.1 antibody	axitinib
AUP	Hyb 1.19.1 antibody	CDDO-Me
AUQ	Hyb 1.19.1 antibody	CDDO-Imm
AUR	Hyb 1.19.1 antibody	shikonin
AUS	Hyb 1.19.1 antibody	beta-hydroxyisovalerylshikonin
AUT	Hyb 1.19.1 antibody	ganglioside GM3
AUU	Hyb 1.19.1 antibody	DC101 antibody
AUV	Hyb 1.19.1 antibody	Mab25 antibody
AUX	Hyb 1.19.1 antibody	Mab73 antibody
AUY	Hyb 1.19.1 antibody	4A5 antibody
AUZ	Hyb 1.19.1 antibody	4E10 antibody
AVA	Hyb 1.19.1 antibody	5F12 antibody
AVB	Hyb 1.19.1 antibody	VA01 antibody
AVC	Hyb 1.19.1 antibody	BL2 antibody
AVD	Hyb 1.19.1 antibody	VEGF-related protein
AVE	Hyb 1.19.1 antibody	sFLT01
AVF	Hyb 1.19.1 antibody	sFLT02
AVG	Hyb 1.19.1 antibody	Peptide B3
AVH	Hyb 1.19.1 antibody	TG100801
AVI	Hyb 1.19.1 antibody	sorafenib
AVJ	Hyb 1.19.1 antibody	G6-31 antibody
AVK	Hyb 1.23.1 antibody	ranibizumab
AVL	Hyb 1.23.1 antibody	bevacizumab
AVM	Hyb 1.23.1 antibody	aflibercept
AVN	Hyb 1.23.1 antibody	KH902 VEGF receptor-Fc fusion protein
AVO	Hyb 1.23.1 antibody	2C3 antibody

AVP	Hyb 1.23.1 antibody	ORA102
AVQ	Hyb 1.23.1 antibody	pegaptanib
AVR	Hyb 1.23.1 antibody	bevasiranib
AVS	Hyb 1.23.1 antibody	SIRNA-027
AVT	Hyb 1.23.1 antibody	decursin
AVU	Hyb 1.23.1 antibody	decursinol
AVV	Hyb 1.23.1 antibody	picropodophyllin
AVW	Hyb 1.23.1 antibody	guggulsterone
AVX	Hyb 1.23.1 antibody	PLG101
AVY	Hyb 1.23.1 antibody	eicosanoid LXA4
AVZ	Hyb 1.23.1 antibody	PTK787
AWA	Hyb 1.23.1 antibody	pazopanib
AWB	Hyb 1.23.1 antibody	axitinib
AWC	Hyb 1.23.1 antibody	CDDO-Me
AWD	Hyb 1.23.1 antibody	CDDO-Imm
AWE	Hyb 1.23.1 antibody	shikonin
AWF	Hyb 1.23.1 antibody	beta-hydroxyisovalerylshikonin
AWG	Hyb 1.23.1 antibody	ganglioside GM3
AWH	Hyb 1.23.1 antibody	DC101 antibody
AWI	Hyb 1.23.1 antibody	Mab25 antibody
AWJ	Hyb 1.23.1 antibody	Mab73 antibody
AWK	Hyb 1.23.1 antibody	4A5 antibody
AWL	Hyb 1.23.1 antibody	4E10 antibody
AWM	Hyb 1.23.1 antibody	5F12 antibody
AWN	Hyb 1.23.1 antibody	VA01 antibody
AWO	Hyb 1.23.1 antibody	BL2 antibody
AWP	Hyb 1.23.1 antibody	VEGF-related protein
AWQ	Hyb 1.23.1 antibody	sFLT01
AWR	Hyb 1.23.1 antibody	sFLT02
AWS	Hyb 1.23.1 antibody	Peptide B3
AWT	Hyb 1.23.1 antibody	TG100801
AWU	Hyb 1.23.1 antibody	sorafenib
AWV	Hyb 1.23.1 antibody	G6-31 antibody
AWW	Hyb 1.24 antibody	ranibizumab
AWX	Hyb 1.24 antibody	bevacizumab
AWY	Hyb 1.24 antibody	aflibercept
AWZ	Hyb 1.24 antibody	KH902 VEGF receptor-Fc fusion protein
AXA	Hyb 1.24 antibody	2C3 antibody
AXB	Hyb 1.24 antibody	ORA102
AXC	Hyb 1.24 antibody	pegaptanib
AXD	Hyb 1.24 antibody	bevasiranib

AXE	Hyb 1.24 antibody	SIRNA-027
AXF	Hyb 1.24 antibody	decursin
AXG	Hyb 1.24 antibody	decursinol
AXH	Hyb 1.24 antibody	picropodophyllin
AXI	Hyb 1.24 antibody	guggulsterone
AXJ	Hyb 1.24 antibody	PLG101
AXK	Hyb 1.24 antibody	eicosanoid LXA4
AXL	Hyb 1.24 antibody	PTK787
AXM	Hyb 1.24 antibody	pazopanib
AXN	Hyb 1.24 antibody	axitinib
AXO	Hyb 1.24 antibody	CDDO-Me
AXP	Hyb 1.24 antibody	CDDO-Imm
AXQ	Hyb 1.24 antibody	shikonin
AXR	Hyb 1.24 antibody	beta-hydroxyisovalerylshikonin
AXS	Hyb 1.24 antibody	ganglioside GM3
AXT	Hyb 1.24 antibody	DC101 antibody
AXU	Hyb 1.24 antibody	Mab25 antibody
AXV	Hyb 1.24 antibody	Mab73 antibody
AXW	Hyb 1.24 antibody	4A5 antibody
AXX	Hyb 1.24 antibody	4E10 antibody
AXY	Hyb 1.24 antibody	5F12 antibody
AXZ	Hyb 1.24 antibody	VA01 antibody
AYA	Hyb 1.24 antibody	BL2 antibody
AYB	Hyb 1.24 antibody	VEGF-related protein
AYC	Hyb 1.24 antibody	sFLT01
AYD	Hyb 1.24 antibody	sFLT02
AYE	Hyb 1.24 antibody	Peptide B3
AYF	Hyb 1.24 antibody	TG100801
AYG	Hyb 1.24 antibody	sorafenib
AYH	Hyb 1.24 antibody	G6-31 antibody
AYI	Hyb 1.25 antibody	ranibizumab
AYJ	Hyb 1.25 antibody	bevacizumab
AYK	Hyb 1.25 antibody	aflibercept
AYL	Hyb 1.25 antibody	KH902 VEGF receptor-Fc fusion protein
AYM	Hyb 1.25 antibody	2C3 antibody
AYN	Hyb 1.25 antibody	ORA102
AYO	Hyb 1.25 antibody	pegaptanib
AYP	Hyb 1.25 antibody	bevasiranib
AYQ	Hyb 1.25 antibody	SIRNA-027
AYR	Hyb 1.25 antibody	decursin
AYS	Hyb 1.25 antibody	decursinol

AYT	Hyb 1.25 antibody	picropodophyllin
AYU	Hyb 1.25 antibody	guggulsterone
AYV	Hyb 1.25 antibody	PLG101
AYW	Hyb 1.25 antibody	eicosanoid LXA4
AYX	Hyb 1.25 antibody	PTK787
AYY	Hyb 1.25 antibody	pazopanib
AYZ	Hyb 1.25 antibody	axitinib
AZA	Hyb 1.25 antibody	CDDO-Me
AZB	Hyb 1.25 antibody	CDDO-Imm
AZC	Hyb 1.25 antibody	shikonin
AZD	Hyb 1.25 antibody	beta-hydroxyisovalerylshikonin
AZE	Hyb 1.25 antibody	ganglioside GM3
AZF	Hyb 1.25 antibody	DC101 antibody
AZG	Hyb 1.25 antibody	Mab25 antibody
AZH	Hyb 1.25 antibody	Mab73 antibody
AZI	Hyb 1.25 antibody	4A5 antibody
AZJ	Hyb 1.25 antibody	4E10 antibody
AZK	Hyb 1.25 antibody	5F12 antibody
AZL	Hyb 1.25 antibody	VA01 antibody
AZM	Hyb 1.25 antibody	BL2 antibody
AZN	Hyb 1.25 antibody	VEGF-related protein
AZO	Hyb 1.25 antibody	sFLT01
AZP	Hyb 1.25 antibody	sFLT02
AZQ	Hyb 1.25 antibody	Peptide B3
AZR	Hyb 1.25 antibody	TG100801
AZS	Hyb 1.25 antibody	sorafenib
AZT	Hyb 1.25 antibody	G6-31 antibody
AZU	Hyb 1.29 antibody	ranibizumab
AZV	Hyb 1.29 antibody	bevacizumab
AZW	Hyb 1.29 antibody	aflibercept
AZX	Hyb 1.29 antibody	KH902 VEGF receptor-Fc fusion protein
AZY	Hyb 1.29 antibody	2C3 antibody
AZZ	Hyb 1.29 antibody	ORA102
BAA	Hyb 1.29 antibody	pegaptanib
BAB	Hyb 1.29 antibody	bevasiranib
BAC	Hyb 1.29 antibody	SIRNA-027
BAD	Hyb 1.29 antibody	decursin
BAE	Hyb 1.29 antibody	decursinol
BAF	Hyb 1.29 antibody	picropodophyllin
BAG	Hyb 1.29 antibody	guggulsterone
BAH	Hyb 1.29 antibody	PLG101

BAI	Hyb 1.29 antibody	eicosanoid LXA4
BAJ	Hyb 1.29 antibody	PTK787
BAK	Hyb 1.29 antibody	pazopanib
BAL	Hyb 1.29 antibody	axitinib
BAM	Hyb 1.29 antibody	CDDO-Me
BAN	Hyb 1.29 antibody	CDDO-Imm
BAO	Hyb 1.29 antibody	shikonin
BAP	Hyb 1.29 antibody	beta-hydroxyisovalerylshikonin
BAQ	Hyb 1.29 antibody	ganglioside GM3
BAR	Hyb 1.29 antibody	DC101 antibody
ABS	Hyb 1.29 antibody	Mab25 antibody
BAT	Hyb 1.29 antibody	Mab73 antibody
BAU	Hyb 1.29 antibody	4A5 antibody
BAV	Hyb 1.29 antibody	4E10 antibody
BAW	Hyb 1.29 antibody	5F12 antibody
BAX	Hyb 1.29 antibody	VA01 antibody
BAY	Hyb 1.29 antibody	BL2 antibody
BAZ	Hyb 1.29 antibody	VEGF-related protein
BBA	Hyb 1.29 antibody	sFLT01
BBB	Hyb 1.29 antibody	sFLT02
BBC	Hyb 1.29 antibody	Peptide B3
BBD	Hyb 1.29 antibody	TG100801
BBE	Hyb 1.29 antibody	sorafenib
BBF	Hyb 1.29 antibody	G6-31 antibody
BBG	Hyb 1.33 antibody	ranibizumab
BBH	Hyb 1.33 antibody	bevacizumab
BBI	Hyb 1.33 antibody	aflibercept
BBJ	Hyb 1.33 antibody	KH902 VEGF receptor-Fc fusion protein
BBK	Hyb 1.33 antibody	2C3 antibody
BBL	Hyb 1.33 antibody	ORA102
BBM	Hyb 1.33 antibody	pegaptanib
BBN	Hyb 1.33 antibody	bevasiranib
BBO	Hyb 1.33 antibody	SIRNA-027
BBP	Hyb 1.33 antibody	decursin
BBQ	Hyb 1.33 antibody	decursinol
BBR	Hyb 1.33 antibody	picropodophyllin
BBS	Hyb 1.33 antibody	guggulsterone
BBT	Hyb 1.33 antibody	PLG101
BBU	Hyb 1.33 antibody	eicosanoid LXA4
BBV	Hyb 1.33 antibody	PTK787
BBW	Hyb 1.33 antibody	pazopanib

BBX	Hyb 1.33 antibody	axitinib
BBY	Hyb 1.33 antibody	CDDO-Me
BBZ	Hyb 1.33 antibody	CDDO-Imm
BCA	Hyb 1.33 antibody	shikonin
BCB	Hyb 1.33 antibody	beta-hydroxyisovalerylshikonin
BCC	Hyb 1.33 antibody	ganglioside GM3
BCD	Hyb 1.33 antibody	DC101 antibody
BCE	Hyb 1.33 antibody	Mab25 antibody
BCF	Hyb 1.33 antibody	Mab73 antibody
BCG	Hyb 1.33 antibody	4A5 antibody
BCH	Hyb 1.33 antibody	4E10 antibody
BCI	Hyb 1.33 antibody	5F12 antibody
BCJ	Hyb 1.33 antibody	VA01 antibody
BCK	Hyb 1.33 antibody	BL2 antibody
BCL	Hyb 1.33 antibody	VEGF-related protein
BCM	Hyb 1.33 antibody	sFLT01
BCN	Hyb 1.33 antibody	sFLT02
BCO	Hyb 1.33 antibody	Peptide B3
BCP	Hyb 1.33 antibody	TG100801
BCQ	Hyb 1.33 antibody	sorafenib
BCR	Hyb 1.33 antibody	G6-31 antibody
BCS	Hyb 1.38 antibody	ranibizumab
BCT	Hyb 1.38 antibody	bevacizumab
BCU	Hyb 1.38 antibody	aflibercept
BCV	Hyb 1.38 antibody	KH902 VEGF receptor-Fc fusion protein
BCW	Hyb 1.38 antibody	2C3 antibody
BCX	Hyb 1.38 antibody	ORA102
BCY	Hyb 1.38 antibody	pegaptanib
BCZ	Hyb 1.38 antibody	bevasiranib
BDA	Hyb 1.38 antibody	SIRNA-027
BDB	Hyb 1.38 antibody	decursin
BDC	Hyb 1.38 antibody	decursinol
BDD	Hyb 1.38 antibody	picropodophyllin
BDE	Hyb 1.38 antibody	guggulsterone
BDF	Hyb 1.38 antibody	PLG101
BDG	Hyb 1.38 antibody	eicosanoid LXA4
BDH	Hyb 1.38 antibody	PTK787
BDI	Hyb 1.38 antibody	pazopanib
BDJ	Hyb 1.38 antibody	axitinib
BDK	Hyb 1.38 antibody	CDDO-Me
BDL	Hyb 1.38 antibody	CDDO-Imm

BDM	Hyb 1.38 antibody	shikonin
BDN	Hyb 1.38 antibody	beta-hydroxyisovalerylshikonin
BDO	Hyb 1.38 antibody	ganglioside GM3
BDP	Hyb 1.38 antibody	DC101 antibody
BDQ	Hyb 1.38 antibody	Mab25 antibody
BDR	Hyb 1.38 antibody	Mab73 antibody
BDS	Hyb 1.38 antibody	4A5 antibody
BDT	Hyb 1.38 antibody	4E10 antibody
BDU	Hyb 1.38 antibody	5F12 antibody
BDV	Hyb 1.38 antibody	VA01 antibody
BDW	Hyb 1.38 antibody	BL2 antibody
BDX	Hyb 1.38 antibody	VEGF-related protein
BDY	Hyb 1.38 antibody	sFLT01
BDZ	Hyb 1.38 antibody	sFLT02
BEA	Hyb 1.38 antibody	Peptide B3
BEB	Hyb 1.38 antibody	TG100801
BEC	Hyb 1.38 antibody	sorafenib
BED	Hyb 1.38 antibody	G6-31 antibody
BEF	Hyb 1.39 antibody	ranibizumab
BEG	Hyb 1.39 antibody	bevacizumab
BEH	Hyb 1.39 antibody	aflibercept
BEI	Hyb 1.39 antibody	KH902 VEGF receptor-Fc fusion protein
BEJ	Hyb 1.39 antibody	2C3 antibody
BEK	Hyb 1.39 antibody	ORA102
BEL	Hyb 1.39 antibody	pegaptanib
BEM	Hyb 1.39 antibody	bevasiranib
BEN	Hyb 1.39 antibody	SIRNA-027
BEO	Hyb 1.39 antibody	decursin
BEP	Hyb 1.39 antibody	decursinol
BEQ	Hyb 1.39 antibody	picropodophyllin
BER	Hyb 1.39 antibody	guggulsterone
BES	Hyb 1.39 antibody	PLG101
BET	Hyb 1.39 antibody	eicosanoid LXA4
BEU	Hyb 1.39 antibody	PTK787
BEV	Hyb 1.39 antibody	pazopanib
BEW	Hyb 1.39 antibody	axitinib
BEX	Hyb 1.39 antibody	CDDO-Me
BEY	Hyb 1.39 antibody	CDDO-Imm
BEZ	Hyb 1.39 antibody	shikonin
BFA	Hyb 1.39 antibody	beta-hydroxyisovalerylshikonin
BFB	Hyb 1.39 antibody	ganglioside GM3

BFC	Hyb 1.39 antibody	DC101 antibody
BFD	Hyb 1.39 antibody	Mab25 antibody
BFE	Hyb 1.39 antibody	Mab73 antibody
BFF	Hyb 1.39 antibody	4A5 antibody
BFG	Hyb 1.39 antibody	4E10 antibody
BFH	Hyb 1.39 antibody	5F12 antibody
BFI	Hyb 1.39 antibody	VA01 antibody
BFJ	Hyb 1.39 antibody	BL2 antibody
BFK	Hyb 1.39 antibody	VEGF-related protein
BFL	Hyb 1.39 antibody	sFLT01
BFM	Hyb 1.39 antibody	sFLT02
BFN	Hyb 1.39 antibody	Peptide B3
BFO	Hyb 1.39 antibody	TG100801
BFP	Hyb 1.39 antibody	sorafenib
BFQ	Hyb 1.39 antibody	G6-31 antibody
BFR	Hyb 1.40 antibody	ranibizumab
BFS	Hyb 1.40 antibody	bevacizumab
BFT	Hyb 1.40 antibody	aflibercept
BFU	Hyb 1.40 antibody	KH902 VEGF receptor-Fc fusion protein
BFV	Hyb 1.40 antibody	2C3 antibody
BFW	Hyb 1.40 antibody	ORA102
BFX	Hyb 1.40 antibody	pegaptanib
BFY	Hyb 1.40 antibody	bevasiranib
BFZ	Hyb 1.40 antibody	SIRNA-027
BGA	Hyb 1.40 antibody	decursin
BGB	Hyb 1.40 antibody	decursinol
BGC	Hyb 1.40 antibody	picropodophyllin
BGD	Hyb 1.40 antibody	guggulsterone
BGE	Hyb 1.40 antibody	PLG101
BGF	Hyb 1.40 antibody	eicosanoid LXA4
BGG	Hyb 1.40 antibody	PTK787
BGH	Hyb 1.40 antibody	pazopanib
BGI	Hyb 1.40 antibody	axitinib
BGJ	Hyb 1.40 antibody	CDDO-Me
BGK	Hyb 1.40 antibody	CDDO-Imm
BGL	Hyb 1.40 antibody	shikonin
BGM	Hyb 1.40 antibody	beta-hydroxyisovalerylshikonin
BGN	Hyb 1.40 antibody	ganglioside GM3
BGO	Hyb 1.40 antibody	DC101 antibody
BGP	Hyb 1.40 antibody	Mab25 antibody
BGBGQ	Hyb 1.40 antibody	Mab73 antibody

BGR	Hyb 1.40 antibody	4A5 antibody
BGS	Hyb 1.40 antibody	4E10 antibody
BGT	Hyb 1.40 antibody	5F12 antibody
BGU	Hyb 1.40 antibody	VA01 antibody
BGV	Hyb 1.40 antibody	BL2 antibody
BGW	Hyb 1.40 antibody	VEGF-related protein
BGX	Hyb 1.40 antibody	sFLT01
BGY	Hyb 1.40 antibody	sFLT02
BGZ	Hyb 1.40 antibody	Peptide B3
BHA	Hyb 1.40 antibody	TG100801
BHB	Hyb 1.40 antibody	sorafenib
BHC	Hyb 1.40 antibody	G6-31 antibody
BHD	Hyb 1.45 antibody	ranibizumab
BHE	Hyb 1.45 antibody	bevacizumab
BHF	Hyb 1.45 antibody	aflibercept
BHG	Hyb 1.45 antibody	KH902 VEGF receptor-Fc fusion protein
BHH	Hyb 1.45 antibody	2C3 antibody
BHI	Hyb 1.45 antibody	ORA102
BHJ	Hyb 1.45 antibody	pegaptanib
BHK	Hyb 1.45 antibody	bevasiranib
BHL	Hyb 1.45 antibody	SIRNA-027
BHM	Hyb 1.45 antibody	decursin
BHN	Hyb 1.45 antibody	decursinol
BHO	Hyb 1.45 antibody	picropodophyllin
BHP	Hyb 1.45 antibody	guggulsterone
BHQ	Hyb 1.45 antibody	PLG101
BHR	Hyb 1.45 antibody	eicosanoid LXA4
BHS	Hyb 1.45 antibody	PTK787
BHT	Hyb 1.45 antibody	pazopanib
BHU	Hyb 1.45 antibody	axitinib
BHV	Hyb 1.45 antibody	CDDO-Me
BHW	Hyb 1.45 antibody	CDDO-Imm
BHX	Hyb 1.45 antibody	shikonin
BHY	Hyb 1.45 antibody	beta-hydroxyisovalerylshikonin
BHZ	Hyb 1.45 antibody	ganglioside GM3
BIA	Hyb 1.45 antibody	DC101 antibody
BIB	Hyb 1.45 antibody	Mab25 antibody
BIC	Hyb 1.45 antibody	Mab73 antibody
BID	Hyb 1.45 antibody	4A5 antibody
BIE	Hyb 1.45 antibody	4E10 antibody
BIF	Hyb 1.45 antibody	5F12 antibody

BIG	Hyb 1.45 antibody	VA01 antibody
BIH	Hyb 1.45 antibody	BL2 antibody
BIJ	Hyb 1.45 antibody	VEGF-related protein
BIK	Hyb 1.45 antibody	sFLT01
BIL	Hyb 1.45 antibody	sFLT02
BIM	Hyb 1.45 antibody	Peptide B3
BIN	Hyb 1.45 antibody	TG100801
BIO	Hyb 1.45 antibody	sorafenib
BIP	Hyb 1.45 antibody	G6-31 antibody
BIQ	Hyb 1.46 antibody	ranibizumab
BIR	Hyb 1.46 antibody	bevacizumab
BIS	Hyb 1.46 antibody	aflibercept
BIT	Hyb 1.46 antibody	KH902 VEGF receptor-Fc fusion protein
BIU	Hyb 1.46 antibody	2C3 antibody
BIV	Hyb 1.46 antibody	ORA102
BIW	Hyb 1.46 antibody	pegaptanib
BIX	Hyb 1.46 antibody	bevasiranib
BIY	Hyb 1.46 antibody	SIRNA-027
BIZ	Hyb 1.46 antibody	decursin
BJA	Hyb 1.46 antibody	decursinol
BJB	Hyb 1.46 antibody	picropodophyllin
BJC	Hyb 1.46 antibody	guggulsterone
BJD	Hyb 1.46 antibody	PLG101
BJE	Hyb 1.46 antibody	eicosanoid LXA4
BJF	Hyb 1.46 antibody	PTK787
BJG	Hyb 1.46 antibody	pazopanib
BJH	Hyb 1.46 antibody	axitinib
BJI	Hyb 1.46 antibody	CDDO-Me
BJJ	Hyb 1.46 antibody	CDDO-Imm
BJK	Hyb 1.46 antibody	shikonin
BJL	Hyb 1.46 antibody	beta-hydroxyisovalerylshikonin
BJM	Hyb 1.46 antibody	ganglioside GM3
BJN	Hyb 1.46 antibody	DC101 antibody
BJO	Hyb 1.46 antibody	Mab25 antibody
BJP	Hyb 1.46 antibody	Mab73 antibody
BJQ	Hyb 1.46 antibody	4A5 antibody
BJR	Hyb 1.46 antibody	4E10 antibody
BJS	Hyb 1.46 antibody	5F12 antibody
BJT	Hyb 1.46 antibody	VA01 antibody
BJU	Hyb 1.46 antibody	BL2 antibody
BJV	Hyb 1.46 antibody	VEGF-related protein

BJW	Hyb 1.46 antibody	sFLT01
BJX	Hyb 1.46 antibody	sFLT02
BJY	Hyb 1.46 antibody	Peptide B3
BJZ	Hyb 1.46 antibody	TG100801
BKA	Hyb 1.46 antibody	sorafenib
BKB	Hyb 1.46 antibody	G6-31 antibody
BKC	Hyb 1.48 antibody	ranibizumab
BKD	Hyb 1.48 antibody	bevacizumab
BKE	Hyb 1.48 antibody	aflibercept
BKF	Hyb 1.48 antibody	KH902 VEGF receptor-Fc fusion protein
BKG	Hyb 1.48 antibody	2C3 antibody
BKH	Hyb 1.48 antibody	ORA102
BKI	Hyb 1.48 antibody	pegaptanib
BKJ	Hyb 1.48 antibody	bevasiranib
BKK	Hyb 1.48 antibody	SIRNA-027
BKL	Hyb 1.48 antibody	decursin
BKM	Hyb 1.48 antibody	decursinol
BKN	Hyb 1.48 antibody	picropodophyllin
BKO	Hyb 1.48 antibody	guggulsterone
BKP	Hyb 1.48 antibody	PLG101
BKQ	Hyb 1.48 antibody	eicosanoid LXA4
BKR	Hyb 1.48 antibody	PTK787
BKS	Hyb 1.48 antibody	pazopanib
BKT	Hyb 1.48 antibody	axitinib
BKU	Hyb 1.48 antibody	CDDO-Me
BKV	Hyb 1.48 antibody	CDDO-Imm
BKW	Hyb 1.48 antibody	shikonin
BKX	Hyb 1.48 antibody	beta-hydroxyisovalerylshikonin
BKY	Hyb 1.48 antibody	ganglioside GM3
BKZ	Hyb 1.48 antibody	DC101 antibody
BLA	Hyb 1.48 antibody	Mab25 antibody
BLB	Hyb 1.48 antibody	Mab73 antibody
BLC	Hyb 1.48 antibody	4A5 antibody
BLD	Hyb 1.48 antibody	4E10 antibody
BLE	Hyb 1.48 antibody	5F12 antibody
BLF	Hyb 1.48 antibody	VA01 antibody
BLG	Hyb 1.48 antibody	BL2 antibody
BLH	Hyb 1.48 antibody	VEGF-related protein
BLI	Hyb 1.48 antibody	sFLT01
BLJ	Hyb 1.48 antibody	sFLT02
BLK	Hyb 1.48 antibody	Peptide B3

BLL	Hyb 1.48 antibody	TG100801
BLM	Hyb 1.48 antibody	sorafenib
BLN	Hyb 1.48 antibody	G6-31 antibody
BLO	Hyb 1.49 antibody	ranibizumab
BLP	Hyb 1.49 antibody	bevacizumab
BLQ	Hyb 1.49 antibody	aflibercept
BLR	Hyb 1.49 antibody	KH902 VEGF receptor-Fc fusion protein
BLS	Hyb 1.49 antibody	2C3 antibody
BLT	Hyb 1.49 antibody	ORA102
BLU	Hyb 1.49 antibody	pegaptanib
BLV	Hyb 1.49 antibody	bevasiranib
BLW	Hyb 1.49 antibody	SIRNA-027
BLX	Hyb 1.49 antibody	decursin
BLY	Hyb 1.49 antibody	decursinol
BLZ	Hyb 1.49 antibody	picropodophyllin
BMA	Hyb 1.49 antibody	guggulsterone
BMB	Hyb 1.49 antibody	PLG101
BMC	Hyb 1.49 antibody	eicosanoid LXA4
BMD	Hyb 1.49 antibody	PTK787
BME	Hyb 1.49 antibody	pazopanib
BMF	Hyb 1.49 antibody	axitinib
BMG	Hyb 1.49 antibody	CDDO-Me
BMH	Hyb 1.49 antibody	CDDO-Imm
BMI	Hyb 1.49 antibody	shikonin
BMJ	Hyb 1.49 antibody	beta-hydroxyisovalerylshikonin
BMK	Hyb 1.49 antibody	ganglioside GM3
BML	Hyb 1.49 antibody	DC101 antibody
BMM	Hyb 1.49 antibody	Mab25 antibody
BMN	Hyb 1.49 antibody	Mab73 antibody
BMO	Hyb 1.49 antibody	4A5 antibody
BMP	Hyb 1.49 antibody	4E10 antibody
BMQ	Hyb 1.49 antibody	5F12 antibody
BMR	Hyb 1.49 antibody	VA01 antibody
BMS	Hyb 1.49 antibody	BL2 antibody
BMT	Hyb 1.49 antibody	VEGF-related protein
BMU	Hyb 1.49 antibody	sFLT01
BMV	Hyb 1.49 antibody	sFLT02
BMW	Hyb 1.49 antibody	Peptide B3
BMX	Hyb 1.49 antibody	TG100801
BMY	Hyb 1.49 antibody	sorafenib
BMZ	Hyb 1.49 antibody	G6-31 antibody

BNA	Hyb 1.51 antibody	ranibizumab
BNB	Hyb 1.51 antibody	bevacizumab
BNC	Hyb 1.51 antibody	aflibercept
BND	Hyb 1.51 antibody	KH902 VEGF receptor-Fc fusion protein
BNE	Hyb 1.51 antibody	2C3 antibody
BNF	Hyb 1.51 antibody	ORA102
BNG	Hyb 1.51 antibody	pegaptanib
BNH	Hyb 1.51 antibody	bevasiranib
BNI	Hyb 1.51 antibody	SIRNA-027
BNJ	Hyb 1.51 antibody	decursin
BNK	Hyb 1.51 antibody	decursinol
BNL	Hyb 1.51 antibody	picropodophyllin
BNM	Hyb 1.51 antibody	guggulsterone
BNN	Hyb 1.51 antibody	PLG101
BNO	Hyb 1.51 antibody	eicosanoid LXA4
BNP	Hyb 1.51 antibody	PTK787
BNQ	Hyb 1.51 antibody	pazopanib
BNR	Hyb 1.51 antibody	axitinib
BNS	Hyb 1.51 antibody	CDDO-Me
BNT	Hyb 1.51 antibody	CDDO-Imm
BNU	Hyb 1.51 antibody	shikonin
BNV	Hyb 1.51 antibody	beta-hydroxyisovalerylshikonin
BNW	Hyb 1.51 antibody	ganglioside GM3
BNX	Hyb 1.51 antibody	DC101 antibody
BNY	Hyb 1.51 antibody	Mab25 antibody
BNZ	Hyb 1.51 antibody	Mab73 antibody
BOA	Hyb 1.51 antibody	4A5 antibody
BOB	Hyb 1.51 antibody	4E10 antibody
BOC	Hyb 1.51 antibody	5F12 antibody
BOD	Hyb 1.51 antibody	VA01 antibody
BOE	Hyb 1.51 antibody	BL2 antibody
BOF	Hyb 1.51 antibody	VEGF-related protein
BOG	Hyb 1.51 antibody	sFLT01
BOH	Hyb 1.51 antibody	sFLT02
BOI	Hyb 1.51 antibody	Peptide B3
BOJ	Hyb 1.51 antibody	TG100801
BOK	Hyb 1.51 antibody	sorafenib
BOL	Hyb 1.51 antibody	G6-31 antibody
BOM	Hyb 6.4.1 antibody	ranibizumab
BON	Hyb 6.4.1 antibody	bevacizumab
BOP	Hyb 6.4.1 antibody	aflibercept

BOQ	Hyb 6.4.1 antibody	KH902 VEGF receptor-Fc fusion protein
BOR	Hyb 6.4.1 antibody	2C3 antibody
BOS	Hyb 6.4.1 antibody	ORA102
BOT	Hyb 6.4.1 antibody	pegaptanib
BOU	Hyb 6.4.1 antibody	bevasiranib
BOV	Hyb 6.4.1 antibody	SIRNA-027
BOW	Hyb 6.4.1 antibody	decursin
BOX	Hyb 6.4.1 antibody	decursinol
BOY	Hyb 6.4.1 antibody	picropodophyllin
BOZ	Hyb 6.4.1 antibody	guggulsterone
BPA	Hyb 6.4.1 antibody	PLG101
BPB	Hyb 6.4.1 antibody	eicosanoid LXA4
BPC	Hyb 6.4.1 antibody	PTK787
BPD	Hyb 6.4.1 antibody	pazopanib
BPE	Hyb 6.4.1 antibody	axitinib
BPF	Hyb 6.4.1 antibody	CDDO-Me
BPG	Hyb 6.4.1 antibody	CDDO-Imm
BPH	Hyb 6.4.1 antibody	shikonin
BPI	Hyb 6.4.1 antibody	beta-hydroxyisovalerylshikonin
BPJ	Hyb 6.4.1 antibody	ganglioside GM3
BPK	Hyb 6.4.1 antibody	DC101 antibody
BPL	Hyb 6.4.1 antibody	Mab25 antibody
BPM	Hyb 6.4.1 antibody	Mab73 antibody
BPN	Hyb 6.4.1 antibody	4A5 antibody
BPO	Hyb 6.4.1 antibody	4E10 antibody
BPP	Hyb 6.4.1 antibody	5F12 antibody
BPQ	Hyb 6.4.1 antibody	VA01 antibody
BPR	Hyb 6.4.1 antibody	BL2 antibody
BPS	Hyb 6.4.1 antibody	VEGF-related protein
BPT	Hyb 6.4.1 antibody	sFLT01
BPU	Hyb 6.4.1 antibody	sFLT02
BPV	Hyb 6.4.1 antibody	Peptide B3
BPW	Hyb 6.4.1 antibody	TG100801
BPX	Hyb 6.4.1 antibody	sorafenib
BPY	Hyb 6.4.1 antibody	G6-31 antibody
BPZ	F3 antibody	ranibizumab
BQA	F3 antibody	bevacizumab
BQB	F3 antibody	aflibercept
BQC	F3 antibody	KH902 VEGF receptor-Fc fusion protein
BQD	F3 antibody	2C3 antibody
BQE	F3 antibody	ORA102

BQF	F3 antibody	pegaptanib
BQG	F3 antibody	bevasiranib
BQH	F3 antibody	SIRNA-027
BQI	F3 antibody	decursin
BQJ	F3 antibody	decursinol
BQK	F3 antibody	picropodophyllin
BQL	F3 antibody	guggulsterone
BQM	F3 antibody	PLG101
BQN	F3 antibody	eicosanoid LXA4
BQO	F3 antibody	PTK787
BQP	F3 antibody	pazopanib
BQQ	F3 antibody	axitinib
BQR	F3 antibody	CDDO-Me
BQS	F3 antibody	CDDO-Imm
BQT	F3 antibody	shikonin
BQU	F3 antibody	beta-hydroxyisovalerylshikonin
BQV	F3 antibody	ganglioside GM3
BQW	F3 antibody	DC101 antibody
BQX	F3 antibody	Mab25 antibody
BQY	F3 antibody	Mab73 antibody
BQZ	F3 antibody	4A5 antibody
BRA	F3 antibody	4E10 antibody
BRB	F3 antibody	5F12 antibody
BRC	F3 antibody	VA01 antibody
BRD	F3 antibody	BL2 antibody
BRE	F3 antibody	VEGF-related protein
BRF	F3 antibody	sFLT01
BRG	F3 antibody	sFLT02
BRH	F3 antibody	Peptide B3
BRI	F3 antibody	TG100801
BRJ	F3 antibody	sorafenib
BRK	F3 antibody	G6-31 antibody
BRL	Humanized F3 antibody	ranibizumab
BRM	Humanized F3 antibody	bevacizumab
BRN	Humanized F3 antibody	aflibercept
BRO	Humanized F3 antibody	KH902 VEGF receptor-Fc fusion protein
BRP	Humanized F3 antibody	2C3 antibody
BRQ	Humanized F3 antibody	ORA102
BRR	Humanized F3 antibody	pegaptanib
BRS	Humanized F3 antibody	bevasiranib
BRT	Humanized F3 antibody	SIRNA-027

BRU	Humanized F3 antibody	decursin
BRV	Humanized F3 antibody	decursinol
BRW	Humanized F3 antibody	picropodophyllin
BRX	Humanized F3 antibody	guggulsterone
BRY	Humanized F3 antibody	PLG101
BRZ	Humanized F3 antibody	eicosanoid LXA4
BSA	Humanized F3 antibody	PTK787
BSB	Humanized F3 antibody	pazopanib
BSC	Humanized F3 antibody	axitinib
BSD	Humanized F3 antibody	CDDO-Me
BSE	Humanized F3 antibody	CDDO-Imm
BSF	Humanized F3 antibody	shikonin
BSG	Humanized F3 antibody	beta-hydroxyisovalerylshikonin
BSH	Humanized F3 antibody	ganglioside GM3
BSI	Humanized F3 antibody	DC101 antibody
BSJ	Humanized F3 antibody	Mab25 antibody
BSK	Humanized F3 antibody	Mab73 antibody
BSL	Humanized F3 antibody	4A5 antibody
BSM	Humanized F3 antibody	4E10 antibody
BSN	Humanized F3 antibody	5F12 antibody
BSO	Humanized F3 antibody	VA01 antibody
BSP	Humanized F3 antibody	BL2 antibody
BSQ	Humanized F3 antibody	VEGF-related protein
BSR	Humanized F3 antibody	sFLT01
BSS	Humanized F3 antibody	sFLT02
BST	Humanized F3 antibody	Peptide B3
BSU	Humanized F3 antibody	TG100801
BSV	Humanized F3 antibody	sorafenib
BSW	Humanized F3 antibody	G6-31 antibody
BSX	C1 antibody	ranibizumab
BSY	C1 antibody	bevacizumab
BSZ	C1 antibody	aflibercept
BTA	C1 antibody	KH902 VEGF receptor-Fc fusion protein
BTB	C1 antibody	2C3 antibody
BTC	C1 antibody	ORA102
BTD	C1 antibody	pegaptanib
BTE	C1 antibody	bevasiranib
BTF	C1 antibody	SIRNA-027
BTG	C1 antibody	decursin
BTH	C1 antibody	decursinol
BTI	C1 antibody	picropodophyllin

BTJ	C1 antibody	guggulsterone
BTK	C1 antibody	PLG101
BTL	C1 antibody	eicosanoid LXA4
BTM	C1 antibody	PTK787
BTN	C1 antibody	pazopanib
BTO	C1 antibody	axitinib
BTP	C1 antibody	CDDO-Me
BTQ	C1 antibody	CDDO-Imm
BTR	C1 antibody	shikonin
BTS	C1 antibody	beta-hydroxyisovalerylshikonin
BTT	C1 antibody	ganglioside GM3
BTU	C1 antibody	DC101 antibody
BTV	C1 antibody	Mab25 antibody
BTW	C1 antibody	Mab73 antibody
BTX	C1 antibody	4A5 antibody
BTY	C1 antibody	4E10 antibody
BTZ	C1 antibody	5F12 antibody
BUA	C1 antibody	VA01 antibody
BUB	C1 antibody	BL2 antibody
BUC	C1 antibody	VEGF-related protein
BUD	C1 antibody	sFLT01
BUE	C1 antibody	sFLT02
BUF	C1 antibody	Peptide B3
BUG	C1 antibody	TG100801
BUH	C1 antibody	sorafenib
BUI	C1 antibody	G6-31 antibody
BUJ	Humanized C1 antibody	ranibizumab
BUK	Humanized C1 antibody	bevacizumab
BUL	Humanized C1 antibody	aflibercept
BUM	Humanized C1 antibody	KH902 VEGF receptor-Fc fusion protein
BUN	Humanized C1 antibody	2C3 antibody
BUO	Humanized C1 antibody	ORA102
BUP	Humanized C1 antibody	pegaptanib
BUQ	Humanized C1 antibody	bevasiranib
BUR	Humanized C1 antibody	SIRNA-027
BUS	Humanized C1 antibody	decursin
BUT	Humanized C1 antibody	decursinol
BUU	Humanized C1 antibody	picropodophyllin
BUV	Humanized C1 antibody	guggulsterone
BUW	Humanized C1 antibody	PLG101
BUX	Humanized C1 antibody	eicosanoid LXA4

BUY	Humanized C1 antibody	PTK787
BUZ	Humanized C1 antibody	pazopanib
BVA	Humanized C1 antibody	axitinib
BVB	Humanized C1 antibody	CDDO-Me
BVC	Humanized C1 antibody	CDDO-Imm
BVD	Humanized C1 antibody	shikonin
BVE	Humanized C1 antibody	beta-hydroxyisovalerylshikonin
BVF	Humanized C1 antibody	ganglioside GM3
BVG	Humanized C1 antibody	DC101 antibody
BVH	Humanized C1 antibody	Mab25 antibody
BVI	Humanized C1 antibody	Mab73 antibody
BVJ	Humanized C1 antibody	4A5 antibody
BVK	Humanized C1 antibody	4E10 antibody
BVL	Humanized C1 antibody	5F12 antibody
BVM	Humanized C1 antibody	VA01 antibody
BVN	Humanized C1 antibody	BL2 antibody
BVO	Humanized C1 antibody	VEGF-related protein
BVP	Humanized C1 antibody	sFLT01
BVQ	Humanized C1 antibody	sFLT02
BVR	Humanized C1 antibody	Peptide B3
BVS	Humanized C1 antibody	TG100801
BVT	Humanized C1 antibody	sorafenib
BVU	Humanized C1 antibody	G6-31 antibody
BVV	6.4 antibody	ranibizumab
BVW	6.4 antibody	bevacizumab
BVX	6.4 antibody	aflibercept
BVY	6.4 antibody	KH902 VEGF receptor-Fc fusion protein
BVZ	6.4 antibody	2C3 antibody
BWA	6.4 antibody	ORA102
BWB	6.4 antibody	pegaptanib
BWC	6.4 antibody	bevasiranib
BWD	6.4 antibody	SIRNA-027
BWE	6.4 antibody	decursin
BWF	6.4 antibody	decursinol
BWG	6.4 antibody	picropodophyllin
BWH	6.4 antibody	guggulsterone
BWI	6.4 antibody	PLG101
BWJ	6.4 antibody	eicosanoid LXA4
BWK	6.4 antibody	PTK787
BWL	6.4 antibody	pazopanib
BWM	6.4 antibody	axitinib

BWN	6.4 antibody	CDDO-Me
BWO	6.4 antibody	CDDO-Imm
BWP	6.4 antibody	shikonin
BWQ	6.4 antibody	beta-hydroxyisovalerylshikonin
BWR	6.4 antibody	ganglioside GM3
BWS	6.4 antibody	DC101 antibody
BWT	6.4 antibody	Mab25 antibody
BWU	6.4 antibody	Mab73 antibody
BWV	6.4 antibody	4A5 antibody
BWW	6.4 antibody	4E10 antibody
BWX	6.4 antibody	5F12 antibody
BWY	6.4 antibody	VA01 antibody
BWZ	6.4 antibody	BL2 antibody
BXA	6.4 antibody	VEGF-related protein
BXB	6.4 antibody	sFLT01
BXC	6.4 antibody	sFLT02
BXD	6.4 antibody	Peptide B3
BXE	6.4 antibody	TG100801
BXF	6.4 antibody	sorafenib
BXG	6.4 antibody	G6-31 antibody
BXH	anti-mPDGF-C goat IgG antibody	ranibizumab
BXI	anti-mPDGF-C goat IgG antibody	bevacizumab
BXJ	anti-mPDGF-C goat IgG antibody	aflibercept
BXK	anti-mPDGF-C goat IgG antibody	KH902 VEGF receptor-Fc fusion protein
BXL	anti-mPDGF-C goat IgG antibody	2C3 antibody
BXM	anti-mPDGF-C goat IgG antibody	ORA102
BXN	anti-mPDGF-C goat IgG antibody	pegaptanib
BXO	anti-mPDGF-C goat IgG antibody	bevasiranib
BXP	anti-mPDGF-C goat IgG antibody	SIRNA-027
BXQ	anti-mPDGF-C goat IgG antibody	decursin
BXR	anti-mPDGF-C goat IgG antibody	decursinol
BXS	anti-mPDGF-C goat IgG antibody	picropodophyllin
BXT	anti-mPDGF-C goat IgG antibody	guggulsterone
BXU	anti-mPDGF-C goat IgG antibody	PLG101
BXV	anti-mPDGF-C goat IgG antibody	eicosanoid LXA4
BXW	anti-mPDGF-C goat IgG antibody	PTK787
BXX	anti-mPDGF-C goat IgG antibody	pazopanib
BXY	anti-mPDGF-C goat IgG antibody	axitinib
BXZ	anti-mPDGF-C goat IgG antibody	CDDO-Me
BYA	anti-mPDGF-C goat IgG antibody	CDDO-Imm
BYB	anti-mPDGF-C goat IgG antibody	shikonin

BYC	anti-mPDGF-C goat IgG antibody	beta-hydroxyisovalerylshikonin
BYD	anti-mPDGF-C goat IgG antibody	ganglioside GM3
BYE	anti-mPDGF-C goat IgG antibody	DC101 antibody
BYF	anti-mPDGF-C goat IgG antibody	Mab25 antibody
BYG	anti-mPDGF-C goat IgG antibody	Mab73 antibody
BYH	anti-mPDGF-C goat IgG antibody	4A5 antibody
BYI	anti-mPDGF-C goat IgG antibody	4E10 antibody
BYJ	anti-mPDGF-C goat IgG antibody	5F12 antibody
BYK	anti-mPDGF-C goat IgG antibody	VA01 antibody
BYL	anti-mPDGF-C goat IgG antibody	BL2 antibody
BYM	anti-mPDGF-C goat IgG antibody	VEGF-related protein
BYN	anti-mPDGF-C goat IgG antibody	sFLT01
BYO	anti-mPDGF-C goat IgG antibody	sFLT02
BYP	anti-mPDGF-C goat IgG antibody	Peptide B3
BYQ	anti-mPDGF-C goat IgG antibody	TG100801
BYR	anti-mPDGF-C goat IgG antibody	sorafenib
BYS	anti-mPDGF-C goat IgG antibody	G6-31 antibody
BYT	C3.1 antibody	ranibizumab
BYU	C3.1 antibody	bevacizumab
BYV	C3.1 antibody	aflibercept
BYW	C3.1 antibody	KH902 VEGF receptor-Fc fusion protein
BYX	C3.1 antibody	2C3 antibody
BYY	C3.1 antibody	ORA102
BYZ	C3.1 antibody	pegaptanib
BZA	C3.1 antibody	bevasiranib
BZB	C3.1 antibody	SIRNA-027
BZC	C3.1 antibody	decursin
BZD	C3.1 antibody	decursinol
BZE	C3.1 antibody	picropodophyllin
BZF	C3.1 antibody	guggulsterone
BZG	C3.1 antibody	PLG101
BZH	C3.1 antibody	eicosanoid LXA4
BZI	C3.1 antibody	PTK787
BZJ	C3.1 antibody	pazopanib
BZK	C3.1 antibody	axitinib
BZL	C3.1 antibody	CDDO-Me
BZM	C3.1 antibody	CDDO-Imm
BZN	C3.1 antibody	shikonin
BZO	C3.1 antibody	beta-hydroxyisovalerylshikonin
BZP	C3.1 antibody	ganglioside GM3
BZQ	C3.1 antibody	DC101 antibody

BZR	C3.1 antibody	Mab25 antibody
BZS	C3.1 antibody	Mab73 antibody
BZT	C3.1 antibody	4A5 antibody
BZU	C3.1 antibody	4E10 antibody
BZV	C3.1 antibody	5F12 antibody
BZW	C3.1 antibody	VA01 antibody
BZX	C3.1 antibody	BL2 antibody
BZY	C3.1 antibody	VEGF-related protein
BZZ	C3.1 antibody	sFLT01
CAA	C3.1 antibody	sFLT02
CAB	C3.1 antibody	Peptide B3
CAC	C3.1 antibody	TG100801
CAD	C3.1 antibody	sorafenib
CAE	C3.1 antibody	G6-31 antibody
CAF	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	ranibizumab
CAG	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	bevacizumab
CAH	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	aflibercept
CAI	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	KH902 VEGF receptor-Fc fusion protein
CAJ	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	2C3 antibody
CAK	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	ORA102
CAL	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	pegaptanib
CAM	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	bevasiranib
CAN	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	SIRNA-027
CAO	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	decursin
CAP	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	decursinol
CAQ	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	picropodophyllin
CAR	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	guggulsterone
CAS	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	PLG101

CAT	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	eicosanoid LXA4
CAU	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	PTK787
CAV	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	pazopanib
CAW	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	axitinib
CAX	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	CDDO-Me
CAY	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	CDDO-Imm
CAZ	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	shikonin
CBA	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	beta-hydroxyisovalerylshikonin
CBB	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	ganglioside GM3
CBC	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	DC101 antibody
CBD	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	Mab25 antibody
CBE	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	Mab73 antibody
CBF	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	4A5 antibody
CBG	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	4E10 antibody
CBH	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	5F12 antibody
CBI	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	VA01 antibody
CBJ	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	BL2 antibody
CBK	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	VEGF-related protein
CBL	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	sFLT01
CBM	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	sFLT02
CBN	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	Peptide B3

CBO	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	TG100801
CBP	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	sorafenib
CBQ	5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine	G6-31 antibody
CBR	Interferon	ranibizumab
CBS	Interferon	bevacizumab
CBT	Interferon	aflibercept
CBU	Interferon	KH902 VEGF receptor-Fc fusion protein
CBV	Interferon	2C3 antibody
CBW	Interferon	ORA102
CBX	Interferon	pegaptanib
CBY	Interferon	bevasiranib
CBZ	Interferon	SIRNA-027
CCA	Interferon	decursin
CCB	Interferon	decursinol
CCC	Interferon	picropodophyllin
CCD	Interferon	guggulsterone
CCE	Interferon	PLG101
CCF	Interferon	eicosanoid LXA4
CCG	Interferon	PTK787
CCH	Interferon	pazopanib
CCI	Interferon	axitinib
CCJ	Interferon	CDDO-Me
CCK	Interferon	CDDO-Imm
CCL	Interferon	shikonin
CCM	Interferon	beta-hydroxyisovalerylshikonin
CCN	Interferon	ganglioside GM3
CCO	Interferon	DC101 antibody
CCP	Interferon	Mab25 antibody
CCQ	Interferon	Mab73 antibody
CCR	Interferon	4A5 antibody
CCS	Interferon	4E10 antibody
CCT	Interferon	5F12 antibody
CCU	Interferon	VA01 antibody
CCV	Interferon	BL2 antibody
CCW	Interferon	VEGF-related protein
CCX	Interferon	sFLT01
CCY	Interferon	sFLT02
CCZ	Interferon	Peptide B3

CDA	Interferon	TG100801
CDB	Interferon	sorafenib
CDC	Interferon	G6-31 antibody
CDD	Protamine	ranibizumab
CDE	Protamine	bevacizumab
CDF	Protamine	aflibercept
CDG	Protamine	KH902 VEGF receptor-Fc fusion protein
CDH	Protamine	2C3 antibody
CDI	Protamine	ORA102
CDJ	Protamine	pegaptanib
CDK	Protamine	bevasiranib
CDL	Protamine	SIRNA-027
CDM	Protamine	decursin
CDN	Protamine	decursinol
CDO	Protamine	picropodophyllin
CDP	Protamine	guggulsterone
CDQ	Protamine	PLG101
CDR	Protamine	eicosanoid LXA4
CDS	Protamine	PTK787
CDT	Protamine	pazopanib
CDU	Protamine	axitinib
CDV	Protamine	CDDO-Me
CDW	Protamine	CDDO-Imm
CDX	Protamine	shikonin
CDY	Protamine	beta-hydroxyisovalerylshikonin
CDZ	Protamine	ganglioside GM3
CEA	Protamine	DC101 antibody
CEB	Protamine	Mab25 antibody
CEC	Protamine	Mab73 antibody
CED	Protamine	4A5 antibody
CEE	Protamine	4E10 antibody
CEF	Protamine	5F12 antibody
CEG	Protamine	VA01 antibody
CEH	Protamine	BL2 antibody
CEI	Protamine	VEGF-related protein
CEJ	Protamine	sFLT01
CEK	Protamine	sFLT02
CEL	Protamine	Peptide B3
CEM	Protamine	TG100801
CEN	Protamine	sorafenib
CEO	Protamine	G6-31 antibody

CEP	PDGFR-B1 monoclonal antibody	ranibizumab
CEQ	PDGFR-B1 monoclonal antibody	bevacizumab
CER	PDGFR-B1 monoclonal antibody	aflibercept
CES	PDGFR-B1 monoclonal antibody	KH902 VEGF receptor-Fc fusion protein
CET	PDGFR-B1 monoclonal antibody	2C3 antibody
CEU	PDGFR-B1 monoclonal antibody	ORA102
CEV	PDGFR-B1 monoclonal antibody	pegaptanib
CEW	PDGFR-B1 monoclonal antibody	bevasiranib
CEX	PDGFR-B1 monoclonal antibody	SIRNA-027
CEY	PDGFR-B1 monoclonal antibody	decursin
CEZ	PDGFR-B1 monoclonal antibody	decursinol
CFA	PDGFR-B1 monoclonal antibody	picropodophyllin
CFB	PDGFR-B1 monoclonal antibody	guggulsterone
CFC	PDGFR-B1 monoclonal antibody	PLG101
CFD	PDGFR-B1 monoclonal antibody	eicosanoid LXA4
CFE	PDGFR-B1 monoclonal antibody	PTK787
CFF	PDGFR-B1 monoclonal antibody	pazopanib
CFG	PDGFR-B1 monoclonal antibody	axitinib
CFH	PDGFR-B1 monoclonal antibody	CDDO-Me
CFI	PDGFR-B1 monoclonal antibody	CDDO-Imm
CFJ	PDGFR-B1 monoclonal antibody	shikonin
CFK	PDGFR-B1 monoclonal antibody	beta-hydroxyisovalerylshikonin
CFL	PDGFR-B1 monoclonal antibody	ganglioside GM3
CFM	PDGFR-B1 monoclonal antibody	DC101 antibody
CFN	PDGFR-B1 monoclonal antibody	Mab25 antibody
CFO	PDGFR-B1 monoclonal antibody	Mab73 antibody
CFP	PDGFR-B1 monoclonal antibody	4A5 antibody
CFQ	PDGFR-B1 monoclonal antibody	4E10 antibody
CFR	PDGFR-B1 monoclonal antibody	5F12 antibody
CFS	PDGFR-B1 monoclonal antibody	VA01 antibody
CFT	PDGFR-B1 monoclonal antibody	BL2 antibody
CFU	PDGFR-B1 monoclonal antibody	VEGF-related protein
CFV	PDGFR-B1 monoclonal antibody	sFLT01
CFW	PDGFR-B1 monoclonal antibody	sFLT02
CFX	PDGFR-B1 monoclonal antibody	Peptide B3
CFY	PDGFR-B1 monoclonal antibody	TG100801
CFZ	PDGFR-B1 monoclonal antibody	sorafenib
CGA	PDGFR-B1 monoclonal antibody	G6-31 antibody
CGB	PDGFR-B2 monoclonal antibody	ranibizumab
CGC	PDGFR-B2 monoclonal antibody	bevacizumab
CGD	PDGFR-B2 monoclonal antibody	aflibercept

CGE	PDGFR-B2 monoclonal antibody	KH902 VEGF receptor-Fc fusion protein
CGF	PDGFR-B2 monoclonal antibody	2C3 antibody
CGG	PDGFR-B2 monoclonal antibody	ORA102
CGH	PDGFR-B2 monoclonal antibody	pegaptanib
CGI	PDGFR-B2 monoclonal antibody	bevasiranib
CGJ	PDGFR-B2 monoclonal antibody	SIRNA-027
CGK	PDGFR-B2 monoclonal antibody	decursin
CGL	PDGFR-B2 monoclonal antibody	decursinol
CGM	PDGFR-B2 monoclonal antibody	picropodophyllin
CGN	PDGFR-B2 monoclonal antibody	guggulsterone
CGO	PDGFR-B2 monoclonal antibody	PLG101
CGP	PDGFR-B2 monoclonal antibody	eicosanoid LXA4
CGQ	PDGFR-B2 monoclonal antibody	PTK787
CGR	PDGFR-B2 monoclonal antibody	pazopanib
CGS	PDGFR-B2 monoclonal antibody	axitinib
CGT	PDGFR-B2 monoclonal antibody	CDDO-Me
CGU	PDGFR-B2 monoclonal antibody	CDDO-Imm
CGV	PDGFR-B2 monoclonal antibody	shikonin
CGW	PDGFR-B2 monoclonal antibody	beta-hydroxyisovalerylshikonin
CGX	PDGFR-B2 monoclonal antibody	ganglioside GM3
CGY	PDGFR-B2 monoclonal antibody	DC101 antibody
CGZ	PDGFR-B2 monoclonal antibody	Mab25 antibody
CHA	PDGFR-B2 monoclonal antibody	Mab73 antibody
CHB	PDGFR-B2 monoclonal antibody	4A5 antibody
CHC	PDGFR-B2 monoclonal antibody	4E10 antibody
CHD	PDGFR-B2 monoclonal antibody	5F12 antibody
CHE	PDGFR-B2 monoclonal antibody	VA01 antibody
CHF	PDGFR-B2 monoclonal antibody	BL2 antibody
CHG	PDGFR-B2 monoclonal antibody	VEGF-related protein
CHH	PDGFR-B2 monoclonal antibody	sFLT01
CHI	PDGFR-B2 monoclonal antibody	sFLT02
CHJ	PDGFR-B2 monoclonal antibody	Peptide B3
CHK	PDGFR-B2 monoclonal antibody	TG100801
CHL	PDGFR-B2 monoclonal antibody	sorafenib
CHM	PDGFR-B2 monoclonal antibody	G6-31 antibody
CHN	6D11 monoclonal antibody	ranibizumab
CHO	6D11 monoclonal antibody	bevacizumab
CHP	6D11 monoclonal antibody	aflibercept
CHQ	6D11 monoclonal antibody	KH902 VEGF receptor-Fc fusion protein
CHR	6D11 monoclonal antibody	2C3 antibody
CHS	6D11 monoclonal antibody	ORA102

CHT	6D11 monoclonal antibody	pegaptanib
CHU	6D11 monoclonal antibody	bevasiranib
CHV	6D11 monoclonal antibody	SIRNA-027
CHW	6D11 monoclonal antibody	decursin
CHX	6D11 monoclonal antibody	decursinol
CHY	6D11 monoclonal antibody	picropodophyllin
CHZ	6D11 monoclonal antibody	guggulsterone
CIA	6D11 monoclonal antibody	PLG101
CIB	6D11 monoclonal antibody	eicosanoid LXA4
CIC	6D11 monoclonal antibody	PTK787
CID	6D11 monoclonal antibody	pazopanib
CIE	6D11 monoclonal antibody	axitinib
CIF	6D11 monoclonal antibody	CDDO-Me
CIG	6D11 monoclonal antibody	CDDO-Imm
CIH	6D11 monoclonal antibody	shikonin
CII	6D11 monoclonal antibody	beta-hydroxyisovalerylshikonin
CIJ	6D11 monoclonal antibody	ganglioside GM3
CIK	6D11 monoclonal antibody	DC101 antibody
CIL	6D11 monoclonal antibody	Mab25 antibody
CIM	6D11 monoclonal antibody	Mab73 antibody
CIN	6D11 monoclonal antibody	4A5 antibody
CIO	6D11 monoclonal antibody	4E10 antibody
CIP	6D11 monoclonal antibody	5F12 antibody
CIQ	6D11 monoclonal antibody	VA01 antibody
CIR	6D11 monoclonal antibody	BL2 antibody
CIS	6D11 monoclonal antibody	VEGF-related protein
CIT	6D11 monoclonal antibody	sFLT01
CIU	6D11 monoclonal antibody	sFLT02
CIV	6D11 monoclonal antibody	Peptide B3
CIW	6D11 monoclonal antibody	TG100801
CIX	6D11 monoclonal antibody	sorafenib
CIY	6D11 monoclonal antibody	G6-31 antibody
CIZ	Sis 1 monoclonal antibody	ranibizumab
CJA	Sis 1 monoclonal antibody	bevacizumab
CJB	Sis 1 monoclonal antibody	aflibercept
CJC	Sis 1 monoclonal antibody	KH902 VEGF receptor-Fc fusion protein
CJD	Sis 1 monoclonal antibody	2C3 antibody
CJE	Sis 1 monoclonal antibody	ORA102
CJF	Sis 1 monoclonal antibody	pegaptanib
CJG	Sis 1 monoclonal antibody	bevasiranib
CJH	Sis 1 monoclonal antibody	SIRNA-027

CJI	Sis 1 monoclonal antibody	decursin
CJJ	Sis 1 monoclonal antibody	decursinol
CJK	Sis 1 monoclonal antibody	picropodophyllin
CJL	Sis 1 monoclonal antibody	guggulsterone
CJM	Sis 1 monoclonal antibody	PLG101
CJN	Sis 1 monoclonal antibody	eicosanoid LXA4
CJO	Sis 1 monoclonal antibody	PTK787
CJP	Sis 1 monoclonal antibody	pazopanib
CJQ	Sis 1 monoclonal antibody	axitinib
CJR	Sis 1 monoclonal antibody	CDDO-Me
CJS	Sis 1 monoclonal antibody	CDDO-Imm
CJT	Sis 1 monoclonal antibody	shikonin
CJU	Sis 1 monoclonal antibody	beta-hydroxyisovalerylshikonin
CJV	Sis 1 monoclonal antibody	ganglioside GM3
CJW	Sis 1 monoclonal antibody	DC101 antibody
CJX	Sis 1 monoclonal antibody	Mab25 antibody
CJY	Sis 1 monoclonal antibody	Mab73 antibody
CJZ	Sis 1 monoclonal antibody	4A5 antibody
CKA	Sis 1 monoclonal antibody	4E10 antibody
CKB	Sis 1 monoclonal antibody	5F12 antibody
CKC	Sis 1 monoclonal antibody	VA01 antibody
CKD	Sis 1 monoclonal antibody	BL2 antibody
CKE	Sis 1 monoclonal antibody	VEGF-related protein
CKF	Sis 1 monoclonal antibody	sFLT01
CKG	Sis 1 monoclonal antibody	sFLT02
CKH	Sis 1 monoclonal antibody	Peptide B3
CKI	Sis 1 monoclonal antibody	TG100801
CKJ	Sis 1 monoclonal antibody	sorafenib
CKK	Sis 1 monoclonal antibody	G6-31 antibody
CKL	PR7212 monoclonal antibody	ranibizumab
CKM	PR7212 monoclonal antibody	bevacizumab
CKN	PR7212 monoclonal antibody	aflibercept
CKO	PR7212 monoclonal antibody	KH902 VEGF receptor-Fc fusion protein
CKP	PR7212 monoclonal antibody	2C3 antibody
CKQ	PR7212 monoclonal antibody	ORA102
CKR	PR7212 monoclonal antibody	pegaptanib
CKS	PR7212 monoclonal antibody	bevasiranib
CKT	PR7212 monoclonal antibody	SIRNA-027
CKU	PR7212 monoclonal antibody	decursin
CKV	PR7212 monoclonal antibody	decursinol
CKW	PR7212 monoclonal antibody	picropodophyllin

CKX	PR7212 monoclonal antibody	guggulsterone
CKY	PR7212 monoclonal antibody	PLG101
CKZ	PR7212 monoclonal antibody	eicosanoid LXA4
CLA	PR7212 monoclonal antibody	PTK787
CLB	PR7212 monoclonal antibody	pazopanib
CLC	PR7212 monoclonal antibody	axitinib
CLD	PR7212 monoclonal antibody	CDDO-Me
CLE	PR7212 monoclonal antibody	CDDO-Imm
CLF	PR7212 monoclonal antibody	shikonin
CLG	PR7212 monoclonal antibody	beta-hydroxyisovalerylshikonin
CLH	PR7212 monoclonal antibody	ganglioside GM3
CLI	PR7212 monoclonal antibody	DC101 antibody
CLJ	PR7212 monoclonal antibody	Mab25 antibody
CLK	PR7212 monoclonal antibody	Mab73 antibody
CLL	PR7212 monoclonal antibody	4A5 antibody
CLM	PR7212 monoclonal antibody	4E10 antibody
CLN	PR7212 monoclonal antibody	5F12 antibody
CLO	PR7212 monoclonal antibody	VA01 antibody
CLP	PR7212 monoclonal antibody	BL2 antibody
CLQ	PR7212 monoclonal antibody	VEGF-related protein
CLR	PR7212 monoclonal antibody	sFLT01
CLS	PR7212 monoclonal antibody	sFLT02
CLT	PR7212 monoclonal antibody	Peptide B3
CLU	PR7212 monoclonal antibody	TG100801
CLV	PR7212 monoclonal antibody	sorafenib
CLW	PR7212 monoclonal antibody	G6-31 antibody
CLX	PR292 monoclonal antibody	ranibizumab
CLY	PR292 monoclonal antibody	bevacizumab
CLZ	PR292 monoclonal antibody	aflibercept
CMA	PR292 monoclonal antibody	KH902 VEGF receptor-Fc fusion protein
CMB	PR292 monoclonal antibody	2C3 antibody
CMC	PR292 monoclonal antibody	ORA102
CMD	PR292 monoclonal antibody	pegaptanib
CME	PR292 monoclonal antibody	bevasiranib
CMF	PR292 monoclonal antibody	SIRNA-027
CMG	PR292 monoclonal antibody	decursin
CMH	PR292 monoclonal antibody	decursinol
CMI	PR292 monoclonal antibody	picropodophyllin
CMJ	PR292 monoclonal antibody	guggulsterone
CMK	PR292 monoclonal antibody	PLG101
CML	PR292 monoclonal antibody	eicosanoid LXA4

CMM	PR292 monoclonal antibody	PTK787
CMN	PR292 monoclonal antibody	pazopanib
CMO	PR292 monoclonal antibody	axitinib
CMP	PR292 monoclonal antibody	CDDO-Me
CMQ	PR292 monoclonal antibody	CDDO-Imm
CMR	PR292 monoclonal antibody	shikonin
CMS	PR292 monoclonal antibody	beta-hydroxyisovalerylshikonin
CMT	PR292 monoclonal antibody	ganglioside GM3
CMU	PR292 monoclonal antibody	DC101 antibody
CMV	PR292 monoclonal antibody	Mab25 antibody
CMW	PR292 monoclonal antibody	Mab73 antibody
CMX	PR292 monoclonal antibody	4A5 antibody
CMY	PR292 monoclonal antibody	4E10 antibody
CMZ	PR292 monoclonal antibody	5F12 antibody
CNA	PR292 monoclonal antibody	VA01 antibody
CNB	PR292 monoclonal antibody	BL2 antibody
CNC	PR292 monoclonal antibody	VEGF-related protein
CND	PR292 monoclonal antibody	sFLT01
CNE	PR292 monoclonal antibody	sFLT02
CNF	PR292 monoclonal antibody	Peptide B3
CNG	PR292 monoclonal antibody	TG100801
CNH	PR292 monoclonal antibody	sorafenib
CNI	PR292 monoclonal antibody	G6-31 antibody
CNJ	HYB 9610 monoclonal antibody	ranibizumab
CNK	HYB 9610 monoclonal antibody	bevacizumab
CNL	HYB 9610 monoclonal antibody	aflibercept
CNM	HYB 9610 monoclonal antibody	KH902 VEGF receptor-Fc fusion protein
CNN	HYB 9610 monoclonal antibody	2C3 antibody
CNO	HYB 9610 monoclonal antibody	ORA102
CNP	HYB 9610 monoclonal antibody	pegaptanib
CNQ	HYB 9610 monoclonal antibody	bevasiranib
CNR	HYB 9610 monoclonal antibody	SIRNA-027
CNS	HYB 9610 monoclonal antibody	decursin
CNT	HYB 9610 monoclonal antibody	decursinol
CNU	HYB 9610 monoclonal antibody	picropodophyllin
CNV	HYB 9610 monoclonal antibody	guggulsterone
CNW	HYB 9610 monoclonal antibody	PLG101
CNX	HYB 9610 monoclonal antibody	eicosanoid LXA4
CNY	HYB 9610 monoclonal antibody	PTK787
CNZ	HYB 9610 monoclonal antibody	pazopanib
COA	HYB 9610 monoclonal antibody	axitinib

COB	HYB 9610 monoclonal antibody	CDDO-Me
COC	HYB 9610 monoclonal antibody	CDDO-Imm
COD	HYB 9610 monoclonal antibody	shikonin
COE	HYB 9610 monoclonal antibody	beta-hydroxyisovalerylshikonin
COF	HYB 9610 monoclonal antibody	ganglioside GM3
COG	HYB 9610 monoclonal antibody	DC101 antibody
COH	HYB 9610 monoclonal antibody	Mab25 antibody
COI	HYB 9610 monoclonal antibody	Mab73 antibody
COJ	HYB 9610 monoclonal antibody	4A5 antibody
COK	HYB 9610 monoclonal antibody	4E10 antibody
COL	HYB 9610 monoclonal antibody	5F12 antibody
COM	HYB 9610 monoclonal antibody	VA01 antibody
CON	HYB 9610 monoclonal antibody	BL2 antibody
COO	HYB 9610 monoclonal antibody	VEGF-related protein
COP	HYB 9610 monoclonal antibody	sFLT01
COQ	HYB 9610 monoclonal antibody	sFLT02
COR	HYB 9610 monoclonal antibody	Peptide B3
COS	HYB 9610 monoclonal antibody	TG100801
COT	HYB 9610 monoclonal antibody	sorafenib
COU	HYB 9610 monoclonal antibody	G6-31 antibody
COV	HYB 9611 monoclonal antibody	ranibizumab
COW	HYB 9611 monoclonal antibody	bevacizumab
COX	HYB 9611 monoclonal antibody	aflibercept
COY	HYB 9611 monoclonal antibody	KH902 VEGF receptor-Fc fusion protein
COZ	HYB 9611 monoclonal antibody	2C3 antibody
CPA	HYB 9611 monoclonal antibody	ORA102
CPB	HYB 9611 monoclonal antibody	pegaptanib
CPC	HYB 9611 monoclonal antibody	bevasiranib
CPD	HYB 9611 monoclonal antibody	SIRNA-027
CPE	HYB 9611 monoclonal antibody	decursin
CPF	HYB 9611 monoclonal antibody	decursinol
CPG	HYB 9611 monoclonal antibody	picropodophyllin
CPH	HYB 9611 monoclonal antibody	guggulsterone
CPI	HYB 9611 monoclonal antibody	PLG101
CPJ	HYB 9611 monoclonal antibody	eicosanoid LXA4
CPK	HYB 9611 monoclonal antibody	PTK787
CPL	HYB 9611 monoclonal antibody	pazopanib
CPM	HYB 9611 monoclonal antibody	axitinib
CPN	HYB 9611 monoclonal antibody	CDDO-Me
CPO	HYB 9611 monoclonal antibody	CDDO-Imm
CPP	HYB 9611 monoclonal antibody	shikonin

CPQ	HYB 9611 monoclonal antibody	beta-hydroxyisovalerylshikonin
CPR	HYB 9611 monoclonal antibody	ganglioside GM3
CPS	HYB 9611 monoclonal antibody	DC101 antibody
CPT	HYB 9611 monoclonal antibody	Mab25 antibody
CPU	HYB 9611 monoclonal antibody	Mab73 antibody
CPV	HYB 9611 monoclonal antibody	4A5 antibody
CPW	HYB 9611 monoclonal antibody	4E10 antibody
CPX	HYB 9611 monoclonal antibody	5F12 antibody
CPY	HYB 9611 monoclonal antibody	VA01 antibody
CPZ	HYB 9611 monoclonal antibody	BL2 antibody
CQA	HYB 9611 monoclonal antibody	VEGF-related protein
CQB	HYB 9611 monoclonal antibody	sFLT01
CQC	HYB 9611 monoclonal antibody	sFLT02
CQD	HYB 9611 monoclonal antibody	Peptide B3
CQE	HYB 9611 monoclonal antibody	TG100801
CQF	HYB 9611 monoclonal antibody	sorafenib
CQG	HYB 9611 monoclonal antibody	G6-31 antibody
CQH	HYB 9612 monoclonal antibody	ranibizumab
CQI	HYB 9612 monoclonal antibody	bevacizumab
CQJ	HYB 9612 monoclonal antibody	aflibercept
CQK	HYB 9612 monoclonal antibody	KH902 VEGF receptor-Fc fusion protein
CQL	HYB 9612 monoclonal antibody	2C3 antibody
CQM	HYB 9612 monoclonal antibody	ORA102
CQN	HYB 9612 monoclonal antibody	pegaptanib
CQO	HYB 9612 monoclonal antibody	bevasiranib
CQP	HYB 9612 monoclonal antibody	SIRNA-027
CQQ	HYB 9612 monoclonal antibody	decursin
CQR	HYB 9612 monoclonal antibody	decursinol
CQS	HYB 9612 monoclonal antibody	picropodophyllin
CQT	HYB 9612 monoclonal antibody	guggulsterone
CQU	HYB 9612 monoclonal antibody	PLG101
CQV	HYB 9612 monoclonal antibody	eicosanoid LXA4
CQW	HYB 9612 monoclonal antibody	PTK787
CQX	HYB 9612 monoclonal antibody	pazopanib
CQY	HYB 9612 monoclonal antibody	axitinib
CQZ	HYB 9612 monoclonal antibody	CDDO-Me
CRA	HYB 9612 monoclonal antibody	CDDO-Imm
CRB	HYB 9612 monoclonal antibody	shikonin
CRC	HYB 9612 monoclonal antibody	beta-hydroxyisovalerylshikonin
CRD	HYB 9612 monoclonal antibody	ganglioside GM3
CRE	HYB 9612 monoclonal antibody	DC101 antibody

CRF	HYB 9612 monoclonal antibody	Mab25 antibody
CRG	HYB 9612 monoclonal antibody	Mab73 antibody
CRH	HYB 9612 monoclonal antibody	4A5 antibody
CRI	HYB 9612 monoclonal antibody	4E10 antibody
CRJ	HYB 9612 monoclonal antibody	5F12 antibody
CRK	HYB 9612 monoclonal antibody	VA01 antibody
CRL	HYB 9612 monoclonal antibody	BL2 antibody
CRM	HYB 9612 monoclonal antibody	VEGF-related protein
CRN	HYB 9612 monoclonal antibody	sFLT01
CRO	HYB 9612 monoclonal antibody	sFLT02
CRP	HYB 9612 monoclonal antibody	Peptide B3
CRQ	HYB 9612 monoclonal antibody	TG100801
CRR	HYB 9612 monoclonal antibody	sorafenib
CRS	HYB 9612 monoclonal antibody	G6-31 antibody
CRT	HYB 9613 monoclonal antibody	ranibizumab
CRU	HYB 9613 monoclonal antibody	bevacizumab
CRV	HYB 9613 monoclonal antibody	aflibercept
CRW	HYB 9613 monoclonal antibody	KH902 VEGF receptor-Fc fusion protein
CRX	HYB 9613 monoclonal antibody	2C3 antibody
CRY	HYB 9613 monoclonal antibody	ORA102
CRZ	HYB 9613 monoclonal antibody	pegaptanib
CSA	HYB 9613 monoclonal antibody	bevasiranib
CSB	HYB 9613 monoclonal antibody	SIRNA-027
CSC	HYB 9613 monoclonal antibody	decursin
CSD	HYB 9613 monoclonal antibody	decursinol
CSE	HYB 9613 monoclonal antibody	picropodophyllin
CSF	HYB 9613 monoclonal antibody	guggulsterone
CSG	HYB 9613 monoclonal antibody	PLG101
CSH	HYB 9613 monoclonal antibody	eicosanoid LXA4
CSI	HYB 9613 monoclonal antibody	PTK787
CSJ	HYB 9613 monoclonal antibody	pazopanib
CSK	HYB 9613 monoclonal antibody	axitinib
CSL	HYB 9613 monoclonal antibody	CDDO-Me
CSM	HYB 9613 monoclonal antibody	CDDO-Imm
CSN	HYB 9613 monoclonal antibody	shikonin
CSO	HYB 9613 monoclonal antibody	beta-hydroxyisovalerylshikonin
CSP	HYB 9613 monoclonal antibody	ganglioside GM3
CSQ	HYB 9613 monoclonal antibody	DC101 antibody
CSR	HYB 9613 monoclonal antibody	Mab25 antibody
CSS	HYB 9613 monoclonal antibody	Mab73 antibody
CST	HYB 9613 monoclonal antibody	4A5 antibody

CSU	HYB 9613 monoclonal antibody	4E10 antibody
CSV	HYB 9613 monoclonal antibody	5F12 antibody
CSW	HYB 9613 monoclonal antibody	VA01 antibody
CSX	HYB 9613 monoclonal antibody	BL2 antibody
CSY	HYB 9613 monoclonal antibody	VEGF-related protein
CSZ	HYB 9613 monoclonal antibody	sFLT01
CTA	HYB 9613 monoclonal antibody	sFLT02
CTB	HYB 9613 monoclonal antibody	Peptide B3
CTC	HYB 9613 monoclonal antibody	TG100801
CTD	HYB 9613 monoclonal antibody	sorafenib
CTE	HYB 9613 monoclonal antibody	G6-31 antibody
CTF	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	ranibizumab
CTG	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	bevacizumab
CTH	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	aflibercept
CTI	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	KH902 VEGF receptor-Fc fusion protein
CTJ	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	2C3 antibody
CTK	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	ORA102
CTL	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	pegaptanib
CTM	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	bevasiranib
CTN	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	SIRNA-027
CTO	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	decursin
CTP	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	decursinol
CTQ	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	picropodophyllin
CTR	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	guggulsterone
CTS	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	PLG101
CTT	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	eicosanoid LXA4
CTU	4-(2-(N-(-2-carboxamidoindole)	PTK787

	aminoethyl)-benzenesulfonamide	
CTV	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	pazopanib
CTW	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	axitinib
CTX	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	CDDO-Me
CTY	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	CDDO-Imm
CTZ	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	shikonin
CUA	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	beta-hydroxyisovalerylshikonin
CUB	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	ganglioside GM3
CUC	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	DC101 antibody
CUD	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	Mab25 antibody
CUE	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	Mab73 antibody
CUF	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	4A5 antibody
CUG	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	4E10 antibody
CUH	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	5F12 antibody
CUI	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	VA01 antibody
CUJ	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	BL2 antibody
CUK	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	VEGF-related protein
CUL	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	sFLT01
CUM	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	sFLT02
CUN	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	Peptide B3
CUO	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	TG100801
CUP	4-(2-(N-(-2-carboxamidoindole)	sorafenib

	aminoethyl)-benzenesulfonamide	
CUQ	4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide	G6-31 antibody
CUR	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	ranibizumab
CUS	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	bevacizumab
CUT	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	aflibercept
CUU	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	KH902 VEGF receptor-Fc fusion protein
CUV	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	2C3 antibody
CUW	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	ORA102
CUX	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	pegaptanib
CUY	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	bevasiranib
CUZ	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	SIRNA-027
CVA	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	decursin
CVB	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	decursinol
CVC	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	picropodophyllin
CVD	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	guggulsterone

CVE	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	PLG101
CVF	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	eicosanoid LXA4
CVG	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	PTK787
CVH	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	pazopanib
CVI	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	axitinib
CVJ	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	CDDO-Me
CVK	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	CDDO-Imm
CVL	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	shikonin
CVM	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	beta-hydroxyisovalerylshikonin
CVN	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	ganglioside GM3
CVO	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	DC101 antibody
CVP	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	Mab25 antibody
CVQ	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	Mab73 antibody
CVR	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	4A5 antibody

CVS	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	4E10 antibody
CVT	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	5F12 antibody
CVU	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	VA01 antibody
CVV	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	BL2 antibody
CVW	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	VEGF-related protein
CVX	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	sFLT01
CVY	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	sFLT02
CVZ	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	Peptide B3
CWA	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	TG100801
CWB	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	sorafenib
CWC	4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea	G6-31 antibody
CWD	CGP 53716	ranibizumab
CWE	CGP 53716	bevacizumab
CWF	CGP 53716	aflibercept
CWG	CGP 53716	KH902 VEGF receptor-Fc fusion protein
CWH	CGP 53716	2C3 antibody
CWI	CGP 53716	ORA102
CWJ	CGP 53716	pegaptanib
CWK	CGP 53716	bevasiranib
CWL	CGP 53716	SIRNA-027

CWM	CGP 53716	decursin
CWN	CGP 53716	decursinol
CWO	CGP 53716	picropodophyllin
CWP	CGP 53716	guggulsterone
CWQ	CGP 53716	PLG101
CWR	CGP 53716	eicosanoid LXA4
CWS	CGP 53716	PTK787
CWT	CGP 53716	pazopanib
CWU	CGP 53716	axitinib
CWV	CGP 53716	CDDO-Me
CWW	CGP 53716	CDDO-Imm
CWX	CGP 53716	shikonin
CWY	CGP 53716	beta-hydroxyisovalerylshikonin
CWZ	CGP 53716	ganglioside GM3
CXA	CGP 53716	DC101 antibody
CXB	CGP 53716	Mab25 antibody
CXC	CGP 53716	Mab73 antibody
CXD	CGP 53716	4A5 antibody
CXE	CGP 53716	4E10 antibody
CXF	CGP 53716	5F12 antibody
CXG	CGP 53716	VA01 antibody
CXH	CGP 53716	BL2 antibody
CXI	CGP 53716	VEGF-related protein
CXJ	CGP 53716	sFLT01
CXK	CGP 53716	sFLT02
CXL	CGP 53716	Peptide B3
CXM	CGP 53716	TG100801
CXN	CGP 53716	sorafenib
CXO	CGP 53716	G6-31 antibody
CXP	G162 antibody	ranibizumab
CXQ	G162 antibody	bevacizumab
CXR	G162 antibody	aflibercept
CXS	G162 antibody	KH902 VEGF receptor-Fc fusion protein
CXT	G162 antibody	2C3 antibody
CXU	G162 antibody	ORA102
CXV	G162 antibody	pegaptanib
CXW	G162 antibody	bevasiranib
CXX	G162 antibody	SIRNA-027
CXY	G162 antibody	decursin
CXZ	G162 antibody	decursinol
CYA	G162 antibody	picropodophyllin

CYB	G162 antibody	guggulsterone
CYC	G162 antibody	PLG101
CYD	G162 antibody	eicosanoid LXA4
CYE	G162 antibody	PTK787
CYF	G162 antibody	pazopanib
CYG	G162 antibody	axitinib
CYH	G162 antibody	CDDO-Me
CYI	G162 antibody	CDDO-Imm
CYJ	G162 antibody	shikonin
CYK	G162 antibody	beta-hydroxyisovalerylshikonin
CYL	G162 antibody	ganglioside GM3
CYM	G162 antibody	DC101 antibody
CYN	G162 antibody	Mab25 antibody
CYO	G162 antibody	Mab73 antibody
CYP	G162 antibody	4A5 antibody
CYQ	G162 antibody	4E10 antibody
CYR	G162 antibody	5F12 antibody
CYS	G162 antibody	VA01 antibody
CYT	G162 antibody	BL2 antibody
CYU	G162 antibody	VEGF-related protein
CYV	G162 antibody	sFLT01
CYW	G162 antibody	sFLT02
CYX	G162 antibody	Peptide B3
CYY	G162 antibody	TG100801
CYZ	G162 antibody	sorafenib
CZA	G162 antibody	G6-31 antibody
CZB	pyrazolo[3,4-g]quinoxaline	ranibizumab
CZC	pyrazolo[3,4-g]quinoxaline	bevacizumab
CZD	pyrazolo[3,4-g]quinoxaline	aflibercept
CZE	pyrazolo[3,4-g]quinoxaline	KH902 VEGF receptor-Fc fusion protein
CZF	pyrazolo[3,4-g]quinoxaline	2C3 antibody
CZG	pyrazolo[3,4-g]quinoxaline	ORA102
CZH	pyrazolo[3,4-g]quinoxaline	pegaptanib
CZI	pyrazolo[3,4-g]quinoxaline	bevasiranib
CZJ	pyrazolo[3,4-g]quinoxaline	SIRNA-027
CZK	pyrazolo[3,4-g]quinoxaline	decursin
CZL	pyrazolo[3,4-g]quinoxaline	decursinol
CZM	pyrazolo[3,4-g]quinoxaline	picropodophyllin
CZN	pyrazolo[3,4-g]quinoxaline	guggulsterone
CZO	pyrazolo[3,4-g]quinoxaline	PLG101
CZP	pyrazolo[3,4-g]quinoxaline	eicosanoid LXA4

CZQ	pyrazolo[3,4-g]quinoxaline	PTK787
CZR	pyrazolo[3,4-g]quinoxaline	pazopanib
CZS	pyrazolo[3,4-g]quinoxaline	axitinib
CZT	pyrazolo[3,4-g]quinoxaline	CDDO-Me
CZU	pyrazolo[3,4-g]quinoxaline	CDDO-Imm
CZV	pyrazolo[3,4-g]quinoxaline	shikonin
CZW	pyrazolo[3,4-g]quinoxaline	beta-hydroxyisovalerylshikonin
CZX	pyrazolo[3,4-g]quinoxaline	ganglioside GM3
CZY	pyrazolo[3,4-g]quinoxaline	DC101 antibody
CZZ	pyrazolo[3,4-g]quinoxaline	Mab25 antibody
DAA	pyrazolo[3,4-g]quinoxaline	Mab73 antibody
DAB	pyrazolo[3,4-g]quinoxaline	4A5 antibody
DAC	pyrazolo[3,4-g]quinoxaline	4E10 antibody
DAD	pyrazolo[3,4-g]quinoxaline	5F12 antibody
DAE	pyrazolo[3,4-g]quinoxaline	VA01 antibody
DAF	pyrazolo[3,4-g]quinoxaline	BL2 antibody
DAG	pyrazolo[3,4-g]quinoxaline	VEGF-related protein
DAH	pyrazolo[3,4-g]quinoxaline	sFLT01
DAI	pyrazolo[3,4-g]quinoxaline	sFLT02
DAJ	pyrazolo[3,4-g]quinoxaline	Peptide B3
DAK	pyrazolo[3,4-g]quinoxaline	TG100801
DAL	pyrazolo[3,4-g]quinoxaline	sorafenib
DAM	pyrazolo[3,4-g]quinoxaline	G6-31 antibody
DAN	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	ranibizumab
DAO	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	bevacizumab
DAP	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	aflibercept
DAQ	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	KH902 VEGF receptor-Fc fusion protein
DAR	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-	2C3 antibody

	indazole	
DAS	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	ORA102
DAT	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	pegaptanib
DAU	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	bevasiranib
DAV	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	SIRNA-027
DAW	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	decursin
DAX	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	decursinol
DAY	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	picropodophyllin
DAZ	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	guggulsterone
DBA	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	PLG101
DBB	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	eicosanoid LXA4
DBC	6-[2-	PTK787

	(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	
DBD	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	pazopanib
DBE	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	axitinib
DBF	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	CDDO-Me
DBG	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	CDDO-Imm
DBH	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	shikonin
DBI	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	beta-hydroxyisovalerylshikonin
DBJ	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	ganglioside GM3
DBK	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	DC101 antibody
DBL	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	Mab25 antibody
DBM	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-	Mab73 antibody

	indazole	
DBN	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	4A5 antibody
DBO	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	4E10 antibody
DBP	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	5F12 antibody
DBQ	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	VA01 antibody
DBR	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	BL2 antibody
DBS	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	VEGF-related protein
DBT	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	sFLT01
DBU	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	sFLT02
DBV	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	Peptide B3
DBW	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	TG100801
DBX	6-[2-	sorafenib

	(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	
DBY	6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole	G6-31 antibody
DBZ	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	ranibizumab
DCA	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	bevacizumab
DCB	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	aflibercept
DCC	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	KH902 VEGF receptor-Fc fusion protein
DCD	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	2C3 antibody
DCE	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	ORA102
DCF	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	pegaptanib
DCG	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	bevasiranib
DCH	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	SIRNA-027
DCI	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	decursin
DCJ	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	decursinol
DCK	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-	picropodophyllin

	yl}-piperidine-4-ylamine	
DCL	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	guggulsterone
DCM	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	PLG101
DCN	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	eicosanoid LXA4
DCO	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	PTK787
DCP	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	pazopanib
DCQ	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	axitinib
DCR	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	CDDO-Me
DCS	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	CDDO-Imm
DCT	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	shikonin
DCU	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	beta-hydroxyisovalerylshikonin
DCV	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	ganglioside GM3
DCW	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	DC101 antibody
DCX	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	Mab25 antibody
DCY	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-	Mab73 antibody

	yl}-piperidine-4-ylamine	
DCZ	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	4A5 antibody
DDA	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	4E10 antibody
DDB	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	5F12 antibody
DDC	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	VA01 antibody
DDD	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	BL2 antibody
DDE	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	VEGF-related protein
DDF	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	sFLT01
DDG	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	sFLT02
DDH	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	Peptide B3
DDI	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	TG100801
DDJ	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	sorafenib
DDK	1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine	G6-31 antibody
DDL	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	ranibizumab
DDM	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-	bevacizumab

	dimethoxyquinazoline	
DDN	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	aflibercept
DDO	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	KH902 VEGF receptor-Fc fusion protein
DDP	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	2C3 antibody
DDQ	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	ORA102
DDR	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	pegaptanib
DDS	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	bevasiranib
DDT	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	SIRNA-027
DDU	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	decursin
DDV	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	decursinol
DDW	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	picropodophyllin
DDX	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	guggulsterone
DDY	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	PLG101
DDZ	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	eicosanoid LXA4
DEA	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-	PTK787

	dimethoxyquinazoline	
DEB	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	pazopanib
DEC	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	axitinib
DED	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	CDDO-Me
DEE	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	CDDO-Imm
DEF	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	shikonin
DEG	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	beta-hydroxyisovalerylshikonin
DEH	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	ganglioside GM3
DEI	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	DC101 antibody
DEJ	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	Mab25 antibody
DEK	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	Mab73 antibody
DEL	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	4A5 antibody
DEM	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	4E10 antibody
DEN	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	5F12 antibody
DEO	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-	VA01 antibody

	dimethoxyquinazoline	
DEP	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	BL2 antibody
DEQ	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	VEGF-related protein
DER	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	sFLT01
DES	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	sFLT02
DET	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	Peptide B3
DEU	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	TG100801
DEV	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	sorafenib
DEW	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	G6-31 antibody
DEX	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	ranibizumab
DEY	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	bevacizumab
DEZ	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	aflibercept
DFA	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	KH902 VEGF receptor-Fc fusion protein
DFB	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	2C3 antibody
DFC	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-	ORA102

	2-yl)-1H-quinoline-2-one	
DFD	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	pegaptanib
DFE	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	bevasiranib
DFF	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	SIRNA-027
DFG	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	decursin
DFH	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	decursinol
DFI	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	picropodophyllin
DFJ	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	guggulsterone
DFK	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	PLG101
DFL	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	eicosanoid LXA4
DFM	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	PTK787
DFN	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	pazopanib
DFO	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	axitinib
DFP	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	CDDO-Me
DFQ	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-	CDDO-Imm

	2-yl)-1H-quinoline-2-one	
DFR	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	shikonin
DFS	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	beta-hydroxyisovalerylshikonin
DFT	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	ganglioside GM3
DFU	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	DC101 antibody
DFV	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	Mab25 antibody
DFW	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	Mab73 antibody
DFX	4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline	4A5 antibody
DFY	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	4E10 antibody
DFZ	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	5F12 antibody
DGA	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	VA01 antibody
DGB	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	BL2 antibody
DGC	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	VEGF-related protein
DGD	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	sFLT01
DGE	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-	sFLT02

	2-yl)-1H-quinoline-2-one	
DGF	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	Peptide B3
DGG	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	TG100801
DGH	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	sorafenib
DGI	4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one	G6-31 antibody
DGJ	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	ranibizumab
DGK	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	bevacizumab
DGL	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	aflibercept
DGM	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	KH902 VEGF receptor-Fc fusion protein
DGN	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	2C3 antibody
DGO	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	ORA102
DGP	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	pegaptanib
DGQ	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	bevasiranib
DGR	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	SIRNA-027
DGS	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-	decursin

	quinolyl)oxy]phenyl}methaneone	
DGT	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	decursinol
DGU	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	picropodophyllin
DGV	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	guggulsterone
DGW	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	PLG101
DGX	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	eicosanoid LXA4
DGY	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	PTK787
DGZ	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	pazopanib
DHA	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	axitinib
DHB	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	CDDO-Me
DHC	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	CDDO-Imm
DHD	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	shikonin
DHE	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	beta-hydroxyisovalerylshikonin
DHF	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	ganglioside GM3
DHG	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-	DC101 antibody

	quinolyl)oxy]phenyl}methaneone	
DHH	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	Mab25 antibody
DHI	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	Mab73 antibody
DHJ	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	4A5 antibody
DHK	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	4E10 antibody
DHL	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	5F12 antibody
DHM	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	VA01 antibody
DHN	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	BL2 antibody
DHO	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	VEGF-related protein
DHP	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	sFLT01
DHQ	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	sFLT02
DHR	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	Peptide B3
DHS	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	TG100801
DHT	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone	sorafenib
DHU	(4-tert-butylphenyl){4-[(6,7-dimethoxy-4-	G6-31 antibody

	quinolyl)oxy]phenyl}methaneone	
DHV	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	ranibizumab
DHW	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	bevacizumab
DHX	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	aflibercept
DHY	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	KH902 VEGF receptor-Fc fusion protein
DHZ	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	2C3 antibody
DIA	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	ORA102
DIB	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	pegaptanib
DIC	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	bevasiranib
DID	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	SIRNA-027
DIE	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	decursin
DIF	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	decursinol
DIG	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	picropodophyllin
DIH	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	guggulsterone
DII	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-	PLG101

	isoxazolecarboxamide	
DIJ	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	eicosanoid LXA4
DIK	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	PTK787
DIL	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	pazopanib
DIM	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	axitinib
DIN	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	CDDO-Me
DIO	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	CDDO-Imm
DIP	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	shikonin
DIQ	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	beta-hydroxyisovalerylshikonin
DIR	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	ganglioside GM3
DIS	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	DC101 antibody
DIT	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	Mab25 antibody
DIU	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	Mab73 antibody
DIV	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	4A5 antibody
DIW	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-	4E10 antibody

	isoxazolecarboxamide	
DIX	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	5F12 antibody
DIY	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	VA01 antibody
DIZ	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	BL2 antibody
DJA	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	VEGF-related protein
DJB	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	sFLT01
DJC	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	sFLT02
DJD	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	Peptide B3
DJE	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	TG100801
DJF	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	sorafenib
DJG	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	G6-31 antibody
DJH	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	ranibizumab
DJI	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	bevacizumab
DJJ	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	aflibercept
DJK	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	KH902 VEGF receptor-Fc fusion protein
DJL	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	2C3 antibody
DJM	trans-4-[(6,7-dimethoxyquinoxaline-	ORA102

	2-yl)amino]cyclohexanol	
DJN	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	pegaptanib
DJO	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	bevasiranib
DJP	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	SIRNA-027
DJQ	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	decursin
DJR	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	decursinol
DJS	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	picropodophyllin
DJT	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	guggulsterone
DJU	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	PLG101
DJV	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	eicosanoid LXA4
DJW	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	PTK787
DJX	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	pazopanib
DJY	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	axitinib
DJZ	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	CDDO-Me
DKA	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	CDDO-Imm
DKB	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	shikonin
DKC	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	beta-hydroxyisovalerylshikonin
DKD	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	ganglioside GM3
DKE	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	DC101 antibody
DKF	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	Mab25 antibody
DKG	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	Mab73 antibody
DKH	trans-4-[(6,7-dimethoxyquinoxaline-	4A5 antibody

	2-yl)amino]cyclohexanol	
DKI	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	4E10 antibody
DKJ	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	5F12 antibody
DKK	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	VA01 antibody
DKL	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	BL2 antibody
DKM	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	VEGF-related protein
DKN	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	sFLT01
DKO	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	sFLT02
DKP	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	Peptide B3
DKQ	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	TG100801
DKR	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	sorafenib
DKS	trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol	G6-31 antibody
DKT	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	ranibizumab
DKU	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	bevacizumab
DKV	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	aflibercept
DKW	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	KH902 VEGF receptor-Fc fusion protein
DKX	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	2C3 antibody
DKY	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	ORA102
DKZ	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-	pegaptanib

	dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	
DLA	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	bevasiranib
DLB	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	SIRNA-027
DLC	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	decursin
DLD	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	decursinol
DLE	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	picropodophyllin
DLF	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	guggulsterone
DLG	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	PLG101
DLH	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	eicosanoid LXA4
DLI	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	PTK787
DLJ	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	pazopanib
DLK	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	axitinib
DLL	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	CDDO-Me
DLM	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	CDDO-Imm
DLN	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-	shikonin

	dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	
DLO	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	beta-hydroxyisovalerylshikonin
DLP	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	ganglioside GM3
DLQ	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	DC101 antibody
DLR	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	Mab25 antibody
DLS	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	Mab73 antibody
DLT	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	4A5 antibody
DLU	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	4E10 antibody
DLV	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	5F12 antibody
DLW	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	VA01 antibody
DLX	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	BL2 antibody
DLY	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	VEGF-related protein
DLZ	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	sFLT01
DMA	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	sFLT02
DMB	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-	Peptide B3

	dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	
DMC	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	TG100801
DMD	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	sorafenib
DME	(Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid	G6-31 antibody
DMF	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	ranibizumab
DMG	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	bevacizumab
DMH	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	aflibercept
DMI	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	KH902 VEGF receptor-Fc fusion protein
DMJ	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	2C3 antibody
DMK	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	ORA102
DML	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	pegaptanib
DMM	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic	bevasiranib

	acid	
DMN	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	SIRNA-027
DMO	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	decursin
DMP	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	decursinol
DMQ	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	picropodophyllin
DMR	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	guggulsterone
DMS	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	PLG101
DMT	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	eicosanoid LXA4
DMU	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	PTK787
DMV	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	pazopanib
DMW	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	axitinib
DMX	5-(5-fluoro-2-oxo-1,2-	CDDO-Me

	dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	
DMY	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	CDDO-Imm
DMZ	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	shikonin
DNA	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	beta-hydroxyisovalerylshikonin
DNB	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	ganglioside GM3
DNC	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	DC101 antibody
DND	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	Mab25 antibody
DNE	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	Mab73 antibody
DNF	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	4A5 antibody
DNG	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	4E10 antibody
DNH	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic	5F12 antibody

	acid	
DNI	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	VA01 antibody
DNJ	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	BL2 antibody
DNK	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	VEGF-related protein
DNL	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	sFLT01
DNM	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	sFLT02
DNN	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	Peptide B3
DNO	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	TG100801
DNP	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	sorafenib
DNQ	5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid	G6-31 antibody
DNR	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	ranibizumab
DNS	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	bevacizumab
DNT	1-(4-chloroanilino)-4-(4-	aflibercept

	pyridylmethyl)phthalazine	
DNU	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	KH902 VEGF receptor-Fc fusion protein
DNV	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	2C3 antibody
DNW	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	ORA102
DNX	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	pegaptanib
DNY	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	bevasiranib
DNZ	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	SIRNA-027
DOA	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	decursin
DOB	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	decursinol
DOC	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	picropodophyllin
DOD	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	guggulsterone
DOE	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	PLG101
DOF	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	eicosanoid LXA4
DOG	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	PTK787
DOH	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	pazopanib
DOI	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	axitinib
DOJ	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	CDDO-Me
DOK	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	CDDO-Imm
DOL	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	shikonin
DOM	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	beta-hydroxyisovalerylshikonin
DON	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	ganglioside GM3
DOO	1-(4-chloroanilino)-4-(4-	DC101 antibody

	pyridylmethyl)phthalazine	
DOP	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	Mab25 antibody
DOQ	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	Mab73 antibody
DOR	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	4A5 antibody
DOS	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	4E10 antibody
DOT	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	5F12 antibody
DOU	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	VA01 antibody
DOV	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	BL2 antibody
DOW	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	VEGF-related protein
DOX	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	sFLT01
DOY	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	sFLT02
DOZ	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	Peptide B3
DPA	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	TG100801
DPB	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	sorafenib
DPC	1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine	G6-31 antibody
DPD	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	ranibizumab
DPE	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	bevacizumab
DPF	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	aflibercept
DPG	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	KH902 VEGF receptor-Fc fusion protein
DPH	N-[4-(3-amino-1H-indazole-4-	2C3 antibody

	yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	
DPI	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	ORA102
DPJ	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	pegaptanib
DPK	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	bevasiranib
DPL	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	SIRNA-027
DPM	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	decursin
DPN	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	decursinol
DPO	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	picropodophyllin
DPP	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	guggulsterone
DPQ	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	PLG101
DPR	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	eicosanoid LXA4
DPS	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	PTK787
DPT	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	pazopanib
DPU	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	axitinib
DPV	N-[4-(3-amino-1H-indazole-4-	CDDO-Me

	yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	
DPW	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	CDDO-Imm
DPX	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	shikonin
DPY	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	beta-hydroxyisovalerylshikonin
DPZ	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	ganglioside GM3
DQA	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	DC101 antibody
DQB	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	Mab25 antibody
DQC	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	Mab73 antibody
DQD	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	4A5 antibody
DQE	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	4E10 antibody
DQF	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	5F12 antibody
DQG	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	VA01 antibody
DQH	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	BL2 antibody
DQI	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	VEGF-related protein
DQJ	N-[4-(3-amino-1H-indazole-4-	sFLT01

	yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	
DQK	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	sFLT02
DQL	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	Peptide B3
DQM	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	TG100801
DQN	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	sorafenib
DQO	N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea	G6-31 antibody
DQP	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	ranibizumab
DQQ	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	bevacizumab
DQR	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	aflibercept
DQS	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	KH902 VEGF receptor-Fc fusion protein
DQT	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	2C3 antibody
DQU	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	ORA102
DQV	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	pegaptanib
DQW	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	bevasiranib
DQX	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	SIRNA-027
DQY	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	decursin
DQZ	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	decursinol
DRA	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	picropodophyllin
DRB	1, 2-dimethyl-7- (2-thiophene)	guggulsterone

	imidazolo [5, 4-g] quinoxaline	
DRC	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	PLG101
DRD	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	eicosanoid LXA4
DRE	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	PTK787
DRF	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	pazopanib
DRG	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	axitinib
DRH	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	CDDO-Me
DRI	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	CDDO-Imm
DRJ	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	shikonin
DRK	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	beta-hydroxyisovalerylshikonin
DRL	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	ganglioside GM3
DRM	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	DC101 antibody
DRN	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	Mab25 antibody
DRO	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	Mab73 antibody
DRP	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	4A5 antibody
DRQ	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	4E10 antibody
DRR	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	5F12 antibody
DRS	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	VA01 antibody
DRT	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	BL2 antibody
DRU	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	VEGF-related protein
DRV	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	sFLT01
DRW	1, 2-dimethyl-7- (2-thiophene)	sFLT02

	imidazolo [5, 4-g] quinoxaline	
DRX	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	Peptide B3
DRY	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	TG100801
DRZ	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	sorafenib
DSA	1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline	G6-31 antibody
DSB	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	ranibizumab
DSC	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	bevacizumab
DSD	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	aflibercept
DSE	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	KH902 VEGF receptor-Fc fusion protein
DSF	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	2C3 antibody
DSG	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	ORA102
DSH	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	pegaptanib
DSI	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	bevasiranib
DSJ	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	SIRNA-027
DSK	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	decursin
DSL	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	decursinol
DSM	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	picropodophyllin
DSN	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	guggulsterone
DSO	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	PLG101
DSP	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	eicosanoid LXA4
DSQ	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	PTK787
DSR	1, 2-dimethyl-6-phenyl imidazolo [5,	pazopanib

	4-g] quinoxaline	
DSS	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	axitinib
DST	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	CDDO-Me
DSU	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	CDDO-Imm
DSV	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	shikonin
DSW	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	beta-hydroxyisovalerylshikonin
DSX	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	ganglioside GM3
DSY	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	DC101 antibody
DSZ	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	Mab25 antibody
DTA	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	Mab73 antibody
DTB	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	4A5 antibody
DTC	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	4E10 antibody
DTD	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	5F12 antibody
DTE	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	VA01 antibody
DTF	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	BL2 antibody
DTG	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	VEGF-related protein
DTH	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	sFLT01
DTI	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	sFLT02
DTJ	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	Peptide B3
DTK	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	TG100801
DTL	1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline	sorafenib
DTM	1, 2-dimethyl-6-phenyl imidazolo [5,	G6-31 antibody

	4-g] quinoxaline	
DTN	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	ranibizumab
DTO	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	bevacizumab
DTP	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	aflibercept
DTQ	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	KH902 VEGF receptor-Fc fusion protein
DTR	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	2C3 antibody
DTS	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	ORA102
DTT	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	pegaptanib
DTU	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	bevasiranib
DTV	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	SIRNA-027
DTW	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	decursin
DTX	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	decursinol
DTY	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	picropodophyllin
DTZ	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	guggulsterone
DUA	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	PLG101
DUB	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	eicosanoid LXA4
DUC	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	PTK787
DUD	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	pazopanib
DUE	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	axitinib
DUF	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	CDDO-Me
DUG	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	CDDO-Imm
DUH	1, 2-dimethyl-6- (2-thiophene)	shikonin

	imidazolo [5, 4-g] quinoxaline	
DUI	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	beta-hydroxyisovalerylshikonin
DUJ	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	ganglioside GM3
DUK	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	DC101 antibody
DUL	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	Mab25 antibody
DUM	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	Mab73 antibody
DUN	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	4A5 antibody
DUO	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	4E10 antibody
DUP	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	5F12 antibody
DUQ	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	VA01 antibody
DUR	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	BL2 antibody
DUS	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	VEGF-related protein
DUT	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	sFLT01
DUU	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	sFLT02
DUV	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	Peptide B3
DUW	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	TG100801
DUX	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	sorafenib
DUY	1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline	G6-31 antibody
DUZ	AG1295	ranibizumab
DVA	AG1295	bevacizumab
DVB	AG1295	aflibercept
DVC	AG1295	KH902 VEGF receptor-Fc fusion protein
DVD	AG1295	2C3 antibody
DVE	AG1295	ORA102
DVF	AG1295	pegaptanib

DVG	AG1295	bevasiranib
DVH	AG1295	SIRNA-027
DVI	AG1295	decursin
DVJ	AG1295	decursinol
DVK	AG1295	picropodophyllin
DVL	AG1295	guggulsterone
DVM	AG1295	PLG101
DVN	AG1295	eicosanoid LXA4
DVO	AG1295	PTK787
DVP	AG1295	pazopanib
DVQ	AG1295	axitinib
DVR	AG1295	CDDO-Me
DVS	AG1295	CDDO-Imm
DVT	AG1295	shikonin
DVU	AG1295	beta-hydroxyisovalerylshikonin
DVV	AG1295	ganglioside GM3
DVW	AG1295	DC101 antibody
DVX	AG1295	Mab25 antibody
DVY	AG1295	Mab73 antibody
DVZ	AG1295	4A5 antibody
DWA	AG1295	4E10 antibody
DWB	AG1295	5F12 antibody
DWC	AG1295	VA01 antibody
DWD	AG1295	BL2 antibody
DWE	AG1295	VEGF-related protein
DWF	AG1295	sFLT01
DWG	AG1295	sFLT02
DWH	AG1295	Peptide B3
DWI	AG1295	TG100801
DWJ	AG1295	sorafenib
DWK	AG1295	G6-31 antibody
DWL	AG1296	ranibizumab
DWM	AG1296	bevacizumab
DWN	AG1296	aflibercept
DWO	AG1296	KH902 VEGF receptor-Fc fusion protein
DWP	AG1296	2C3 antibody
DWQ	AG1296	ORA102
DWR	AG1296	pegaptanib
DWS	AG1296	bevasiranib
DWT	AG1296	SIRNA-027
DWU	AG1296	decursin

DWV	AG1296	decursinol
DWW	AG1296	picropodophyllin
DWX	AG1296	guggulsterone
DWY	AG1296	PLG101
DWZ	AG1296	eicosanoid LXA4
DXA	AG1296	PTK787
DXB	AG1296	pazopanib
DXC	AG1296	axitinib
DXD	AG1296	CDDO-Me
DXE	AG1296	CDDO-Imm
DXF	AG1296	shikonin
DXG	AG1296	beta-hydroxyisovalerylshikonin
DXH	AG1296	ganglioside GM3
DXI	AG1296	DC101 antibody
DXJ	AG1296	Mab25 antibody
DXK	AG1296	Mab73 antibody
DXL	AG1296	4A5 antibody
DXM	AG1296	4E10 antibody
DXN	AG1296	5F12 antibody
DXO	AG1296	VA01 antibody
DXP	AG1296	BL2 antibody
DXQ	AG1296	VEGF-related protein
DXR	AG1296	sFLT01
DXS	AG1296	sFLT02
DXT	AG1296	Peptide B3
DXU	AG1296	TG100801
DXV	AG1296	sorafenib
DXW	AG1296	G6-31 antibody
DXX	3-arylquinoline	ranibizumab
DXY	3-arylquinoline	bevacizumab
DXZ	3-arylquinoline	aflibercept
DYA	3-arylquinoline	KH902 VEGF receptor-Fc fusion protein
DYB	3-arylquinoline	2C3 antibody
DYC	3-arylquinoline	ORA102
DYD	3-arylquinoline	pegaptanib
DYE	3-arylquinoline	bevasiranib
DYF	3-arylquinoline	SIRNA-027
DYG	3-arylquinoline	decursin
DYH	3-arylquinoline	decursinol
DYI	3-arylquinoline	picropodophyllin
DYJ	3-arylquinoline	guggulsterone

DYK	3-arylquinoline	PLG101
DYL	3-arylquinoline	eicosanoid LXA4
DYM	3-arylquinoline	PTK787
DYN	3-arylquinoline	pazopanib
DYO	3-arylquinoline	axitinib
DYP	3-arylquinoline	CDDO-Me
DYQ	3-arylquinoline	CDDO-Imm
DYR	3-arylquinoline	shikonin
DYS	3-arylquinoline	beta-hydroxyisovalerylshikonin
DYT	3-arylquinoline	ganglioside GM3
DYU	3-arylquinoline	DC101 antibody
DYV	3-arylquinoline	Mab25 antibody
DYW	3-arylquinoline	Mab73 antibody
DYX	3-arylquinoline	4A5 antibody
DYY	3-arylquinoline	4E10 antibody
DYZ	3-arylquinoline	5F12 antibody
DZA	3-arylquinoline	VA01 antibody
DZB	3-arylquinoline	BL2 antibody
DZC	3-arylquinoline	VEGF-related protein
DZD	3-arylquinoline	sFLT01
DZE	3-arylquinoline	sFLT02
DZF	3-arylquinoline	Peptide B3
DZG	3-arylquinoline	TG100801
DZH	3-arylquinoline	sorafenib
DZI	3-arylquinoline	G6-31 antibody
DZJ	4-pyridyl-2-arylpyrimidine	ranibizumab
DZK	4-pyridyl-2-arylpyrimidine	bevacizumab
DZL	4-pyridyl-2-arylpyrimidine	aflibercept
DZM	4-pyridyl-2-arylpyrimidine	KH902 VEGF receptor-Fc fusion protein
DZN	4-pyridyl-2-arylpyrimidine	2C3 antibody
DZO	4-pyridyl-2-arylpyrimidine	ORA102
DZP	4-pyridyl-2-arylpyrimidine	pegaptanib
DZQ	4-pyridyl-2-arylpyrimidine	bevasiranib
DZR	4-pyridyl-2-arylpyrimidine	SIRNA-027
DZS	4-pyridyl-2-arylpyrimidine	decursin
DZT	4-pyridyl-2-arylpyrimidine	decursinol
DZU	4-pyridyl-2-arylpyrimidine	picropodophyllin
DZV	4-pyridyl-2-arylpyrimidine	guggulsterone
DZW	4-pyridyl-2-arylpyrimidine	PLG101
DZX	4-pyridyl-2-arylpyrimidine	eicosanoid LXA4
DZY	4-pyridyl-2-arylpyrimidine	PTK787

DZZ	4-pyridyl-2-arylpyrimidine	pazopanib
EAA	4-pyridyl-2-arylpyrimidine	axitinib
EAB	4-pyridyl-2-arylpyrimidine	CDDO-Me
EAC	4-pyridyl-2-arylpyrimidine	CDDO-Imm
EAD	4-pyridyl-2-arylpyrimidine	shikonin
EAE	4-pyridyl-2-arylpyrimidine	beta-hydroxyisovalerylshikonin
EAF	4-pyridyl-2-arylpyrimidine	ganglioside GM3
EAG	4-pyridyl-2-arylpyrimidine	DC101 antibody
EAH	4-pyridyl-2-arylpyrimidine	Mab25 antibody
EAI	4-pyridyl-2-arylpyrimidine	Mab73 antibody
EAJ	4-pyridyl-2-arylpyrimidine	4A5 antibody
EAK	4-pyridyl-2-arylpyrimidine	4E10 antibody
EAL	4-pyridyl-2-arylpyrimidine	5F12 antibody
EAM	4-pyridyl-2-arylpyrimidine	VA01 antibody
EAN	4-pyridyl-2-arylpyrimidine	BL2 antibody
EAO	4-pyridyl-2-arylpyrimidine	VEGF-related protein
EAP	4-pyridyl-2-arylpyrimidine	sFLT01
EAQ	4-pyridyl-2-arylpyrimidine	sFLT02
EAR	4-pyridyl-2-arylpyrimidine	Peptide B3
EAS	4-pyridyl-2-arylpyrimidine	TG100801
EAT	4-pyridyl-2-arylpyrimidine	sorafenib
EAU	4-pyridyl-2-arylpyrimidine	G6-31 antibody
EAV	MLN518	ranibizumab
EAW	MLN518	bevacizumab
EAX	MLN518	aflibercept
EAY	MLN518	KH902 VEGF receptor-Fc fusion protein
EAZ	MLN518	2C3 antibody
EBA	MLN518	ORA102
EBB	MLN518	pegaptanib
EBC	MLN518	bevasiranib
EBD	MLN518	SIRNA-027
EBE	MLN518	decursin
EBF	MLN518	decursinol
EBG	MLN518	picropodophyllin
EBH	MLN518	guggulsterone
EBI	MLN518	PLG101
EBJ	MLN518	eicosanoid LXA4
EBK	MLN518	PTK787
EBL	MLN518	pazopanib
EBM	MLN518	axitinib
EBN	MLN518	CDDO-Me

EBO	MLN518	CDDO-Imm
EBP	MLN518	shikonin
EBQ	MLN518	beta-hydroxyisovalerylshikonin
EBR	MLN518	ganglioside GM3
EBS	MLN518	DC101 antibody
EBT	MLN518	Mab25 antibody
EBU	MLN518	Mab73 antibody
EBV	MLN518	4A5 antibody
EBW	MLN518	4E10 antibody
EBX	MLN518	5F12 antibody
EBY	MLN518	VA01 antibody
EBZ	MLN518	BL2 antibody
ECA	MLN518	VEGF-related protein
ECB	MLN518	sFLT01
ECC	MLN518	sFLT02
ECD	MLN518	Peptide B3
ECE	MLN518	TG100801
ECF	MLN518	sorafenib
ECG	MLN518	G6-31 antibody
ECH	PKC412	ranibizumab
ECI	PKC412	bevacizumab
ECJ	PKC412	aflibercept
ECK	PKC412	KH902 VEGF receptor-Fc fusion protein
ECL	PKC412	2C3 antibody
ECM	PKC412	ORA102
ECN	PKC412	pegaptanib
ECO	PKC412	bevasiranib
ECP	PKC412	SIRNA-027
ECQ	PKC412	decursin
ECR	PKC412	decursinol
ECS	PKC412	picropodophyllin
ECT	PKC412	guggulsterone
ECU	PKC412	PLG101
ECV	PKC412	eicosanoid LXA4
ECW	PKC412	PTK787
ECX	PKC412	pazopanib
ECY	PKC412	axitinib
ECZ	PKC412	CDDO-Me
EDA	PKC412	CDDO-Imm
EDB	PKC412	shikonin
EDC	PKC412	beta-hydroxyisovalerylshikonin

EDD	PKC412	ganglioside GM3
EDE	PKC412	DC101 antibody
EDF	PKC412	Mab25 antibody
EDG	PKC412	Mab73 antibody
EDH	PKC412	4A5 antibody
EDI	PKC412	4E10 antibody
EDJ	PKC412	5F12 antibody
EDK	PKC412	VA01 antibody
EDL	PKC412	BL2 antibody
EDM	PKC412	VEGF-related protein
EDN	PKC412	sFLT01
EDO	PKC412	sFLT02
EDP	PKC412	Peptide B3
EDQ	PKC412	TG100801
EDR	PKC412	sorafenib
EDS	PKC412	G6-31 antibody
EDT	AMN107	ranibizumab
EDU	AMN107	bevacizumab
EDV	AMN107	aflibercept
EDW	AMN107	KH902 VEGF receptor-Fc fusion protein
EDX	AMN107	2C3 antibody
EDY	AMN107	ORA102
EDZ	AMN107	pegaptanib
EEA	AMN107	bevasiranib
EEB	AMN107	SIRNA-027
EEC	AMN107	decursin
EED	AMN107	decursinol
EEF	AMN107	picropodophyllin
EEG	AMN107	guggulsterone
EEH	AMN107	PLG101
EEI	AMN107	eicosanoid LXA4
EEJ	AMN107	PTK787
EEK	AMN107	pazopanib
EEL	AMN107	axitinib
EEM	AMN107	CDDO-Me
EEN	AMN107	CDDO-Imm
EEO	AMN107	shikonin
EEP	AMN107	beta-hydroxyisovalerylshikonin
EEQ	AMN107	ganglioside GM3
EER	AMN107	DC101 antibody
EES	AMN107	Mab25 antibody

EET	AMN107	Mab73 antibody
EEU	AMN107	4A5 antibody
EEV	AMN107	4E10 antibody
EEW	AMN107	5F12 antibody
EEX	AMN107	VA01 antibody
EEY	AMN107	BL2 antibody
EEZ	AMN107	VEGF-related protein
EFA	AMN107	sFLT01
EFB	AMN107	sFLT02
EFC	AMN107	Peptide B3
EFD	AMN107	TG100801
EFE	AMN107	sorafenib
EFF	AMN107	G6-31 antibody
EFG	Suramin	ranibizumab
EFH	Suramin	bevacizumab
EFI	Suramin	aflibercept
EFJ	Suramin	KH902 VEGF receptor-Fc fusion protein
EFK	Suramin	2C3 antibody
EFL	Suramin	ORA102
EFM	Suramin	pegaptanib
EFN	Suramin	bevasiranib
EFO	Suramin	SIRNA-027
EFP	Suramin	decursin
EFQ	Suramin	decursinol
EFR	Suramin	picropodophyllin
EFS	Suramin	guggulsterone
EFT	Suramin	PLG101
EFU	Suramin	eicosanoid LXA4
EFV	Suramin	PTK787
EFW	Suramin	pazopanib
EFX	Suramin	axitinib
EFY	Suramin	CDDO-Me
EFZ	Suramin	CDDO-Imm
EGA	Suramin	shikonin
EGB	Suramin	beta-hydroxyisovalerylshikonin
EGC	Suramin	ganglioside GM3
EGD	Suramin	DC101 antibody
EGE	Suramin	Mab25 antibody
EGF	Suramin	Mab73 antibody
EGG	Suramin	4A5 antibody
EGH	Suramin	4E10 antibody

EGI	Suramin	5F12 antibody
EGJ	Suramin	VA01 antibody
EGK	Suramin	BL2 antibody
EGL	Suramin	VEGF-related protein
EGM	Suramin	sFLT01
EGN	Suramin	sFLT02
EGO	Suramin	Peptide B3
EGP	Suramin	TG100801
EGQ	Suramin	sorafenib
EGR	Suramin	G6-31 antibody
EGS	Neomycin	ranibizumab
EGT	Neomycin	bevacizumab
EGU	Neomycin	aflibercept
EGV	Neomycin	KH902 VEGF receptor-Fc fusion protein
EGW	Neomycin	2C3 antibody
EGX	Neomycin	ORA102
EGY	Neomycin	pegaptanib
EGZ	Neomycin	bevasiranib
EHA	Neomycin	SIRNA-027
EHB	Neomycin	decursin
EHC	Neomycin	decursinol
EHD	Neomycin	picropodophyllin
EHE	Neomycin	guggulsterone
EHF	Neomycin	PLG101
EHG	Neomycin	eicosanoid LXA4
EHH	Neomycin	PTK787
EHI	Neomycin	pazopanib
EHJ	Neomycin	axitinib
EHK	Neomycin	CDDO-Me
EHL	Neomycin	CDDO-Imm
EHM	Neomycin	shikonin
EHN	Neomycin	beta-hydroxyisovalerylshikonin
EHO	Neomycin	ganglioside GM3
EHP	Neomycin	DC101 antibody
EHQ	Neomycin	Mab25 antibody
EHR	Neomycin	Mab73 antibody
EHS	Neomycin	4A5 antibody
EHT	Neomycin	4E10 antibody
EHU	Neomycin	5F12 antibody
EHV	Neomycin	VA01 antibody
EHW	Neomycin	BL2 antibody

EHX	Neomycin	VEGF-related protein
EHY	Neomycin	sFLT01
EHZ	Neomycin	sFLT02
EIA	Neomycin	Peptide B3
EIB	Neomycin	TG100801
EIC	Neomycin	sorafenib
EID	Neomycin	G6-31 antibody

[00105] The invention further provides compositions comprising an effective amount of a PDGF antagonist and a VEGF antagonist of Table 1. The compositions are useful for treating or preventing an ophthalmological disease. In another embodiment, the PDGF antagonist and VEGF antagonist are those, respectively, of any of pairs A-EID set forth in Table 2. In a particular embodiment, the PDGF antagonist of the present compositions is Antagonist A or a pharmaceutically acceptable salt thereof. In a particular embodiment, the PDGF antagonist of the present compositions is Antagonist B or a pharmaceutically acceptable salt thereof. In a particular embodiment, the PDGF antagonist of the present compositions is Antagonist C or a pharmaceutically acceptable salt thereof. In a particular embodiment, the PDGF antagonist of the present compositions is Antagonist D or a pharmaceutically acceptable salt thereof. In another embodiment, the VEGF antagonist is ranibizumab, bevacizumab or aflibercept, or a pharmaceutically acceptable salt thereof.

[00106] The methods or compositions according to the invention can be administered alone or in conjunction with another therapy and can be provided at home, a doctor's office, a clinic, a hospital's outpatient department, or a hospital. Treatment can begin at a hospital so that the doctor can observe the therapy's effects closely and make any adjustments that are needed. The duration of the administration can depend on the type of ophthalmological disease being treated or prevented, the age and condition of the mammal, the stage and type of the mammal's disease, and how the mammal responds to the treatment. Additionally, a person having a greater risk of developing an ophthalmological disease (*e.g.*, a diabetic patient) can receive treatment to inhibit or delay the onset of symptoms. In one embodiment, the present methods or compositions allow for the administration of a relatively lower dose of each antagonist.

[00107] The dosage and frequency of administration of each antagonist can be controlled independently. For example, one antagonist can be administered three times per day, while the other antagonist can be administered once per day. Administration can be performed in on-and-off cycles that include rest periods so that the mammal's body has a chance to recover from a side effect, if any. The antagonists can also be present in the same composition.

[00108] 5.3 Agents useful for treatmnet or prevention of an opthalmological disease

[00109] 5.3.1 PDGF Antagonists

[00110] In one embodiment, the PDGF antagonist of Table 1 or 2 is ARC-127. ARC-127 is a 40kD PEGylated, anti-PDGF aptamer having the sequence CAGGCUACGN CGTAGAGCAU CANTGATCCU GT (see Examples 3 and 6 of US Patent Application No. 20050096257, incorporated herein by reference in its entirety) having 2′-fluoro-2′-deoxyuridine at positions 6, 20 and 30; 2′-fluoro-2′-deoxycytidine at positions 8, 21, 28, and 29; 2′-O-Methyl-2′-deoxyguanosine at positions 9, 15, 17, and 31; 2′-O-Methyl-2′-deoxyadenosine at position 22; "N" in positions 10 and 23 from a hexaethylene-glycol phosphoramidite; and an inverted orientation T (i.e., 3′-3′-linked) at position 32.

[00111] In another embodiment, the PDGF antagonist of Table 1 or 2 is a compound of Formula A (see Figure 6), wherein w is an integer from 2 to 12. In another embodiment, the PDGF antagonist is a compound of Formula A, wherein w is an integer from 4 to 10. In another embodiment, the PDGF antagonist is a compound of Formula A, wherein w is 5, 6, 7, or 8. In one embodiment, the PDGF antagonist is a compound of Formula A, wherein w is 5.

In another embodiment, the PDGF antagonist is a compound of Formula A, wherein w is 6. In another embodiment, the PDGF antagonist is a compound of Formula A, wherein w is 7. In another embodiment, the PDGF antagonist is a compound of Formula A, wherein w is 8. In one embodiment, the PDGF antagonist has the structure of Figure 7.

[00112] In another embodiment, the PDGF antagonist of Table 1 or 2 is Antagonist A or a pharmaceutically acceptable salt thereof. The chemical name of Antagonist A is [(monomethoxy 20K polyethylene glycol carbamoyl-N2-) (monomethoxy 20K polyethylene glycol carbamoyl-N6-)]-lysine-amido-6-hexandilyl-(1-5')-2'-deoxycytidylyl-(3'-5')-2'-deoxyadenylyl-(3'-5')-2'-deoxyguanylyl-(3'-5')-2'-deoxyguanylyl-(3'-5')-2'-deoxycytidylyl-(3'-5')-2'-deoxy-2'-fluorouridylyl-(3'-5')-2'-deoxyadenylyl-(3'-5')-2'- deoxy-2'-fluorocytidylyl-(3'-5')-2'- deoxy-2'-methoxyguanylyl-(3'-1)-PO_3- hexa(ethyloxy)-(18-5')-2'-deoxycytidylyl-(3'-5')-2'-deoxyguanylyl-(3'-5')- thymidylyl-(3'-5')-2'-deoxyadenylyl-(3'-5')-2'- deoxy-2'-methoxyguanylyl-(3'-5')-2'-deoxyadenylyl-(3'-5')-2'- deoxy-2'-methoxyguanylyl-(3'-5')-2'-deoxycytidylyl-(3'-5')-2'-deoxyadenylyl-(3'-5')-2'- deoxy-2'-fluorouridylyl-(3'-5')-2'- deoxy-2'-fluorocytidylyl-(3'-5')-2'- deoxy-2'-methoxyadenylyl-(3'-1)- PO_3-hexa(ethyloxy)-(18-5')-thymidylyl-(3'-5')-2'-deoxyguanylyl-(3'-5')-2'-deoxyadenylyl-(3'-5')-thymidylyl-(3'-5')-2'- deoxy-2'-fluorocytidylyl-(3'-5')-2'- deoxy-2'-fluorocytidylyl-(3'-5')-2'- deoxy-2'-fluorouridylyl-(3'-5')-2'-methoxyguanylyl-(3'-3')-thymidine.

[00113] The structure of Antagonist A is shown in Figure 7.

[00114] The sequence of Antagonist A is:

5'-[mPEG2 40kD]- [(HN-$(CH_2)_6$O] CAGGCU_fA$C_{cf}$$G_m$ [(PO_3($CH_2CH_2O)_6$] CGTAG_mAG_mCA$U_f$$C_f$$A_m$ [O($CH_2CH_2O)_6$] TGAT$C_f$$C_f$$U_f$$G_m$-iT-3'

where:

[mPEG2 40 kD] represents two 20 kD polyethylene glycol (PEG) polymer chains, in one embodiment two about 20 kD PEG polymer chains, that are covalently attached to the two amino groups of a lysine residue via carbamate linkages. This moiety is in turn linked with the oligonucleotide via the amino linker described below.

[(HN-$(CH_2)_6$O] represents a bifunctional α-hydroxy-ω-amino linker that is covalently attached to the PEG polymer via an amide bond. The linker is attached to the oligonucleotide at the 5'-end of Antagonist A by a phosphodiester linkage.

[PO_3($CH_2CH_2O)_6$] represents the hexaethylene glycol (HEX) moieties that join segments of the oligonucleotide via phosphodiester linkages. Antagonist A has two HEX linkages that join together the 9^{th} and 10^{th} nucleotides and 21^{st} and 22^{nd} nucleotides via phosphodiester linkages between the linker and the respective nucleotides.

C, A, G, and T represent the single letter code for the 2'-deoxy derivatives of cytosine, adenosine, guanosine, and thymidine nucleic acids, respectively. Antagonist A has four 2'-deoxyribocytosine, six 2'-deoxyriboadenosine, four 2'-deoxyriboguanosine, and four 2'-deoxyribothymidine.

G_m and A_m represent 2'-methoxy substituted forms of guanosine and adenosine, respectively. Antagonist A has four 2'-methoxyguanosines and one 2'-methoxyadenosine. C_f and U_f represent the 2'-fluoro substituted forms of cytosine and uridine, respectively. Antagonist A has four 2'-fluorocytosines and three 2'-fluorouridines.

[00115] The phosphodiester linkages in the oligonucleotide, with the exception of the 3'-terminus, connect the 5'- and 3'-oxygens of the ribose ring with standard nucleoside phosphodiester linkages. The phosphodiester linkage between the 3'-terminal thymidine and the penultimate G_m links their respective 3'-oxygens, which is referred to as the 3',3'-cap.

[00116] Antagonist A has a molecular weight from 40,000 to 60,000 Daltons, in one embodiment from about 40,000 to about 60,000 Daltons, and can be colorless to slightly yellow in solution. Antagonist A can be present in a solution of monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate as buffering

agents and sodium chloride as a tonicity adjuster. Antagonist A is a hydrophilic polymer. The Antagonist A sodium salt is soluble in water and in phosphate-buffered saline (PBS), as assessed by visual inspection, to at least 50 mg (based on oligonucleotide weight)/mL solution.

[00117] In one embodiment, Antagonist A is manufactured using an iterative chemical synthesis procedure to produce the oligonucleotide portion, which is then covalently bonded to a pegylation reagent, as further described in Example 4.

[00118] In another embodiment, the PDGF antagonist of Table 1 or 2 is a compound of Formula B (see Figure 8), wherein w is an integer from 2 to 12. In another embodiment, the PDGF antagonist is a compound of Formula B, wherein w is an integer from 4 to 10. In another embodiment, the PDGF antagonist is a compound of Formula B, wherein w is 5, 6, 7, or 8. In one embodiment, the PDGF antagonist is a compound of Formula B, wherein w is 5. In another embodiment, the PDGF antagonist is a compound of Formula B, wherein w is 6. In another embodiment, the PDGF antagonist is a compound of Formula B, wherein w is 7. In another embodiment, the PDGF antagonist is a compound of Formula B, wherein w is 8. In one embodiment, the PDGF antagonist is a compound of Formula B having two 20 kD polyethylene glycol (PEG) polymer chains. In one embodiment, the PDGF antagonist is a compound of Formula B having an α-hydroxy-ω-amino group. In one embodiment, the α-hydroxy-ω-amino group is attached to the oligonucleotide by a phosphodiester linkage. In one embodiment, the α-hydroxy-ω-amino group is attached at the 5'-end of the oligonucleotide. In one embodiment, the PDGF antagonist is a compound of Formula B having hexaethylene glycol (HEX) moieties that join segments of the oligonucleotide via phosphodiester linkages. In one embodiment, the PDGF antagonist hexaethylene glycol (HEX) moieties join together the 9th and 10th nucleotides and 21st and 22nd nucleotides of the oligonucleotide via phosphodiester linkages between the linker and the respective nucleotides. In one embodiment, the PDGF antagonist has the structure of Figure 9.

[00119] In another embodiment, the PDGF antagonist of Table 1 or 2 is Antagonist B or a pharmaceutically acceptable salt thereof.

[00120] The structure of Antagonist B is shown in Figure 9.

[00121] In another embodiment, the PDGF antagonist of Table 1 or 2 is a compound of Formula C (see Figure 10), wherein w is an integer from 2 to 12. In another embodiment, the PDGF antagonist is a compound of Formula C, wherein w is an integer from 4 to 10. In another embodiment, the PDGF antagonist is a compound of Formula C, wherein w is 5, 6, 7, or 8. In one embodiment, the PDGF antagonist is a compound of Formula C, wherein w is 5. In another embodiment, the PDGF antagonist is a compound of Formula C, wherein w is 6. In another embodiment, the PDGF antagonist is a compound of Formula C, wherein w is 7. In another embodiment, the PDGF antagonist is a compound of Formula C, wherein w is 8. In one embodiment, the PDGF antagonist is a compound of Formula C having an α-hydroxy-ω-amino group. In one embodiment, the α-hydroxy-ω-amino group is attached to the oligonucleotide by a phosphodiester linkage. In one embodiment, the α-hydroxy-ω-amino group is attached at the 5'-end of the oligonucleotide. In one embodiment, the PDGF antagonist is a compound of Formula C having hexaethylene glycol (HEX) moieties that join segments of the oligonucleotide via phosphodiester linkages. In one embodiment, the PDGF antagonist hexaethylene glycol (HEX) moieties join together the 9th and 10th nucleotides and 21st and 22nd nucleotides of the oligonucleotide via phosphodiester linkages between the linker and the respective nucleotides. In one embodiment, the PDGF antagonist has the structure of Figure 11.

[00122] In another embodiment, the PDGF antagonist of Table 1 or 2 is Antagonist C or a pharmaceutically acceptable salt thereof.

[00123] The structure of Antagonist C is shown in Figure 11.

[00124] The phosphodiester linkages in the oligonucleotide, with the exception of the 3'-terminus, connect the 5'- and 3'-oxygens of the ribose ring with standard nucleoside phosphodiester linkages. The phosphodiester linkage

between the 3'-terminal thymidine and the penultimate G_m links their respective 3'-oxygens, which is referred to as the 3',3'-cap.

[00125] In another embodiment, the PDGF antagonist of Table 1 or 2 is Antagonist D or a pharmaceutically acceptable salt thereof.

[00126] The structure of Antagonist D is shown in Figure 12.

[00127] In another embodiment, the PDGF antagonist of Table 1 or 2 is a compound of Formula E (see Figure 13), wherein L is a linker, Y is 0 or 1, R is a nonphysiologically active group, lipophilic group or High Molecular Weight Compound, and X is an integer ranging from 1 to 4.

[00128] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody 1B3 or a pharmaceutically acceptable salt thereof (US Patent Publication No. 20090053241 (paragraph 0073 and Table 1), which is hereby incorporated by reference in its entirety).

[00129] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody CDP860 or a pharmaceutically acceptable salt thereof (Serruys et al. (2003) Int. J. Cardiovasc Intervent. 5:214-22, which is hereby incorporated by reference in its entirety).

[00130] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody IMC-3G3 or a pharmaceutically acceptable salt thereof (Dolloff et al. (2007) Cancer Res. 67:555-62, which is hereby incorporated by reference in its entirety).

[00131] In one embodiment, the PDGF antagonist of Table 1 or 2 is imatinib or a pharmaceutically acceptable salt thereof. A composition comprising imatinib mesylate is commercially available under the trademark Gleevec.

[00132] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody 162.62 or a pharmaceutically acceptable salt thereof (US Patent No. 5,976,534, which is hereby incorporated by reference in its entirety).

[00133] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody 163.31 or a pharmaceutically acceptable salt thereof (US Patent No. 5,976,534, which is hereby incorporated by reference in its entirety).

[00134] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody 169.14 or a pharmaceutically acceptable salt thereof (US Patent No. 5,976,534, which is hereby incorporated by reference in its entirety).

[00135] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody 169.31 or a pharmaceutically acceptable salt thereof (US Patent No. 5,976,534, which is hereby incorporated by reference in its entirety).

[00136] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody αR1 or a pharmaceutically acceptable salt thereof (US Patent No. 5,833,986 (Column 4, lines 46-51), which is hereby incorporated by reference in its entirety).

[00137] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody 2A1E2 or a pharmaceutically acceptable salt thereof (US Patent No. 5,817,310 (Column 11, lines 52-59), which is hereby incorporated by reference in its entirety).

[00138] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody M4TS.11 or a pharmaceutically acceptable salt thereof (US Patent No. 5,882,644 (Figure 7), which is hereby incorporated by reference in its entirety).

[00139] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody M4TS.22 or a pharmaceutically acceptable salt thereof (US Patent No. 5,882,644 (Figure 1), which is hereby incorporated by reference in its entirety).

[00140] In another embodiment, the PDGF antagonist of Table 1 or 2 is A10 or a pharmaceutically acceptable salt thereof (US Patent No. 6,331,555 (Figure 1), which is hereby incorporated by reference in its entirety).

[00141] In another embodiment, the PDGF antagonist of Table 1 or 2 is brefeldin A or a pharmaceutically acceptable salt thereof (US Patent No. 5,618,837 (Column 2, lines 15-19), which is hereby incorporated by reference in its entirety).

[00142] In another embodiment, the PDGF antagonist of Table 1 or 2 is sunitinib or a pharmaceutically acceptable salt thereof. A composition comprising sunitinib malate is commercially available under the trademark Sutent.

[00143] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 120.1.2.1.2 or a pharmaceutically acceptable salt thereof (US Patent No. 5,094,941 (Example VI, col. 32, lines 1-15), which is hereby incorporated by reference in its entirety).

[00144] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 121.6.1.1.1 or a pharmaceutically acceptable salt thereof (US Patent No. 5,094,941 (Example VI, col. 32, lines 1-15), which is hereby incorporated by reference in its entirety).

[00145] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 127.5.7.3.1 or a pharmaceutically acceptable salt thereof (US Patent No. 5,094,941 (Example VII, col. 33, lines 1-15), which is hereby incorporated by reference in its entirety).

[00146] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 127.8.2.2.2 or a pharmaceutically acceptable salt thereof (US Patent No. 5,094,941 (Example VII, col. 33, lines 1-15), which is hereby incorporated by reference in its entirety).

[00147] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.6.1 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00148] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.11.1 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00149] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.17.1 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00150] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.18.1 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00151] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.19.1 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00152] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.23.1 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00153] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.24 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00154] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.25 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00155] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.29 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00156] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.33 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00157] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.38 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00158] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.39 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00159] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.40 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00160] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.45 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00161] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.46 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00162] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.48 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00163] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.49 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00164] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 1.51 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00165] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Hyb 6.4.1 or a pharmaceutically acceptable salt thereof (US Patent No. 7,135,174 (col. 32, lines 34-42), which is hereby incorporated by reference in its entirety).

[00166] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody F3 or a pharmaceutically acceptable salt thereof (US Patent Publication No. 20030219839 (paragraph 144), which is hereby incorporated by reference in its entirety).

[00167] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Humanized F3 or a pharmaceutically acceptable salt thereof (US Patent Publication No. 20030219839 (paragraph 153-183), which is hereby incorporated by reference in its entirety).

[00168] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody C1 or a pharmaceutically acceptable salt thereof (US Patent Publication No. 20030219839 (paragraph 192-196), which is hereby incorporated by reference in its entirety).

[00169] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody Humanized C1 or a pharmaceutically acceptable salt thereof (US Patent Publication No. 20030219839 (paragraph 197-199), which is hereby incorporated by reference in its entirety).

[00170] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody 6.4.1 or a pharmaceutically acceptable salt thereof (US Patent Publication No. 20040141969 (Example 4, paragraph 192-197), which is hereby incorporated by reference in its entirety).

[00171] In another embodiment, the PDGF antagonist of Table 1 or 2 is the anti-mPDGF-C goat IgG antibody or a pharmaceutically acceptable salt thereof (Crawford et al. (2009) Cancer Cell 15:21-34, which is hereby incorporated by reference in its entirety).

[00172] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody C3.1 or a pharmaceutically acceptable salt thereof (Kawahara et al. (1987) Biochem. Biophys. Res. Commun. 147:839-845, which is hereby incorporated by reference in its entirety).

[00173] In another embodiment, the PDGF antagonist of Table 1 or 2 is 5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine or a pharmaceutically acceptable salt thereof (Ohnishi et al. (1983) Life Sci. 31:2595-2602, which is hereby incorporated by reference in its entirety).

[00174] In another embodiment, the PDGF antagonist of Table 1 or 2 is interferon or a pharmaceutically acceptable salt thereof (Zagari et al. (1988) Biochem. Biophys 150:1207-12, which is hereby incorporated by reference in its entirety).

[00175] In another embodiment, the PDGF antagonist of Table 1 or 2 is protamine or a pharmaceutically acceptable salt thereof (Huang (1984) J. Cell. Biol. 26:205-220, which is hereby incorporated by reference in its entirety).

[00176] In another embodiment, the PDGF antagonist of Table 1 or 2 is the monoclonal antibody PDGFR-B1 or a pharmaceutically acceptable salt thereof (Ronnestrand, L. and Terracio, L. (1988) J. Biol. Chem. 263: 10429-10435, which is hereby incorporated by reference in its entirety).

[00177] In another embodiment, the PDGF antagonist of Table 1 or 2 is the monoclonal antibody PDGFR-B2 or a pharmaceutically acceptable salt thereof (Ronnestrand, L. and Terracio, L. (1988) J. Biol. Chem. 263: 10429-10435, which is hereby incorporated by reference in its entirety).

[00178] In another embodiment, the PDGF antagonist of Table 1 or 2 is the monoclonal antibody 6D11 or a pharmaceutically acceptable salt thereof (Vassbotn et al. (1990) Biochim. Biophy. Acta, 1054: 246-249, which is hereby incorporated by reference in its entirety).

[00179] In another embodiment, the PDGF antagonist of Table 1 or 2 is the monoclonal antibody Sis 1 or a pharmaceutically acceptable salt thereof (La Rochelle et al. (1989) Mol. Cell. Bio., 9: 3538-3542, which is hereby incorporated by reference in its entirety).

[00180] In another embodiment, the PDGF antagonist of Table 1 or 2 is the monoclonal antibody PR7212 or a pharmaceutically acceptable salt thereof (Seifert et al. (1989) J. Biol. Chem. 264: 8771-8778, which is hereby incorporated by reference in its entirety).

[00181] In another embodiment, the PDGF antagonist of Table 1 or 2 is the monoclonal antibody PR292 or a pharmaceutically acceptable salt thereof (La Rochelle et al. (1993) Cell Growth Differ. 4:547-53, which is hereby incorporated by reference in its entirety).

[00182] In another embodiment, the PDGF antagonist of Table 1 or 2 is the monoclonal antibody HYB 9610 or a pharmaceutically acceptable salt thereof (EP0798002 (see para (0023)), which is hereby incorporated by reference in its entirety).

[00183] In another embodiment, the PDGF antagonist of Table 1 or 2 is the monoclonal antibody HYB 9611 or a pharmaceutically acceptable salt thereof (EP0798002 (see para (0023)), which is hereby incorporated by reference in its entirety).

[00184] In another embodiment, the PDGF antagonist of Table 1 or 2 is the monoclonal antibody HYB 9612 or a pharmaceutically acceptable salt thereof (EP0798002 (see para (0023)), which is hereby incorporated by reference in its entirety).

[00185] In another embodiment, the PDGF antagonist of Table 1 or 2 is the monoclonal antibody HYB 9613 or a pharmaceutically acceptable salt thereof (EP0798002 (see para (0023)), which is hereby incorporated by reference in its entirety).

[00186] In another embodiment, the PDGF antagonist of Table 1 or 2 is 4-(2-(N-(-2-carboxamidoindole) aminoethyl)-benzenesulfonamide or a pharmaceutically acceptable salt thereof (EP0835115, which is hereby incorporated by reference in its entirety).

[00187] In another embodiment, the PDGF antagonist of Table 1 or 2 is 4-(2-(N-(-2-carboxamidoindole)aminoethyl)-sulfonylurea or a pharmaceutically acceptable salt thereof (EP0835115, which is hereby incorporated by reference in its entirety).

[00188] In another embodiment, the PDGF antagonist of Table 1 or 2 is CGP 53716 or a pharmaceutically acceptable salt thereof (Buchdunger, et al. (1995) Proc. Natl. Acad. Sci.;92:2558-2562, which is hereby incorporated by reference in its entirety).

[00189] In another embodiment, the PDGF antagonist of Table 1 or 2 is the antibody g162 or a pharmaceutically acceptable salt thereof (WO1998025971 (see Example 7), which is hereby incorporated by reference in its entirety).

[00190] In another embodiment, the PDGF antagonist of Table 1 or 2 is pyrazolo[3,4-g]quinoxaline or a pharmaceutically acceptable salt thereof (US Pat No. 5476851, which is hereby incorporated by reference in its entirety).

[00191] In another embodiment, the PDGF antagonist of Table 1 or 2 is 6-[2-(methylcarbamoyl)phenylsulphanyl]-3-E-[2-(pyridine-2-yl)ethenyl]-indazole or a pharmaceutically acceptable salt thereof (EP1925941 (see para (0121)), which is hereby incorporated by reference in its entirety).

[00192] In another embodiment, the PDGF antagonist of Table 1 or 2 is 1-{2-[5-(2-methoxy-ethoxy)-benzoimidazole-1-yl]-quinoline-8-yl}-piperidine-4-ylamine or a pharmaceutically acceptable salt thereof (EP1925941 (see para (0121)), which is hereby incorporated by reference in its entirety).

[00193] In another embodiment, the PDGF antagonist of Table 1 or 2 is 4-[4-[N-(4-nitrophenyl)carbamoyl]-1-piperazinyl]-6,7-dimethoxyquinazoline or a pharmaceutically acceptable salt thereof (EP1925941 (see para (0121)), which is hereby incorporated by reference in its entirety).

[00194] In another embodiment, the PDGF antagonist of Table 1 or 2 is 4-amino-5-fluoro-3-(6-(4-methyl-piperazine-1-yl)-1H-benzimidazole-2-yl)-1H-quinoline-2-one or a pharmaceutically acceptable salt thereof (EP1925941 (see para (0121)), which is hereby incorporated by reference in its entirety).

[00195] In another embodiment, the PDGF antagonist of Table 1 or 2 is (4-tert-butylphenyl){4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}methaneone or a pharmaceutically acceptable salt thereof (EP1925941 (see para (0121)), which is hereby incorporated by reference in its entirety).

[00196] In another embodiment, the PDGF antagonist of Table 1 or 2 is 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide or a pharmaceutically acceptable salt thereof (EP1925941 (see para (0121)), which is hereby incorporated by reference in its entirety).

[00197] In another embodiment, the PDGF antagonist of Table 1 or 2 is trans-4-[(6,7-dimethoxyquinoxaline-2-yl)amino]cyclohexanol or a pharmaceutically acceptable salt thereof (EP1925941 (see para (0121)), which is hereby incorporated by reference in its entirety).

[00198] In another embodiment, the PDGF antagonist of Table 1 or 2 is (Z)-3-[(2,4-dimethyl-5-(2-oxo-1,2-dihydroindole-3-ylidenemethyl)-1H-pyrrole-3-yl)-propionic acid or a pharmaceutically acceptable salt thereof (EP1925941 (see para (0121)), which is hereby incorporated by reference in its entirety).

[00199] In another embodiment, the PDGF antagonist of Table 1 or 2 is 5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid or a pharmaceutically acceptable salt thereof (EP1925941 (see para (0121)), which is hereby incorporated by reference in its entirety).

[00200] In another embodiment, the PDGF antagonist of Table 1 or 2 is 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof (EP1925941 (see para (0121)), which is hereby incorporated by reference in its entirety).

[00201] In another embodiment, the PDGF antagonist of Table 1 or 2 is N-[4-(3-amino-1H-indazole-4-yl)phenyl-N'-(2-fluoro-5-methylphenyl)urea or a pharmaceutically acceptable salt thereof (EP1925941 (see para (0121)), which is hereby incorporated by reference in its entirety).

[00202] In another embodiment, the PDGF antagonist of Table 1 or 2 is 1, 2-dimethyl-7- (2-thiophene) imidazolo [5, 4-g] quinoxaline or a pharmaceutically acceptable salt thereof (US Patent No. 6,358,954 (see Figure 4), which is hereby incorporated by reference in its entirety).

[00203] In another embodiment, the PDGF antagonist of Table 1 or 2 is 1, 2-dimethyl-6-phenyl imidazolo [5, 4-g] quinoxaline or a pharmaceutically acceptable salt thereof (US Patent No. 6,358,954 (see Figure 6), which is hereby incorporated by reference in its entirety).

[00204] In another embodiment, the PDGF antagonist of Table 1 or 2 is 1, 2-dimethyl-6- (2-thiophene) imidazolo [5, 4-g] quinoxaline or a pharmaceutically acceptable salt thereof (US Patent No. 6,358,954 (see Figure 2), which is hereby incorporated by reference in its entirety).

[00205] In another embodiment, the PDGF antagonist of Table 1 or 2 is AG1295 or a pharmaceutically acceptable salt thereof (Kovalenko et al. (1994) Cancer Research 54: 6106-6114, which is hereby incorporated by reference in its entirety).

[00206] In another embodiment, the PDGF antagonist of Table 1 or 2 is AG1296 or a pharmaceutically acceptable salt thereof (Kovalenko et al. (1994) Cancer Research 54: 6106-6114, which is hereby incorporated by reference in its entirety).

[00207] In another embodiment, the PDGF antagonist of Table 1 or 2 is 3-arylquinoline or a pharmaceutically acceptable salt thereof (Dolle et al. (1994) J. Med. Chem. 37, 2627-2629, which is hereby incorporated by reference in its entirety).

[00208] In another embodiment, the PDGF antagonist of Table 1 or 2 is 4-pyridyl-2-arylpyrimidine or a pharmaceutically acceptable salt thereof (Buchdunger et al. (1995) Proc. Natl. Acad. Sci. USA. 92: 2558-62, which is hereby incorporated by reference in its entirety).

[00209] In another embodiment, the PDGF antagonist of Table 1 or 2 is sorafenib or a pharmaceutically acceptable salt thereof (US2009081709 (see para (0007)), which is hereby incorporated by reference in its entirety).

[00210] In another embodiment, the PDGF antagonist of Table 1 or 2 is MLN518 or a pharmaceutically acceptable salt thereof (US2009081709 (see para (0007)), which is hereby incorporated by reference in its entirety).

[00211] In another embodiment, the PDGF antagonist of Table 1 or 2 is PKC412 or a pharmaceutically acceptable salt thereof (US2009081709 (see para (0007)), which is hereby incorporated by reference in its entirety).

[00212] In another embodiment, the PDGF antagonist of Table 1 or 2 is AMN107 or a pharmaceutically acceptable salt thereof (US2009081709 (see para (0007)), which is hereby incorporated by reference in its entirety).

[00213] In another embodiment, the PDGF antagonist of Table 1 or 2 is suramin or a pharmaceutically acceptable salt thereof (Williams et al. (1984) J. Biol. Chem. 259:287-5294, which is hereby incorporated by reference in its entirety).

[00214] In another embodiment, the PDGF antagonist of Table 1 or 2 is neomycin or a pharmaceutically acceptable salt thereof (Vassbotn et al. (1992) J. Biol. Chem. 267:15635-15641, which is hereby incorporated by reference in its entirety).

[00215] In another embodiment, the PDGF antagonist of Table 1 or 2 is an antibody or an antibody fragment which binds to an epitope PDGF-C (SEQ ID NO:11), PDGF-C (SEQ ID NO:12), PDGF-D (SEQ ID NO:13) or PDGF-D (SEQ ID NO:14), or any portion of the epitopes.

[00216] PDGF-C epitope: Arg Lys Ser Arg Val Val Asp Leu Asn Leu Leu Thr Glu Glu Val Arg Leu Tyr Ser Cys Thr Pro Arg Asn Phe Ser Val Ser Ile Arg Glu Glu Leu Lys Arg Thr Asp Thr Ile Phe Trp Pro Gly Cys (SEQ ID NO:11)

[00217] PDGF-C epitope: Arg Lys Ser Arg Val Val Asp Leu Asn Leu Leu Thr Glu Glu Val Arg Leu Tyr Ser Cys (SEQ ID NO: 12)

[00218] PDGF-D epitope: Arg Lys Ser Lys Val Asp Leu Asp Arg Leu Asn Asp Asp Ala Lys Arg Tyr Ser Cys Thr Pro Arg Asn Tyr Ser Val Asn Ile Arg Glu Glu Leu Lys Leu Ala Asn Val Val Phe Phe Pro Arg Cys (SEQ ID NO:13)

[00219] PDGF-D epitope: Cys Lys Ser Lys Val Asp Leu Asp Arg Leu Asn Asp Asp Ala Lys Arg Tyr Ser Cys (SEQ ID NO: 14)

[00220] In another embodiment, the PDGF antagonist of Table 1 or 2 is an antibody or an antibody fragment which binds to an epitope of PDGF, such as an epitope of PDGF-A, PDGF-B, PDGF-C, or PDGF-D. In some embodiments, the PDGF antagonist binds to an epitope of PDGF such that binding of PDGF and PDGFR are inhibited. In one embodiment, the epitope encompasses a component of the three dimensional structure of PDGF that is displayed, such that the epitope is exposed on the surface of the folded PDGF molecule. In one embodiment, the epitope is a linear amino acid sequence from PDGF.

[00221] 5.3.2 VEGF Antagonists

[00222] In one embodiment, the VEGF antagonist of Table 1 or 2 is the antibody ranibizumab or a pharmaceutically acceptable salt thereof (see US Patent No. 7,060,269 (Figure 1) for the heavy chain and light chain variable region sequences, which is hereby incorporated by reference in its entirety). Ranibizumab is commercially available under the trademark Lucentis.

[00223] In another embodiment, the VEGF antagonist of Table 1 or 2 is the antibody bevacizumab or a pharmaceutically acceptable salt thereof (see US Patent No. 6,054,297 (Figure 1) for the heavy chain and light chain variable region sequences, which is hereby incorporated by reference in its entirety). Bevacizumab is commercially available under the trademark Avastin.

[00224] In another embodiment, the VEGF antagonist of Table 1 or 2 is aflibercept or a pharmaceutically acceptable salt thereof (Do et al. (2009) Br J Ophthalmol. 93:144-9, which is hereby incorporated by reference in its entirety).

[00225] In another embodiment, the VEGF antagonist of Table 1 or 2 is KH902 or a pharmaceutically acceptable salt thereof (Zhang et al. (2008) Mol Vis. 14:37-49, which is hereby incorporated by reference in its entirety).

[00226] In another embodiment, the VEGF antagonist of Table 1 or 2 is the antibody 2C3 or a pharmaceutically acceptable salt thereof (US Patent No. 6,342,221 (Column 8, lines 48-67, Column 9, lines 1-21), which is hereby incorporated by reference in its entirety).

[00227] In another embodiment, the VEGF antagonist is ORA102 or a pharmaceutically acceptable salt thereof (Ora Bio, Ltd).

[00228] In one embodiment, the VEGF antagonist of Table 1 or 2 is pegaptanib or a pharmaceutically acceptable salt thereof (US Patent No. 6,051,698 (Figure 1), which is hereby incorporated by reference in its entirety). A composition comprising pegaptanib is commercially available under the trademark Macugen.

[00229] In another embodiment, the VEGF antagonist of Table 1 or 2 is bevasiranib or a pharmaceutically acceptable salt thereof (Dejneka et al. (2008) Mol Vis. 14:997-1005, which is hereby incorporated by reference in its entirety).

[00230] In another embodiment, the VEGF antagonist of Table 1 or 2 is Sirna-027 or a pharmaceutically acceptable salt thereof (Shen et al. (2006) Gene Ther. 13:225-34, which is hereby incorporated by reference in its entirety).

[00231] In another embodiment, the VEGF antagonist of Table 1 or 2 is decursin or a pharmaceutically acceptable salt thereof (US Patent No. 6,525,089 (Column 3, lines 5-16), which is hereby incorporated by reference in its entirety).

[00232] In another embodiment, the VEGF antagonist of Table 1 or 2 is decursinol or a pharmaceutically acceptable salt thereof (Ahn et al. (1997) Planta Med. 63:360-1, which is hereby incorporated by reference in its entirety).

[00233] In another embodiment, the VEGF antagonist of Table 1 or 2 is picropodophyllin or a pharmaceutically acceptable salt thereof (Economou (2008) Investigative Ophthalmology & Visual Science. 49:2620-6, which is hereby incorporated by reference in its entirety).

[00234] In another embodiment, the VEGF antagonist of Table 1 or 2 is guggulsterone or a pharmaceutically acceptable salt thereof (Kim et al. (2008) Oncol. Rep. 20:1321-7, which is hereby incorporated by reference in its entirety).

[00235] In another embodiment, the VEGF antagonist of Table 1 or 2 is PLG101 or a pharmaceutically acceptable salt thereof (Ahmadi and Lim (2008) Expert Opin Pharmacother. 9:3045-52, which is hereby incorporated by reference in its entirety).

[00236] In another embodiment, the VEGF antagonist of Table 1 or 2 is PLG201 or a pharmaceutically acceptable salt thereof (Ahmadi and Lim (2008) Expert Opin Pharmacother. 9:3045-52, which is hereby incorporated by reference in its entirety).

[00237] In another embodiment, the VEGF antagonist of Table 1 or 2 is eicosanoid LXA4 or a pharmaceutically acceptable salt thereof (Baker et al (2009) J Immun. 182:3819-26, which is hereby incorporated by reference in its entirety).

[00238] In another embodiment, the VEGF antagonist of Table 1 or 2 is PTK787 or a pharmaceutically acceptable salt thereof (Barakat and Kaiser (2009) Expert Opin Investig Drugs 18:637-46, which is hereby incorporated by reference in its entirety). A composition comprising PTK787 is commercially available under the trademark Vitalanib.

[00239] In another embodiment, the VEGF antagonist of Table 1 or 2 is pazopanib or a pharmaceutically acceptable salt thereof (Takahashi et al. (2009) Arch Ophthalmol. 127:494-9, which is hereby incorporated by reference in its entirety).

[00240] In another embodiment, the VEGF antagonist of Table 1 or 2 is axitinib or a pharmaceutically acceptable salt thereof (Hu-Lowe et al. (2008) Clin Cancer Res. 14:7272-83, which is hereby incorporated by reference in its entirety).

[00241] In another embodiment, the VEGF antagonist of Table 1 or 2 is CDDO-Me or a pharmaceutically acceptable salt thereof (Sogno et al. (2009) Recent Results Cancer Res. 181:209-12, which is hereby incorporated by reference in its entirety).

[00242] In another embodiment, the VEGF antagonist of Table 1 or 2 is CDDO-Imm or a pharmaceutically acceptable salt thereof (Sogno et al. (2009) Recent Results Cancer Res. 181:209-12, which is hereby incorporated by reference in its entirety).

[00243] In another embodiment, the VEGF antagonist of Table 1 or 2 is shikonin or a pharmaceutically acceptable salt thereof (Hisa et al. (1998) Anticancer Res. 18:783-90, which is hereby incorporated by reference in its entirety).

[00244] In another embodiment, the VEGF antagonist of Table 1 or 2 is beta-hydroxyisovalerylshikonin or a pharmaceutically acceptable salt thereof (Hisa et al. (1998) Anticancer Res. 18:783-90, which is hereby incorporated by reference in its entirety).

[00245] In another embodiment, the VEGF antagonist of Table 1 or 2 is ganglioside GM3 or a pharmaceutically acceptable salt thereof (Chung et al. (2009) Glycobio. 19:229-39, which is hereby incorporated by reference in its entirety).

[00246] In another embodiment, the VEGF antagonist of Table 1 or 2 is the antibody DC101 or a pharmaceutically acceptable salt thereof (US Patent No. 6,448,077 (Column 2, lines 61-65), which is hereby incorporated by reference in its entirety).

[00247] In another embodiment, the VEGF antagonist of Table 1 or 2 is the antibody Mab25 or a pharmaceutically acceptable salt thereof (US Patent No. 6,448,077 (Column 2, lines 61-65), which is hereby incorporated by reference in its entirety).

[00248] In another embodiment, the VEGF antagonist of Table 1 or 2 is the antibody Mab73 or a pharmaceutically acceptable salt thereof (US Patent No. 6,448,077 (Column 2, lines 61-65), which is hereby incorporated by reference in its entirety).

[00249] In another embodiment, the VEGF antagonist of Table 1 or 2 is the antibody 4A5 or a pharmaceutically acceptable salt thereof (US Patent No. 6,383,484 (Column 12, lines 50-54), which is hereby incorporated by reference in its entirety).

[00250] In another embodiment, the VEGF antagonist of Table 1 or 2 is the antibody 4E10 or a pharmaceutically acceptable salt thereof (US Patent No. 6,383,484 (Column 10, l ines 66-67, Column 11, lines 1-2), which is hereby incorporated by reference in its entirety).

[00251] In another embodiment, the VEGF antagonist of Table 1 or 2 is the antibody 5F12 or a pharmaceutically acceptable salt thereof (US Patent No. 6,383,484 (Column 10, lines 62-65), which is hereby incorporated by reference in its entirety).

[00252] In another embodiment, the VEGF antagonist of Table 1 or 2 is the antibody VA01 or a pharmaceutically acceptable salt thereof (US Patent No. 5,730,977 (Column 6, lines 26-30), which is hereby incorporated by reference in its entirety).

[00253] In another embodiment, the VEGF antagonist of Table 1 or 2 is the antibody BL2 or a pharmaceutically acceptable salt thereof (US Patent No. 5,730,977 (Column 6, lines 30-32), which is hereby incorporated by reference in its entirety).

[00254] In one embodiment, the VEGF antagonist of Table 1 or 2 is VEGF-related protein or a pharmaceutically acceptable salt thereof (US Patent No. 6,451,764 (Figure 1), which is hereby incorporated by reference in its entirety).

[00255] In another embodiment, the VEGF antagonist of Table 1 or 2 is sFLT01 or a pharmaceutically acceptable salt thereof (Pechan et al. (2009) Gene Ther. 16:10-6, which is hereby incorporated by reference in its entirety).

[00256] In another embodiment, the VEGF antagonist of Table 1 or 2 is sFLT02 or a pharmaceutically acceptable salt thereof (Pechan et al. (2009) Gene Ther. 16:10-6, which is hereby incorporated by reference in its entirety).

[00257] In another embodiment, the VEGF antagonist of Table 1 or 2 is Peptide B3 or a pharmaceutically acceptable salt thereof (Lacal et al. (2008) Eur J Cancer 44:1914-21, which is hereby incorporated by reference in its entirety).

[00258] In another embodiment, the VEGF antagonist of Table 1 or 2 is TG100801 or a pharmaceutically acceptable salt thereof (Palanki et al. (2008) J Med Chem. 51:1546-59, which is hereby incorporated by reference in its entirety).

[00259] In another embodiment, the VEGF antagonist of Table 1 or 2 is sorafenib or a pharmaceutically acceptable salt thereof (Kernt et al. (2008) Acta Ophthalmol. 86:456-8, which is hereby incorporated by reference in its entirety). A composition comprising sorafenib is commercially available under the trademark Nexavar.

[00260] In another embodiment, the VEGF antagonist of Table 1 or 2 is G6-31 antibody or a pharmaceutically acceptable salt thereof (Crawford et al. (2009) Cancer Cell 15:21-34, which is hereby incorporated by reference in its entirety).

[00261] In another embodiment, the VEGF antagonist of Table 1 or 2 is an antibody or an antibody fragment which binds to an epitope VEGF-A (SEQ ID NO:15) or VEGF-B (SEQ ID NO:16), or any portion of the epitopes.

[00262] VEGF-A epitope: Cys Asn Asp Glu Gly Leu Glu Cys Val Pro Thr Glu Glu Ser Asn Ile (SEQ ID NO:15)

[00263] VEGF-B epitope: Cys Pro Asp Asp Gly Lue Glu Cys Val Pro Thr Gly Gln His Gln Val (SEQ ID NO:16)

[00264] In one embodiment, the PDGF or VEGF antagonist of Table 1 or 2 is an antibody or antibody fragment that binds to one or more of an epitope of PDGF (e.g. SEQ ID NO:11-14) and one or more of an epitope of VEGF (e.g., SEQ ID NO:15-16)

[00265] In another embodiment, the VEGF antagonist of Table 1 or 2 is an antibody or an antibody fragment which binds to an epitope of VEGF, such as an epitope of VEGF-A, VEGF-B, VEGF-C, VEGF-D, or VEGF-E. In some embodiments, the VEGF antagonist binds to an epitope of VEGF such that binding of VEGF and VEGFR are inhibited. In one embodiment, the epitope encompasses a component of the three dimensional structure of VEGF that is displayed, such that the epitope is exposed on the surface of the folded VEGF molecule. In one embodiment, the epitope is a linear amino acid sequence from VEGF.

[00266] 5.3.3 Other agents for treatment or prevention of an ophthalmological disease

[00267] In another embodiment, another agent useful for treating or preventing an ophthalmological disease is volociximab or a pharmaceutically acceptable salt thereof (Ramakrishnan et al. (2008) J Exp Ther Oncol. 5:273-86, which is hereby incorporated by reference in its entirety).

[00268] 5.4 Modification of antagonist agents

[00269] *Aptamer Antagonists*

[00270] Where an antagonist of the present invention is an aptamer, the invention emcompasses modified versions thereof, as set forth below. In some embodiments, an aptamer can have chemically modified nucleotides, including 5-X and/or 2'-Y substitutions in pyrimidine bases and 8-X and/or 2'-Y substitutions in purine bases. 2'-Modifications, such as 2'-fluoro and 2'-O-Me, can be utilized for stabilization against nucleases without compromising the aptamer binding interaction with the target. See, e.g., Lin et al., Nucleic Acids Res., 22, 5229-5234 (1994); Jellinek et al., Biochemistry, 34, 11363-1137 (1995); Lin et al., Nucleic Acids Res., 22, 5229-5234 (1994); Kubik et al., J. Immunol., 159(1), 259-267 (1997); Pagratis et al., Nat. Biotechnol., 1, 68-73 (1997); and Wilson et al., Curr Opin Chem Biol, 10(6), 607-614 (2006). In some embodiments, the chemical substitution can be a chemical substitution at a sugar position; a chemical substitution at a base position or a chemical substitution at a phosphate position.

[00271] Modifications of aptamers of this invention include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrophobicity, hydrogen bonding, electrostatic

interaction, or fluxionality to the aptamer bases or to the aptamer as a whole. Such modifications include, but are not limited to, 2′-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil; backbone modifications, phosphorothioate or alkyl phosphate modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications can also include 3′ and 5′ modifications such as capping or modification with sugar moieties. In some embodiments of the instant invention, the aptamers are RNA molecules that are 2′-fluoro (2′-F) modified on the sugar moiety of pyrimidine residues.

[00272] The stability of the aptamer can be increased by the introduction of such modifications and as well as by modifications and substitutions along the phosphate backbone of the RNA. In addition, a variety of modifications can be made on the nucleobases themselves which both inhibit degradation and which can increase desired nucleotide interactions or decrease undesired nucleotide interactions. Accordingly, once the sequence of an aptamer is known, modifications or substitutions can be made by the synthetic procedures described below or by procedures known to those of skill in the art.

[00273] Other modifications include the incorporation of modified bases (or modified nucleoside or modified nucleotides) that are variations of standard bases, sugars and/or phosphate backbone chemical structures occurring in ribonucleic (*i.e.*, A, C, G and U) and deoxyribonucleic (*i.e.*, A, C, G and T) acids. Included within this scope are, for example: Gm (2'-methoxyguanylic acid), Am (2'-methoxyadenylic acid), Cf (2'-fluorocytidylic acid), Uf (2'-fluorouridylic acid), Ar (riboadenylic acid). The aptamers can also include cytosine or any cytosine-related base including 5-methylcytosine, 4-acetylcytosine, 3-methylcytosine, 5-hydroxymethyl cytosine, 2-thiocytosine, 5-halocytosine (*e.g.*, 5-fluorocytosine, 5-bromocytosine, 5-chlorocytosine, and 5-iodocytosine), 5-propynyl cytosine, 6-azocytosine, 5-trifluoromethylcytosine, N4, N4-ethanocytosine, phenoxazine cytidine, phenothiazine cytidine, carbazole cytidine or pyridoindole cytidine. The aptamer can further include guanine or any guanine-related base including 6-methylguanine, 1-methylguanine, 2,2-dimethylguanine, 2-methylguanine, 7-methylguanine, 2-propylguanine, 6-propylguanine, 8-haloguanine (*e.g.*, 8-fluoroguanine, 8-bromoguanine, 8-chloroguanine, and 8-iodoguanine), 8-aminoguanine, 8-sulfhydrylguanine, 8-thioalkylguanine, 8-hydroxylguanine, 7-methylguanine, 8-azaguanine, 7-deazaguanine or 3-deazaguanine. The aptamer may still further include adenine or any adenine-related base including 6-methyladenine, N6-isopentenyladenine, N6-methyladenine, 1-methyladenine, 2-methyladenine, 2-methylthio-N6-isopentenyladenine, 8-haloadenine (*e.g.*, 8-fluoroadenine, 8-bromoadenine, 8-chloroadenine, and 8-iodoadenine), 8-aminoadenine, 8-sulfhydryladenine, 8-thioalkyladenine, 8-hydroxyladenine, 7-methyladenine, 2-haloadenine (*e.g.*, 2-fluoroadenine, 2-bromoadenine, 2-chloroadenine, and 2-iodoadenine), 2-aminoadenine, 8-azaadenine, 7-deazaadenine or 3-deazaadenine. Also included are uracil or any uracil-related base including 5-halouracil (*e.g.*, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil), 5-(carboxyhydroxylmethyl)uracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, 1-methylpseudouracil, 5-methoxyaminomethyl-2-thiouracil, 5′-methoxycarbonylmethyluracil, 5-methoxyuracil, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, 5-methyl-2-thiouracil, 2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl)uracil, 5-methylaminomethyluracil, 5-propynyl uracil, 6-azouracil, or 4-thiouracil.

[00274] Examples of other modified base variants known in the art include, without limitation, 4-acetylcytidine, 5-(carboxyhydroxylmethyl) uridine, 2'-methoxycytidine, 5-carboxymethylaminomethyl-2-thioridine, 5-carboxymethylaminomethyluridine, dihydrouridine, 2'-O-methylpseudouridine, b-D-galactosylqueosine, inosine, N6-isopentenyladenosine, 1-methyladenosine, 1-methylpseudouridine, 1-methylguanosine, 1-methylinosine, 2,2-dimethylguanosine, 2-methyladenosine, 2-methylguanosine, 3-methylcytidine, 5-methylcytidine, N6-methyladenosine, 7-methylguanosine, 5-methylaminomethyluridine, 5-methoxyaminomethyl-2-thiouridine, b-D-

mannosylqueosine, 5-methoxycarbonylmethyluridine, 5-methoxyuridine, 2-methylthio-N6-isopentenyladenosine, N-((9-b-D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine, N-((9-b-D-ribofuranosylpurine-6-yl)N-methyl-carbamoyl)threonine, urdine-5-oxyacetic acid methylester, uridine-5-oxyacetic acid, wybutoxosine, pseudouridine, queosine, 2-thiocytidine, 5-methyl-2-thiouridine, 2-thiouridine, 4-thiouridine, 5-methyluridine, N-((9-b-D-ribofuranosylpurine-6-yl)carbamoyl)threonine, 2'-O-methyl-5-methyluridine, 2'-O-methyluridine, wybutosine, 3-(3-amino-3-carboxypropyl)uridine.

[00275] Examples of modified nucleoside and nucleotide sugar backbone variants known in the art include, without limitation, those having, *e.g.*, 2' ribosyl substituents such as F, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2, CH3, ONO2, NO2, N3, NH2, OCH2CH2OCH3, O(CH2)2ON(CH3)2, OCH2OCH2N(CH3)2, O(C1-10 alkyl), O(C2-10 alkenyl), O(C2-10 alkynyl), S(C1-10 alkyl), S(C2-10 alkenyl), S(C2-10 alkynyl), NH(C1-10 alkyl), NH(C2-10 alkenyl), NH(C2-10 alkynyl), and O-alkyl-O-alkyl. Desirable 2′ ribosyl substituents include 2′-methoxy (2′-OCH3), 2′-aminopropoxy (2′ OCH2CH2CH2NH2), 2′-allyl (2′-CH2-CH=CH2), 2′-O-allyl (2′-O-CH2-CH=CH2), 2′-amino (2′-NH2), and 2′-fluoro (2′-F). The 2′-substituent may be in the arabino (up) position or ribo (down) position.

[00276] Examples of modifications include: a purine substitution for a pyrimidine; a 2'-deoxy dihydrouridine substitution for a uridine; a 2'-deoxy-5-methyl cytidine for a cytidine; a 2-amino purine substitution for a purine; a phosphorothioate substituted for a phosphodiester; a phosphorodithioate substituted for a phosphodiester; a deoxynucleotide substituted for a 2'-OH nucleotide; a 2'-OMe nucleotide, a 2'-fluoro nucleotide or a 2'-O-methoxyethyl nucleotide substituted for a 2'-OH or deoxynucleotide; the addition of a PEG or PAG polymer; the addition of a large steric molecule; the addition of a 3' cap; or any other modification known to block nuclease degradation. See, for example, U.S. Patent Publication No. 20090075342, which is incorporated by reference in its entirety.

[00277] The aptamers of the invention may be made up of nucleotides and/or nucleotide analogs such as described above, or a combination of both, or are oligonucleotide analogs. The aptamers of the invention may contain nucleotide analogs at positions which do not affect the function of the oligomer, for example, to bind PDGF or VEGF (or their cognate receptors).

[00278] The aptamers described herein can be linked with one or more non-physiologically active groups, such as a lipophilic compound (e.g., cholesterol); non-immunogenic high molecular weight compounds; or attached to or encapsulated in a complex comprising a lipophilic component (eg., a liposome). In one embodiment, the linked aptamers enhance the cellular uptake of the aptamers by a cell for delivery of the aptamers to an intracellular target. U.S. Patent No. 6,011,020 describes a method for preparing a therapeutic or diagnostic compounds of an aptamer linked with lipophilic compound or a non-immunogenic, high molecular weight compound.

[00279] The invention further encompasses linking selected aptamers with one or more non-physiologically active group, such as lipophilic or Non-Immunogenic, High Molecular Weight compounds, in a diagnostic or therapeutic complex as described in U.S. Patent No. 6,011,020. Aptamers that are linked with a Lipophilic Compound, such as diacyl glycerol or dialkyl glycerol, in a diagnostic or therapeutic complex are described in U.S. Patent No. 5,859,228. Aptamers that are linked with a Lipophilic Compound, such as a glycerol lipid, or a Non-Immunogenic, High Molecular Weight Compound, such as polyalkylene glycol, are further described in U.S. Patent No. 6,051,698. Aptamers that are linked with a Non-Immunogenic, High Molecular Weight compound or a lipophilic compound are also further described in PCT/US97/18944, filed Oct. 17, 1997, entitled "Vascular Endothelial Growth Factor (VEGF) Nucleic Acid Ligand Complexes." Each of the above described patents and patent applications are specifically incorporated by reference herein in its entirety.

[00280] Certain embodiments of the present invention provide compounds comprising one or more aptamers covalently linked with a Non-Immunogenic, High Molecular Weight compound or lipophilic compound. A Non-Immunogenic, High Molecular Weight compound can be a compound that has a molecular weight of about 100 Da to 1,000,000 Da, about 1000 Da to 500,000 Da, or about 1000 Da to 200,000 Da, that typically does not generate an immunogenic response. For the purposes of this invention, an immunogenic response is one that causes the organism to make antibody proteins directed to the non-physiologically active group. In one embodiment, the Non-Immunogenic, High Molecular Weight compound can be a polyalkylene glycol. In another embodiment, the polyalkylene glycol can be polyethylene glycol (PEG). In some embodiments, the PEG has a molecular weight of about 10-80K or a molecular weight of about 20-45K. In some embodiments, the Non-Immunogenic, High Molecular Weight compound can be an aptamer.

[00281] Another embodiment of the invention is directed to compounds comprising an aptamer linked with lipophilic compound. Lipophilic compounds are compounds that have the propensity to associate with or partition into lipid and/or other materials or phases having a low dielectric constant, including compounds based mostly on lipophilic components. Lipophilic compounds include lipids as well as non-lipid containing compounds that have the propensity to associate with lipids (and/or other materials or phases with low dielectric constants). Cholesterol, phospholipid, and glycerol lipids, such as dialkyl glycerol, diacyl glycerol, and glycerol amide lipids are further examples of lipophilic compounds. In one embodiment, the lipophilic compound is a glycerol lipid.

[00282] The Non-Immunogenic, High Molecular Weight compound or lipophilic compound can be covalently bound to a variety of positions on the aptamer, such as to an exocyclic amino group on a nucleotide's base, the 5-position of a pyrimidine nucleotide, the 8-position of a purine nucleotide, the hydroxyl group of a nucleotide's phosphate, or a hydroxyl group or other group at the 5' or 3' terminus of the aptamer. In some embodiments where the lipophilic compound is a glycerol lipid, or the Non-Immunogenic, High Molecular Weight compound is polyalkylene glycol or polyethylene glycol, the Non-Immunogenic, High Molecular Weight compound can be bonded to the 5' or 3' hydroxyl of the phosphate group thereof. In one embodiment, the lipophilic compound or Non-Immunogenic, High Molecular Weight compound is bonded to the 5' phosphate group of the aptamer. Attachment of the Non-Immunogenic, High Molecular Weight compound or lipophilic compound to the aptamer can be done directly or with the utilization of one or more linkers that interpose between the aptamer and lipophilic compound or Non-Immunogenic, High Molecular Weight compound. When attachment is done directly, on the other hand, no linker is present.

[00283] A linker is a molecular entity that connects two or more molecular entities through covalent bonds or non-covalent interactions, and can allow spatial separation of the molecular entities in a manner that preserves the functional properties of one or more of the molecular entities.

[00284] In one embodiment of the invention, the Non-Immunogenic, High Molecular Weight Compound covalently linked with the aptamer is a polyalkylene glycol and has the structure $R(O(CH_2)_x)_n O$--, where R is independently selected from the group consisting of H and CH_3, x=2-5, and n ≈ MW of the Polyalkylene Glycol/(16+14x). In one embodiment of the present invention, the molecular weight of the polyalkylene glycol is about between 10-80 kDa. In another embodiment, the molecular weight of the polyalkylene glycol is about between 20-45 kDa. In yet another embodiment, x=2 and $n=9X10^2$. There can be one or more Polyalkylene Glycols attached to the same aptamer.

[00285] In one embodiment, a Complex of the present invention is a PDGF aptamer covalently linked with a Non-Immunogenic, High Molecular Weight Compound such as Polyalkylene Glycol or PEG. In this embodiment, the pharmacokinetic properties of the Complex are improved relative to the PDGF aptamer alone. The Polyalkylene Glycol or PEG can be covalently bound to a variety of positions on the PDGF aptamer. In embodiments where

Polyalkylene Glycol or PEG are used, the PDGF aptamer can be bonded through the 5' hydroxyl group via a phosphodiester linkage.

[00286] In some embodiments, a plurality of aptamers can be associated with a single Non-Immunogenic, High Molecular Weight Compound, such as Polyalkylene Glycol or PEG, or a Lipophilic Compound, such as a glycerolipid. The aptamers can all be to one target or to different targets. In embodiments where a compound comprises more than one PDGF aptamer, there can be an increase in avidity due to multiple binding interactions with a target, such as PDGF or VEGF. In yet further embodiments, a plurality of Polyalkylene Glycol, PEG, glycerol lipid molecules can be attached to each other. In these embodiments, one or more aptamers can be associated with each Polyalkylene Glycol, PEG, or glycerol lipid. This can result in an increase in avidity of each aptamer to its target. In addition, in embodiments where there are aptamers to PDGF or aptamers to PDGF and different Targets associated with Polyalkylene Glycol, PEG, or glycerol lipid, a drug can also be associated with, e.g., covalently bonded to, Polyalkylene Glycol, PEG, or glycerol lipid. Thus the compound would provide targeted delivery of the drug, with Polyalkylene Glycol, PEG, or glycerol lipid serving as a Linker, optionally, with one or more additional linkers.

[00287] Aptamers can be 5′-capped and/or 3′-capped with a 5′-5′ inverted nucleoside cap structure at the 5′ end and/or a 3′-3′ inverted nucleoside cap structure at the 3′ end. In several embodiments, Antagonist A, Antagonist B, Antagonist C, Antagonist D, pegaptanib, bevasiranib and Sirna-027 are 5' or 3' end-capped.

[00288] *Antibody Antagonists*

[00289] Where the PDGF antagonist or VEGF antagonist of Table 1 or 2 is an antibody, such as for example 1B3, CDP860, 162.62, 163.31, 169.14, 169.31, αR1, 2A1E2, M4TS.11, M4TS.22, Hyb 120.1.2.1.2 antibody, Hyb 121.6.1.1.1 antibody, Hyb 127.5.7.3.1 antibody, Hyb 127.8.2.2.2 antibody, Hyb 1.6.1 antibody, Hyb 1.11.1 antibody, Hyb 1.17.1 antibody, Hyb 1.18.1 antibody, Hyb 1.19.1 antibody, Hyb 1.23.1 antibody, Hyb 1.24 antibody, Hyb 1.25 antibody, Hyb 1.29 antibody, Hyb 1.33 antibody, Hyb 1.38 antibody, Hyb 1.39 antibody, Hyb 1.40 antibody, Hyb 1.45 antibody, Hyb 1.46 antibody, Hyb 1.48 antibody, Hyb 1.49 antibody, Hyb 1.51 antibody, Hyb 6.4.1 antibody, F3 antibody, Humanized F3 antibody, C1 antibody, Humanized C1 antibody, 6.4 antibody, anti-mPDGF-C goat IgG antibody, C3.1 antibody, PDGFR-B1 monoclonal antibody, PDGFR-B2 monoclonal antibody, 6D11 monoclonal antibody, Sis 1 monoclonal antibody, PR7212 monoclonal antibody, PR292 monoclonal antibody, HYB 9610 monoclonal antibody, HYB 9611 monoclonal antibody, HYB 9612 monoclonal antibody, HYB 9613 monoclonal antibody, human antibody g162, ranibizumab, bevacizumab, KH902, DC101, Mab25, Mab73, 4A5, 4E10, 5F12, VA01, BL2, G6-31 antibody, or anti-mPDGF-C goat IgG antibody, the invention also relates to antibody fragments. Unless specified otherwise, the term antibody refers only to whole antibodies.

[00290] The antagonist antibodies of the invention include monoclonal inhibitory antibodies. Monoclonal antibodies, or fragments thereof, encompass all immunoglobulin classes such as IgM, IgG, IgD, IgE, IgA, or their subclasses, such as the IgG subclasses or mixtures thereof. IgG and its subclasses are useful, such as IgG_1, IgG_2, IgG_{2a}, IgG_{2b}, IgG_3 or IgG_M. The IgG subtypes $IgG_{1/kappa}$ and $IgG_{2b/kapp}$ are included as useful embodiments. Fragments of the invention are truncated or modified antibody fragments with an antigen-complementary binding site. In some embodiments, an antibody fragment is formed by light and heavy chains, such as Fv, Fab or $F(ab')_2$ fragments, or single-stranded fragments.

[00291] The invention further includes derivatives of antibodies of the present invention which retain their antagonist activity while altering one or more other properties related to their use as a pharmaceutical agent, *e.g.*, serum stability or efficiency of production. Examples of such antibody derivatives include peptides, peptidomimetics derived from the antigen-binding regions of the antibodies, and antibodies, antibody fragments or peptides bound to solid or liquid carriers such as polyethylene glycol, glass, synthetic polymers such as polyacrylamide, polystyrene,

polypropylene, polyethylene or natural polymers such as cellulose, sepharose or agarose, or conjugates with enzymes, toxins or radioactive or nonradioactive markers such as ^{3}H, ^{123}I, ^{125}I, ^{131}I, ^{32}P, ^{35}S, ^{14}C, ^{51}Cr, ^{36}Cl, ^{57}Co, ^{55}Fe, ^{59}Fe, ^{90}Y, ^{99m}Tc, ^{75}Se, or antibodies, fragments, or peptides covalently bonded to fluorescent/chemiluminescent labels such as rhodamine, fluorescein, isothiocyanate, phycoerythrin, phycocyanin, fluorescamine, metal chelates, avidin, streptavidin or biotin.

[00292] In some embodiments, a monoclonal antibody of the present invention can be modified by splicing a variable (including hypervariable) domain of the antibody with a constant domain (*e.g.*, "humanized" antibodies), or a light chain with a heavy chain, or a chain from one species with a chain from another species, or fusions with heterologous proteins, regardless of species of origin or immunoglobulin class or subclass designation, as well as antibody fragments, so long as they exhibit the desired biological activity. See, for example, U.S. Patent No. 4,816,567 and Mage & Lamoyi, in Monoclonal Antibody Production Techniques and Applications, pp.79-97 (Marcel Dekker, Inc.), New York (1987). Methods for humanizing non-human antibodies are well known in the art.

[00293] 5.5 Treatment or Prevention of an Ophthalmological disease

[00294] In some embodiments of the invention, the ophthalmological disease is a neovascular disorder. In other embodiments of the invention, the ophthalmological disease results in retinal edema. Illustrative ophthalmological disease are listed below.

[00295] 5.5.1 Treatment or Prevention of age-related macular degeneration

[00296] In one embodiment, the ophthalmological disease is age-related macular degeneration. Examples of age-related macular degeneration are nonneovascular (also known as "Dry") and neovascular (also known as "Wet") macular degeneration. In one embodiment the dry age-related macular degeneration is associated with the formation of drusen. Treating or preventing dry macular degeneration also encompasses treating or preventing an abnormality of the retinal pigment epithelium. Examples of abnormalities of the retinal pigment epithelium include geographic atrophy, non-geographic atrophy, focal hypopigmentation, and focal hyperpigmentation. Treating or preventing wet age-related macular degeneration also encompasses treating or preventing choroidal neovascularization or pigment epithelial detachment.

[00297] 5.5.2 Treatment or Prevention of polypoidal choroidal vasculopathy

[00298] In one embodiment, the ophthalmological disease is polypoidal choroidal vasculopathy. Polypoidal choroidal vasculopathy is characterized by a lesion from an inner choroidal vascular network of vessels ending in an aneurysmal bulge or outward projection (Ciardella et al. (2004) Surv Ophthalmol. 49:25-37).

[00299] 5.5.3 Treatment or Prevention of a condition associated with choroidal neovascularization

[00300] In one embodiment, the ophthalmological disease is a condition associated with choroidal neovascularization. Examples of conditions associated with choroidal neovascularization include a degenerative, inflammatory, traumatic or idiopathic condition. Treating or preventing a degenerative disorder associated with choroidal neovascularization also encompasses treating or preventing a heredodegerative disorder. Examples of heredodegerative disorders include vitelliform macular dystrophy, fundus flavimaculatus and optic nerve head drusen. Examples of degenerative conditions associated with choroidal neovascularization include myopic degeneration or angioid streaks. Treating or preventing an inflammatory disorder associated with choroidal neovascularization also encompasses treating or preventing ocular histoplasmosis syndrome, multifocal choroiditis, serpininous choroiditis, toxoplasmosis, toxocariasis, rubella, Vogt-Koyanagi-Harada syndrome, Behcet syndrome or sympathetic ophthalmia. Treating or preventing a traumatic disorder associated with choroidal neovascularization also encompasses treating or preventing choroidal rupture or a traumatic condition caused by intense photocoagulation.

[00301] 5.5.4 Treatment or Prevention of hypertensive retinopathy

[00302] In one embodiment, the ophthalmological disease is hypertensive retinopathy.

[00303] 5.5.5 Treatment or Prevention of diabetic retinopathy

[00304] In one embodiment, the ophthalmological disease is diabetic retinopathy. Diabetic retinopathy can be nonproliferative or proliferative diabetic retinopathy. Examples of nonproliferative diabetic retinopathy include macular edema and macular ischemia.

[00305] 5.5.6 Treatment or Prevention of sickle cell retinopathy

[00306] In one embodiment, the ophthalmological disease is sickle cell retinopathy.

[00307] 5.5.7 Treatment or Prevention of a condition associated with peripheral retinal neovascularization

[00308] In one embodiment, the ophthalmological disease is a condition associated with peripheral retinal neovascularization. Examples of conditions associated with peripheral retinal neovascularization include ischemic vascular disease, inflammatory disease with possible ischemia, incontinentia pigmenti, retinitis pigmentosa, retinoschisis or chronic retinal detachment.

[00309] Examples of ischemic vascular disease include proliferative diabetic retinopathy, branch retinal vein occlusion, branch retinal arteriolar occlusion, carotid cavernous fistula, sickling hemoglobinopathy, non-sickling hemoglobinopathy, IRVAN syndrome (retinal vasculitic disorder characterized by idiopathic retinal vasculitis, an aneurysm, and neuroretinitis), retinal embolization, retinopathy of prematurity, familial exudative vitreoretinopathy, hyperviscosity syndrome, aortic arch syndrome or Eales disease. Examples of sickling hemoglobinopathy include SS hemoglobinopathy and SC hemoglobinopathy. Examples of non-sickling hemoglobinopathy include AC hemoglobinopathy and AS hemoglobinopathy. Examples of hyperviscosity syndrome include leukemia, Waldenstrom macroglobulinemia, multiple myeloma, polycythemia or myeloproliferative disorder.

[00310] Treating or preventing an inflammatory disease with possible ischemia also encompasses treating or preventing retinal vasculitis associated with systemic disease, retinal vasculitis associated with an infectious agent, uveitis or birdshot retinopathy. Examples of systemic diseases include systemic lupus erythematosis, Behcet's disease, inflammatory bowel disease, sarcoidosis, multiple sclerosis, Wegener's granulomatosis and polyarteritis nodosa. Examples of infectious agents include a bacterial agent that is the causative agent for syphilis, tuberculosis, Lyme disease or cat-scratch disease, a virus such as herpesvirus, or a parasite such as Toxocara canis or Toxoplasma gondii. Examples of uveitis include pars planitis or Fuchs uveitis syndrome.

[00311] 5.5.8 Treatment or Prevention of retinopathy of prematurity

[00312] In one embodiment, the ophthalmological disease is retinopathy of prematurity. Retinopathy of prematurity can result from abnormal growth of blood vessels in the vascular bed supporting the developing retina (Pollan C (2009) Neonatal Netw. 28:93-101).

[00313] 5.5.9 Treatment or Prevention of venous occlusive disease

[00314] In one embodiment, the ophthalmological disease is venous occlusive disease. Examples of venous occlusive disease include branch retinal vein occlusion and central retinal vein occlusion. A branch retinal vein occlusion can be a blockage of the portion of the circulation that drains the retina of blood. The blockage can cause back–up pressure in the capillaries, which can lead to hemorrhages and also to leakage of fluid and other constituents of blood.

[00315] 5.5.10 Treatment or Prevention of arterial occlusive disease

[00316] In one embodiment, the ophthalmological disease is arterial occlusive disease. Examples of arterial occlusive disease include branch retinal artery occlusion, central retinal artery occlusion or ocular ischemic syndrome. A branch retinal artery occlusion (BRAO) can occur when one of the branches of the arterial supply to the retina becomes occluded.

[00317] 5.5.11 Treatment or Prevention of central serous chorioretinopathy

[00318] In one embodiment, the ophthalmological disease is central serous chorioretinopathy (CSC). In one embodiment, CSC is characterized by leakage of fluid in the central macula.

[00319] 5.5.12 Treatment or Prevention of cystoid macular edema

[00320] In one embodiment, the ophthalmological disease is cystoid macular edema (CME). In one embodiment, CME affects the central retina or macula. In another embodiment, CME occurs after cataract surgery.

[00321] 5.5.13 Treatment or Prevention of retinal telangiectasia

[00322] In one embodiment, the ophthalmological disease is retinal telangiectasia. In one embodiment, retinal telangiectasia is characterized by dilation and tortuosity of retinal vessels and formation of multiple aneurysms. Idiopathic JXT, Leber's miliary aneurysms, and Coats' disease are three types of retinal telangiectasias.

[00323] 5.5.14 Treatment or Prevention of arterial macroaneurysm

[00324] In one embodiment, the ophthalmological disease is arterial macroaneurysm.

[00325] 5.5.15 Treatment or Prevention of retinal angiomatosis

[00326] In one embodiment, the ophthalmological disease is retinal angiomatosis. In one embodiment, retinal angiomatosis occurs when the ocular vessels form multiple angiomas.

[00327] 5.5.16 Treatment or Prevention of radiation-induced retinopathy

[00328] In one embodiment, the ophthalmological disease is radiation-induced retinopathy (RIRP). In one embodiment, RIRP may display symptoms such as macular edema and nonproliferative and proliferative retinopathy.

[00329] 5.5.17 Treatment or Prevention of Rubeosis iridis

[00330] In one embodiment, the ophthalmological disease is rubeosis iridis. In another embodiment, rubeosis iridis results in the formation of neovascular glaucoma. In another embodiment, rubeosis iridis is caused by diabetic retinopathy, central retinal vein occlusion, ocular ischemic syndrome, or chronic retinal detachment.

[00331] 5.5.16 Treatment or Prevention of a neoplasm

[00332] In one embodiment, the ophthalmological disease is a neoplasm. Examples of neoplams include an eyelid tumor, a conjunctival tumor, a choroidal tumor, an iris tumor, an optic nerve tumor, a retinal tumor, an infiltrative intraocular tumor or an orbital tumor. Examples of an eyelid tumor include basal cell carcinoma, squamous carcinoma, sebaceous carcinoma, malignant melanoma, capillary hemangioma, hydrocystoma, nevus or seborrheic keratosis. Examples of a conjunctival tumor include conjunctival Kaposi's sarcoma, squamous carcinoma, intraepithelial neoplasia of the conjunctiva, epibular dermoid, lymphoma of the conjunctiva, melanoma, pingueculum, or pterygium. Examples of a choroidal tumor include choroidal nevus, choroidal hemangioma, metastatic choroidal tumor, choroidal osteoma, choroidal melanoma, ciliary body melanoma or nevus of Ota. Examples of an iris tumor include anterior uveal metastasis, iris cyst, iris melanocytoma, iris melanoma, or pearl cyst of the iris. Examples of an optic nerve tumor include optic nerve melanocytoma, optic nerve sheath meningioma, choroidal melanoma affecting the optic nerve, or circumpapillary metastasis with optic neuropathy. Examples of a retinal tumor include retinal pigment epithelial (RPE) hypertrophy, RPE adenoma, RPE carcinoma, retinoblastoma, hamartoma of the RPE, or von Hippel angioma. Examples of an infiltrative intraocular tumor include chronic lymphocytic leukemia, infiltrative choroidopathy, or intraocular lymphoma. Examples of an orbital tumor include adenoid cystic carcinoma of the lacrimal gland, cavernous hemangioma of the orbit, lymphangioma of the orbit, orbital mucocele, orbital pseudotumor, orbital rhabdomyosarcoma, periocular hemangioma of childhood, or sclerosing orbital psuedotumor.

[00333] 5.6 Compositions for Therapeutic or Prophylactic Administration

[00334] The PDGF antagonist or VEGF antagonist of Table 1 or 2 can be administered as a component of a composition that further comprises a pharmaceutically acceptable carrier or vehicle. In one embodiment, a

composition of the invention comprises an effective amount of a PDGF antagonist, a VEGF antagonist of Table 1 or 2 and a pharmaceutically accetable carrier or vehicle. In another embodiment, a composition comprising a PDGF antagonist and another composition comprising a VEGF antagonist are administered.

[00335] Administration of each antagonist may be by any suitable means that results in an amount of PDGF antagonist and VEGF antagonist of Table 1 or 2 that is effective for the treatment or prevention of an ophthalmological disease. Each antagonist, for example, can be admixed with a suitable carrier substance, and is generally present in an amount of 1-95% by weight of the total weight of the composition. The composition may be provided in a dosage form that is suitable for ophthalmic, oral, parenteral (*e.g.*, intravenous, intramuscular, subcutaneous), rectal, transdermal, nasal, or inhalant administration. In one embodiment, the composition is in a form that is suitable for injection directly in the eye. The composition may be in form of, *e.g.*, tablets, capsules, pills, powders, granulates, suspensions, emulsions, solutions, gels including hydrogels, pastes, ointments, creams, plasters, delivery devices, suppositories, enemas, injectables, implants, sprays, drops or aerosols. The compositions comprising one or more antagonists can be formulated according to conventional pharmaceutical practice (see, *e.g.*, Remington: The Science and Practice of Pharmacy, (20th ed.) ed. A. R. Gennaro, 2000, Lippincott Williams & Wilkins, Philadelphia, PA and Encyclopedia of Pharmaceutical Technology, eds., J. Swarbrick and J. C. Boylan, 1988-2002, Marcel Dekker, New York).

[00336] The compositions are, in one useful aspect, administered parenterally (*e.g.*, by intramuscular, intraperitoneal, intravenous, intraocular, intravitreal, retro-bulbar, subconjunctival, subtenon or subcutaneous injection or implant) or systemically. Formulations for parenteral or systemic administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. A variety of aqueous carriers can be used, *e.g.*, water, buffered water, saline, and the like. Examples of other suitable vehicles include polypropylene glycol, polyethylene glycol, vegetable oils, gelatin, hydrogels, hydrogenated naphalenes, and injectable organic esters, such as ethyl oleate. Such formulations may also contain auxiliary substances, such as preserving, wetting, buffering, emulsifying, and/or dispersing agents. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the active ingredients.

[00337] Alternatively, the compositions can be administered by oral ingestion. Compositions intended for oral use can be prepared in solid or liquid forms, according to any method known to the art for the manufacture of pharmaceutical compositions.

[00338] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. Generally, these pharmaceutical preparations contain active ingredients admixed with non-toxic pharmaceutically acceptable excipients. These include, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, sucrose, glucose, mannitol, cellulose, starch, calcium phosphate, sodium phosphate, kaolin and the like. Binding agents, buffering agents, and/or lubricating agents (*e.g.*, magnesium stearate) may also be used. Tablets and pills can additionally be prepared with enteric coatings. The compositions may optionally contain sweetening, flavoring, coloring, perfuming, and preserving agents in order to provide a more palatable preparation.

[00339] For example, compositions of the present invention may be administered intraocularly by intravitreal injection into the eye as well as by subconjunctival and subtenon injections. Other routes of administration include transcleral, retrobulbar, intraperitoneal, intramuscular, and intravenous. Alternatively, compositions can be administered using a drug delivery device or an intraocular implant (see below).

[00340] Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and soft gelatin capsules. These forms can contain inert diluents commonly used in the art, such as water or an oil medium, and can also include adjuvants, such as wetting agents, emulsifying agents, and suspending agents.

[00341] In some instances, the compositions can also be administered topically, for example, by patch or by direct application to a region, such as the epidermis or the eye, susceptible to or affected by a neovascular disorder, or by iontophoresis.

[00342] Compositions useful for ophthalmic use include tablets comprising one or more antagonists in admixture with a pharmaceutically acceptable excipient. These excipients may be, for example, inert diluents or fillers (*e.g.*, sucrose and sorbitol), lubricating agents, glidants, and antiadhesives (*e.g.*, magnesium stearate, zinc stearate, stearic acid, silicas, hydrogenated vegetable oils, or talc).

[00343] The antagonists of the present invention may be admixed in a tablet or other vehicle, or may be partitioned. In one example, one antagonist is contained on the inside of the tablet, and the other antagonist is on the outside, such that a substantial portion of the other antagonist is released prior to the release of the contained antagonist. If desired, antagonists in a tablet form may be administered using a drug delivery device (see below).

[00344] In one embodiment, compositions that comprise a PDGF antagonist can comprise one or more pharmaceutically acceptable excipients. In one embodiment, excipients for compositions that comprise a PDGF antagonist include, but are not limited to, buffering agents, nonionic surfactants, preservatives, tonicity agents, amino acids, and pH-adjusting agents. Suitable buffering agents include, but are not limited to, monobasic sodium phosphate, dibasic sodium phosphate, and sodium acetate. Suitable nonionic surfactants include, but are not limited to, polyoxyethylene sorbitan fatty acid esters such as polysorbate 20 and polysorbate 80. Suitable preservatives include, but are not limited to, benzyl alcohol. Suitable tonicity agents include, but are not limited to sodium chloride, mannitol, and sorbitol. Suitable amino acids include, but are not limited to glycine and histidine. Suitable pH-adjusting agents include, but are not limited to, hydrochloric acid, acetic acid, and sodium hydroxide. In one embodiment, the pH-adjusting agent or agents are present in an amount effective to provide a pH of about 3 to about 8, about 4 to about 7, about 5 to about 6, about 6 to about 7, or about 7 to about 7.5. In one embodiment, a composition comprising a PDGF antagonist does not comprise a preservative. In another embodiment, a composition comprising a PDGF antagonist does not comprise an antimicrobial agent. In another embodiment, a composition comprising a PDGF antagonist does not comprise a bacteriostat.

[00345] In one embodiment, a composition comprising a PDGF antagonist is in the form of an aqueous solution that is suitable for injection. In one embodiment, a composition comprises a PDGF antagonist, a buffering agent, a pH-adjusting agent, and water for injection. In another embodiment, a composition comprises a PDGF antagonist, monobasic sodium phosphate, dibasic sodium phosphate, sodium chloride, hydrochloride acid, and sodium hydroxide. In one embodiment, the PDGF antagonist is a pegylated anti-PDGF aptamer. In another embodiment, the pegylated anti-PDGF aptamer is ARC-127. In another embodiment, the pegylated anti-PDGF antagonist is a compound of Formula A. In another embodiment, the pegylated anti-PDGF antagonist is Antagonist A. In another embodiment, the pegylated anti-PDGF antagonist is a compound of Formula B. In another embodiment, the pegylated anti-PDGF antagonist is Antagonist B. In another embodiment, the pegylated anti-PDGF antagonist is a compound of Formula C. In another embodiment, the pegylated anti-PDGF antagonist is a compound of Formula D. In another embodiment, the PDGF antagonist is a non-pegylated anti-PDGF aptamer. In another embodiment, the non-pegylated aptamer is Antagonist C. In another embodiment, the non-pegylated aptamer is Antagonist D.

[00346] In one embodiment, compositions that comprise a VEGF antagonist can comprise one or more pharmaceutically acceptable excipients. In one embodiment, excipients for compositions that comprise a VEGF antagonist include, but are not limited to, buffering agents, nonionic surfactants, preservatives, tonicity agents, sugars, amino acids, and pH-adjusting agents. Suitable buffering agents include, but are not limited to, monobasic sodium phosphate, dibasic sodium phosphate, and sodium acetate. Suitable nonionic surfactants include, but are not limited to, polyoxyethylene sorbitan fatty acid esters such as polysorbate 20 and polysorbate 80. Suitable

preservatives include, but are not limited to, benzyl alcohol. Suitable tonicity agents include, but are not limited to sodium chloride, mannitol, and sorbitol. Suitable sugars include, but are not limited to, α,α-trehalose. Suitable amino acids include, but are not limited to, glycine and histidine. Suitable pH-adjusting agents include, but are not limited to, hydrochloric acid, acetic acid, and sodium hydroxide. In one embodiment, the pH-adjusting agent or agents are present in an amount effective to provide a pH of about 3 to about 8, about 4 to about 7, about 5 to about 6, about 6 to about 7, or about 7 to about 7.5. In one embodiment, a composition comprising a VEGF antagonist does not comprise a preservative. Suitable excipients for the VEGF antagonist also include those described in U.S. Patent No. 7,365,166, the contents of which are herein incorporated by reference in their entirety.

[00347] In one embodiment, the composition is in the form of an aqueous solution that is suitable for injection. In one embodiment, the composition comprises a VEGF antagonist, a buffering agent, a sugar, a nonionic surfactant, and water for injection. In another embodiment, the composition comprises a VEGF antagonist, monobasic sodium phosphate, dibasic sodium phosphate, α,α-trehalose dehydrate, and polysorbate 20. In one embodiment, the composition comprises a VEGF antagonist, a buffering agent, a pH-adjusting agent, a tonicity agent, and water that is suitable for injection. In another embodiment, the composition comprises a VEGF antagonist, monobasic sodium phosphate, dibasic sodium phosphate, sodium chloride, hydrochloric acid, and sodium hydroxide. In one embodiment, the VEGF antagonist is a pegylated anti-VEGF aptamer.

[00348] In another embodiment, the VEGF antagonist is ranibizumab or bevacizumab. This invention includes the pharmaceutically acceptable salts of the antagonists of Table 1 or 2. An antagonist of the present invention can possess a sufficiently basic functional group, which can react with any of a number of inorganic and organic acids, to form a pharmaceutically acceptable salt. A pharmaceutically-acceptable acid addition salt is formed from a pharmaceutically-acceptable acid, as is well known in the art. Such salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2-19 (1977) and The Handbook of Pharmaceutical Salts; Properties, Selection, and Use. P. H. Stahl and C. G. Wermuth (ED.s), Verlag, Zurich (Switzerland) 2002, which are hereby incorporated by reference in their entirety.

[00349] Pharmaceutically acceptable salts include sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, pamoate, phenylacetate, trifluoroacetate, acrylate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, isobutyrate, phenylbutyrate, .alpha.-hydroxybutyrate, butyne-1,4-dicarboxylate, hexyne-1,4-dicarboxylate, caprate, caprylate, cinnamate, glycollate, heptanoate, hippurate, malate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, phthalate, teraphthalate, propiolate, propionate, phenylpropionate, sebacate, suberate, p-bromobenzenesulfonate, chlorobenzenesulfonate, ethylsulfonate, 2-hydroxyethylsulfonate, methylsulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, naphthalene-1,5-sulfonate, xylenesulfonate, and tartarate salts. The term "pharmaceutically acceptable salt" also refers to a salt of an antagonists of the present invention having an acidic functional group, such as a carboxylic acid functional group, and a base. Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metal such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, and organic amines, such as unsubstituted or hydroxy-substituted mono-, di-, or tri-alkylamines, dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-OH-lower alkylamines), such as mono-; bis-, or tris-(2-hydroxyethyl)amine, 2-hydroxy-tert-butylamine, or tris-(hydroxymethyl)methylamine, N,N-di-lower alkyl-N-(hydroxyl-lower alkyl)-amines, such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine; N-

methyl-D-glucamine; and amino acids such as arginine, lysine, and the like. The term "pharmaceutically acceptable salt" also includes a hydrate of a compound of the invention.

[00350] In one embodiment, each of the PDGF and VEGF antagonists of Table 1 or 2 is administered in an amount effective to treat or prevent an ophthalmological disease. The amount of antagonist that is admixed with the carrier materials to produce a single dosage can vary depending upon the mammal being treated and the particular mode of administration.

[00351] The dosage of each antagonist can depend on several factors including the severity of the condition, whether the condition is to be treated or prevented, and the age, weight, and health of the person to be treated. Additionally, pharmacogenomic (the effect of genotype on the pharmacokinetic, pharmacodynamic or efficacy profile of a therapeutic) information about a particular patient may affect dosage used. Furthermore, the exact individual dosages can be adjusted somewhat depending on a variety of factors, including the specific combination of antagonists being administered, the time of administration, the route of administration, the nature of the formulation, the rate of excretion, the particular ophthalmological disease being treated, the severity of the disorder, and the anatomical location of the neovascular disorder. Some variations in the dosage can be expected.

[00352] Generally, when orally administered to a mammal, the dosage of an antagonist of the present invention is normally 0.001 mg/kg/day to 100 mg/kg/day, 0.01 mg/kg/day to 50 mg/kg/day, or 0.1 mg/kg/day to 10 mg/kg/day. Generally, when orally administered to a human, the dosage of an antagonist of the present invention is normally 0.001 mg to 300 mg per day, 1 mg to 200 mg per day, or 5 mg to 50 mg per day. Dosages up to 200 mg per day may be necessary. For administration of an antagonist of the present invention by parenteral injection, the dosage is normally 0.1 mg to 250 mg per day, 1 mg to 20 mg per day, or 3 mg to 5 mg per day. Injections may be given up to four times daily. Generally, when orally or parenterally administered, the dosage of a PDGF or VEGF antagonist of Table 1 or 2 for use in the present invention is normally 0.1 mg to 1500 mg per day, or 0.5 mg to 10 mg per day, or 0.5 mg to 5 mg per day. A dosage of up to 3000 mg per day can be administered.

[00353] When ophthalmologically administered to a human, for example intravitreally, the dosage of an antagonist of Table 1 or 2 is normally 0.003 mg to 5.0 mg per eye per administration, or 0.03 mg to 3.0 mg per eye per administration, or 0.1 mg to 1.0 mg per eye per administration. In one embodiment, the dosage of PDGF antagonist of Table 1 or 2 is 0.03 mg, 0.3 mg, 1.5 mg or 3.0 mg per eye. In another ambodiment, the dosage of VEGF antagonist of Table 1 or 2 is 0.5 mg per eye. The dosage can range from 0.01 mL to 0.2 mL administered per eye, or 0.03 mL to 0.15 mL administered per eye, or 0.05 mL to 0.10 mL administered per eye.

[00354] For example, the PDGF aptamer Antagonist A, Antagonist B or Antagonist C or a pharmaceutically acceptable salt thereof can be delivered intravitreally at up to 30 mg/ml with injection volumes up to 100 μL.

[00355] Administration of each antagonist of Table 1 or 2 can, independently, be one to four times daily or one to four times per month or one to six times per year or once every two, three, four or five years. Administration can be for the duration of one day or one month, two months, three months, six months, one year, two years, three years, and may even be for the life of the patient. In one embodiment, the administration is performed once a month for three months. Chronic, long-term administration will be indicated in many cases. The dosage may be administered as a single dose or divided into multiple doses. In general, the desired dosage should be administered at set intervals for a prolonged period, usually at least over several weeks or months, although longer periods of administration of several months or years or more may be needed.

[00356] In addition to treating pre-existing ophthalmological diseases, the compositions can be administered prophylactically in order to prevent or slow the onset of these disorders. In prophylactic applications, the composition can be administered to a patient susceptible to or otherwise at risk of a particular ophthalmological disease.

[00357] In one embodiment, the PDGF antagonist and the VEGF antagonist of Table 1 or 2 are administered to a mammal in need of treatment therewith, typically in the form of an injectable pharmaceutical composition. The PDGF antagonist and VEGF antagonist of Table 1 or 2 can be administered either in separate compositions or in a pharmaceutical composition comprising both the PDGF antagonist and VEGF antagonist. The administration can be by injection, for example by intraocular injection, or by using a drug delivery device. Parenteral, systemic, or transdermal administration is also within the scope of the invention.

[00358] The administration of the PDGF antagonist and the VEGF antagonist of Table 1 or 2 can be sequential in time or concurrent. When administered sequentially, the administration of each can be by the same or different route. In one embodiment, a PDGF antagonist of Table 1 or 2 is administered within 90 days, 30 days, 10 days, 5 days, 24 hours , 1 hour, 30 minutes, 10 minutes, 5 minutes or one minute of administration of a VEGF antagonist of Table 1 or 2. Where the PDGF antagonist is administered prior to the VEGF antagonist, the VEGF antagnoist is administered within a time and in an amount such that the total amount of PDGF antagonist and VEGF antagonist is effective to treat or prevent an ophthalmological disease. Where the VEGF antagonist is administered prior to the PDGF antagonist, the PDGF antagnoist is administered within a time and in an amount such that the total amount of PDGF antagonist and VEGF antagonist is effective to treat or prevent an ophthalmological disease.

[00359] Pharmaceutical compositions according to the invention may be formulated to release a PDGF or VEGF antagonist of Table 1 or 2 substantially immediately upon administration or at any predetermined time period after administration, using controlled release formulations. For example, a pharmaceutical composition can be provided in sustained-release form. The use of immediate or sustained release compositions depends on the nature of the condition being treated. If the condition consists of an acute disorder, treatment with an immediate release form can be utilized over a prolonged release composition. For certain preventative or long-term treatments, a sustained released composition can also be appropriate.

[00360] Administration of one or both of the antagonists of Table 1 or 2 in controlled release formulations can be useful where the antagonist, either alone or in combination, has (i) a narrow therapeutic index (*e.g.*, the difference between the plasma concentration leading to harmful side effects or toxic reactions and the plasma concentration leading to a therapeutic effect is small; generally, the therapeutic index, TI, is defined as the ratio of median lethal dose (LD_{50}) to median effective dose (ED_{50})); (ii) a narrow absorption window in the gastro-intestinal tract; or (iii) a short biological half-life, so that frequent dosing during a day is required in order to sustain the plasma level at a therapeutic level.

[00361] Many strategies can be pursued to obtain controlled release in which the rate of release outweighs the rate of degradation or metabolism of the therapeutic antagonist. For example, controlled release can be obtained by the appropriate selection of formulation parameters and ingredients, including, *e.g.*, appropriate controlled release compositions and coatings. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, nanoparticles, patches, and liposomes. Methods for preparing such sustained or controlled release formulations are well known in the art.

[00362] The PDGF antagonist or VEGF antagonist can also be delivered using a drug-delivery device such as an implant. Such implants can be biodegradable and/or biocompatible, or can be non-biodegradable. The implants can be permeable to the PDGF antagonist or VEGF antagonist. Ophthalmic drug delivery devices can be inserted into a chamber of the eye, such as the anterior or posterior chamber or can be implanted in or on the sclera, choroidal space, or an avascularized region exterior to the vitreous. In one embodiment, the implant can be positioned over an avascular region, such as on the sclera, so as to allow for transcleral diffusion of the PDGF antagonist or VEGF antagonist to the desired site of treatment, *e.g.*, the intraocular space and macula of the eye. Furthermore, the site of transcleral diffusion can be proximal to a site of neovascularization such as a site proximal to the macula. Suitable

drug delivery devices are described, for example, in U.S. Publication Nos. 2008/0286334; 2008/0145406; 2007/0184089; 2006/0233860; 2005/0244500; 2005/0244471; and 2005/0244462, and U.S. Patent Nos. 6,808,719 and 5,322,691, the contents of each of which is herein incorporated by reference in its entirety.

[00363] In one embodiment, the implant comprises a PDGF antagonist and/or VEGF antagonist dispersed in a biodegradable polymer matrix. The matrix can comprise PLGA (polylactic acid-polyglycolic acid copolymer), an ester-end capped polymer, an acid end-capped polymer, or a mixture thereof. In another embodiment, the implant comprises a PDGF antagonist and/or a VEGF antagonist, a surfactant, and lipophilic compound. The lipophilic compound can be present in an amount of about 80-99% by weight of the implant. Suitable lipophilic compounds include, but are not limited to, glyceryl palmitostearate, diethylene glycol monostearate, propylene glycol monostearate, glyceryl monostearate, glyceryl monolinoleate, glyceryl monooleate, glyceryl monopalmitate, glyceryl monolaurate, glyceryl dilaurate, glyceryl monomyristate, glyceryl dimyristate, glyceryl monopalmitate, glyceryl dipalmitate, glyceryl monostearate, glyceryl distearate, glyceryl monooleate, glyceryl dioleate, glyceryl monolinoleate, glyceryl dilinoleate, glyceryl monoarachidate, glyceryl diarachidate, glyceryl monobehenate, glyceryl dibehenate, and mixtures thereof. In another embodiment, the implant comprises a PDGF antagonist and/or a VEGF antagonist housed within a hollow sleeve. The PDGF antagonist or VEGF antagonist, or both, are delivered to the eye by inserting the sleeve into the eye, releasing the implant from the sleeve into the eye, and then removing the sleeve from the eye. An example of this delivery device is described in U.S. Publication No. 2005/0244462, which is hereby incorporated by reference in its entirety.

[00364] In one embodiment, the implant is a flexible ocular insert device adapted for the controlled sustained release of a PDGF antagonist and/or a VEGF antagonist into the eye. In one embodiment, the device includes an elongated body of a polymeric material in the form of a rod or tube containing a PDGF antagonist, VEGF antagonist or both, and with at least two anchoring protrusions extending radially outwardly from the body. The device may have a length of at least 8 mm and the diameter of its body portion including the protrusions does not exceed 1.9 mm. The sustained release mechanism can, for example, be by diffusion or by osmosis or bioerosion. The insert device can be inserted into the upper or lower fornix of the eye so as to be independent of movement of the eye by virtue of the fornix anatomy. The protrusions can be of various shapes such as, for example, ribs, screw threads, dimples or bumps, truncated cone-shaped segments or winding braid segments. In a further embodiment, the polymeric material for the body is selected as one which swells in a liquid environment. Thus a device of smaller initial size can be employed. The insert device can be of a size and configuration such that, upon insertion into the upper or lower fornix, the device remains out of the field of vision so as to be well retained in place and imperceptible by a recipient over a prolonged period of use. The device can be retained in the upper or lower fornix for 7 to 14 days or longer. An example of this device is described in U.S. Patent No. 5,322,691, which is hereby incorporated by reference in its entirety.

[00365] The invention relates to kits comprising one or more pharmaceutical compositions and instructions for use. At least two antagonists of Table 1 or 2 can be formulated together or in separate compositions and in individual dosage amounts. The antagonists of Table 1 or 2 are also useful when formulated as pharmaceutically acceptable salts. In one embodiment, the kits comprise a composition comprising a PDGF antagonist and a pharmaceutically acceptable carrier or vehicle and another composition comprising a VEGF antagonist and a pharmaceutically acceptable carrier or vehicle. In another embodiment, the kits comprise a composition comprising a VEGF antagonist, a PDGF antagonist and a pharmaceutically acceptable carrier or vehicle. Each of the kits' compositions can be contained in a container.

[00366] The kits can comprise (1) an amount of a PDGF antagonist of Table 1 or 2 and a pharmaceutically acceptable carrier, vehicle, or diluent in a first unit dosage form; (2) an amount of a VEGF antagonist of Table 1 or 2

and a pharmaceutically acceptable carrier, vehicle, or diluent in a second unit dosage form; and (3) a container. The container can be used to separate components and include, for example, a divided bottle or a divided foil packet. The separate antagonist compositions may also, if desired, be contained within a single, undivided container. The kits can also comprise directions for the administration of the antagonists. The kits are particularly advantageous when the separate components are administered in different dosage forms, are administered at different dosage levels, or when titration of the individual antagonists is desired.

7. EXAMPLES

[00367] *Example 1: Corneal Neovascularization (Corneal NV)*

[00368] Corneal Neovascularization is a widely used animal model that allows clear visualization of abnormal vascular growth in the eye. The vessels that grow into the normally avascular cornea, can become well established, making this an attractive model to study vessel regression. To induce experimental corneal NV, male C57BL/6 mice (18-20 g; Charles River, Wilmington, MA) are anesthetized with intramuscular ketamine hydrochloride (25 mg/kg) and xylazine (10 mg/kg). NaOH (2 ul of 0.2 mM) is applied topically. The corneal and limbal epithelia are removed by applying a rotary motion parallel to the limbus using #21 blade (Feather, Osaka, Japan). After 7 days, mice are treated with intra-peritoneal injections of 2.0 mg/ml of Antagonist A, an anti-PDGF aptamer, agent twice a day or by intra-peritoneal injections of 2.0 mg/mL of ranibizumab (as the commercially available composition Lucentis®, an anti-VEGF antibody agent, twice a day or both for 7 days. At day 14 following corneal NV induction, mice receive 20 ug/g of fluorescein-isothiocyanate coupled concanavalin A lectin (Vector Laboratories, Burlingame, CA) intravenously while deeply anesthetized with xylazine hydrochloride and ketamine hydrochloride. Thirty minutes later, mice eyes are enucleated, and the corneas flat-mounted. Corneal NV is visualized using fluorescence microscopy and quantified using Openlab software. The percent of cornea covered by vessels is calculated as a percentage of total corneal area.

[00369] The effects of the administration of Antagonist A and ranibizumab are measured for decrease in vessel growth and pictures of the fluorescent microscopic image are taken.

[00370] *Example 2: Administration of Antagonist A and Ranibizumab*

[00371] The objectives of this study were to assess safety of Antagonist A, an intravitreal anti-PDGF aptamer targeting pericytes, in combination with ranibizumab in subjects with neovascular age-related macular degeneration (NV-AMD).

[00372] Dose-escalating, uncontrolled, single- and multiple-dose, multicenter phase 1 study. Included were subjects with predominantly or minimally classic subfoveal NV-AMD $\leq$ 5 disc areas in total lesion size. Subjects were enrolled in a dose escalation scheme to a single injection of 0.03 mg/eye and 3 monthly injections of ranibizumab (as the commercially available composition Lucentis®) 0.5 mg/eye (n=3), or to three monthly injections of one of 4 different doses of Antagonist A (0.03, 0.3, 1.5, 3.0 mg/eye) and ranibizumab (as the commercially available composition Lucentis®) (0.5mg/eye) (n=3-8/dose), administered as separate injections. Assessments included vital signs and clinical lab tests, complete ocular examination with intraocular pressure, standardized ETDRS visual acuity, color fundus photos and fluorescein angiography, and optical coherence tomography.

[00373] No evidence of drug related adverse events were detected. All of the ocular adverse events were associated with the intravitreal injection. In the combined analysis of 22 subjects over 12 weeks, 36%, 45% and 59% of the subjects gained $\geq$ 15 letters at weeks 4, 8, and 12 respectively. The mean change in visual acuity was +11.2, +12.3 and + 14.0 ETDRS letters at weeks 4 (n=22), 8 (n=22), and 12 (n=22). The mean center point retinal thickness was 387 μm at baseline and 230 μm at week 12 (see Figure 5). Analysis of FA by independent readers revealed a mean decrease in CNV area of 86% at Week 12 compared to baseline.

[00374] These results suggest potential bioactivity associated with regression of the neovascular membrane.

[00375] *Example 3: Patterns of choroidal neovascularization (CNV) Fluorescein and Indocyanine Green Angiographic Regression Responses After Ranibizumab Monotherapy or Ranibizumab and Antagonist A Combotherapy*

[00376] Anti-VEGF monotherapy for NV-AMD can cause stabilization of CNV lesion size and leakage. The fluorescein angiographic (FA) and dynamic indocyanine green angiographic (ICGA) patterns of CNV regression responses in eyes receiving either ranibizumab only or ranibizumab and Antagonist A were compared.

[00377] A retrospective review was performed of 20 cases of NV-AMD in which 2-3 doses of intravitreal ranibizumab (as the commercially available composition Lucentis®) monotherapy successfully induced anatomic improvement by OCT. These eyes were compared with 13 eyes of patients in a study of monthly intravitreal ranibizumab (as the commercially available composition Lucentis®) (up to 3 doses) plus intravitreal Antagonist A (at least one but up to 3 doses). Eyes were imaged by FA pretreatment and at various times post treatment. Eyes could also be imaged by dynamic ICGA (Spectralis, Heidelberg). Angiograms were evaluated to assess the changes in lesion size and vascular perfusion.

[00378] Three angiographic patterns of "OCT successful" responses to treatment were observed. (1) Stable inactivity was characterized by FA with stable lesion size and uniform low grade fluorescein hyperfluorescence (staining) of the CNV. ICGA typically demonstrated persistence of feeder arteries with branching arterioles. (2) Vascular regression demonstrated FA with stable CNV area but shrinkage of area of fluorescein staining. ICGA demonstrated disappearance of homogenous capillaries and small branching arterioles. (3) Lesion regression was characterized by partial to nearly complete disappearance of both the CNV lesion and hyperfluorescent staining. Persistent hypofluorescence in the bed of the CNV was often present. ICGA revealed significant disappearance of most vascular components. Partial or extensive lesion regression occurred in 85% (11 of 13 eyes) treated with ranibizumab and Antagonist A, compared with only 20% (4 of 20 eyes) treated with ranibizumab monotherapy. In contrast, stable inactivity was observed in only 15% (2 of 13 eyes) treated with ranibizumab and Antagonist A versus 55% (11 of 20 eyes) treated with ranibizumab monotherapy.

[00379] *Example 4: Synthesis of Antagonist A*

[00380] The iterative chemical synthesis of the 32-mer oligonucleotide of Antagonist A was performed on a solid phase inverted deoxyribothymidine controlled pore glass (CPG) support using a flow through reactor design. The oligonucleotide synthesis process was comprised of four chemical reactions carried out in the following sequence: (a) deblocking of the dimethyoxytrityl (DMT) protected nucleoside or nascent oligonucleotide (detritylation); (b) activation and coupling of the incoming phosphoramidite (amidite); (c) oxidation of the resultant phosphite triester to the pentavalent phosphate linkage; and (d) capping of oligonucleotide chains that failed to successfully couple.

[00381] Starting with an inverted thymidine CPG support (3´-DMT-5´-dT-CPG) the four steps above were repeated to add phosphoramidites in the order of the sequence until the desired oligonucleotide, terminating in the hexylamino linker, was synthesized. The internal hexaethylene glycol spacers were coupled in the same manner as the other phosphoramidites.

[00382] The first step in the cycle involved removal of the dimethyoxytrityl protecting group on the terminal hydroxyl group of the nascent oligonucleotide chain. This was achieved by treating the DMT protected oligonucleotide on CPG with a solution of dichloroacetic acid in dichloromethane. This reaction produced the unprotected terminal hydroxyl group. The cleaved DMT group was removed with the dichloroacetic acid/dichloromethane (DCA/DCM) solvent. The CPG was then washed with acetonitrile (ACN).

[00383] The second step involved activation of the incoming phosphoramidite with ethylthiotetrazole (ETT) to produce a species that would quickly couple with the terminal hydroxyl group produced in the previous step. The resultant phosphite triester was washed with ACN to remove activator and unreacted phosphoramidite.

[00384] The third step is oxidation of the newly formed phosphite triester to the pentavalent phosphate. This was accomplished by reacting the phosphite triester with a mixture of iodine and pyridine in water. Unused oxidant was washed from the CPG with ACN.

[00385] The fourth step involved capping of any unreacted hydroxyls that had failed to couple. The CPG was treated with a mixture of CAP NMI (N-methylimidazole in ACN) and CAP ALA (acetic anhydride, 2,6-lutidine, ACN). These reagents were washed from the CPG with ACN.

[00386] This cycle of four reactions was repeated until an oligonucleotide of the correct length and sequence was assembled on the solid support. The last phosphoramidite (hexylamino linker at the 5´ terminus of the oligonucleotide) was reacted in the same fashion as the other phosphoramidites used in the synthesis; however, this linker was not capped.

[00387] The oligonucleotide was deprotected and cleaved by treating the solid support, containing the crude synthesized oligonucleotide, with a t-butyl amine/ammonium hydroxide solution. The CPG was separated from the deprotected and cleaved oligonucleotide. The purity of the crude fully deprotected oligonucleotide was determined by analytical anion exchange chromatography and met a specification of greater than 50%.

[00388] The resultant oligonucleotide from Stage 1 was filtered, diluted and purified by preparative anion exchange chromatography (AX HPLC). Fractions were analyzed for product purity by analytical anion exchange HPLC. Individual fractions with a purity greater than 70% unpegylated aptamer, defined as the full length oligonucleotide that contains the 5´-hexylamino linker, were combined. In preparation for pegylation, the resultant fraction pool was first desalted and then concentrated using ultrafiltration. In some instances, the anion exchange chromatography step was replaced by a step in which diafiltration against sodium chloride was used to remove amine salts prior to Stage3.

[00389] In forming a covalent bond between the primary amine on the 5´ end of the oligonucleotide and the pegylation reagent (mPEG2- NHS ester), the reaction was conducted at pH 9 in sodium borate buffer. The reaction has been demonstrated to be site specific to the hexylamino linker at the 5´ end of the oligonucleotide using the pegylation conditions described.

[00390] The pegylated oligonucleotide was purified from unconjugated PEG reagent, unpegylated aptamer, and other by-products by the same preparative AX HPLC method described above for Stage 2. The individual fractions were analyzed by analytical AX HPLC. Fractions with greater than 85% full length pegylated oligonucleotide were pooled and the resultant pool was desalted, concentrated, and filtered.

[00391] The resultant drug substance was vacuum freeze dried to reduce the water content.

[00392] *Example 5: Choroidal Neovascularization (CNV)*

[00393] Experimental CNV is useful as a model for Age-related Macular degeneration (AMD). In CNV, vessels of the choroid grow through breaks in Bruch's membrane and into the retina, similar to what is observed in AMD patients. To induce experimental CNV, male C57BL/6 mice (18-20 g; Charles River, Wilmington, MA) are anesthetized with intramuscular ketamine hydrochloride (25 mg/kg) and xylazine (10 mg/kg) and the mice pupils are dilated with 1% tropicamide. Four burns are generated using diode laser photocoagulation (75-μm spot size, 0.1-second duration, 90 mW, Oculight SL laser, IRIDEX, Mountain View,CA) and a hand-held cover slide as a contact lens. Burns are localized to the 3, 6, 9 and 12 o'clock positions of the posterior pole of the retina. Production of a bubble in the choroid at the time of laser photocoagulation, which indicates rupture of Bruch's membrane, is an important factor in obtaining choroidal neovascularization, so only mice in which a bubble is produced for all four burns are included in the study. After 7 days, mice are treated with (a) an intra-peritoneal injection of 2.0 mg/ml of

Antagonist A twice a day for seven days; (b) an intra-peritoneal injection of 2.0 mg/mL of ranibizumab (as the commercially available composition Lucentis®) twice a day for 7 days; or (c) an intra-peritoneal injection of 2.0 mg/ml of Antagonist A and an intra-peritoneal injection of 2.0 mg/mL of ranibizumab (as the commercially available composition Lucentis®), both being administered twice a day for 7 days. The area of choroidal NV lesions is measured in flat-mounted choroid stained with platelet endothelial cell adhesion molecule (PECAM) antibody. Flat-mounts are examined by fluorescence microscopy and quantified using Openlab software.

[00394] The effects of the administration of one or more of (a), (b) and (c) are measured for decrease in CNV area compared to untreated controls.

8. INCORPORATION BY REFERENCE

[00395] All publications and patent applications disclosed in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

CLAIMS

WHAT IS CLAIMED IS:

1. A method for treating or preventing an ophthalmological disease, comprising administering to a mammal in need thereof an effective amount of:

(a) Antagonist A or a pharmaceutically acceptable salt thereof; and

(b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof.

2. A method for treating or preventing an ophthalmological disease, comprising administering to a mammal in need thereof an effective amount of:

(a) a compound of Formula B or a pharmaceutically acceptable salt thereof; and

(b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof.

3. A method for treating or preventing an ophthalmological disease, comprising administering to a mammal in need thereof an effective amount of:

(a) a compound of Formula C or a pharmaceutically acceptable salt thereof; and

(b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof.

4. A method for treating or preventing an ophthalmological disease, comprising administering to a mammal in need thereof an effective amount of:

(a) Antagonist D or a pharmaceutically acceptable salt thereof; and

(b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof.

5. A method for treating or preventing an ophthalmological disease, comprising administering to a mammal in need thereof an effective amount of:

(a) a compound of Formula E or a pharmaceutically acceptable salt thereof; and

(b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody, or a pharmaceutically acceptable salt thereof.

6. The method of claim 1, wherein the ophthalmological disease is age-related macular degeneration, polypoidal choroidal vasculopathy, condition associated with choroidal neovascularization, hypertensive retinopathy, diabetic retinopathy, sickle cell retinopathy, condition associated with peripheral retinal neovascularization, retinopathy of prematurity, venous occlusive disease, arterial occlusive disease, central serous chorioretinopathy, cystoid macular edema, retinal telangiectasia, arterial macroaneurysm, retinal angiomatosis, radiation-induced retinopathy, rubeosis iridis, or a neoplasm.

7. The method of claim 2, wherein the ophthalmological disease is age-related macular degeneration, polypoidal choroidal vasculopathy, condition associated with choroidal neovascularization, hypertensive retinopathy, diabetic retinopathy, sickle cell retinopathy, condition associated with peripheral retinal neovascularization, retinopathy of prematurity, venous occlusive disease, arterial occlusive disease, central serous chorioretinopathy, cystoid macular edema, retinal telangiectasia, arterial macroaneurysm, retinal angiomatosis, radiation-induced retinopathy, rubeosis iridis, or a neoplasm.

8. The method of claim 3, wherein the ophthalmological disease is age-related macular degeneration, polypoidal choroidal vasculopathy, condition associated with choroidal neovascularization, hypertensive retinopathy, diabetic retinopathy, sickle cell retinopathy, condition associated with peripheral retinal neovascularization, retinopathy of prematurity, venous occlusive disease, arterial occlusive disease, central serous chorioretinopathy, cystoid macular edema, retinal telangiectasia, arterial macroaneurysm, retinal angiomatosis, radiation-induced retinopathy, rubeosis iridis, or a neoplasm.

9. The method of claim 4, wherein the ophthalmological disease is age-related macular degeneration, polypoidal choroidal vasculopathy, condition associated with choroidal neovascularization, hypertensive retinopathy, diabetic retinopathy, sickle cell retinopathy, condition associated with peripheral retinal neovascularization, retinopathy of prematurity, venous occlusive disease, arterial occlusive disease, central serous chorioretinopathy, cystoid macular edema, retinal telangiectasia, arterial macroaneurysm, retinal angiomatosis, radiation-induced retinopathy, rubeosis iridis, or a neoplasm.

10. The method of claim 5, wherein the ophthalmological disease is age-related macular degeneration, polypoidal choroidal vasculopathy, condition associated with choroidal neovascularization, hypertensive retinopathy, diabetic retinopathy, sickle cell retinopathy, condition associated with peripheral retinal neovascularization, retinopathy of prematurity, venous occlusive disease, arterial occlusive disease, central serous chorioretinopathy, cystoid macular edema, retinal telangiectasia, arterial macroaneurysm, retinal angiomatosis, radiation-induced retinopathy, rubeosis iridis, or a neoplasm.

11. The method of claim 1, wherein (a) and (b) are administered within 24 hours of each other.

12. The method of claim 2, wherein (a) and (b) are administered within 24 hours of each other.

13. The method of claim 3, wherein (a) and (b) are administered within 24 hours of each other.

14. The method of claim 4, wherein (a) and (b) are administered within 24 hours of each other.

15. The method of claim 5, wherein (a) and (b) are administered within 24 hours of each other.

16. The method of claim 1, wherein (a) and (b) are administered within 60 minutes of each other.

17. The method of claim 2, wherein (a) and (b) are administered within 60 minutes of each other.

18. The method of claim 3, wherein (a) and (b) are administered within 60 minutes of each other.

19. The method of claim 4, wherein (a) and (b) are administered within 60 minutes of each other.

20. The method of claim 5, wherein (a) and (b) are administered within 60 minutes of each other.

21. The method of claim 1, wherein (a) and (b) are administered concurrently.

22. The method of claim 2, wherein (a) and (b) are administered concurrently.

23. The method of claim 3, wherein (a) and (b) are administered concurrently.

24. The method of claim 4, wherein (a) and (b) are administered concurrently.

25. The method of claim 5, wherein (a) and (b) are administered concurrently.

26. The method of claim 1, wherein (a) and (b) are present in the same composition.

27. The method of claim 2, wherein (a) and (b) are present in the same composition.

28. The method of claim 3, wherein (a) and (b) are present in the same composition.

29. The method of claim 4, wherein (a) and (b) are present in the same composition.

30. The method of claim 5, wherein (a) and (b) are present in the same composition.

31. The method of claim 1, further comprising administering an effective amount of another agent useful for treating or preventing an ophthalmological disease.

32. The method of claim 2, further comprising administering an effective amount of another agent useful for treating or preventing an ophthalmological disease.

33. The method of claim 3, further comprising administering an effective amount of another agent useful for treating or preventing an ophthalmological disease.

34. The method of claim 4, further comprising administering an effective amount of another agent useful for treating or preventing an ophthalmological disease.

35. The method of claim 5, further comprising administering an effective amount of another agent useful for treating or preventing an ophthalmological disease.

36. The method of claim 1, wherein (a) or (b) are present in a drug-delivery device.

37. The method of claim 2, wherein (a) or (b) are present in a drug-delivery device.

38. The method of claim 3, wherein (a) or (b) are present in a drug-delivery device.

39. The method of claim 4, wherein (a) or (b) are present in a drug-delivery device.

40. The method of claim 5, wherein (a) or (b) are present in a drug-delivery device.

41. The method of claim 1, wherein (a) and (b) are present in a drug-delivery device.

42. The method of claim 2, wherein (a) and (b) are present in a drug-delivery device.

43. The method of claim 3, wherein (a) and (b) are present in a drug-delivery device.

44. The method of claim 4, wherein (a) and (b) are present in a drug-delivery device.

45. The method of claim 5, wherein (a) and (b) are present in a drug-delivery device.

46. The method of claim 1, wherein (a) and (b) are present in the same drug-delivery device.

47. The method of claim 2, wherein (a) and (b) are present in the same drug-delivery device.

48. The method of claim 3, wherein (a) and (b) are present in the same drug-delivery device.

49. The method of claim 4, wherein (a) and (b) are present in the same drug-delivery device.

50. The method of claim 5, wherein (a) and (b) are present in the same drug-delivery device.

51. The method of claim 1, wherein (a) or (b) are administered intraocularly.

52. The method of claim 2, wherein (a) or (b) are administered intraocularly.

53. The method of claim 3, wherein (a) or (b) are administered intraocularly.

54. The method of claim 4, wherein (a) or (b) are administered intraocularly.

55. The method of claim 5, wherein (a) or (b) are administered intraocularly.

56. The method of claim 1, wherein (a) and (b) are administered intraocularly.

57. The method of claim 2, wherein (a) and (b) are administered intraocularly.

58. The method of claim 3, wherein (a) and (b) are administered intraocularly.

59. The method of claim 4, wherein (a) and (b) are administered intraocularly.

60. The method of claim 5, wherein (a) and (b) are administered intraocularly.

61. The method of claim 51, wherein intraocular administration is by intravitreal administration or anterior chamber administration.

62. The method of claim 52, wherein intraocular administration is by intravitreal administration or anterior chamber administration.

63. The method of claim 53, wherein intraocular administration is by intravitreal administration or anterior chamber administration.

64. The method of claim 54, wherein intraocular administration is by intravitreal administration or anterior chamber administration.

65. The method of claim 55, wherein intraocular administration is by intravitreal administration or anterior chamber administration.

66. The method of claim 56, wherein intraocular administration is by intravitreal administration or anterior chamber administration.

67. The method of claim 57, wherein intraocular administration is by intravitreal administration or anterior chamber administration.

68. The method of claim 58, wherein intraocular administration is by intravitreal administration or anterior chamber administration.

69. The method of claim 59, wherein intraocular administration is by intravitreal administration or anterior chamber administration.

70. The method of claim 60, wherein intraocular administration is by intravitreal administration or anterior chamber administration.

71. The method of claim 1, wherein the mammal is a human.

72. The method of claim 2, wherein the mammal is a human.

73. The method of claim 3, wherein the mammal is a human.

74. The method of claim 4, wherein the mammal is a human.

75. The method of claim 5, wherein the mammal is a human.

76. The method of claim 1, wherein the (a) is administered at a dosage of at least 0.003 mg.

77. The method of claim 2, wherein the (a) is administered at a dosage of at least 0.003 mg.

78. The method of claim 3, wherein the (a) is administered at a dosage of at least 0.003 mg.

79. The method of claim 4, wherein the (a) is administered at a dosage of at least 0.003 mg.

80. The method of claim 5, wherein the (a) is administered at a dosage of at least 0.003 mg.

81. The method of claim 1, wherein the (b) is administered at a dosage of at least 0.003 mg.

82. The method of claim 2, wherein the (b) is administered at a dosage of at least 0.003 mg.

83. The method of claim 3, wherein the (b) is administered at a dosage of at least 0.003 mg.

84. The method of claim 4, wherein the (b) is administered at a dosage of at least 0.003 mg.

85. The method of claim 5, wherein the (b) is administered at a dosage of at least 0.003 mg.

86. The method of claim 1, wherein (b) is ranibizumab or a pharmaceutically acceptable salt thereof.

87. The method of claim 1, wherein (b) is bevacizumab or a pharmaceutically acceptable salt thereof.

88. The method of claim 1, wherein (b) is aflibercept or a pharmaceutically acceptable salt thereof.

89. The method of claim 2, wherein the compound of Formula B is Antagonist B or a pharmaceutically acceptable salt thereof.

90. The method of claim 72, wherein (b) is ranibizumab or a pharmaceutically acceptable salt thereof.

91. The method of claim 72, wherein (b) is bevacizumab or a pharmaceutically acceptable salt thereof.

92. The method of claim 72, wherein (b) is aflibercept or a pharmaceutically acceptable salt thereof.

93. The method of claim 3, wherein the compound of Formula C is Antagonist C or a pharmaceutically acceptable salt thereof.

94. The method of claim 93, wherein (b) is ranibizumab or a pharmaceutically acceptable salt thereof.

95. The method of claim 93, wherein (b) is bevacizumab or a pharmaceutically acceptable salt thereof.

96. The method of claim 93, wherein (b) is aflibercept or a pharmaceutically acceptable salt thereof.

97. The method of claim 4, wherein (b) is ranibizumab or a pharmaceutically acceptable salt thereof.

98. The method of claim 4, wherein (b) is bevacizumab or a pharmaceutically acceptable salt thereof.

99. The method of claim 4, wherein (b) is aflibercept or a pharmaceutically acceptable salt thereof.

100. A composition comprising an effective amount of:

(a) Antagonist A, a compound of Formula B, a compound of Formula C, Antagonist D, a compound of Formula E or a pharmaceutically acceptable salt thereof;

(b) ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fc fusion protein, 2C3 antibody, ORA102, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLG101, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxyisovalerylshikonin, or ganglioside GM3, DC101 antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4E10 antibody, 5F12 antibody, VA01 antibody, BL2 antibody, VEGF-related protein, sFLT01, sFLT02, Peptide B3, TG100801, sorafenib, or G6-31 antibody; and

(c) a pharmaceutically acceptable carrier or vehicle.

101. The composition of claim 100, further comprising an effective amount of another agent useful for treating or preventing an ophthalmological disease.

102. The composition of claim 100, wherein (a) is Antagonist A or a pharmaceutically acceptable salt thereof.

103. The composition of claim 102, wherein (b) is ranibizumab or a pharmaceutically acceptable salt thereof.

104. The composition of claim 102, wherein (b) is bevacizumab or a pharmaceutically acceptable salt thereof.

105. The composition of claim 102, wherein (b) is aflibercept or a pharmaceutically acceptable salt thereof.

106. The composition of claim 100, wherein the compound of Formula B is Antagonist B or a pharmaceutically acceptable salt thereof.

107. The composition of claim 106, wherein (b) is ranibizumab or a pharmaceutically acceptable salt thereof.

108. The composition of claim 106, wherein (b) is bevacizumab or a pharmaceutically acceptable salt thereof.

109. The composition of claim 106, wherein (b) is aflibercept or a pharmaceutically acceptable salt thereof.

110. The composition of claim 100, wherein the compound of Formula C is Antagonist C or a pharmaceutically acceptable salt thereof.

111. The composition of claim 110, wherein (b) is ranibizumab or a pharmaceutically acceptable salt thereof.

112. The composition of claim 110, wherein (b) is bevacizumab or a pharmaceutically acceptable salt thereof.

113. The composition of claim 110, wherein (b) is aflibercept or a pharmaceutically acceptable salt thereof.

114. The composition of claim 100, wherein (a) is Antagonist D or a pharmaceutically acceptable salt thereof.

115. The composition of claim 114, wherein (b) is ranibizumab or a pharmaceutically acceptable salt thereof.

116. The composition of claim 114, wherein (b) is bevacizumab or a pharmaceutically acceptable salt thereof.

117. The composition of claim 114, wherein (b) is aflibercept or a pharmaceutically acceptable salt thereof.

118. The composition of claim 100, wherein (a) is a compound of Formula E or a pharmaceutically acceptable salt thereof.

119. The composition of claim 118, wherein (b) is ranibizumab or a pharmaceutically acceptable salt thereof.

120. The composition of claim 118, wherein (b) is bevacizumab or a pharmaceutically acceptable salt thereof.

121. The composition of claim 118, wherein (b) is aflibercept or a pharmaceutically acceptable salt thereof.

122. Antagonist A or a pharmaceutically acceptable salt thereof.

123. A composition comprising: (a) an effective amount of Antagonist A or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier or vehicle.

124. A compound of Formula B or a pharmaceutically acceptable salt thereof.

125. A composition comprising: (a) an effective amount of a compound of Formula B or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier or vehicle.

126. The compound of claim 124, wherein the compound is Antagonist B.

127. The composition of claim 125, wherein the compound is Antagonist B.

128. A compound of Formula C or a pharmaceutically acceptable salt thereof.

129. A composition comprising: (a) an effective amount of a compound of Formula C or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier or vehicle.

130. The compound of claim 128, wherein the compound is Antagonist C.

131. The composition of claim 129, wherein the compound is Antagonist C.

132. A compound of Formula E or a pharmaceutically acceptable salt thereof.

133. A composition comprising: (a) an effective amount of a compound of Formula E or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier or vehicle.

134. The compound of claim 132, wherein the compound is Antagonist D.

135. The composition of claim 133, wherein the compound is Antagonist D.

Figure 1 (A) **Sequence of PDGF-B nucleic acid (GenBank Accession No. X02811) (SEQ ID NO: 1)**

CCCTGCCTGC CTCCCTGCGC ACCCGCAGCC TCCCCCGCTG CCTCCCTAGG GCTCCCCTCC

GGCCGCCAGC GCCCATTTTT CATTCCCTAG ATAGAGATAC TTTGCGCGCA CACACATACA

TACGCGCGCA AAAAGGAAAA AAAAAAAAAA AAGCCCACCC TCCAGCCTCG CTGCAAAGAG

AAAACCGGAG CAGCCGCAGC TCGCAGCTCG CAGCCCGCAG CCCGCAGAGG ACGCCCAGAG

CGGCGAGCGG GCGGGCAGAC GGACCGACGG ACTCGCGCCG CGTCCACCTG TCGGCCGGGC

CCAGCCGAGC GCGCAGCGGG CACGCCGCGC GCGCGGAGCA GCCGTGCCCG CCGCCCGGGC

CCGCCGCCAG GGCGCACACG CTCCCGCCCC CCTACCCGGC CCGGGCGGGA GTTTGCACCT

CTCCCTGCCC GGGTGCTCGA GCTGCCGTTG CAAAGCCAAC TTTGGAAAAA GTTTTTTGGG

GGAGACTTGG GCCTTGAGGT GCCCAGCTCC GCGCTTTCCG ATTTTGGGGG CCTTTCCAGA

AAATGTTGCA AAAAAGCTAA GCCGGCGGGC AGAGGAAAAC GCCTGTAGCC GGCGAGTGAA

GACGAACCAT CGACTGCCGT GTTCCTTTTC CTCTTGGAGG TTGGAGTCCC CTGGGCGCCC

CCACACGGCT AGACGCCTCG GCTGGTTCGC GACGCAGCCC CCCGGCCGTG GATGCTGCAC

TCGGGCTCGG GATCCGCCCA GGTAGCGGCC TCGGACCCAG GTCCTGCGCC CAGGTCCTCC

CCTGCCCCCC AGCGACGGAG CCGGGGCCGG GGGCGGCGGC GCCGGGGGCA TGCGGGTGAG

CCGCGGCTGC AGAGGCCTGA GCGCCTGATC GCCGCGGACC CGAGCCGAGC CCACCCCCCT

CCCCAGCCCC CCACCCTGGC CGCGGGGGCG GCGCGCTCGA TCTACGCGTT CGGGGCCCCG

CGGGGCCGGG CCCGGAGTCG GCATGAATCG CTGCTGGGCG CTCTTCCTGT CTCTCTGCTG

CTACCTGCGT CTGGTCAGCG CCGAGGGGGA CCCCATTCCC GAGGAGCTTT ATGAGATGCT

GAGTGACCAC TCGATCCGCT CCTTTGATGA TCTCCAACGC CTGCTGCACG GAGACCCCGG

AGAGGAAGAT GGGGCCGAGT TGGACCTGAA CATGACCCGC TCCCACTCTG GAGGCGAGCT

GGAGAGCTTG GCTCGTGGAA GAAGGAGCCT GGGTTCCCTG ACCATTGCTG AGCCGGCCAT

GATCGCCGAG TGCAAGACGC GCACCGAGGT GTTCGAGATC TCCCGGCGCC TCATAGACCG

CACCAACGCC AACTTCCTGG TGTGGCCGCC CTGTGTGGAG GTGCAGCGCT GCTCCGGCTG

CTGCAACAAC CGCAACGTGC AGTGCCGCCC CACCCAGGTG CAGCTGCGAC CTGTCCAGGT

GAGAAAGATC GAGATTGTGC GGAAGAAGCC AATCTTTAAG AAGGCCACGG TGACGCTGGA

AGACCACCTG GCATGCAAGT GTGAGACAGT GGCAGCTGCA CGGCCTGTGA CCCGAAGCCC

GGGGGGTTCC CAGGAGCAGC GAGCCAAAAC GCCCCAAACT CGGGTGACCA TTCGGACGGT

GCGAGTCCGC CGGCCCCCCA AGGGCAAGCA CCGGAAATTC AAGCACACGC ATGACAAGAC

GGCACTGAAG GAGACCCTTG GAGCCTAGGG GCATCGGCAG GAGAGTGTGT GGGCAGGGTT

ATTTAATATG GTATTTGCTG TATTGCCCCC ATGGGGCCTT GGAGTAGATA ATATTGTTTC

CCTCGTCCGT CTGTCTCGAT GCCTGATTCG GACGGCCAAT GGTGCCTCCC CCACCCCTCC

ACGTGTCCGT CCACCCTTCC ATCAGCGGGT CTCCTCCCAG CGGCCTCCGG CTCTTGCCCA

GCAGCTCAAG AAGAAAAAGA AGGACTGAAC TCCATCGCCA TCTTCTTCCC TTAACTCCAA

GAACTTGGGA TAAGAGTGTG AGAGAGACTG ATGGGGTCGC TCTTTGGGGG AAACGGGTTC

CTTCCCCTGC ACCTGGCCTG GGCCACACCT GAGCGCTGTG GACTGTCCTG AGGAGCCCTG

AGGACCTCTC AGCATAGCCT GCCTGATCCC TGAACCC

Figure 1 (B) Sequence of PDGF-B propeptide (GenBank Accession No. CAA26579) (SEQ ID NO: 2)

MNRCWALFLS LCCYLRLVSA EGDPIPEELY EMLSDHSIRS FDDLQRLLHG DPGEEDGAEL

DLNMTRSHSG GELESLARGR RSLGSLTIAE PAMIAECKTR TEVFEISRRL IDRTNANFLV

WPPCVEVQRC SGCCNNRNVQ CRPTQVQLRP VQVRKIEIVR KKPIFKKATV TLEDHLACKC

ETVAAARPVT RSPGGSQEQR AKTPQTRVTI RTVRVRRPPK GKHRKFKHTH DKTALKETLG

A

Figure 1 (C) **Sequence of PDGF-A nucleic acid (GenBank Accession No. X06374) (SEQ ID NO: 11)**

TTCTTGGGGC TGATGTCCGC AAATATGCAG AATTACCGGC CGGGTCGCTC CTGAAGCCAG

CGCGGGGAGC GAGCGCGGCG GCGGCCAGCA CCGGGAACGC ACCGAGGAAG AAGCCCAGCC

CCCGCCCTCC GCCCCTTCCG TCCCCACCCC CTACCCGGCG GCCCAGGAGG CTCCCCGGCT

GCGGCGCGCA CTCCCTGTTT CTCCTCCTCC TGGCTGGCGC TGCCTGCCTC TCCGCACTCA

CTGCTCGCCG GGCGCCGTCC GCCAGCTCCG TGCTCCCCGC GCCACCCTCC TCCGGGCCGC

GCTCCCTAAG GGATGGTACT GAATTTCGCC GCCACAGGAG ACCGGCTGGA GCGCCCGCCC

CGCGCCTCGC CTCTCCTCCG AGCAGCCAGC GCCTCGGGAC GCGATGAGGA CCTTGGCTTG

CCTGCTGCTC CTCGGCTGCG GATACCTCGC CCATGTTCTG GCCGAGGAAG CCGAGATCCC

CCGCGAGGTG ATCGAGAGGC TGGCCCGCAG TCAGATCCAC AGCATCCGGG ACCTCCAGCG

ACTCCTGGAG ATAGACTCCG TAGGGAGTGA GGATTCTTTG GACACCAGCC TGAGAGCTCA

CGGGGTCCAC GCCACTAAGC ATGTGCCCGA GAAGCGGCCC CTGCCCATTC GGAGGAAGAG

AAGCATCGAG GAAGCTGTCC CCGCTGTCTG CAAGACCAGG ACGGTCATTT ACGAGATTCC

TCGGAGTCAG GTCGACCCCA CGTCCGCCAA CTTCCTGATC TGGCCCCCGT GCGTGGAGGT

GAAACGCTGC ACCGGCTGCT GCAACACGAG CAGTGTCAAG TGCCAGCCCT CCCGCGTCCA

CCACCGCAGC GTCAAGGTGG CCAAGGTGGA ATACGTCAGG AAGAAGCCAA AATTAAAAGA

AGTCCAGGTG AGGTTAGAGG AGCATTTGGA GTGCGCCTGC GCGACCACAA GCCTGAATCC

GGATTATCGG GAAGAGGACA CGGATGTGAG GTGAGGATGA GCCGCAGCCC TTTCCTGGGA

CATGGATGTA CATGGCGTGT TACATTCCTG AACCTACTAT GTACGGTGCT TTATTGCCAG

TGTGCGGTCT TTGTTCTCCT CCGTGAAAAA CTGTGTCCGA GAACACTCGG GAGAACAAAG

AGACAGTGCA CATTTGTTTA ATGTGACATC AAAGCAAGTA TTGTAGCACT CGGTGAAGCA

GTAAGAAGCT TCCTTGTCAA AAAGAGAGAG AGAGAGAGAG AGAGAGAAAA CAAAACCACA

AATGACAAAA ACAAAACGGA CTCACAAAAA TATCTAAACT CGATGAGATG GAGGGTCGCC

CCGTGGGATG GAAGTGCAGA GGTCTCAGCA GACTGGATTT CTGTCCGGGT GGTCACAGGT

GCTTTTTTGC CGAGGATGCA GAGCCTGCTT TGGGAACGAC TCCAGAGGGG TGCTGGTGGG

CTCTGCAGGG CCCGCAGGAA GCAGGAATGT CTTGGAAACC GCCACGCGAA CTTTAGAAAC

CACACCTCCT CGCTGTAGTA TTTAAGCCCA TACAGAAACC TTCCTGAGAG CCTTAAGTGG

TTTTTTTTTT TGTTTTTGTT TTGTTTTTTT TTTTTTGTT TTTTTTTTTT TTTTTTTTTT

TTACACCATA AAGTGATTAT TAAGCTTCCT TTTACTCTTT GGCTAGCTTT TTTTTTTTT

TTTTTTTTTT TTTTTTTTAA TTATCTCTTG GATGACATTT ACACCGATAA CACACAGGCT
GCTGTAACTG TCAGGACAGT GCGACGGTAT TTTTCCTAGC AAGATGCAAA CTAATGAGAT
GTATTAAAAT AAACATGGTA TACCTACCTA TGCATCATTT CCTAAATGTT TCTGGCTTTG
TGTTTCTCCC TTACCCTGCT TTATTTGTTA ATTTAAGCCA TTTTGAAAGA ACTATGCGTC
AACCAATCGT ACGCCGTCCC TGCGGCACCT GCCCCAGAGC CCGTTTGTGG CTGAGTGACA
ACTTGTTCCC CGCAGTGCAC ACCTAGAATG CTGTGTTCCC ACGCGGCACG TGAGATGCAT
TGCCGCTTCT GTCTGTGTTG TTGGTGTGCC CTGGTGCCGT GGTGGCGGTC ACTCCCTCTG
CTGCCAGTGT TTGGACAGAA CCCAAATTCT TTATTTTTGG TAAGATATTG TGCTTTACCT
GTATTAACAG AAATGTGTGT GTGTGGTTTG TTTTTTTGTA AAGGTGAAGT TTGTATGTTT
ACCTAATATT ACCTGTTTTG TATACCTGAG AGCCTGCTAT GTTCTTCTTT TGTTGATCCA
AAATTAAAAA AAAAATACCA CCAAC

Figure 1 (D) **Sequence of PDGF-A polypeptide (GenBank Accession No. CAA29677) (SEQ ID NO: 12)**

MRTLACLLLL GCGYLAHVLA EEAEIPREVI ERLARSQIHS IRDLQRLLEI DSVGSEDSLD
TSLRAHGVHA TKHVPEKRPL PIRRKRSIEE AVPAVCKTRT VIYEIPRSQV DPTSANFLIW
PPCVEVKRCT GCCNTSSVKC QPSRVHHRSV KVAKVEYVRK KPKLKEVQVR LEEHLECACA
TTSLNPDYRE EDTDVR

Figure 1 (E) **Sequence of PDGF-C nucleic acid (GenBank Accession No. NM_016205) (SEQ ID NO: 17)**

GCCCGGAGAG CCGCATCTAT TGGCAGCTTT GTTATTGATC AGAAACTGCT CGCCGCCGAC

TTGGCTTCCA GTCTGGCTGC GGGCAACCCT TGAGTTTTCG CCTCTGTCCT GTCCCCCGAA

CTGACAGGTG CTCCCAGCAA CTTGCTGGGG ACTTCTCGCC GCTCCCCCGC GTCCCCACCC

CCTCATTCCT CCCTCGCCTT CACCCCCACC CCCACCACTT CGCCACAGCT CAGGATTTGT

TTAAACCTTG GGAAACTGGT TCAGGTCCAG GTTTTGCTTT GATCCTTTTC AAAAACTGGA

GACACAGAAG AGGGCTCTAG GAAAAAGTTT TGGATGGGAT TATGTGGAAA CTACCCTGCG

ATTCTCTGCT GCCAGAGCAG GCTCGGCGCT TCCACCCCAG TGCAGCCTTC CCCTGGCGGT

GGTGAAAGAG ACTCGGGAGT CGCTGCTTCC AAAGTGCCCG CCGTGAGTGA GCTCTCACCC

CAGTCAGCCA AATGAGCCTC TTCGGGCTTC TCCTGCTGAC ATCTGCCCTG GCCGGCCAGA

GACAGGGGAC TCAGGCGGAA TCCAACCTGA GTAGTAAATT CCAGTTTTCC AGCAACAAGG

AACAGAACGG AGTACAAGAT CCTCAGCATG AGAGAATTAT TACTGTGTCT ACTAATGGAA

GTATTCACAG CCCAAGGTTT CCTCATACTT ATCCAAGAAA TACGGTCTTG GTATGGAGAT

TAGTAGCAGT AGAGGAAAAT GTATGGATAC AACTTACGTT TGATGAAAGA TTTGGGCTTG

AAGACCCAGA AGATGACATA TGCAAGTATG ATTTTGTAGA AGTTGAGGAA CCCAGTGATG

GAACTATATT AGGGCGCTGG TGTGGTTCTG GTACTGTACC AGGAAAACAG ATTTCTAAAG

GAAATCAAAT TAGGATAAGA TTTGTATCTG ATGAATATTT TCCTTCTGAA CCAGGGTTCT

GCATCCACTA CAACATTGTC ATGCCACAAT TCACAGAAGC TGTGAGTCCT TCAGTGCTAC

CCCCTTCAGC TTTGCCACTG GACCTGCTTA ATAATGCTAT AACTGCCTTT AGTACCTTGG

AAGACCTTAT TCGATATCTT GAACCAGAGA GATGGCAGTT GGACTTAGAA GATCTATATA

GGCCAACTTG GCAACTTCTT GGCAAGGCTT TTGTTTTTGG AAGAAAATCC AGAGTGGTGG

ATCTGAACCT TCTAACAGAG GAGGTAAGAT TATACAGCTG CACACCTCGT AACTTCTCAG

TGTCCATAAG GGAAGAACTA AAGAGAACCG ATACCATTTT CTGGCCAGGT TGTCTCCTGG

TTAAACGCTG TGGTGGGAAC TGTGCCTGTT GTCTCCACAA TTGCAATGAA TGTCAATGTG

TCCCAAGCAA AGTTACTAAA AAATACCACG AGGTCCTTCA GTTGAGACCA AAGACCGGTG

TCAGGGGATT GCACAAATCA CTCACCGACG TGGCCCTGGA GCACCATGAG GAGTGTGACT

GTGTGTGCAG AGGGAGCACA GGAGGATAGC CGCATCACCA CCAGCAGCTC TTGCCCAGAG

CTGTGCAGTG CAGTGGCTGA TTCTATTAGA GAACGTATGC GTTATCTCCA TCCTTAATCT

CAGTTGTTTG CTTCAAGGAC CTTTCATCTT CAGGATTTAC AGTGCATTCT GAAAGAGGAG

ACATCAAACA GAATTAGGAG TTGTGCAACA GCTCTTTTGA GAGGAGGCCT AAAGGACAGG
AGAAAAGGTC TTCAATCGTG GAAAGAAAAT TAAATGTTGT ATTAAATAGA TCACCAGCTA
GTTTCAGAGT TACCATGTAC GTATTCCACT AGCTGGGTTC TGTATTTCAG TTCTTTCGAT
ACGGCTTAGG GTAATGTCAG TACAGGAAAA AAACTGTGCA AGTGAGCACC TGATTCCGTT
GCCTTGCTTA ACTCTAAAGC TCCATGTCCT GGGCCTAAAA TCGTATAAAA TCTGGATTTT
TTTTTTTTTT TTTGCTCATA TTCACATATG TAAACCAGAA CATTCTATGT ACTACAAACC
TGGTTTTTAA AAAGGAACTA TGTTGCTATG AATTAAACTT GTGTCGTGCT GATAGGACAG
ACTGGATTTT TCATATTTCT TATTAAAATT TCTGCCATTT AGAAGAAGAG AACTACATTC
ATGGTTTGGA AGAGATAAAC CTGAAAAGAA GAGTGGCCTT ATCTTCACTT TATCGATAAG
TCAGTTTATT TGTTTCATTG TGTACATTTT TATATTCTCC TTTTGACATT ATAACTGTTG
GCTTTTCTAA TCTTGTTAAA TATATCTATT TTTACCAAAG GTATTTAATA TTCTTTTTTA
TGACAACTTA GATCAACTAT TTTTAGCTTG GTAAATTTTT CTAAACACAA TTGTTATAGC
CAGAGGAACA AAGATGATAT AAAATATTGT TGCTCTGACA AAAATACATG TATTTCATTC
TCGTATGGTG CTAGAGTTAG ATTAATCTGC ATTTTAAAAA ACTGAATTGG AATAGAATTG
GTAAGTTGCA AAGACTTTTT GAAAATAATT AAATTATCAT ATCTTCCATT CCTGTTATTG
GAGATGAAAA TAAAAAGCAA CTTATGAAAG TAGACATTCA GATCCAGCCA TTACTAACCT
ATTCCTTTTT TGGGGAAATC TGAGCCTAGC TCAGAAAAAC ATAAAGCACC TTGAAAAAGA
CTTGGCAGCT TCCTGATAAA GCGTGCTGTG CTGTGCAGTA GGAACACATC CTATTTATTG
TGATGTTGTG GTTTTATTAT CTTAAACTCT GTTCCATACA CTTGTATAAA TACATGGATA
TTTTTATGTA CAGAAGTATG TCTCTTAACC AGTTCACTTA TTGTACTCTG GCAATTTAAA
AGAAAATCAG TAAAATATTT TGCTTGTAAA ATGCTTAATA TCGTGCCTAG GTTATGTGGT
GACTATTTGA ATCAAAAATG TATTGAATCA TCAAATAAAA GAATGTGGCT ATTTTGGGGA
GAAAATT

Figure 1 (F) **Sequence of PDGF-C polypeptide (GenBank Accession No. NP_057289) (SEQ ID NO: 18)**

MSLFGLLLLT SALAGQRQGT QAESNLSSKF QFSSNKEQNG VQDPQHERII TVSTNGSIHS
PRFPHTYPRN TVLVWRLVAV EENVWIQLTF DERFGLEDPE DDICKYDFVE VEEPSDGTIL
GRWCGSGTVP GKQISKGNQI RIRFVSDEYF PSEPGFCIHY NIVMPQFTEA VSPSVLPPSA
LPLDLLNNAI TAFSTLEDLI RYLEPERWQL DLEDLYRPTW QLLGKAFVFG RKSRVVDLNL
LTEEVRLYSC TPRNFSVSIR EELKRTDTIF WPGCLLVKRC GGNCACCLHN CNECQCVPSK
VTKKYHEVLQ LRPKTGVRGL HKSLTDVALE HHEECDCVCR GSTGG

Figure 1 (G) **Sequence of PDGF-D, variant 1 nucleic acid (GenBank Accession No. NM_025208) (SEQ ID NO: 19)**

TCTCAGGGGC CGCGGCCGGG GCTGGAGAAC GCTGCTGCTC CGCTCGCCTG CCCCGCTAGA TTCGGCGCTG
CCCGCCCCCT GCAGCCTGTG CTGCAGCTGC CGGCCACCGG AGGGGGCGAA CAAACAAACG TCAACCTGTT
GTTTGTCCCG TCACCATTTA TCAGCTCAGC ACCACAAGGA AGTGCGGCAC CCACACGCGC TCGGAAAGTT
CAGCATGCAG GAAGTTTGGG GAGAGCTCGG CGATTAGCAC AGCGACCCGG GCCAGCGCAG GGCGAGCGCA
GGCGGCGAGA GCGCAGGGCG GCGCGGCGTC GGTCCCGGGA GCAGAACCCG GCTTTTTCTT GGAGCGACGC
TGTCTCTAGT CGCTGATCCC AAATGCACCG GCTCATCTTT GTCTACACTC TAATCTGCGC AAACTTTTGC
AGCTGTCGGG ACACTTCTGC AACCCCGCAG AGCGCATCCA TCAAAGCTTT GCGCAACGCC AACCTCAGGC
GAGATGAGAG CAATCACCTC ACAGACTTGT ACCGAAGAGA TGAGACCATC CAGGTGAAAG GAAACGGCTA
CGTGCAGAGT CCTAGATTCC CGAACAGCTA CCCCAGGAAC CTGCTCCTGA CATGGCGGCT TCACTCTCAG
GAGAATACAC GGATACAGCT AGTGTTTGAC AATCAGTTTG GATTAGAGGA AGCAGAAAAT GATATCTGTA
GGTATGATTT TGTGGAAGTT GAAGATATAT CCGAAACCAG TACCATTATT AGAGGACGAT GGTGTGGACA
CAAGGAAGTT CCTCCAAGGA TAAAATCAAG AACGAACCAA ATTAAAATCA CATTCAAGTC CGATGACTAC
TTTGTGGCTA AACCTGGATT CAAGATTTAT TATTCTTTGC TGGAAGATTT CCAACCCGCA GCAGCTTCAG
AGACCAACTG GGAATCTGTC ACAAGCTCTA TTTCAGGGGT ATCCTATAAC TCTCCATCAG TAACGGATCC
CACTCTGATT GCGGATGCTC TGGACAAAAA AATTGCAGAA TTTGATACAG TGGAAGATCT GCTCAAGTAC
TTCAATCCAG AGTCATGGCA AGAAGATCTT GAGAATATGT ATCTGGACAC CCCTCGGTAT CGAGGCAGGT
CATACCATGA CCGGAAGTCA AAAGTTGACC TGGATAGGCT CAATGATGAT GCCAAGCGTT ACAGTTGCAC
TCCCAGGAAT TACTCGGTCA ATATAAGAGA AGAGCTGAAG TTGGCCAATG TGGTCTTCTT TCCACGTTGC
CTCCTCGTGC AGCGCTGTGG AGGAAATTGT GGCTGTGGAA CTGTCAACTG GAGGTCCTGC ACATGCAATT
CAGGGAAAAC CGTGAAAAAG TATCATGAGG TATTACAGTT TGAGCCTGGC CACATCAAGA GGAGGGGTAG
AGCTAAGACC ATGGCTCTAG TTGACATCCA GTTGGATCAC CATGAACGAT GTGATTGTAT CTGCAGCTCA
AGACCACCTC GATAAGAGAA TGTGCACATC CTTACATTAA GCCTGAAAGA ACCTTTAGTT TAAGGAGGGT
GAGATAAGAG ACCCTTTTCC TACCAGCAAC CAAACTTACT ACTAGCCTGC AATGCAATGA ACACAAGTGG
TTGCTGAGTC TCAGCCTTGC TTTGTTAATG CCATGGCAAG TAGAAAGGTA TATCATCAAC TTCTATACCT
AAGAATATAG GATTGCATTT AATAATAGTG TTTGAGGTTA TATATGCACA AACACACACA GAAATATATT
CATGTCTATG TGTATATAGA TCAAATGTTT TTTTTGGTAT ATATAACCAG GTACACCAGA GCTTACATAT
GTTTGAGTTA GACTCTTAAA ATCCTTTGCC AAAATAAGGG ATGGTCAAAT ATATGAAACA TGTCTTTAGA
AAATTTAGGA GATAAATTTA TTTTTAAATT TTGAAACACA AAACAATTTT GAATCTTGCT CTCTTAAAGA
AAGCATCTTG TATATTAAAA ATCAAAAGAT GAGGCTTTCT TACATATACA TCTTAGTTGA TTATTAAAAA
AGGAAAAATA TGGTTTCCAG AGAAAAGGCC AATACCTAAG CATTTTTTCC ATGAGAAGCA CTGCATACTT

ACCTATGTGG ACTATAATAA CCTGTCTCCA AAACCATGCC ATAATAATAT AAGTGCTTTA GAAATTAAAT
CATTGTGTTT TTTATGCATT TTGCTGAGGC ATGCTTATTC ATTTAACACC TATCTCAAAA ACTTACTTAG
AAGGTTTTTT ATTATAGTCC TACAAAAGAC AATGTATAAG CTGTAACAGA ATTTTGAATT GTTTTTCTTT
GCAAAACCCC TCCACAAAAG CAAATCCTTT CAAGAATGGC ATGGGCATTC TGTATGAACC TTTCCAGATG
GTGTTCAGTG AAAGATGTGG GTAGTTGAGA ACTTAAAAAG TGAACATTGA AACATCGACG TAACTGGAAA
TTAGGTGGGA TATTTGATAG GATCCATATC TAATAATGGA TTCGAACTCT CCAAACTACA CCAATTAATT
TAATGTATCT TGCTTTTGTG TTCCCGTCTT TTTGAAATAT AGACATGGAT TTATAATGGC ATTTTATATT
TGGCAGGCCA TCATAGATTA TTTACAACCT AAAAGCTTTT GTGTATCAAA AAAATCACAT TTTATTAATG
TAAATTTCTA ATCGTATACT TGCTCACTGT TCTGATTTCC TGTTTCTGAA CCAAGTAAAA TCAGTCCTAG
AGGCTATGGT TCTTAATCTA TGGAGCTTGC TTTAAGAAGC CAGTTGTCAA TTGTGGTAAC ACAAGTTTGG
CCCTGCTGTC CTACTGTTTA ATAGAAAACT GTTTTACATT GGTTAATGGT ATTTAGAGTA ATTTTTTCTC
TCTGCCTCCT TTGTGTCTGT TTTAAAGGAG ACTAACTCCA GGAGTAGGAA ATGATTCATC ATCCTCCAAA
GCAAGAGGCT TAAGAGAGAA ACACCGAAAT TCAGATAGCT CAGGGACTGC TAACAGAGAA CTACATTTTT
CTTATTGCCT TGAAAGTTAA AAGGAAAGCA GATTTCTTCA GTGACTTTGT GGTCCTACTA ACTACAACCA
GTTTGGGTGA CAGGGCTGGT AAAGTCCCAG TGTTAGATGA GTGACCTAAA TATACTTAGA TTTCTAAGTA
TGGTGCTCTC AGGTCCAAGT TCAACTATTC TTAAGCAGTG CAATTCTTCC CAGTTATTTG AGATGAAAGA
TCTCTGCTTA TTGAAGATGT ACCTTCTAAA ACTTTCCTAA AAGTGTCTGA TGTTTTTACT CAAGAGGGGA
GTGGTAAAAT TAAATACTCT ATTGTTCAAT TCTCTAAAAT CCCAGAACAC AATCAGAAAT AGCTCAGGCA
GACACTAATA ATTAAGAACG CTCTTCCTCT TCATAACTGC TTTGCAAGTT TCCTGTGAAA ACATCAGTTT
CCTGTACCAA AGTCAAAATG AACGTTACAT CACTCTAACC TGAACAGCTC ACAATGTAGC TGTAAATATA
AAAAATGAGA GTGTTCTACC CAGTTTTCAA TAAACCTTCC AGGCTGCAAT AACCAGCAAG GTTTTCAGTT
AAAGCCCTAT CTGCACTTTT TATTTATTAG CTGAAATGTA AGCAGGCATA TTCACTCACT TTTCTTTGCC
TTTCCTGAGA GTTTTATTAA AACTTCTCCC TTGGTTACCT GTTATCTTTT GCACTTCTAA CATGTAGCCA
ATAAATCTAT TTGATAGCCA TCAAAGGAAT AAAAAGCTGG CCGTACAAAT TACATTTCAA AACAAACCCT
AATAAATCCA CATTTCCGCA TGGCTCATTC ACCTGGAATA ATGCCTTTTA TTGAATATGT TCTTATAGGG
CAAAACACTT TCATAAGTAG AGTTTTTTAT GTTTTTTGTC ATATCGGTAA CATGCAGCTT TTTCCTCTCA
TAGCATTTTC TATAGCGAAT GTAATATGCC TCTTATCTTC ATGAAAAATA AATATTGCTT TTGAACAAAA
CTAAAAA

Figure 1 (H) **Sequence of PDGF-D, variant 1 polypeptide (GenBank Accession No. NP_079484) (SEQ ID NO: 20)**

MHRLIFVYTL ICANFCSCRD TSATPQSASI KALRNANLRR DESNHLTDLY RRDETIQVKG
NGYVQSPRFP NSYPRNLLLT WRLHSQENTR IQLVFDNQFG LEEAENDICR YDFVEVEDIS
ETSTIIRGRW CGHKEVPPRI KSRTNQIKIT FKSDDYFVAK PGFKIYYSLL EDFQPAAASE
TNWESVTSSI SGVSYNSPSV TDPTLIADAL DKKIAEFDTV EDLLKYFNPE SWQEDLENMY
LDTPRYRGRS YHDRKSKVDL DRLNDDAKRY SCTPRNYSVN IREELKLANV VFFPRCLLVQ
RCGGNCGCGT VNWRSCTCNS GKTVKKYHEV LQFEPGHIKR RGRAKTMALV DIQLDHHERC
DCICSSRPPR

Figure 1 (I) **Sequence of PDGF-D, variant 2 nucleic acid (GenBank Accession No. NM_033135) (SEQ ID NO: 21)**

TCTCAGGGGC CGCGGCCGGG GCTGGAGAAC GCTGCTGCTC CGCTCGCCTG CCCCGCTAGA TTCGGCGCTG
CCCGCCCCCT GCAGCCTGTG CTGCAGCTGC CGGCCACCGG AGGGGGCGAA CAAACAAACG TCAACCTGTT
GTTTGTCCCG TCACCATTTA TCAGCTCAGC ACCACAAGGA AGTGCGGCAC CCACACGCGC TCGGAAAGTT
CAGCATGCAG GAAGTTTGGG GAGAGCTCGG CGATTAGCAC AGCGACCCGG GCCAGCGCAG GGCGAGCGCA
GGCGGCGAGA GCGCAGGGCG GCGCGGCGTC GGTCCCGGGA GCAGAACCCG GCTTTTTCTT GGAGCGACGC
TGTCTCTAGT CGCTGATCCC AAATGCACCG GCTCATCTTT GTCTACACTC TAATCTGCGC AAACTTTTGC
AGCTGTCGGG ACACTTCTGC AACCCCGCAG AGCGCATCCA TCAAAGCTTT GCGCAACGCC AACCTCAGGC
GAGATGACTT GTACCGAAGA GATGAGACCA TCCAGGTGAA AGGAAACGGC TACGTGCAGA GTCCTAGATT
CCCGAACAGC TACCCCAGGA ACCTGCTCCT GACATGGCGG CTTCACTCTC AGGAGAATAC ACGGATACAG
CTAGTGTTTG ACAATCAGTT TGGATTAGAG GAAGCAGAAA ATGATATCTG TAGGTATGAT TTTGTGGAAG
TTGAAGATAT ATCCGAAACC AGTACCATTA TTAGAGGACG ATGGTGTGGA CACAAGGAAG TTCCTCCAAG
GATAAAATCA AGAACGAACC AAATTAAAAT CACATTCAAG TCCGATGACT ACTTTGTGGC TAAACCTGGA
TTCAAGATTT ATTATTCTTT GCTGGAAGAT TTCCAACCCG CAGCAGCTTC AGAGACCAAC TGGGAATCTG
TCACAAGCTC TATTTCAGGG GTATCCTATA ACTCTCCATC AGTAACGGAT CCCACTCTGA TTGCGGATGC
TCTGGACAAA AAAATTGCAG AATTTGATAC AGTGGAAGAT CTGCTCAAGT ACTTCAATCC AGAGTCATGG
CAAGAAGATC TTGAGAATAT GTATCTGGAC ACCCCTCGGT ATCGAGGCAG GTCATACCAT GACCGGAAGT
CAAAAGTTGA CCTGGATAGG CTCAATGATG ATGCCAAGCG TTACAGTTGC ACTCCCAGGA ATTACTCGGT
CAATATAAGA GAAGAGCTGA AGTTGGCCAA TGTGGTCTTC TTTCCACGTT GCCTCCTCGT GCAGCGCTGT
GGAGGAAATT GTGGCTGTGG AACTGTCAAC TGGAGGTCCT GCACATGCAA TTCAGGGAAA ACCGTGAAAA
AGTATCATGA GGTATTACAG TTTGAGCCTG GCCACATCAA GAGGAGGGGT AGAGCTAAGA CCATGGCTCT
AGTTGACATC CAGTTGGATC ACCATGAACG ATGTGATTGT ATCTGCAGCT CAAGACCACC TCGATAAGAG
AATGTGCACA TCCTTACATT AAGCCTGAAA GAACCTTTAG TTTAAGGAGG GTGAGATAAG AGACCCTTTT
CCTACCAGCA ACCAAACTTA CTACTAGCCT GCAATGCAAT GAACACAAGT GGTTGCTGAG TCTCAGCCTT
GCTTTGTTAA TGCCATGGCA AGTAGAAAGG TATATCATCA ACTTCTATAC CTAAGAATAT AGGATTGCAT
TTAATAATAG TGTTTGAGGT TATATATGCA CAAACACACA CAGAAATATA TTCATGTCTA TGTGTATATA
GATCAAATGT TTTTTTTGGT ATATATAACC AGGTACACCA GAGCTTACAT ATGTTTGAGT TAGACTCTTA
AAATCCTTTG CCAAAATAAG GGATGGTCAA ATATATGAAA CATGTCTTTA GAAAATTTAG GAGATAAATT
TATTTTTAAA TTTTGAAACA CAAAACAATT TTGAATCTTG CTCTCTTAAA GAAAGCATCT TGTATATTAA
AAATCAAAAG ATGAGGCTTT CTTACATATA CATCTTAGTT GATTATTAAA AAAGGAAAAA TATGGTTTCC
AGAGAAAAGG CCAATACCTA AGCATTTTTT CCATGAGAAG CACTGCATAC TTACCTATGT GGACTATAAT

AACCTGTCTC CAAAACCATG CCATAATAAT ATAAGTGCTT TAGAAATTAA ATCATTGTGT TTTTTATGCA
TTTTGCTGAG GCATGCTTAT TCATTTAACA CCTATCTCAA AAACTTACTT AGAAGGTTTT TTATTATAGT
CCTACAAAAG ACAATGTATA AGCTGTAACA GAATTTTGAA TTGTTTTTCT TTGCAAAACC CCTCCACAAA
AGCAAATCCT TTCAAGAATG GCATGGGCAT TCTGTATGAA CCTTTCCAGA TGGTGTTCAG TGAAAGATGT
GGGTAGTTGA GAACTTAAAA AGTGAACATT GAAACATCGA CGTAACTGGA AATTAGGTGG GATATTTGAT
AGGATCCATA TCTAATAATG GATTCGAACT CTCCAAACTA CACCAATTAA TTTAATGTAT CTTGCTTTTG
TGTTCCCGTC TTTTTGAAAT ATAGACATGG ATTTATAATG GCATTTTATA TTTGGCAGGC CATCATAGAT
TATTTACAAC CTAAAAGCTT TTGTGTATCA AAAAAATCAC ATTTTATTAA TGTAAATTTC TAATCGTATA
CTTGCTCACT GTTCTGATTT CCTGTTTCTG AACCAAGTAA AATCAGTCCT AGAGGCTATG GTTCTTAATC
TATGGAGCTT GCTTTAAGAA GCCAGTTGTC AATTGTGGTA ACACAAGTTT GGCCCTGCTG TCCTACTGTT
TAATAGAAAA CTGTTTTACA TTGGTTAATG GTATTTAGAG TAATTTTTTC TCTCTGCCTC CTTTGTGTCT
GTTTTAAAGG AGACTAACTC CAGGAGTAGG AAATGATTCA TCATCCTCCA AAGCAAGAGG CTTAAGAGAG
AAACACCGAA ATTCAGATAG CTCAGGGACT GCTAACAGAG AACTACATTT TTCTTATTGC CTTGAAAGTT
AAAAGGAAAG CAGATTTCTT CAGTGACTTT GTGGTCCTAC TAACTACAAC CAGTTTGGGT GACAGGGCTG
GTAAAGTCCC AGTGTTAGAT GAGTGACCTA AATATACTTA GATTTCTAAG TATGGTGCTC TCAGGTCCAA
GTTCAACTAT TCTTAAGCAG TGCAATTCTT CCCAGTTATT TGAGATGAAA GATCTCTGCT TATTGAAGAT
GTACCTTCTA AAACTTTCCT AAAAGTGTCT GATGTTTTTA CTCAAGAGGG GAGTGGTAAA ATTAAATACT
CTATTGTTCA ATTCTCTAAA ATCCCAGAAC ACAATCAGAA ATAGCTCAGG CAGACACTAA TAATTAAGAA
CGCTCTTCCT CTTCATAACT GCTTTGCAAG TTTCCTGTGA AAACATCAGT TTCCTGTACC AAAGTCAAAA
TGAACGTTAC ATCACTCTAA CCTGAACAGC TCACAATGTA GCTGTAAATA TAAAAAATGA GAGTGTTCTA
CCCAGTTTTC AATAAACCTT CCAGGCTGCA ATAACCAGCA AGGTTTTCAG TTAAAGCCCT ATCTGCACTT
TTTATTTATT AGCTGAAATG TAAGCAGGCA TATTCACTCA CTTTTCTTTG CCTTTCCTGA GAGTTTTATT
AAAACTTCTC CCTTGGTTAC CTGTTATCTT TTGCACTTCT AACATGTAGC CAATAAATCT ATTTGATAGC
CATCAAAGGA ATAAAAAGCT GGCCGTACAA ATTACATTTC AAAACAAACC CTAATAAATC CACATTTCCG
CATGGCTCAT TCACCTGGAA TAATGCCTTT TATTGAATAT GTTCTTATAG GGCAAAACAC TTTCATAAGT
AGAGTTTTTT ATGTTTTTTG TCATATCGGT AACATGCAGC TTTTTCCTCT CATAGCATTT TCTATAGCGA
ATGTAATATG CCTCTTATCT TCATGAAAAA TAAATATTGC TTTTGAACAA AACTAAAAA

Figure 1 (J) **Sequence of PDGF-D, variant 2 polypeptide (GenBank Accession No. NP_149126) (SEQ ID NO: 22)**

MHRLIFVYTL ICANFCSCRD TSATPQSASI KALRNANLRR DDLYRRDETI QVKGNGYVQS
PRFPNSYPRN LLLTWRLHSQ ENTRIQLVFD NQFGLEEAEN DICRYDFVEV EDISETSTII
RGRWCGHKEV PPRIKSRTNQ IKITFKSDDY FVAKPGFKIY YSLLEDFQPA AASETNWESV
TSSISGVSYN SPSVTDPTLI ADALDKKIAE FDTVEDLLKY FNPESWQEDL ENMYLDTPRY
RGRSYHDRKS KVDLDRLNDD AKRYSCTPRN YSVNIREELK LANVVFFPRC LLVQRCGGNC
GCGTVNWRSC TCNSGKTVKK YHEVLQFEPG HIKRRGRAKT MALVDIQLDH HERCDCICSS
RPPR

Figure 2 (A) **Sequence of VEGF nucleic acid (GenBank Accession No: NM 003376) (SEQ ID NO: 3)**

TCGCGGAGGC TTGGGGCAGC CGGGTAGCTC GGAGGTCGTG GCGCTGGGGG CTAGCACCAG

CGCTCTGTCG GGAGGCGCAG CGGTTAGGTG GACCGGTCAG CGGACTCACC GGCCAGGGCG

CTCGGTGCTG GAATTTGATA TTCATTGATC CGGGTTTTAT CCCTCTTCTT TTTTCTTAAA

CATTTTTTTT TAAAACTGTA TTGTTTCTCG TTTTAATTTA TTTTTGCTTG CCATTCCCCA

CTTGAATCGG GCCGACGGCT TGGGGAGATT GCTCTACTTC CCCAAATCAC TGTGGATTTT

GGAAACCAGC AGAAAGAGGA AAGAGGTAGC AAGAGCTCCA GAGAGAAGTC GAGGAAGAGA

GAGACGGGGT CAGAGAGAGC GCGCGGGCGT GCGAGCAGCG AAAGCGACAG GGGCAAAGTG

AGTGACCTGC TTTTGGGGGT GACCGCCGGA GCGCGGCGTG AGCCCTCCCC CTTGGGATCC

CGCAGCTGAC CAGTCGCGCT GACGGACAGA CAGACAGACA CCGCCCCCAG CCCCAGCTAC

CACCTCCTCC CCGGCCGGCG GCGGACAGTG GACGCGGCGG CGAGCCGCGG GCAGGGGCCG

GAGCCCGCGC CCGGAGGCGG GGTGGAGGGG GTCGGGGCTC GCGGCGTCGC ACTGAAACTT

TTCGTCCAAC TTCTGGGCTG TTCTCGCTTC GGAGGAGCCG TGGTCCGCGC GGGGGAAGCC

GAGCCGAGCG GAGCCGCGAG AAGTGCTAGC TCGGGCCGGG AGGAGCCGCA GCCGGAGGAG

GGGGAGGAGG AAGAAGAGAA GGAAGAGGAG AGGGGGCCGC AGTGGCGACT CGGCGCTCGG

AAGCCGGGCT CATGGACGGG TGAGGCGGCG GTGTGCGCAG ACAGTGCTCC AGCCGCGCGC

GCTCCCCAGG CCCTGGCCCG GGCCTCGGGC CGGGGAGGAA GAGTAGCTCG CCGAGGCGCC

GAGGAGAGCG GGCCGCCCCA CAGCCCGAGC CGGAGAGGGA GCGCGAGCCG CGCCGGCCCC

GGTCGGGCCT CCGAAACCAT GAACTTTCTG CTGTCTTGGG TGCATTGGAG CCTTGCCTTG

CTGCTCTACC TCCACCATGC CAAGTGGTCC CAGGCTGCAC CCATGGCAGA AGGAGGAGGG

CAGAATCATC ACGAAGTGGT GAAGTTCATG GATGTCTATC AGCGCAGCTA CTGCCATCCA

ATCGAGACCC TGGTGGACAT CTTCCAGGAG TACCCTGATG AGATCGAGTA CATCTTCAAG

CCATCCTGTG TGCCCCTGAT GCGATGCGGG GGCTGCTGCA ATGACGAGGG CCTGGAGTGT

GTGCCCACTG AGGAGTCCAA CATCACCATG CAGATTATGC GGATCAAACC TCACCAAGGC

CAGCACATAG GAGAGATGAG CTTCCTACAG CACAACAAAT GTGAATGCAG ACCAAAGAAA

GATAGAGCAA GACAAGAAAA AAAATCAGTT CGAGGAAAGG GAAAGGGGCA AAAACGAAAG

CGCAAGAAAT CCCGGTATAA GTCCTGGAGC GTTCCCTGTG GGCCTTGCTC AGAGCGGAGA

AAGCATTTGT TTGTACAAGA TCCGCAGACG TGTAAATGTT CCTGCAAAAA CACAGACTCG

CGTTGCAAGG CGAGGCAGCT TGAGTTAAAC GAACGTACTT GCAGATGTGA CAAGCCGAGG

CGGTGAGCCG GGCAGGAGGA AGGAGCCTCC CTCAGGGTTT CGG

Figure 2 (B) Sequence of VEGF polypeptide (GenBank Accession No. NP 003367) (SEQ ID NO: 4)

MNFLLSWVHW SLALLLYLHH AKWSQAAPMA EGGGQNHHEV VKFMDVYQRS YCHPIETLVD

IFQEYPDEIE YIFKPSCVPL MRCGGCCNDE GLECVPTEES NITMQIMRIK PHQGQHIGEM

SFLQHNKCEC RPKKDRARQE KKSVRGKGKG QKRKRKKSRY KSWSVPCGPC SERRKHLFVQ

DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR

Figure 3 (A) Sequence of PDGFR-B nucleic acid (GenBank Accession No. NM 002609) (SEQ ID NO: 5)

GGCCCCTCAG CCCTGCTGCC CAGCACGAGC CTGTGCTCGC CCTGCCCAAC GCAGACAGCC AGACCCAGGG

CGGCCCCTCT GGCGGCTCTG CTCCTCCCGA AGGATGCTTG GGGAGTGAGG CGAAGCTGGG CGCTCCTCTC

CCCTACAGCA GCCCCCTTCC TCCATCCCTC TGTTCTCCTG AGCCTTCAGG AGCCTGCACC AGTCCTGCCT

GTCCTTCTAC TCAGCTGTTA CCCACTCTGG GACCAGCAGT CTTTCTGATA ACTGGGAGAG GGCAGTAAGG

AGGACTTCCT GGAGGGGGTG ACTGTCCAGA GCCTGGAACT GTGCCCACAC CAGAAGCCAT CAGCAGCAAG

GACACCATGC GGCTTCCGGG TGCGATGCCA GCTCTGGCCC TCAAAGGCGA GCTGCTGTTG CTGTCTCTCC

TGTTACTTCT GGAACCACAG ATCTCTCAGG GCCTGGTCGT CACACCCCCG GGGCCAGAGC TTGTCCTCAA

TGTCTCCAGC ACCTTCGTTC TGACCTGCTC GGGTTCAGCT CCGGTGGTGT GGGAACGGAT GTCCCAGGAG

CCCCCACAGG AAATGGCCAA GGCCCAGGAT GGCACCTTCT CCAGCGTGCT CACACTGACC AACCTCACTG

GGCTAGACAC GGGAGAATAC TTTTGCACCC ACAATGACTC CCGTGGACTG GAGACCGATG AGCGGAAACG

GCTCTACATC TTTGTGCCAG ATCCCACCGT GGGCTTCCTC CCTAATGATG CCGAGGAACT ATTCATCTTT

CTCACGGAAA TAACTGAGAT CACCATTCCA TGCCGAGTAA CAGACCCACA GCTGGTGGTG ACACTGCACG

AGAAGAAAGG GGACGTTGCA CTGCCTGTCC CCTATGATCA CCAACGTGGC TTTTCTGGTA TCTTTGAGGA

CAGAAGCTAC ATCTGCAAAA CCACCATTGG GGACAGGGAG GTGGATTCTG ATGCCTACTA TGTCTACAGA

CTCCAGGTGT CATCCATCAA CGTCTCTGTG AACGCAGTGC AGACTGTGGT CCGCCAGGGT GAGAACATCA

CCCTCATGTG CATTGTGATC GGGAATGAGG TGGTCAACTT CGAGTGGACA TACCCCCGCA AAGAAAGTGG

GCGGCTGGTG GAGCCGGTGA CTGACTTCCT CTTGGATATG CCTTACCACA TCCGCTCCAT CCTGCACATC

CCCAGTGCCG AGTTAGAAGA CTCGGGGACC TACACCTGCA ATGTGACGGA GAGTGTGAAT GACCATCAGG

ATGAAAAGGC CATCAACATC ACCGTGGTTG AGAGCGGCTA CGTGCGGCTC CTGGGAGAGG TGGGCACACT

ACAATTTGCT GAGCTGCATC GGAGCCGGAC ACTGCAGGTA GTGTTCGAGG CCTACCCACC GCCCACTGTC

CTGTGGTTCA AAGACAACCG CACCCTGGGC GACTCCAGCG CTGGCGAAAT CGCCCTGTCC ACGCGCAACG

TGTCGGAGAC CCGGTATGTG TCAGAGCTGA CACTGGTTCG CGTGAAGGTG GCAGAGGCTG GCCACTACAC

CATGCGGGCC TTCCATGAGG ATGCTGAGGT CCAGCTCTCC TTCCAGCTAC AGATCAATGT CCCTGTCCGA

GTGCTGGAGC TAAGTGAGAG CCACCCTGAC AGTGGGGAAC AGACAGTCCG CTGTCGTGGC CGGGGCATGC

CCCAGCCGAA CATCATCTGG TCTGCCTGCA GAGACCTCAA AAGGTGTCCA CGTGAGCTGC CGCCCACGCT

GCTGGGGAAC AGTTCCGAAG AGGAGAGCCA GCTGGAGACT AACGTGACGT ACTGGGAGGA GGAGCAGGAG

TTTGAGGTGG TGAGCACACT GCGTCTGCAG CACGTGGATC GGCCACTGTC GGTGCGCTGC ACGCTGCGCA

ACGCTGTGGG CCAGGACACG CAGGAGGTCA TCGTGGTGCC ACACTCCTTG CCCTTTAAGG TGGTGGTGAT

CTCAGCCATC CTGGCCCTGG TGGTGCTCAC CATCATCTCC CTTATCATCC TCATCATGCT TTGGCAGAAG

AAGCCACGTT ACGAGATCCG ATGGAAGGTG ATTGAGTCTG TGAGCTCTGA CGGCCATGAG TACATCTACG

TGGACCCCAT GCAGCTGCCC TATGACTCCA CGTGGGAGCT GCCGCGGGAC CAGCTTGTGC TGGGACGCAC

CCTCGGCTCT GGGGCCTTTG GGCAGGTGGT GGAGGCCACG GCTCATGGCC TGAGCCATTC TCAGGCCACG

ATGAAAGTGG CCGTCAAGAT GCTTAAATCC ACAGCCCGCA GCAGTGAGAA GCAAGCCCTT ATGTCGGAGC

TGAAGATCAT GAGTCACCTT GGGCCCCACC TGAACGTGGT CAACCTGTTG GGGGCCTGCA CCAAAGGAGG

ACCCATCTAT ATCATCACTG AGTACTGCCG CTACGGAGAC CTGGTGGACT ACCTGCACCG CAACAAACAC

ACCTTCCTGC AGCACCACTC CGACAAGCGC CGCCCGCCCA GCGCGGAGCT CTACAGCAAT GCTCTGCCCG

TTGGGCTCCC CCTGCCCAGC CATGTGTCCT TGACCGGGGA GAGCGACGGT GGCTACATGG ACATGAGCAA

GGACGAGTCG GTGGACTATG TGCCCATGCT GGACATGAAA GGAGACGTCA AATATGCAGA CATCGAGTCC

TCCAACTACA TGGCCCCTTA CGATAACTAC GTTCCCTCTG CCCCTGAGAG GACCTGCCGA GCAACTTTGA

TCAACGAGTC TCCAGTGCTA AGCTACATGG ACCTCGTGGG CTTCAGCTAC CAGGTGGCCA ATGGCATGGA

GTTTCTGGCC TCCAAGAACT GCGTCCACAG AGACCTGGCG GCTAGGAACG TGCTCATCTG TGAAGGCAAG

CTGGTCAAGA TCTGTGACTT TGGCCTGGCT CGAGACATCA TGCGGGACTC GAATTACATC TCCAAAGGCA

GCACCTTTTT GCCTTTAAAG TGGATGGCTC CGGAGAGCAT CTTCAACAGC CTCTACACCA CCCTGAGCGA

CGTGTGGTCC TTCGGGATCC TGCTCTGGGA GATCTTCACC TTGGGTGGCA CCCCTTACCC AGAGCTGCCC

ATGAACGAGC AGTTCTACAA TGCCATCAAA CGGGGTTACC GCATGGCCCA GCCTGCCCAT GCCTCCGACG

AGATCTATGA GATCATGCAG AAGTGCTGGG AAGAGAAGTT TGAGATTCGG CCCCCCTTCT CCCAGCTGGT

GCTGCTTCTC GAGAGACTGT TGGGCGAAGG TTACAAAAAG AAGTACCAGC AGGTGGATGA GGAGTTTCTG

AGGAGTGACC ACCCAGCCAT CCTTCGGTCC CAGGCCCGCT TGCCTGGGTT CCATGGCCTC CGATCTCCCC

TGGACACCAG CTCCGTCCTC TATACTGCCG TGCAGCCCAA TGAGGGTGAC AACGACTATA TCATCCCCCT

GCCTGACCCC AAACCCGAGG TTGCTGACGA GGGCCCACTG GAGGGTTCCC CCAGCCTAGC CAGCTCCACC

CTGAATGAAG TCAACACCTC CTCAACCATC TCCTGTGACA GCCCCCTGGA GCCCCAGGAC GAACCAGAGC

CAGAGCCCCA GCTTGAGCTC CAGGTGGAGC CGGAGCCAGA GCTGGAACAG TTGCCGGATT CGGGGTGCCC

TGCGCCTCGG GCGGAAGCAG AGGATAGCTT CCTGTAGGGG GCTGGCCCCT ACCCTGCCCT GCCTGAAGCT

CCCCCCCTGC CAGCACCCAG CATCTCCTGG CCTGGCCTGA CCGGGCTTCC TGTCAGCCAG GCTGCCCTTA

TCAGCTGTCC CCTTCTGGAA GCTTTCTGCT CCTGACGTGT TGTGCCCCAA ACCCTGGGGC TGGCTTAGGA

GGCAAGAAAA CTGCAGGGGC CGTGACCAGC CCTCTGCCTC CAGGGAGGCC AACTGACTCT GAGCCAGGGT

TCCCCCAGGG AACTCAGTTT TCCCATATGT AAGATGGGAA AGTTAGGCTT GATGACCCAG AATCTAGGAT

TCTCTCCCTG GCTGACAGGT GGGGAGACCG AATCCCTCCC TGGGAAGATT CTTGGAGTTA CTGAGGTGGT

AAATTAACTT TTTTCTGTTC AGCCAGCTAC CCCTCAAGGA ATCATAGCTC TCTCCTCGCA CTTTTTATCC

ACCCAGGAGC TAGGGAAGAG ACCCTAGCCT CCCTGGCTGC TGGCTGAGCT AGGGCCTAGC CTTGAGCAGT

GTTGCCTCAT CCAGAAGAAA GCCAGTCTCC TCCCTATGAT GCCAGTCCCT GCGTTCCCTG GCCCGAGCTG

GTCTGGGGCC ATTAGGCAGC CTAATTAATG CTGGAGGCTG AGCCAAGTAC AGGACACCCC CAGCCTGCAG

CCCTTGCCCA GGGCACTTGG AGCACACGCA GCCATAGCAA GTGCCTGTGT CCCTGTCCTT CAGGCCCATC

AGTCCTGGGG CTTTTTCTTT ATCACCCTCA GTCTTAATCC ATCCACCAGA GTCTAGAAGG CCAGACGGGC

CCCGCATCTG TGATGAGAAT GTAAATGTGC CAGTGTGGAG TGGCCACGTG TGTGTGCCAG TATATGGCCC

TGGCTCTGCA TTGGACCTGC TATGAGGCTT TGGAGGAATC CCTCACCCTC TCTGGGCCTC AGTTTCCCCT

TCAAAAAATG AATAAGTCGG ACTTATTAAC TCTGAGTGCC TTGCCAGCAC TAACATTCTA GAGTATTCCA

GGTGGTTGCA CATTTGTCCA GATGAAGCAA GGCCATATAC CCTAAACTTC CATCCTGGGG GTCAGCTGGG

CTCCTGGGAG ATTCCAGATC ACACATCACA CTCTGGGGAC TCAGGAACCA TGCCCCTTCC CCAGGCCCCC

AGCAAGTCTC AAGAACACAG CTGCACAGGC CTTGACTTAG AGTGACAGCC GGTGTCCTGG AAAGCCCCAA

GCAGCTGCCC CAGGGACATG GGAAGACCAC GGGACCTCTT TCACTACCCA CGATGACCTC CGGGGGTATC

CTGGGCAAAA GGGACAAAGA GGGCAAATGA GATCACCTCC TGCAGCCCAC CACTCCAGCA CCTGTGCCGA

GGTCTGCGTC GAAGACAGAA TGGACAGTGA GGACAGTTAT GTCTTGTAAA AGACAAGAAG CTTCAGATGG

TACCCCAAGA AGGATGTGAG AGGTGGCCGC TTGGAGTTTG CCCCTCACCC ACCAGCTGCC CCATCCCTGA

GGCAGCGCTC CATGGGGGTA TGGTTTTGTC ACTGCCCAGA CCTAGCAGTG ACATCTCATT GTCCCCAGCC

CAGTGGGCAT TGGAGGTGCC AGGGGAGTCA GGGTTGTAGC CAAGACGCCC CCGCACGGGG AGGGTTGGGA

AGGGGGTGCA GGAAGCTCAA CCCCTCTGGG CACCAACCCT GCATTGCAGG TTGGCACCTT ACTTCCCTGG

GATCCCCAGA GTTGGTCCAA GGAGGGAGAG TGGGTTCTCA ATACGGTACC AAAGATATAA TCACCTAGGT

TTACAAATAT TTTTAGGACT CACGTTAACT CACATTTATA CAGCAGAAAT GCTATTTTGT ATGCTGTTAA

GTTTTTCTAT CTGTGTACTT TTTTTTAAGG GAAAGATTTT AATATTAAAC CTGGTGCTTC TCACTCAC

Figure 3 (B) Sequence of PDGFR-B polypeptide (GenBank Accession No. NP 002600) (SEQ ID NO: 6)

MRLPGAMPAL ALKGELLLLS LLLLLEPQIS QGLVVTPPGP ELVLNVSSTF VLTCSGSAPV
VWERMSQEPP QEMAKAQDGT FSSVLTLTNL TGLDTGEYFC THNDSRGLET DERKRLYIFV
PDPTVGFLPN DAEELFIFLT EITEITIPCR VTDPQLVVTL HEKKGDVALP VPYDHQRGFS
GIFEDRSYIC KTTIGDREVD SDAYYVYRLQ VSSINVSVNA VQTVVRQGEN ITLMCIVIGN
EVVNFEWTYP RKESGRLVEP VTDFLLDMPY HIRSILHIPS AELEDSGTYT CNVTESVNDH
QDEKAINITV VESGYVRLLG EVGTLQFAEL HRSRTLQVVF EAYPPPTVLW FKDNRTLGDS
SAGEIALSTR NVSETRYVSE LTLVRVKVAE AGHYTMRAFH EDAEVQLSFQ LQINVPVRVL
ELSESHPDSG EQTVRCRGRG MPQPNIIWSA CRDLKRCPRE LPPTLLGNSS EEESQLETNV
TYWEEEQEFE VVSTLRLQHV DRPLSVRCTL RNAVGQDTQE VIVVPHSLPF KVVVISAILA
LVVLTIISLI ILIMLWQKKP RYEIRWKVIE SVSSDGHEYI YVDPMQLPYD STWELPRDQL
VLGRTLGSGA FGQVVEATAH GLSHSQATMK VAVKMLKSTA RSSEKQALMS ELKIMSHLGP
HLNVVNLLGA CTKGGPIYII TEYCRYGDLV DYLHRNKHTF LQHHSDKRRP PSAELYSNAL
PVGLPLPSHV SLTGESDGGY MDMSKDESVD YVPMLDMKGD VKYADIESSN YMAPYDNYVP
SAPERTCRAT LINESPVLSY MDLVGFSYQV ANGMEFLASK NCVHRDLAAR NVLICEGKLV
KICDFGLARD IMRDSNYISK GSTFLPLKWM APESIFNSLY TTLSDVWSFG ILLWEIFTLG
GTPYPELPMN EQFYNAIKRG YRMAQPAHAS DEIYEIMQKC WEEKFEIRPP FSQLVLLLER
LLGEGYKKKY QQVDEEFLRS DHPAILRSQA RLPGFHGLRS PLDTSSVLYT AVQPNEGDND
YIIPLPDPKP EVADEGPLEG SPSLASSTLN EVNTSSTISC DSPLEPQDEP EPEPQLELQV
EPEPELEQLP DSGCPAPRAE
AEDSFL

Figure 3 (C) Sequence of PDGFR-A nucleic acid (GenBank Accession No. NM 006206) (SEQ ID NO: 13)

TTCTCCCCGC CCCCCAGTTG TTGTCGAAGT CTGGGGGTTG GGACTGGACC CCCTGATTGC GTAAGAGCAA

AAAGCGAAGG CGCAATCTGG ACACTGGGAG ATTCGGAGCG CAGGGAGTTT GAGAGAAACT TTTATTTTGA

AGAGACCAAG GTTGAGGGGG GGCTTATTTC CTGACAGCTA TTTACTTAGA GCAAATGATT AGTTTTAGAA

GGATGGACTA TAACATTGAA TCAATTACAA AACGCGGTTT TTGAGCCCAT TACTGTTGGA GCTACAGGGA

GAGAAACAGG AGGAGACTGC AAGAGATCAT TTGGGAAGGC CGTGGGCACG CTCTTTACTC CATGTGTGGG

ACATTCATTG CGGAATAACA TCGGAGGAGA AGTTTCCCAG AGCTATGGGG ACTTCCCATC CGGCGTTCCT

GGTCTTAGGC TGTCTTCTCA CAGGGCTGAG CCTAATCCTC TGCCAGCTTT CATTACCCTC TATCCTTCCA

AATGAAAATG AAAAGGTTGT GCAGCTGAAT TCATCCTTTT CTCTGAGATG CTTTGGGGAG AGTGAAGTGA

GCTGGCAGTA CCCCATGTCT GAAGAAGAGA GCTCCGATGT GGAAATCAGA AATGAAGAAA ACAACAGCGG

CCTTTTTGTG ACGGTCTTGG AAGTGAGCAG TGCCTCGGCG GCCCACACAG GGTTGTACAC TTGCTATTAC

AACCACACTC AGACAGAAGA GAATGAGCTT GAAGGCAGGC ACATTTACAT CTATGTGCCA GACCCAGATG

TAGCCTTTGT ACCTCTAGGA ATGACGGATT ATTTAGTCAT CGTGGAGGAT GATGATTCTG CCATTATACC

TTGTCGCACA ACTGATCCCG AGACTCCTGT AACCTTACAC AACAGTGAGG GGGTGGTACC TGCCTCCTAC

GACAGCAGAC AGGGCTTTAA TGGGACCTTC ACTGTAGGGC CCTATATCTG TGAGGCCACC GTCAAAGGAA

AGAAGTTCCA GACCATCCCA TTTAATGTTT ATGCTTTAAA AGCAACATCA GAGCTGGATC TAGAAATGGA

AGCTCTTAAA ACCGTGTATA AGTCAGGGGA AACGATTGTG GTCACCTGTG CTGTTTTTAA CAATGAGGTG

GTTGACCTTC AATGGACTTA CCCTGGAGAA GTGAAAGGCA AAGGCATCAC AATGCTGGAA GAAATCAAAG

TCCCATCCAT CAAATTGGTG TACACTTTGA CGGTCCCCGA GGCCACGGTG AAAGACAGTG GAGATTACGA

ATGTGCTGCC CGCCAGGCTA CCAGGGAGGT CAAAGAAATG AAGAAAGTCA CTATTTCTGT CCATGAGAAA

GGTTTCATTG AAATCAAACC CACCTTCAGC CAGTTGGAAG CTGTCAACCT GCATGAAGTC AAACATTTTG

TTGTAGAGGT GCGGGCCTAC CCACCTCCCA GGATATCCTG GCTGAAAAAC AATCTGACTC TGATTGAAAA

TCTCACTGAG ATCACCACTG ATGTGGAAAA GATTCAGGAA ATAAGGTATC GAAGCAAATT AAAGCTGATC

CGTGCTAAGG AAGAAGACAG TGGCCATTAT ACTATTGTAG CTCAAAATGA AGATGCTGTG AAGAGCTATA

CTTTTGAACT GTTAACTCAA GTTCCTTCAT CCATTCTGGA CTTGGTCGAT GATCACCATG GCTCAACTGG

GGGACAGACG GTGAGGTGCA CAGCTGAAGG CACGCCGCTT CCTGATATTG AGTGGATGAT ATGCAAAGAT

ATTAAGAAAT GTAATAATGA AACTTCCTGG ACTATTTTGG CCAACAATGT CTCAAACATC ATCACGGAGA

TCCACTCCCG AGACAGGAGT ACCGTGGAGG GCCGTGTGAC TTTCGCCAAA GTGGAGGAGA CCATCGCCGT

GCGATGCCTG GCTAAGAATC TCCTTGGAGC TGAGAACCGA GAGCTGAAGC TGGTGGCTCC CACCCTGCGT

TCTGAACTCA CGGTGGCTGC TGCAGTCCTG GTGCTGTTGG TGATTGTGAT CATCTCACTT ATTGTCCTGG

TTGTCATTTG GAAACAGAAA CCGAGGTATG AAATTCGCTG GAGGGTCATT GAATCAATCA GCCCGGATGG

ACATGAATAT ATTTATGTGG ACCCGATGCA GCTGCCTTAT GACTCAAGAT GGGAGTTTCC AAGAGATGGA

CTAGTGCTTG GTCGGGTCTT GGGGTCTGGA GCGTTTGGGA AGGTGGTTGA AGGAACAGCC TATGGATTAA

GCCGGTCCCA ACCTGTCATG AAAGTTGCAG TGAAGATGCT AAAACCCACG GCCAGATCCA GTGAAAAACA

AGCTCTCATG TCTGAACTGA AGATAATGAC TCACCTGGGG CCACATTTGA ACATTGTAAA CTTGCTGGGA

GCCTGCACCA AGTCAGGCCC CATTTACATC ATCACAGAGT ATTGCTTCTA TGGAGATTTG GTCAACTATT

TGCATAAGAA TAGGGATAGC TTCCTGAGCC ACCACCCAGA GAAGCCAAAG AAAGAGCTGG ATATCTTTGG

ATTGAACCCT GCTGATGAAA GCACACGGAG CTATGTTATT TTATCTTTTG AAAACAATGG TGACTACATG

GACATGAAGC AGGCTGATAC TACACAGTAT GTCCCCATGC TAGAAAGGAA AGAGGTTTCT AAATATTCCG

ACATCCAGAG ATCACTCTAT GATCGTCCAG CCTCATATAA GAAGAAATCT ATGTTAGACT CAGAAGTCAA

AAACCTCCTT TCAGATGATA ACTCAGAAGG CCTTACTTTA TTGGATTTGT TGAGCTTCAC CTATCAAGTT

GCCCGAGGAA TGGAGTTTTT GGCTTCAAAA AATTGTGTCC ACCGTGATCT GGCTGCTCGC AACGTCCTCC

TGGCACAAGG AAAAATTGTG AAGATCTGTG ACTTTGGCCT GGCCAGAGAC ATCATGCATG ATTCGAACTA

TGTGTCGAAA GGCAGTACCT TTCTGCCCGT GAAGTGGATG GCTCCTGAGA GCATCTTTGA CAACCTCTAC

ACCACACTGA GTGATGTCTG GTCTTATGGC ATTCTGCTCT GGGAGATCTT TTCCCTTGGT GGCACCCCTT

ACCCCGGCAT GATGGTGGAT TCTACTTTCT ACAATAAGAT CAAGAGTGGG TACCGGATGG CCAAGCCTGA

CCACGCTACC AGTGAAGTCT ACGAGATCAT GGTGAAATGC TGGAACAGTG AGCCGGAGAA GAGACCCTCC

TTTTACCACC TGAGTGAGAT TGTGGAGAAT CTGCTGCCTG GACAATATAA AAAGAGTTAT GAAAAAATTC

ACCTGGACTT CCTGAAGAGT GACCATCCTG CTGTGGCACG CATGCGTGTG GACTCAGACA ATGCATACAT

TGGTGTCACC TACAAAAACG AGGAAGACAA GCTGAAGGAC TGGGAGGGTG GTCTGGATGA GCAGAGACTG

AGCGCTGACA GTGGCTACAT CATTCCTCTG CCTGACATTG ACCCTGTCCC TGAGGAGGAG GACCTGGGCA

AGAGGAACAG ACACAGCTCG CAGACCTCTG AAGAGAGTGC CATTGAGACG GGTTCCAGCA GTTCCACCTT

CATCAAGAGA GAGGACGAGA CCATTGAAGA CATCGACATG ATGGACGACA TCGGCATAGA CTCTTCAGAC

CTGGTGGAAG ACAGCTTCCT GTAACTGGCG GATTCGAGGG GTTCCTTCCA CTTCTGGGGC CACCTCTGGA

TCCCGTTCAG AAAACCACTT TATTGCAATG CGGAGGTTGA GAGGAGGACT TGGTTGATGT TTAAAGAGAA

GTTCCCAGCC AAGGGCCTCG GGGAGCGTTC TAAATATGAA TGAATGGGAT ATTTTGAAAT GAACTTTGTC

AGTGTTGCCT CTCGCAATGC CTCAGTAGCA TCTCAGTGGT GTGTGAAGTT TGGAGATAGA TGGATAAGGG

AATAATAGGC CACAGAAGGT GAACTTTGTG CTTCAAGGAC ATTGGTGAGA GTCCAACAGA CACAATTTAT

ACTGCGACAG AACTTCAGCA TTGTAATTAT GTAAATAACT CTAACCAAGG CTGTGTTTAG ATTGTATTAA

CTATCTTCTT TGGACTTCTG AAGAGACCAC TCAATCCATC CATGTACTTC CCTCTTGAAA CCTGATGTCA

GCTGCTGTTG AACTTTTTAA AGAAGTGCAT GAAAAACCAT TTTTGAACCT TAAAAGGTAC TGGTACTATA

GCATTTTGCT ATCTTTTTTA GTGTTAAGAG ATAAAGAATA ATAATTAACC AACCTTGTTT AATAGATTTG

GGTCATTTAG AAGCCTGACA ACTCATTTTC ATATTGTAAT CTATGTTTAT AATACTACTA CTGTTATCAG

TAATGCTAAA TGTGTAATAA TGTAACATGA TTTCCCTCCA GAGAAAGCAC AATTTAAAAC AATCCTTACT

AAGTAGGTGA TGAGTTTGAC AGTTTTTGAC ATTTATATTA AATAACATGT TTCTCTATAA AGTATGGTAA

TAGCTTTAGT GAATTAAATT TAGTTGAGCA TAGAGAACAA AGTAAAAGTA GTGTTGTCCA GGAAGTCAGA

ATTTTTAACT GTACTGAATA GGTTCCCCAA TCCATCGTAT TAAAAAACAA TTAACTGCCC TCTGAAATAA

TGGGATTAGA AACAAACAAA ACTCTTAAGT CCTAAAAGTT CTCAATGTAG AGGCATAAAC CTGTGCTGAA

CATAACTTCT CATGTATATT ACCCAATGGA AAATATAATG ATCAGCAAAA AGACTGGATT TGCAGAAGTT

TTTTTTTTTT TTCTTCATGC CTGATGAAAG CTTTGGCAAC CCCAATATAT GTATTTTTTG AATCTATGAA

CCTGAAAAGG GTCAGAAGGA TGCCCAGACA TCAGCCTCCT TCTTTCACCC CTTACCCCAA AGAGAAAGAG

TTTGAAACTC GAGACCATAA AGATATTCTT TAGTGGAGGC TGGATGTGCA TTAGCCTGGA TCCTCAGTTC

TCAAATGTGT GTGGCAGCCA GGATGACTAG ATCCTGGGTT TCCATCCTTG AGATTCTGAA GTATGAAGTC

TGAGGGAAAC CAGAGTCTGT ATTTTTCTAA ACTCCCTGGC TGTTCTGATC GGCCAGTTTT CGGAAACACT

GACTTAGGTT TCAGGAAGTT GCCATGGGAA ACAAATAATT TGAACTTTGG AACAGGGTTG GAATTCAACC

ACGCAGGAAG CCTACTATTT AAATCCTTGG CTTCAGGTTA GTGACATTTA ATGCCATCTA GCTAGCAATT

GCGACCTTAA TTTAACTTTC CAGTCTTAGC TGAGGCTGAG AAAGCTAAAG TTTGGTTTTG ACAGGTTTTC

CAAAAGTAAA GATGCTACTT CCCACTGTAT GGGGGAGATT GAACTTTCCC CGTCTCCCGT CTTCTGCCTC

CCACTCCATA CCCCGCCAAG GAAAGGCATG TACAAAAATT ATGCAATTCA GTGTTCCAAG TCTCTGTGTA

ACCAGCTCAG TGTTTTGGTG GAAAAAACAT TTTAAGTTTT ACTGATAATT TGAGGTTAGA TGGGAGGATG

AATTGTCACA TCTATCCACA CTGTCAAACA GGTTGGTGTG GGTTCATTGG CATTCTTTGC AATACTGCTT

AATTGCTGAT ACCATATGAA TGAAACATGG GCTGTGATTA CTGCAATCAC TGTGCTATCG GCAGATGATG

CTTTGGAAGA TGCAGAAGCA ATAATAAAGT ACTTGACTAC CTACTGGTGT AATCTCAATG CAAGCCCCAA

CTTTCTTATC CAACTTTTTC ATAGTAAGTG CGAAGACTGA GCCAGATTGG CCAATTAAAA ACGAAAACCT

GACTAGGTTC TGTAGAGCCA ATTAGACTTG AAATACGTTT GTGTTTCTAG AATCACAGCT CAAGCATTCT

GTTTATCGCT CACTCTCCCT TGTACAGCCT TATTTTGTTG GTGCTTTGCA TTTTGATATT GCTGTGAGCC

TTGCATGACA TCATGAGGCC GGATGAAACT TCTCAGTCCA GCAGTTTCCA GTCCTAACAA ATGCTCCCAC

CTGAATTTGT ATATGACTGC ATTTGTGGGT GTGTGTGTGT TTTCAGCAAA TTCCAGATTT GTTTCCTTTT

GGCCTCCTGC AAAGTCTCCA GAAGAAAATT TGCCAATCTT TCCTACTTTC TATTTTTATG ATGACAATCA

AAGCCGGCCT GAGAAACACT ATTTGTGACT TTTTAAACGA TTAGTGATGT CCTTAAAATG TGGTCTGCCA

ATCTGTACAA AATGGTCCTA TTTTTGTGAA GAGGGACATA AGATAAAATG ATGTTATACA TCAATATGTA

TATATGTATT TCTATATAGA CTTGGAGAAT ACTGCCAAAA CATTTATGAC AAGCTGTATC ACTGCCTTCG

TTTATATTTT TTTAACTGTG ATAATCCCCA CAGGCACATT AACTGTTGCA CTTTTGAATG TCCAAAATTT

ATATTTTAGA AATAATAAAA AGAAAGATAC TTACATGTTC CCAAAACAAT GGTGTGGTGA ATGTGTGAGA

AAAACTAACT TGATAGGGTC TACCAATACA AAATGTATTA CGAATGCCCC TGTTCATGTT TTTGTTTTAA

AACGTGTAAA TGAAGATCTT TATATTTCAA TAAATGATAT ATAATTTAAA GTT

Figure 3 (D) Sequence of human PDGFR-A polypeptide (GenBank Accession No. NP 006197) (SEQ ID NO: 14)

MGTSHPAFLV LGCLLTGLSL ILCQLSLPSI LPNENEKVVQ LNSSFSLRCF GESEVSWQYP
MSEEEESSDVE IRNEENNSGL FVTVLEVSSA SAAHTGLYTC YYNHTQTEEN ELEGRHIYIY
VPDPDVAFVP LGMTDYLVIV EDDDSAIIPC RTTDPETPVT LHNSEGVVPA SYDSRQGFNG
TFTVGPYICE ATVKGKKFQT IPFNVYALKA TSELDLEMEA LKTVYKSGET IVVTCAVFNN
EVVDLQWTYP GEVKGKGITM LEEIKVPSIK LVYTLTVPEA TVKDSGDYEC AARQATREVK
EMKKVTISVH EKGFIEIKPT FSQLEAVNLH EVKHFVVEVR AYPPPRISWL KNNLTLIENL
TEITTDVEKI QEIRYRSKLK LIRAKEEDSG HYTIVAQNED AVKSYTFELL TQVPSSILDL
VDDHHGSTGG QTVRCTAEGT PLPDIEWMIC KDIKKCNNET SWTILANNVS NIITEIHSRD
RSTVEGRVTF AKVEETIAVR CLAKNLLGAE NRELKLVAPT LRSELTVAAA VLVLLVIVII
SLIVLVVIWK QKPRYEIRWR VIESISPDGH EYIYVDPMQL PYDSRWEFPR DGLVLGRVLG
SGAFGKVVEG TAYGLSRSQP VMKVAVKMLK PTARSSEKQA LMSELKIMTH LGPHLNIVNL
LGACTKSGPI YIITEYCFYG DLVNYLHKNR DSFLSHHPEK PKKELDIFGL NPADESTRSY
VILSFENNGD YMDMKQADTT QYVPMLERKE VSKYSDIQRS LYDRPASYKK KSMLDSEVKN
LLSDDNSEGL TLLDLLSFTY QVARGMEFLA SKNCVHRDLA ARNVLLAQGK IVKICDFGLA
RDIMHDSNYV SKGSTFLPVK WMAPESIFDN LYTTLSDVWS YGILLWEIFS LGGTPYPGMM
VDSTFYNKIK SGYRMAKPDH ATSEVYEIMV KCWNSEPEKR PSFYHLSEIV ENLLPGQYKK
SYEKIHLDFL KSDHPAVARM RVDSDNAYIG VTYKNEEDKL KDWEGGLDEQ RLSADSGYII
PLPDIDPVPE EEDLGKRNRH SSQTSEESAI ETGSSSSTFI KREDETIEDI DMMDDIGIDS
SDLVEDSFL

Figure 4 (A) Sequence of VEGFR-1 (Flt-1) nucleic acid (GenBank Accession No. AF063657) (SEQ ID NO: 7)

ATGGTCAGCT ACTGGGACAC CGGGGTCCTG CTGTGCGCGC TGCTCAGCTG TCTGCTTCTC ACAGGATCTA
GTTCAGGTTC AAAATTAAAA GATCCTGAAC TGAGTTTAAA AGGCACCCAG CACATCATGC AAGCAGGCCA
GACACTGCAT CTCCAATGCA GGGGGGAAGC AGCCCATAAA TGGTCTTTGC CTGAAATGGT GAGTAAGGAA
AGCGAAAGGC TGAGCATAAC TAAATCTGCC TGTGGAAGAA ATGGCAAACA ATTCTGCAGT ACTTTAACCT
TGAACACAGC TCAAGCAAAC CACACTGGCT TCTACAGCTG CAAATATCTA GCTGTACCTA CTTCAAAGAA
GAAGGAAACA GAATCTGCAA TCTATATATT TATTAGTGAT ACAGGTAGAC CTTTCGTAGA GATGTACAGT
GAAATCCCCG AAATTATACA CATGACTGAA GGAAGGGAGC TCGTCATTCC CTGCCGGGTT ACGTCACCTA
ACATCACTGT TACTTTAAAA AAGTTTCCAC TTGACACTTT GATCCCTGAT GGAAAACGCA TAATCTGGGA
CAGTAGAAAG GGCTTCATCA TATCAAATGC AACGTACAAA GAAATAGGGC TTCTGACCTG TGAAGCAACA
GTCAATGGGC ATTTGTATAA GACAAACTAT CTCACACATC GACAAACCAA TACAATCATA GATGTCCAAA
TAAGCACACC ACGCCCAGTC AAATTACTTA GAGGCCATAC TCTTGTCCTC AATTGTACTG CTACCACTCC
CTTGAACACG AGAGTTCAAA TGACCTGGAG TTACCCTGAT GAAAAAAATA AGAGAGCTTC CGTAAGGCGA
CGAATTGACC AAAGCAATTC CCATGCCAAC ATATTCTACA GTGTTCTTAC TATTGACAAA ATGCAGAACA
AAGACAAAGG ACTTTATACT TGTCGTGTAA GGAGTGGACC ATCATTCAAA TCTGTTAACA CCTCAGTGCA
TATATATGAT AAAGCATTCA TCACTGTGAA ACATCGAAAA CAGCAGGTGC TTGAAACCGT AGCTGGCAAG
CGGTCTTACC GGCTCTCTAT GAAAGTGAAG GCATTTCCCT CGCCGGAAGT TGTATGGTTA AAAGATGGGT
TACCTGCGAC TGAGAAATCT GCTCGCTATT TGACTCGTGG CTACTCGTTA ATTATCAAGG ACGTAACTGA
AGAGGATGCA GGGAATTATA CAATCTTGCT GAGCATAAAA CAGTCAAATG TGTTTAAAAA CCTCACTGCC
ACTCTAATTG TCAATGTGAA ACCCCAGATT TACGAAAAGG CCGTGTCATC GTTTCCAGAC CCGGCTCTCT
ACCCACTGGG CAGCAGACAA ATCCTGACTT GTACCGCATA TGGTATCCCT CAACCTACAA TCAAGTGGTT
CTGGCACCCC TGTAACCATA ATCATTCCGA AGCAAGGTGT GACTTTTGTT CCAATAATGA AGAGTCCTTT
ATCCTGGATG CTGACAGCAA CATGGGAAAC AGAATTGAGA GCATCACTCA GCGCATGGCA ATAATAGAAG
GAAAGAATAA GATGGCTAGC ACCTTGGTTG TGGCTGACTC TAGAATTTCT GGAATCTACA TTTGCATAGC
TTCCAATAAA GTTGGGACTG TGGGAAGAAA CATAAGCTTT TATATCACAG ATGTGCCAAA TGGGTTTCAT
GTTAACTTGG AAAAAATGCC GACGGAAGGA GAGGACCTGA AACTGTCTTG CACAGTTAAC AAGTTCTTAT
ACAGAGACGT TACTTGGATT TTACTGCGGA CAGTTAATAA CAGAACAATG CACTACAGTA TTAGCAAGCA
AAAAATGGCC ATCACTAAGG AGCACTCCAT CACTCTTAAT CTTACCATCA TGAATGTTTC CCTGCAAGAT
TCAGGCACCT ATGCCTGCAG AGCCAGGAAT GTATACACAG GGGAAGAAAT CCTCCAGAAG AAAGAAATTA
CAATCAGAGA TCAGGAAGCA CCATACCTCC TGCGAAACCT CAGTGATCAC ACAGTGGCCA TCAGCAGTTC
CACCACTTTA GACTGTCATG CTAATGGTGT CCCCGAGCCT CAGATCACTT GGTTTAAAAA CAACCACAAA
ATACAACAAG AGCCTGGAAT TATTTTAGGA CCAGGAAGCA GCACGCTGTT TATTGAAAGA GTCACAGAAG
AGGATGAAGG TGTCTATCAC TGCAAAGCCA CCAACCAGAA GGGCTCTGTG GAAAGTTCAG CATACCTCAC
TGTTCAAGGA ACCTCGGACA AGTCTAATCT GGAGCTGATC ACTCTAACAT GCACCTGTGT GGCTGCGACT

CTCTTCTGGC TCCTATTAAC CCTCTTTATC CGAAAAATGA AAAGGTCTTC TTCTGAAATA AAGACTGACT

ACCTATCAAT TATAATGGAC CCAGATGAAG TTCCTTTGGA TGAGCAGTGT GAGCGGCTCC CTTATGATGC

CAGCAAGTGG GAGTTTGCCC GGGAGAGACT TAAACTGGGC AAATCACTTG GAAGAGGGGC TTTTGGAAAA

GTGGTTCAAG CATCAGCATT TGGCATTAAG AAATCACCTA CGTGCCGGAC TGTGGCTGTG AAAATGCTGA

AAGAGGGGGC CACGGCCAGC GAGTACAAAG CTCTGATGAC TGAGCTAAAA ATCTTGACCC ACATTGGCCA

CCATCTGAAC GTGGTTAACC TGCTGGGAGC CTGCACCAAG CAAGGAGGGC CTCTGATGGT GATTGTTGAA

TACTGCAAAT ATGGAAATCT CTCCAACTAC CTCAAGAGCA AACGTGACTT ATTTTTTCTC AACAAGGATG

CAGCACTACA CATGGAGCCT AAGAAAGAAA AAATGGAGCC AGGCCTGGAA CAAGGCAAGA AACCAAGACT

AGATAGCGTC ACCAGCAGCG AAAGCTTTGC GAGCTCCGGC TTTCAGGAAG ATAAAAGTCT GAGTGATGTT

GAGGAAGAGG AGGATTCTGA CGGTTTCTAC AAGGAGCCCA TCACTATGGA AGATCTGATT TCTTACAGTT

TTCAAGTGGC CAGAGGCATG GAGTTCCTGT CTTCCAGAAA GTGCATTCAT CGGGACCTGG CAGCGAGAAA

CATTCTTTTA TCTGAGAACA ACGTGGTGAA GATTTGTGAT TTTGGCCTTG CCCGGGATAT TTATAAGAAC

CCCGATTATG TGAGAAAAGG AGATACTCGA CTTCCTCTGA AATGGATGGC TCCTGAATCT ATCTTTGACA

AAATCTACAG CACCAAGAGC GACGTGTGGT CTTACGGAGT ATTGCTGTGG GAAATCTTCT CCTTAGGTGG

GTCTCCATAC CCAGGAGTAC AAATGGATGA GGACTTTTGC AGTCGCCTGA GGGAAGGCAT GAGGATGAGA

GCTCCTGAGT ACTCTACTCC TGAAATCTAT CAGATCATGC TGGACTGCTG GCACAGAGAC CCAAAAGAAA

GGCCAAGATT TGCAGAACTT GTGGAAAAAC TAGGTGATTT GCTTCAAGCA AATGTACAAC AGGATGGTAA

AGACTACATC CCAATCAATG CCATACTGAC AGGAAATAGT GGGTTTACAT ACTCAACTCC TGCCTTCTCT

GAGGACTTCT TCAAGGAAAG TATTTCAGCT CCGAAGTTTA ATTCAGGAAG CTCTGATGAT GTCAGATATG

TAAATGCTTT CAAGTTCATG AGCCTGGAAA GAATCAAAAC CTTTGAAGAA CTTTTACCGA ATGCCACCTC

CATGTTTGAT GACTACCAGG GCGACAGCAG CACTCTGTTG GCCTCTCCCA TGCTGAAGCG CTTCACCTGG

ACTGACAGCA AACCCAAGGC CTCGCTCAAG ATTGACTTGA GAGTAACCAG TAAAAGTAAG GAGTCGGGGC

TGTCTGATGT CAGCAGGCCC AGTTTCTGCC ATTCCAGCTG TGGGCACGTC AGCGAAGGCA AGCGCAGGTT

CACCTACGAC CACGCTGAGC TGGAAAGGAA AATCGCGTGC TGCTCCCCGC CCCCAGACTA CAACTCGGTG

GTCCTGTACT CCACCCCACC CATCTAG

Figure 4 (B) **Sequence of VEGFR-1 (Flt-1) polypeptide (GenBank Accession No.) (SEQ ID NO: 8)**

MVSYWDTGVL LCALLSCLLL TGSSSGSKLK DPELSLKGTQ HIMQAGQTLH LQCRGEAAHK
WSLPEMVSKE SERLSITKSA CGRNGKQFCS TLTLNTAQAN HTGFYSCKYL AVPTSKKKET
ESAIYIFISD TGRPFVEMYS EIPEIIHMTE GRELVIPCRV TSPNITVTLK KFPLDTLIPD
GKRIIWDSRK GFIISNATYK EIGLLTCEAT VNGHLYKTNY LTHRQTNTII DVQISTPRPV
KLLRGHTLVL NCTATTPLNT RVQMTWSYPD EKNKRASVRR RIDQSNSHAN IFYSVLTIDK
MQNKDKGLYT CRVRSGPSFK SVNTSVHIYD KAFITVKHRK QQVLETVAGK RSYRLSMKVK
AFPSPEVVWL KDGLPATEKS ARYLTRGYSL IIKDVTEEDA GNYTILLSIK QSNVFKNLTA
TLIVNVKPQI YEKAVSSFPD PALYPLGSRQ ILTCTAYGIP QPTIKWFWHP CNHNHSEARC
DFCSNNEESF ILDADSNMGN RIESITQRMA IIEGKNKMAS TLVVADSRIS GIYICIASNK
VGTVGRNISF YITDVPNGFH VNLEKMPTEG EDLKLSCTVN KFLYRDVTWI LLRTVNNRTM
HYSISKQKMA ITKEHSITLN LTIMNVSLQD SGTYACRARN VYTGEEILQK KEITIRDQEA
PYLLRNLSDH TVAISSSTTL DCHANGVPEP QITWFKNNHK IQQEPGIILG PGSSTLFIER
VTEEDEGVYH CKATNQKGSV ESSAYLTVQG TSDKSNLELI TLTCTCVAAT LFWLLLTLFI
RKMKRSSSEI KTDYLSIIMD PDEVPLDEQC ERLPYDASKW EFARERLKLG KSLGRGAFGK
VVQASAFGIK KSPTCRTVAV KMLKEGATAS EYKALMTELK ILTHIGHHLN VVNLLGACTK
QGGPLMVIVE YCKYGNLSNY LKSKRDLFFL NKDAALHMEP KKEKMEPGLE QGKKPRLDSV
TSSESFASSG FQEDKSLSDV EEEEDSDGFY KEPITMEDLI SYSFQVARGM EFLSSRKCIH
RDLAARNILL SENNVVKICD FGLARDIYKN PDYVRKGDTR LPLKWMAPES IFDKIYSTKS
DVWSYGVLLW EIFSLGGSPY PGVQMDEDFC SRLREGMRMR APEYSTPEIY QIMLDCWHRD
PKERPRFAEL VEKLGDLLQA NVQQDGKDYI PINAILTGNS GFTYSTPAFS EDFFKESISA
PKFNSGSSDD VRYVNAFKFM SLERIKTFEE LLPNATSMFD DYQGDSSTLL ASPMLKRFTW
TDSKPKASLK IDLRVTSKSK ESGLSDVSRP SFCHSSCGHV SEGKRRFTYD HAELERKIAC
CSPPPDYNSV VLYSTPPI

Figure 4 (C) Sequence of VEGFR-2 (KDR/Flk-1) nucleic acid (GenBank Accession No. AF035121) (SEQ ID NO: 9)

ACTGAGTCCC GGGACCCCGG GAGAGCGGTC AGTGTGTGGT CGCTGCGTTT CCTCTGCCTG CGCCGGGCAT

CACTTGCGCG CCGCAGAAAG TCCGTCTGGC AGCCTGGATA TCCTCTCCTA CCGGCACCCG CAGACGCCCC

TGCAGCCGCC GGTCGGCGCC CGGGCTCCCT AGCCCTGTGC GCTCAACTGT CCTGCGCTGC GGGGTGCCGC

GAGTTCCACC TCCGCGCCTC CTTCTCTAGA CAGGCGCTGG GAGAAAGAAC CGGCTCCCGA GTTCTGGGCA

TTTCGCCCGG CTCGAGGTGC AGGATGCAGA GCAAGGTGCT GCTGGCCGTC GCCCTGTGGC TCTGCGTGGA

GACCCGGGCC GCCTCTGTGG GTTTGCCTAG TGTTTCTCTT GATCTGCCCA GGCTCAGCAT ACAAAAAGAC

ATACTTACAA TTAAGGCTAA TACAACTCTT CAAATTACTT GCAGGGGACA GAGGGACTTG GACTGGCTTT

GGCCCAATAA TCAGAGTGGC AGTGAGCAAA GGGTGGAGGT GACTGAGTGC AGCGATGGCC TCTTCTGTAA

GACACTCACA ATTCCAAAAG TGATCGGAAA TGACACTGGA GCCTACAAGT GCTTCTACCG GGAAACTGAC

TTGGCCTCGG TCATTTATGT CTATGTTCAA GATTACAGAT CTCCATTTAT TGCTTCTGTT AGTGACCAAC

ATGGAGTCGT GTACATTACT GAGAACAAAA ACAAAACTGT GGTGATTCCA TGTCTCGGGT CCATTTCAAA

TCTCAACGTG TCACTTTGTG CAAGATACCC AGAAAAGAGA TTTGTTCCTG ATGGTAACAG AATTTCCTGG

GACAGCAAGA AGGGCTTTAC TATTCCCAGC TACATGATCA GCTATGCTGG CATGGTCTTC TGTGAAGCAA

AAATTAATGA TGAAAGTTAC CAGTCTATTA TGTACATAGT TGTCGTTGTA GGGTATAGGA TTTATGATGT

GGTTCTGAGT CCGTCTCATG GAATTGAACT ATCTGTTGGA GAAAAGCTTG TCTTAAATTG TACAGCAAGA

ACTGAACTAA ATGTGGGGAT TGACTTCAAC TGGGAATACC CTTCTTCGAA GCATCAGCAT AAGAAACTTG

TAAACCGAGA CCTAAAAACC CAGTCTGGGA GTGAGATGAA GAAATTTTTG AGCACCTTAA CTATAGATGG

TGTAACCCGG AGTGACCAAG GATTGTACAC CTGTGCAGCA TCCAGTGGGC TGATGACCAA GAAGAACAGC

ACATTTGTCA GGGTCCATGA AAAACCTTTT GTTGCTTTTG GAAGTGGCAT GGAATCTCTG GTGGAAGCCA

CGGTGGGGGA GCGTGTCAGA ATCCCTGCGA AGTACCTTGG TTACCCACCC CCAGAAATAA AATGGTATAA

AAATGGAATA CCCCTTGAGT CCAATCACAC AATTAAAGCG GGGCATGTAC TGACGATTAT GGAAGTGAGT

GAAAGAGACA CAGGAAATTA CACTGTCATC CTTACCAATC CCATTTCAAA GGAGAAGCAG AGCCATGTGG

TCTCTCTGGT TGTGTATGTC CCACCCCAGA TTGGTGAGAA ATCTCTAATC TCTCCTGTGG ATTCCTACCA

GTACGGCACC ACTCAAACGC TGACATGTAC GGTCTATGCC ATTCCTCCCC CGCATCACAT CCACTGGTAT

TGGCAGTTGG AGGAAGAGTG CGCCAACGAG CCCAGCCAAG CTGTCTCAGT GACAAACCCA TACCCTTGTG

AAGAATGGAG AAGTGTGGAG GACTTCCAGG GAGGAAATAA AATTGAAGTT AATAAAAATC AATTTGCTCT

AATTGAAGGA AAAAACAAAA CTGTAAGTAC CCTTGTTATC CAAGCGGCAA ATGTGTCAGC TTTGTACAAA

TGTGAAGCGG TCAACAAAGT CGGGAGAGGA GAGAGGGTGA TCTCCTTCCA CGTGACCAGG GGTCCTGAAA

TTACTTTGCA ACCTGACATG CAGCCCACTG AGCAGGAGAG CGTGTCTTTG TGGTGCACTG CAGACAGATC

TACGTTTGAG AACCTCACAT GGTACAAGCT TGGCCCACAG CCTCTGCCAA TCCATGTGGG AGAGTTGCCC
ACACCTGTTT GCAAGAACTT GGATACTCTT TGGAAATTGA ATGCCACCAT GTTCTCTAAT AGCACAAATG
ACATTTTGAT CATGGAGCTT AAGAATGCAT CCTTGCAGGA CCAAGGAGAC TATGTCTGCC TTGCTCAAGA
CAGGAAGACC AAGAAAAGAC ATTGCGTGGT CAGGCAGCTC ACAGTCCTAG AGCGTGTGGC ACCCACGATC
ACAGGAAACC TGGAGAATCA GACGACAAGT ATTGGGGAAA GCATCGAAGT CTCATGCACG GCATCTGGGA
ATCCCCCTCC ACAGATCATG TGGTTTAAAG ATAATGAGAC CCTTGTAGAA GACTCAGGCA TTGTATTGAA
GGATGGGAAC CGGAACCTCA CTATCCGCAG AGTGAGGAAG GAGGACGAAG GCCTCTACAC CTGCCAGGCA
TGCAGTGTTC TTGGCTGTGC AAAAGTGGAG GCATTTTTCA TAATAGAAGG TGCCCAGGAA AAGACGAACT
TGGAAATCAT TATTCTAGTA GGCACGGCGG TGATTGCCAT GTTCTTCTGG CTACTTCTTG TCATCATCCT
ACGGACCGTT AAGCGGGCCA ATGGAGGGGA ACTGAAGACA GGCTACTTGT CCATCGTCAT GGATCCAGAT
GAACTCCCAT TGGATGAACA TTGTGAACGA CTGCCTTATG ATGCCAGCAA ATGGGAATTC CCCAGAGACC
GGCTGAAGCT AGGTAAGCCT CTTGGCCGTG GTGCCTTTGG CCAAGTGATT GAAGCAGATG CCTTTGGAAT
TGACAAGACA GCAACTTGCA GGACAGTAGC AGTCAAAATG TTGAAAGAAG GAGCAACACA CAGTGAGCAT
CGAGCTCTCA TGTCTGAACT CAAGATCCTC ATTCATATTG GTCACCATCT CAATGTGGTC AACCTTCTAG
GTGCCTGTAC CAAGCCAGGA GGGCCACTCA TGGTGATTGT GGAATTCTGC AAATTTGGAA ACCTGTCCAC
TTACCTGAGG AGCAAGAGAA ATGAATTTGT CCCCTACAAG ACCAAAGGGG CACGATTCCG TCAAGGGAAA
GACTACGTTG GAGCAATCCC TGTGGATCTG AAACGGCGCT TGGACAGCAT CACCAGTAGC CAGAGCTCAG
CCAGCTCTGG ATTTGTGGAG GAGAAGTCCC TCAGTGATGT AGAAGAAGAG GAAGCTCCTG AAGATCTGTA
TAAGGACTTC CTGACCTTGG AGCATCTCAT CTGTTACAGC TTCCAAGTGG CTAAGGGCAT GGAGTTCTTG
GCATCGCGAA AGTGTATCCA CAGGGACCTG GCGGCACGAA ATATCCTCTT ATCGGAGAAG AACGTGGTTA
AAATCTGTGA CTTTGGCTTG GCCCGGGATA TTTATAAAGA TCCAGATTAT GTCAGAAAAG GAGATGCTCG
CCTCCCTTTG AAATGGATGG CCCCAGAAAC AATTTTTGAC AGAGTGTACA CAATCCAGAG TGACGTCTGG
TCTTTTGGTG TTTTGCTGTG GGAAATATTT TCCTTAGGTG CTTCTCCATA TCCTGGGGTA AAGATTGATG
AAGAATTTTG TAGGCGATTG AAAGAAGGAA CTAGAATGAG GGCCCCTGAT TATACTACAC CAGAAATGTA
CCAGACCATG CTGGACTGCT GGCACGGGGA GCCCAGTCAG AGACCCACGT TTTCAGAGTT GGTGGAACAT
TTGGGAAATC TCTTGCAAGC TAATGCTCAG CAGGATGGCA AAGACTACAT TGTTCTTCCG ATATCAGAGA
CTTTGAGCAT GGAAGAGGAT TCTGGACTCT CTCTGCCTAC CTCACCTGTT TCCTGTATGG AGGAGGAGGA
AGTATGTGAC CCCAAATTCC ATTATGACAA CACAGCAGGA ATCAGTCAGT ATCTGCAGAA CAGTAAGCGA
AAGAGCCGGC CTGTGAGTGT AAAAACATTT GAAGATATCC CGTTAGAAGA ACCAGAAGTA AAAGTAATCC
CAGATGACAA CCAGACGGAC AGTGGTATGG TTCTTGCCTC AGAAGAGCTG AAAACTTTGG AAGACAGAAC
CAAATTATCT CCATCTTTTG GTGGAATGGT GCCCAGCAAA AGCAGGGAGT CTGTGGCATC TGAAGGCTCA
AACCAGACAA GCGGCTACCA GTCCGGATAT CACTCCGATG ACACAGACAC CACCGTGTAC TCCAGTGAGG
AAGCAGAACT TTTAAAGCTG ATAGAGATTG GAGTGCAAAC CGGTAGCACA GCCCAGATTC TCCAGCCTGA

CTCGGGGACC ACACTGAGCT CTCCTCCTGT TTAAAAGGAA GCATCCACAC CCCAACTCCC GGACATCACA
TGAGAGGTCT GCTCAGATTT TGAAGTGTTG TTCTTTCCAC CAGCAGGAAG TAGCCGCATT TGATTTTCAT
TTCGACAACA GAAAAAGGAC CTCGGACTGC AGGGAGCCAG TCTTCTAGGC ATATCCTGGA AGAGGCTTGT
GACCCAAGAA TGTGTCTGTG TCTTCTCCCA GTGTTGACCT GATCCTCTTT TTTCATTCAT TTAAAAAGCA
TTATCATGCC CCTGCTGCGG GTCTCACCAT GGGTTTAGAA CAAAGAGCTT CAAGCAATGG CCCCATCCTC
AAAGAAGTAG CAGTACCTGG GGAGCTGACA CTTCTGTAAA ACTAGAAGAT AAACCAGGCA ACGTAAGTGT
TCGAGGTGTT GAAGATGGGA AGGATTTGCA GGGCTGAGTC TATCCAAGAG GCTTTGTTTA GGACGTGGGT
CCCAAGCCAA GCCTTAAGTG TGGAATTCGG ATTGATAGAA AGGAAGACTA ACGTTACCTT GCTTTGGAGA
GTACTGGAGC CTGCAAATGC ATTGTGTTTG CTCTGGTGGA GGTGGGCATG GGGTCTGTTC TGAAATGTAA
AGGGTTCAGA CGGGGTTTCT GGTTTTAGAA GGTTGCGTGT TCTTCGAGTT GGGCTAAAGT AGAGTTCGTT
GTGCTGTTTC TGACTCCTAA TGAGAGTTCC TTCCAGACCG TTAGCTGTCT CCTTGCCAAG CCCCAGGAAG
AAAATGATGC AGCTCTGGCT CCTTGTCTCC CAGGCTGATC CTTTATTCAG AATACCACAA AGAAAGGACA
TTCAGCTCAA GGCTCCCTGC CGTGTTGAAG AGTTCTGACT GCACAAACCA GCTTCTGGTT TCTTCTGGAA
TGAATACCCT CATATCTGTC CTGATGTGAT ATGTCTGAGA CTGAATGCGG GAGGTTCAAT GTGAAGCTGT
GTGTGGTGTC AAAGTTTCAG GAAGGATTTT ACCCTTTTGT TCTTCCCCCT GTCCCCAACC CACTCTCACC
CCGCAACCCA TCAGTATTTT AGTTATTTGG CCTCTACTCC AGTAAACCTG ATTGGGTTTG TTCACTCTCT
GAATGATTAT TAGCCAGACT TCAAAATTAT TTTATAGCCC AAATTATAAC ATCTATTGTA TTATTTAGAC
TTTTAACATA TAGAGCTATT TCTACTGATT TTTGCCCTTG TTCTGTCCTT TTTTTCAAAA AAGAAAATGT
GTTTTTTGTT TGGTACCATA GTGTGAAATG CTGGGAACAA TGACTATAAG ACATGCTATG GCACATATAT
TTATAGTCTG TTTATGTAGA AACAAATGTA ATATATTAAA GCCTTATATA TAATGAACTT TGTACTATTC
ACATTTTGTA TCAGTATTAT GTAGCATAAC AAAGGTCATA ATGCTTTCAG CAATTGATGT CATTTTATTA
AAGAACATTG AAAAACTTGA

Figure 4 (D) Sequence of VEGFR-2 (KDRJF1k-1) polypeptide (GenBank Accession No. AAB88005) (SEQ ID NO: 10)

MQSKVLLAVA LWLCVETRAA SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD
WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD
YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD
SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE
KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS
DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP
EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP
PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY
PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE
RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT
PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT
VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR
NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGAQEK TNLEIIILVG TAVIAMFFWL
LLVIILRTVK RANGGELKTG YLSIVMDPDE LPLDEHCERL PYDASKWEFP RDRLKLGKPL
GRGAFGQVIE ADAFGIDKTA TCRTVAVKML KEGATHSEHR ALMSELKILI HIGHHLNVVN
LLGACTKPGG PLMVIVEFCK FGNLSTYLRS KRNEFVPYKT KGARFRQGKD YVGAIPVDLK
RRLDSITSSQ SSASSGFVEE KSLSDVEEEE APEDLYKDFL TLEHLICYSF QVAKGMEFLA
SRKCIHRDLA ARNILLSEKN VVKICDFGLA RDIYKDPDYV RKGDARLPLK WMAPETIFDR
VYTIQSDVWS FGVLLWEIFS LGASPYPGVK IDEEFCRRLK EGTRMRAPDY TTPEMYQTML
DCWHGEPSQR PTFSELVEHL GNLLQANAQQ DGKDYIVLPI SETLSMEEDS GLSLPTSPVS
CMEEEEVCDP KFHYDNTAGI SQYLQNSKRK SRPVSVKTFE DIPLEEPEVK VIPDDNQTDS
GMVLASEELK TLEDRTKLSP SFGGMVPSKS RESVASEGSN QTSGYQSGYH SDDTDTTVYS
SEEAELLKLI EIGVQTGSTA QILQPDSGTT LSSPPV

Figure 5.


Mean Change from Baseline Central Foveal Thickness
500
400
300
200
100
0
387
380
245
230
Central Subfield
Center
Baseline
Week 4
Week 8
Week 12

Figure 6



where R represents the following structure:



and n is about 450.

Figure 7



where R represents the following structure:



and n is about 450.

Figure 8



where R represents the following structure:



and n is about 450.

Figure 9



where R represents the following structure:



and n is about 450.

Figure 10



Figure 11



Figure 12



Figure 13



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 10/32816

A. CLASSIFICATION OF SUBJECT MATTER
IPC(8) - A61K 31/7088, A61K 39/395 (2010.01)
USPC - 514/44A, 514/2
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
USPC -- 514/44A, 514/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WEST -- PGPB,USPT,USOC,EPAB,JPAB; Dialog Classic Files -- 654, 652, 351, 349, 6, 35, 65, 155; USPTO Web Page; Google Scholar; Search terms -- ophthalmic disease, intraocular administration, intravireal administration, PEGylated aptamer, PDGF antagonist, VEGF antagonist, combination therapy, bevacizumab, ranibizumab, afilbercept, carrier, simulatane

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 2004/0253679 A1 (EPSTEIN et al.) 16 December 2004 (16.12.2004) para [0002], [0025], [0047], [0052]-[0054], [0163], [0164], [0175], [0176], [0184], [0200], [0204], [0209], [0229], [0235], [0236], [0253], [0282], SEQ ID NO: 8	100, 102, 104, 122, 123 --- 1, 6, 11, 16, 21, 26, 31, 36, 41, 46, 51, 56, 61, 66, 71, 76, 81, 86-88, 101, 103, 105
Y	US 2005/0096257 A1 (SHIMA et al.) 05 May 2005 (05.05.2005) para [[0014], [0022], [0023], [0032], [0107], [0145], [0252], [0253], [0263], [0271], [0290], [0308], [0314], SEQ ID NO: 21	1, 6, 11, 16, 21, 26, 31, 36, 41, 46, 51, 56, 61, 66, 71, 76, 81, 86-88
Y	US 2008/0305115 A1 (TICE et al.) 11 December 2008 (11.12.2008) para [0049], [0070]-[0072]	86, 88, 101, 103, 105

☐ Further documents are listed in the continuation of Box C. ☐

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
07 September 2010 (07.09.2010)	17 SEP 2010
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

Form PCT/ISA/210 (second sheet) (July 2009)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 10/32816

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I: claims 1, 6, 11, 16, 21, 26, 31, 36, 41, 46, 51, 56, 61, 66, 71, 76, 81, 86-88, 100-105, 122 and 123, directed to a method of treating an ophthalmological disease with a combination of antagonist a, and at least one of: ranibizumab, bevacizumab, aflibercept, KH902 VEGF receptor-Fe fusion protein, 2C3 antibody, ORAlO2, pegaptanib, bevasiranib, SIRNA-027, decursin, decursinol, picropodophyllin, guggulsterone, PLGIOI, eicosanoid LXA4, PTK787, pazopanib, axitinib, CDDO-Me, CDDO-Imm, shikonin, beta-hydroxy-isovaleryl-shikonin, or ganglioside GM3, DCIOI antibody, Mab25 antibody, Mab73 antibody, 4A5 antibody, 4EIO antibody, 5F12 antibody, VAOI antibody, BL2 antibody, VEGF-related protein, sFLTOI, sFLT02, Peptide B3, TGIO080I, sorafenib, or G6-3I antibody, or a pharmaceutically acceptable salt thereof.

- Please see extra sheet for continuation -

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1, 6, 11, 16, 21, 26, 31, 36, 41, 46, 51, 56, 61, 66, 71, 76, 81, 86-88, 100-105, 122 and 123

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

Continuation of Box III: Unity of Invention

Group II: claims 2, 7, 12, 17, 22, 27, 32, 37, 42, 47, 52, 57, 62, 67, 72, 77, 82, 89-92, 100, 101, 106-109, 124-127, directed to a method of treating an ophthalmological disease with a combination of antagonist b, and at least one of the combinatorial compounds listed above.
Group III: claims 3, 8, 13, 18, 23, 28, 33, 38, 43, 48, 53, 58, 63, 68, 73, 78, 83, 93-96, 100, 101, 110-113, 128-131, directed to a method of treating an ophthalmological disease with a combination of antagonist c, and at least one of the combinatorial compounds listed above.
Group IV:claims 4, 5, 9, 10, 14, 15, 19, 20, 24, 25, 29, 30, 34, 35, 39, 40, 44, 45, 49, 50, 54, 55, 59, 60, 64, 65, 69, 70, 74, 75, 79, 80, 84, 85, 97-101, 114-121 and 132-135, directed to a method of treating an ophthalmological disease with a combination of a compound having formula E, further wherein the compound may be antagonist d, and at least one of the combinatorial compounds listed above.

The inventions listed as Groups I - IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical features shared amongst the claims of Groups I-IV is a method of treating an ophthalmological disease with a combination of a nucleic acid antagonist further associated with a lipophilic moiety, and at least one of the combinatorial compounds listed above. The special technical feature of each Group is directed to an antagonist having a different particular structure.

The common technical elements shared by the above groups (a method of treating an ophthalmological disease with a combination of a nucleic acid antagonist further associated with a lipophilic moiety, and at least one of the combinatorial compounds listed above) do not represent an improvement over the prior art of of US 2004/0253679 A1 to Epstein (see abstract, para [0163] (SEQ ID NO: 8 in comparison to Applicants' SEQ ID NO: 21, wherein SEQ ID NO: 21 corresponds to the sequence of the nucleic acid portion of compounds A-C; para [0092], [0093] - associated with lipophilic compounds, and para [0175] - The PDGF aptamers of the present invention can be used in combination with a variety of known vascular targeting agents wherein "vascular targeting agent" means a small molecule therapeutic (e.g., irenotecan), a protein therapeutic (e.g., bevicizumab)), when combined with the highly related application US 2005/0096257 A1 to Shima et al., which discloses wherein similar aptamers in combination with lipophilic compounds may be used to treat ophthalmological disease (see abstract; SEQ ID NO: 21 in comparison to Applicants' SEQ ID NO: 21, wherein SEQ ID NO: 21 corresponds to the sequence of the nucleic acid portion of compounds A-C; para [0200] -- combining selected nucleic acid ligands with lipophilic compounds or non-immunogenic, high molecular weight compounds; and para [0012] -- ocular neovascular disease). Treating an ocular neovascular disease as taught by Shima using a combination of the same molecules taught by both Shima and Epstein with an additional vascular targeting agent, as disclosed by Epstein, would have been obvious to a person skilled in the art. Therefore, the inventions of Groups I - IV lack unity of invention under PCT Rule 13 because they do not share a same or corresponding special technical feature.